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Cognitive function constitutes a critical dimension of the health status of
elderly individuals. Age-associated decline in cognitive function may partly be
attributed to the negative effects of systemic medical diseases and related factors,
including cardiovascular diseases (CVDs) and vascular risk factors. Cognitive
decline has been an understudied outcome in cardiovascular epidemiological
research. Few reports have comprehensively examined cognitive function in relation
to clinical manifestations of systemic atherosclerotic disease in different arterial
beds. Inconsistent findings are common in the literature and these arc likely to reflect
the vast differences between studies regarding the choice of population under study,
the methods applied for measuring and defining CVD, the types and timing of
administration of protocols used for assessing cognitive function, and the paths taken
in the analysis of data.
The principal aim of the present study was to examine the longitudinal
change in cognitive test performance in relation to major clinical CVDs and vascular
risk factors in a population-based sample of older people. The administration of a
battery of neuropsychological tests on two separate occasions facilitated the study of
actual change in both general cognition and across different cognitive abilities
according to an objectively-determined CVD status. A valid estimation of peak prior
cognitive ability allowed the exploration of the impact ofCVD and risk factors on
the imputed decline from best-ever level of cognitive function to that measured in old
age.
The analysis is based on a cohort of 809 men and 783 women aged 55-74
years which in 1987/8 was randomly selected from the general population of
Edinburgh. A comprehensive assessment of the prevalence of major CVDs and
vascular risk factors was held at baseline and during two follow-up examinations.
Since baseline, the study sample has been followed up to determine the incidence of
angina pectoris, peripheral arterial disease (PAD), myocardial infarction (MI), and
stroke. Cognitive testing was first held in 1998/9 when the mean age of the surviving
cohort (n=1209) was 73.1 years (SD=5.0) and subsequently about four years later
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using the same test protocol. The present investigation is based on the 452 study
participants who attended follow-up cognitive testing in 2002/3.
Both general cognition, as indexed by a general cognitive factor representing
the variance common to all the cognitive tests used, and most individual cognitive
measures were negatively affected in participants with CVD but no evidence of
stroke relative to non-vascular controls. Of the specific CVD manifestations, stroke
was significantly associated with a steeper four-year decline in both general
cognitive function and verbal memory. When decline was estimated from peak, prior
cognitive level, stroke was related to a greater decline in both general cognition and
verbal fluency. In the absence of stroke, MI was associated with an accelerated four-
year decline in non-verbal reasoning ability but the presence of angina was not
related to cognitive decline in this study. Symptomatic PAD also independently
predicted faster decline in both general cognition and verbal memory over the four-
year follow-up. Several potentially modifiable vascular risk factors, including
education, body mass index, smoking, diastolic blood pressure, inflammatory
markers and blood viscosity were also related to decline in general and specific
cognitive abilities, independently of age, sex, prior cognitive ability and vascular
disease. The associations with decline in specific cognitive measures principally
resulted from the impact of atherosclerotic disease and risk factors on general
cognitive ability rather than the individual functions per se.
The findings from the present study further add to those of previous
investigations demonstrating a relationship between CVDs, vascular risk factors, and
cognitive decline in older people. Specifically, they reveal that, even in the absence
of overt stroke, clinical CVDs are associated with a greater cognitive decline in the
elderly, independently of potential confounding by a wide range of vascular risk
factors. Also, the relationships between several vascular risk factors and cognitive
decline proved to be independent of overt co-existing vascular pathology. Based on
these findings, further study is needed to determine the combined effects of CVDs
and multiple risk factors on cognitive outcomes in samples of older people. In
addition, what the likely pathological mechanisms are underlying cognitive decline
associated with atherosclerotic disease and vascular risk factors needs to be
addressed in future studies. From a perspective of preventing or delaying vascular-
IV
based cognitive decline and impairment, more research is required to assess the
effectiveness ofboth individual and population-based strategies targeting vascular
disease and risk factors in older age groups. Finally, further investigation is needed to
address the potential impact of subtle cognitive deficits on indicators of the quality of
life and the capability of self-maintenance of elderly vascular patients, on adherence
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General Background to Atherosclerotic Diseases, Risk factors and
Neurocognitive Function
1.1. INTRODUCTION
With falling fertility rates and an increase in average life expectancy, which is
largely driven by a shift in mortality into older age, many societies worldwide are
currently facing significant changes in their demographic structure. A major
consequence of this process is the ageing of populations, characterised by both an
absolute and relative increase in older people (OECD, 2005). For example, at the end
of last century in the United States, the proportion of people 65 years and older was
approximately 13% compared to around 4% in 1900 (Fried, 2000). By 2030, the
proportion of those aged over 65 years is projected to increase to more than 20%.
Similar future population trends have also been forecast for many European
countries, including the United Kingdom.
In concert with the ongoing demographic ageing, the need to realise better the
spectrum of health and disease of ageing populations, the underlying contributing
factors, and any opportunities for both preventive strategies and effective
interventions, has taken its place at the forefront of epidemiological research and
public health (Fried, 2000). Concomitantly, there are concerns about how traditional
systems will respond to the future needs of older people for long-term health and
social care. In this context, intact cognitive function, which relates to an individual's
ability to process information, emerges as a critical dimension of the health status of
elderly people (Fried, 2000; Waldstein and Elias, 2003). Whereas subtle cognitive
dysfunction may prevent an individual from performing at the highest possible level
of ability, cognitive impairment, which manifests itself in mild to severe changes
across different cognitive functions, constitutes a major determinant of long-term
institutionalisation and dependency in old age (Melzer et al., 1997; Waldstein and
Elias, 2003).
In addition to placing a greater burden on formal and informal pathways of
care, impaired cognition is further associated with a significantly reduced quality of
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life and survival (Neale et al., 2002). The large projected increase in the prevalence
of cognitive impairment during the 21st century underscores the importance of the
continuing study of aetiological factors, which if appropriately identified and
controlled, may pave the way for delaying the onset and reducing the burden of
cognitive decline (Purandare et al., 2005; Roman, 2003).
A crucial issue in the study of the health status of elderly people is the high
prevalence of chronic diseases and associated risk factors, accompanied by an
elevated risk ofmortality, morbidity, and disability (Fried, 2000). Atherosclerotic
CVDs currently constitute a major cause of mortality and morbidity in elderly people
in many societies (Roman, 2003). Despite a significant decline in mortality from
coronary heart disease (CHD) in most industrialised countries during the latter part
of the last century, CHD remains the leading cause of death among developed
nations and is predicted to achieve that status worldwide over the coming decades
(Tyroler, 2000). In addition, CHD is expected to become a major contributor to the
global disease burden in adults, as measured in Disability Adjusted Life Years
(DALYs) (Roman, 2003).
Similarly, stroke constitutes a leading cause of death in adults worldwide and
is currently the most frequent cause of disability in the elderly population (Di Carlo
et al., 2000; Roman, 2003). Although mortality from stroke may have declined
following improved control of risk factors and therapeutic interventions, stroke-
related morbidity has either remained constant or even increased (Di Carlo et al.,
2000).
For symptomatic atherosclerotic disease in other arterial beds, including the
lower extremities, lack of data on time trends in disease prevalence make it difficult
to predict the morbidity distribution of these conditions. However, it has been
pointed out that the increased survival of persons who otherwise would not have
survived acute CHD or stroke will also lead to an increase in the prevalence of PAD,
thus further contributing to the morbidity burden of older age groups (Fowkes,
2001).
This first chapter of the thesis presents a general background on
atherosclerosis, its major clinical manifestations and risk factors. Following this is an
introduction to the human brain, cognitive function, and the biological and
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pathological changes in cognitive function commonly observed in later life. Chapter
two presents a critical review of published studies investigating the relationships
between vascular diseases, CVD risk factors, and cognitive function in older people.
Chapter three follows with the background and objectives of the present thesis. The
methodology of the current study is described in chapter four. In chapter five the
study results are presented while chapter six is a discussion of the main findings and
methodological issues of the study. In chapter seven, the implications and




Atherosclerosis is a progressive inflammatory disease of large and medium-
sized arteries (Ross, 1999). Atherosclerosis is systemic in nature and broadly similar
pathological features of the disease are commonly found in many major arteries,
including the aorta, carotid, iliofemoral, and coronary arteries (Rauch et al., 2001).
As a pathological entity, atherosclerosis has been recognized for more than a century.
With rapid advances in both basic and clinical research over the past decades,
important insights into its biological basis, risk factors, and clinical consequences,
have been gained (Faxon et al., 2004).
Whereas the exact aetiology of atherosclerotic disease has yet to be revealed,
various causal explanations have been formulated. For example, the response-to-
injury hypothesis states that atherosclerosis constitutes a chronic inflammatory
response of the arterial vessel wall to the injurious effects of atherogenic stimuli,
such as elevated blood lipids, smoking, high blood pressure, diabetes, genetic factors,
infectious agents, and/or other influences (Ross, 1999; Willeit and Kicchl, 2000). In
particular, disruption of normal arterial endothelial function, rather than endothelial
denudation as previously proposed, is now thought to be the pathophysiological




Endothelial dysfunction induces a cascade of structural and functional
alterations within the vessel wall of affected arteries. Characteristic of an
inflammatory response, the adhesiveness of the endothelium to circulating
leukocytes and platelets as well as its cell permeability to lipoproteins and other
plasma proteins increases (Ross, 1999). Specific adhesion molecules displayed on
the surface of endothelial cells have been found to be responsible for the adherence
and migration of leukocytes (mainly monocytes and T lymphocytes) from the blood
stream into the intima, the innermost layer of the arterial wall. Once in the vessel
wall, the blood-derived monocytes (now called macrophages) express scavenger
receptors for lipoproteins, enabling them to ingest lipids (Viles-Gonzalez et al.,
2004). The presence of lipid-laden macrophages (now called foam cells) in the
intima layer of the arterial wall forms the earliest lesion of atherosclerotic disease.
Further progression of early atherosclerotic lesions to so-called fatty streaks
is dependent on the continuing accumulation of lipid-absorbing macrophages and
smooth muscle cells which also contain lipids (Drouet, 2002). In most people,
characteristic aortic fatty streaks may already be manifest by the time of adolescence
(Velican and Velican, 1983). Programmed cell death (apoptosis) may be the eventual
fate ofmany lipid-laden cells, leading to extra-cellular accumulation of lipids.
Coupled with an increased synthesis, and reduced absorption, of collagen fibers by
smooth muscle cells, the atherosclerotic lesion progresses from a fatty streak to an
advanced atherosclerotic plaque which is characterized by a lipid core covered by a
fibrous cap that walls off the lesion from the vessel lumen. This form of the lesion is
thought to represent a type of healing or fibrous response to the initial endothelial
injury (Ross, 1999).
The additional development of the advanced atheromatous plaque may
depend on several factors, most notably its composition (Willeit and Kiechl, 2000).
Continuous plaque growth occurs when atherosclerosis progresses slowly and
equally across diffuse lesions, with the process relying on cumulative exposures to
known atherogenic risk factors. In particular, high content of smooth muscle cells, a
small lipid core, and a dense fibrous cap, are characteristic of stable atheromatous
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plaques. Importantly, in response to the gradual expansion of stable plaques,
compensatory enlargement of the arterial lumen may occur through a process called
'vascular remodeling', whereby normal lumen is maintained during the disease
course despite substantial plaque protrusion and stenosis. Although normal blood
flow may continue uninterrupted, the stable plaque is of considerable clinical
significance since most advanced lesions may undergo compositional changes,
leading to greater lipid accumulation and thinning of the fibrous cap, making them
become unstable and more susceptible to erosion, fissure, and even rupture (Newby
et al., 1999).
Further to plaque compositional factors, inflammation (systemic and within
the plaque core), cytotoxic substances released from inflammatory cells, blood
cholesterol level, and mechanical and haemodynamic factors, have been implicated
in increasing the vulnerability of the plaque to rupture (Willeit and Kiechl, 2000).
When disruption occurs, resulting in a co-called complicated atherosclerotic lesion,
the circulating blood is exposed to a variety of thrombogenic material, predisposing
to atherothombosis. The extent of the resulting thrombotic response may vary
greatly. For example, the thrombus formation may grow slowly and without clinical
consequences in a circulation protected by extensive collateral circulation (Drouet,
2002). Alternatively, a major ischaemic event may occur. In addition to this classical
form of thrombogenesis, microembolic particulate matter may spontaneously be
released from within an active plaque over a period of hours, days, or weeks, which
can lead to microvascular obstruction and clinically silent ischaemic infarcts (Drouet,
2002).
Despite some variation in lesion-structure by anatomical location, stemming
from differences in local blood flow patterns, arterial wall structure, and the
sensitivity and expression of ischaemia in distal tissues, the diffuse involvement of
atherosclerosis has important clinical consequences (Drouet, 2002; Viles-Gonzalez et
al., 2004). Specifically, an atherothrombotic event in one particular arterial site may
imply that other territories in the body may already be affected by the same disease
process (Dawson et al., 2002). This needs to be borne in mind throughout subsequent
sections where the clinical manifestations of atherothrombotic disease in different
arterial beds are reviewed.
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1.2.3. Risk Factors
The main risk factors for atherosclerosis tend to be similar regardless of its
anatomical location, even though some predilection of certain risk factors to the
development and progression of atherosclerosis in different vascular sites is observed
(Kannel, 1994). Extensive evidence shows that these factors are independent of the
end organ supplied by a given arterial bed (Smith et al., 2004). In fact, much of the
present knowledge of risk factors for non-coronary atherosclerosis in population
samples is traditionally derived from studies of CHD.
Environmental as well as hereditary factors are important in the initiation and
progression of atherosclerosis (von Eckardstein, 2005). These have often been
divided according to their potential for modification and with respect to the strength
of evidence in support of their role in the disease process (Goldstein et al., 2001). As
a result, the major non-modifiable risk factors include age, sex, ethnicity, and family
history. Further to this, several potentially modifiable atherosclerotic risk factors
have been identified over decades of epidemiological study of atherosclerotic
coronary disease. More recently, less well-established factors have been added to the
list of potential risk candidates (Katzel and Waldstein, 2001). Associations between
dyslipidaemia, hypertension, smoking, diabetes, obesity, physical inactivity, and
certain psychosocial factors, and CHD have been well-documented. The above risk
factors are presented in further detail below.
Non-Modifiable Risk Factors
The cumulative effects of ageing on the vascular system and the continuous
influence of atherosclerotic risk factors over long periods of time are likely to
contribute to the increased risk of CVDs with age. For instance, for each successive
decade after age 55, the risk of acute cerebral infarction increases more than two-fold
in both sexes. Disease incidence rates are generally higher in men relative to women
even though comparatively more women die from CVDs each year because of their
disproportionately longer survival into older age (Sacco et al., 1997).
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Ethnic stratification of the incidence of cardiovascular disease and the risk of
vascular-related mortality is well established. As an example, evidence has shown
that within the US adult population, African and Hispanic Americans are at a greater
risk of cerebrovascular disease than Whites (Goldstein et al., 2001). Chinese and
Japanese populations are also found to have higher disease rates. A greater exposure
to both genetic and/or environmental risk factors leading to obesity, hypertension,
and diabetes, may in part account for such risk differentials. Inheritance of vascular
risk factors, susceptibility to their effects, or shared cultural and environmental
exposures, could also explain the role of family history in the increased risk of
CVDs.
Major Modifiable Risk Factors
The role of abnormal blood lipid levels, including that of total cholesterol,
low-density lipoprotein (LDL), and triglycerides, in coronary atherosclerosis is well
recognized (von Eckardstein, 2005). However, the association of hyperlipidaemia
with cerebrovascular disease remains unsupported even though a clear relation with
carotid atherosclerosis, a major risk factor for cerebral ischaemia, has been found
(Wilson et ah, 1997). Similarly, the role of blood lipids in the development and
progression of atherosclerosis in the periphery has not been confirmed (Vogt et ah,
1992). Hypertension plays a major role in atherosclerotic disease, and has a positive,
graded association with all main clinical manifestations. Thus, in addition to
contributing to the progression of atherosclerosis, it can induce hypertrophy in the
heart and may lead to cardiomyopathy and congestive cardiac failure (Messerli and
Grodzicki, 1992). Hypertension is the single most important modifiable risk factor
for cerebrovascular disease and the impact of antihypertensive treatment on the
reduction in onset and mortality from cerebral ischaemia has been demonstrated in
clinical trials (Dahlof, 2006). The role of hypertension in peripheral atherosclerotic
disease may be substantial but remains somewhat undetermined.
The adverse effects of cigarette smoking on systemic vasculature and blood
rheology make it an important risk factor for coronary heart disease. Most
epidemiological evidence to date suggests smoking plays a major role in the
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development and progression of peripheral atherosclerosis, and in this respect, its
influence in the periphery may be more important than in the coronary circulation
(Vogt et ah, 1992). Smoking has also been found to have a dose-response
relationship with the risk of developing cerebrovascular disease (Munther and
Rahman, 1998; Wolf et ah, 1988). A clear reduction in the incidence ofCVDs has
been found following smoking cessation (Wannamethee et al., 1995).
Diabetes is associated with greater atherosclerotic risk and diabetic patients
are found to have a higher prevalence of various atherogenic risk factors (Grundy et
al., 1999). Diabetes is also related to a greater burden ofCHD and may have
independent influence on the incidence of cerebrovascular disease. Conflicting
findings have been produced with respect to its role as a risk factor for PAD, but
rather than increasing the risk of disease, it may contribute to occurrence of later-
stage complications experienced by some patients (Fowkes, 2004).
The influence of body weight on CFID morbidity and mortality has been well
documented (Alexander, 2001). Obesity is associated with greater prevalence of
atherosclerotic risk factors, including hypertension and dyslipidaemia, and may
increase the risk of cerebrovascular disease (Isozumi, 2004). In particular, abdominal
obesity in men and weight gain in women may be associated with such elevated risk.
Only weak data link obesity with PAD (Vogt et al., 1992). In a similar vein, the type
and level of physical activity has been little studied in relation to peripheral
atherosclerosis, but evidence points to beneficial effects ofmoderate, regular
exercise on the development of cerebrovascular disease (Noda et al., 2005). Any
protective effects of exercise may be mediated through its positive influence on the
aforementioned atherogenic risk factors.
Other Modifiable Risk Factors
Both depressive symptoms and anxiety states have been found to be
associated aetiologically and prognostically with increased CHD morbidity and
mortality risk (Kubzansky et al., 1998; Rozanski et al., 2005). In contrast, their role
in the development of other vascular diseases, including that of cerebrovascular
disease, remains less certain. Possibly, an association of psychological states with
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atherosclerotic disease is mediated through negative health behaviours and
accumulation of atherogenic risk factors (Kubzansky et al., 1998). Alternatively, the
association may be explained by more direct influence of psychologically-induced
biochemical and physiological changes affecting either the systemic vasculature or
the blood (Stansfeld and Rasul, 2005).
Novel Risk Factors
More recently, there has been an increased interest in the potential role of
several other risk factors for vascular disease, including serum and plasma levels of
homocysteine, lipoprotein (a), and various inflammatory, rheological and coagulation
factors. This has partly been because of recent developments in laboratory science
contributing to the relative ease with which levels of these factors may be measured
in large-scale population-based epidemiological studies (Whincup and Danesh,
2005). Moreover, the identification of new risk factors has provided opportunities for
improving CVD risk predictions beyond that of conventional risk factors (Tsimikas
et al., 2006).
Elevated serum levels of homocysteine, an amino acid formed during the
metabolism of the essential amino acid methionine, have been found to be
independently associated with an increased CHD risk in a dose-response fashion
(Wald et ah, 2005). Similarly, an association with the degree of atherosclerosis in the
carotid arteries and the risk of overt cerebrovascular disease has been noted (Sacco et
al., 1997). Levels of lipoprotein (a), an apolipoprotein homologous with
plasminogen, correlate positively with the risk of developing CHD but studies are
conflicting as to whether there may be a relationship with cerebrovascular disease
(Goldstein et al., 2001).
Haemostatic and rheological factors, including plasma levels of fibrinogen
and blood viscosity, have been found to be positively associated with an elevated risk
of coronary and cerebrovascular events (Meade and MacCallum, 2005). Moreover,
fibrinogen concentrations are related to the development and progression of PAD
(Tzoulaki et al., 2006; Wildman et ah, 2005). The contribution of fibrinogen to the
risk ofCVD may stem from its influence on blood viscosity, platelets, and its blood
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clotting potential (Sacco et al., 1997). In a similar vein, levels of circulating markers
of systemic inflammation have been linked with an increased risk of atherosclerotic
disease. In particular, C-reactive protein (CRP) and several pro-inflammatory
molecules (e.g. various interleukins) may be related to acute coronary disease and
possibly cerebrovascular disease as well. However, whether such inflammatory
markers actually induce CVD or merely reflect vascular risk or subclinical
atherosclerotic disease is still open to debate (Whincup and Danesh, 2005).
1.3. CEREBROVASCULAR DISEASE
1.3.1. Definition
The concept 'cerebrovascular disease' is used as a general term for describing
abnormalities of brain structure and function of vascular causes. A major form of
cerebrovascular disease is stroke, which has clinically been defined as rapidly
developing signs of focal disturbance in cerebral function, with symptoms lasting 24
hours or longer with no apparent cause other than of vascular origin (Merino and
Hachinski, 2001; WHO MONICA Project, Principal Investigators, 1988). With the
increased sophistication and use of brain imaging techniques for early recognition
and diagnosis of stroke, the presence of a defined lesion on imaging with
corresponding symptoms was later been added as a criterion for diagnosing stroke
(Boden-Albala and Sacco, 2004).
The clinical classification of stroke has been widely adopted in
epidemiological research aiming at establishing the prevalence and incidence of
stroke, but is limited with respect to two main aspects of the disease. First, it
excludes a transient ischaemic attack (TIA) which can be regarded as a short-lived
(most TIAs only last a few minutes) loss of function due to focal reduction in
cerebral blood supply (Russell, 1983). Traditionally, it has been assumed that no
structural brain damage has taken place after TIA, whereas in the case of a stroke, at
least a minor ischaemic lesion remains. As indicated above, the distinction between
TIA and stroke has been based on the duration of clinical signs. However, brain
imaging has clearly demonstrated that it may be impossible to exclude cerebral
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ischaemia on symptoms alone. In fact, there seems to be no difference between a
TIA and stroke with respect to aetiology, prognosis, and treatment (Russell, 1983).
Second, from the sole use of the clinical definition, it may be difficult to establish the
aetiology of stroke. For these two reasons, the term stroke has sometimes been used
to denote any neurological dysfunction that is related to alterations of cerebral blood
flow, irrespective of its duration or cause (Merino and Hachinski, 2001).
1.3.2. Stroke Subtypes
Three distinct aetiological categories of stroke are recognised (Boden-Albala
and Sacco, 2004). The most frequent type is stroke caused by cerebral ischaemia
which may account for as many as 70 to 80% of all strokes. To a lesser extent,
intracerebral and subarachnoid haemorrhage make up approximately 15-20% and
less than 10% of all strokes, respectively. Given the relative frequency and
importance of cerebral ischaemia in the general population, the focus of the
remaining text will be on stroke of ischaemic origin.
1.3.3. Pathophysiology
Several underlying pathophysiological mechanisms can lead to ischaemic
stroke (Merino and Flachinski, 2001). In particular, large-vessel atherosclerosis
commonly affects extra- and intracranial arteries. Advanced, vulnerable
atherosclerotic lesions can be found in the carotid arteries in the neck and in the
basilar artery, and sometimes in the middle and posterior cerebral arteries (see
section 1.6.3. for a further discussion of the cerebral arterial vasculature). Where
such lesions undergo plaque rupture and abrupt atherothrombosis, they may be
manifested as large cerebral haemispheric or basilar artery infarcts. However, in the
case of slowly growing stable plaques, leading to lumen stenosis, small reductions in
systemic blood pressure levels can lead to cerebral hypoperfusion and ischaemia in
vulnerable areas (so-called watershed areas). Atherosclerosis in large vessels may
also lead to occlusion of the origin of smaller arterioles which penetrate the brain.
Under these circumstances, small areas of infarction deep within the brain may
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occur, inducing symptoms characteristic of small-vessel disease (the occlusion of
small arteries penetrating the brain may result in deep-lying infarcts, called lacunar
infarcts. A wide range of clinical symptoms may be seen depending on the sub¬
cortical neural substrate affected, see Merino and Hachinski, 2001).
Further to atherothrombosis, artery-to-artery embolism also constitutes a
major cause of acute ischaemic stroke. Despite the many potential origins of cerebral
embolic material, the most common source in older people is an atherosclerotic
lesion in one or more of the carotid arteries of the neck (Rook, 1999). In particular,
the internal carotid artery leads directly to the middle cerebral artery which receives
almost 80% of the blood traveling through the internal carotid. As a result, most
emboli from the internal carotid artery have been found to have a predilection for
lodging in the middle cerebral artery or one of its branches. Embolic material can
also come from other extracranial sources, including a diseased heart. In particular, a
frequent source of cardiogenic emboli is a thrombus lodged within the left auricle of
dysrhythmic individuals, such as those suffering from atrial fibrillation (Bernhardt et
al., 2006; Rook, 1999). A wall or mural thrombus formed on a hypokinetic
endocardial segment following a myocardial infarction may also give rise to cerebral
emboli. Other non-atheromatous embolic material, introduced through other means
into the circulation, may also result in cerebral ischaemia.
1.3.4. Prevalence and Incidence
In most Western countries, stroke is a major cause of death and disability.
Different sources of data may provide population estimates of the prevalence and
incidence of stroke, including national statistics and population surveys. In the
Health Survey for England in 2003, for example, 2.4% ofmen and 2.2% ofwomen
reported ever having had stroke diagnosed by a doctor with steeper rates observed at
greater ages in both sexes (Joint Health Surveys Unit, 2003). In men, the prevalence
rose from 1.2% in those aged 45-54 years to 7.5% men aged 65-74 years, and to
13.3% in those 75 years and older. For women, the proportions with stroke were
0.9%, 5.3%, and 8.8%, respectively. Overall, 0.4% of both men and women reported
having had a stroke in the previous year. In the Scottish counterpart of the Health
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Survey for England, very similar prevalence rates were reported (Scottish Executive
Department ofHealth, 2005). In total, 2.4% ofmen and 2.1% ofwomen noted ever
having had a doctor-diagnosed stroke. Overall, 0.4% ofmen and 0.5% ofwomen
reported having had a stroke during the previous year. Age-specific prevalence rates
for men were as follows: 0.9% in men aged 45-54, 5.9% in those aged between 65
and 74 years, and 11.3% in men 75 years and older. At every age, the prevalence
rates for women were somewhat lower than for men or 0.5%, 5.0%, and 8.3%,
respectively. More or less identical age and sex-specific prevalence rates have been
reported in other Western populations (Thorn et al., 2006).
A large body of evidence exists on the incidence of stroke and its relation
with sociodemographic status, ethnicity, and geographical location, and more
recently, stroke subtype (Boden-Albala and Sacco, 2004). Overall, the incidence of
stroke is higher in men compared to women, and substantial geographical and racial
differences are found both with respect to total stroke as well as specific subtypes. In
the Rochester Epidemiology Project, a male/female ratio of 1.40 was noted for the
four-year incidence of stroke when adjusted for differences in age structure (Petty et
al., 1999). Similarly, in the Erlangen Stroke Project, a higher incidence rate was
observed for men relative to women but this was only applicable to large-vessel
stroke (22.6 versus 13.1 per 100.000 population) and small vessel occlusion (32.9
versus 27.1 per 100.000 population) (Kolominsky-Rabas et al., 2001). Greater
cardioembolic stroke incidence was noted for women (44.5 versus 26.2 per 100.000
population in men). For all the stroke subgroups, however, the incidence rates
increased steeply with age. Moreover, in the Northern Manhattan Study, Whites had
lower incidence rates in all major stroke types relative to either Hispanics or African-
Americans (White et al., 2005). Specifically, African-American subjects experienced
the highest incidence rates irrespective of stroke type.
In a similar vein, vast differences in stroke incidence have been reported
between countries and geographical regions (Thorvaldsen et al., 1995). Whereas
some of the variation may be explained by heterogeneity in methodology, true
differences in levels of exposure to risk factors are also likely to contribute to such
patterns (Boden-Albala and Sacco, 2004).
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1.4. CORONARY HEART DISEASE
1.4.1. Definition
The term 'coronary heart disease' covers a number of different clinical
manifestations of ischaemia in the myocardium (Dawber, 1980). The main cause of
CHD is atherosclerosis in the coronary arteries but the cardiac muscle is primarily
dependent on the coronary circulation for its blood supply and normal functioning. In
this respect, CHD is synonymous with the concept 'coronary artery disease'. It also
embraces the term 'ischaemic heart disease', which is more specific than CHD since
it highlights ischaemia as the underlying pathological mechanism (Tunstall-Pedoe,
1997). However, even though myocardial ischaemia most frequently is the result of
atherosclerotic disease of the coronary arteries, it needs to be acknowledged that
other pathomechanisms may also induce ischaemia in the heart (Tunstall-Pedoe,
1997; Stehbens, 1999).
1.4.2. Pathophysiology
As already discussed, the gradual build-up of atherosclerotic plaques in the
coronary arteries may lead to narrowing of the vessel lumen. However, because of
remodeling of the vessel wall, normal blood flow and perfusion of the cardiac muscle
may be maintained despite a significant degree of arterial stenosis. More recent
insights have moved beyond a notion of progressive occlusion due to lumen stenosis
to one where it is recognised that coronary plaque vulnerability, predisposing to
rupture and thrombosis, may be the lead cause of acute coronary syndromes (Viles-
Gonzales et ah, 2004). As a result, plaque composition, rather than degree of vessel
narrowing, is likely to be a major determinant of CHD. Even though excessive
propagation of atherothombosis may rarely take place, evidence shows that small,
non-stenotic coronary plaques that have undergone rupture may be the cause of
vessel occlusion in a significant number of acute myocardial infarction patients
(Willeit and Kiechl, 2000). Indeed, a discrepancy between the amount of arterial wall
affected by atherosclerosis and the clinical manifestations of CHD has been noted
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(Dawbcr, 1980). Regardless of the process, however, ischaemia of the cardiac muscle
is bound to occur when its demand for oxygen cannot be adequately met. If sufficient
enough, the individual becomes aware of a definite feeling of discomfort in the chest,
often radiating to the neck and down one or both arms.
1.4.3. Coronary Heart Disease Syndromes
Angina Pectoris
A transient shortage of blood supply to the myocardium may lead to the onset
of angina pectoris, which is manifested as a dull or heavy discomfort in the epigastric
area (Dawber, 1980). Typical of angina, symptoms appear with exertion, excitement,
or emotional distress, accompanied by an increase in cardiac output. The discomfort
characteristic of angina is non-specific to the disease and frequently experienced in
other contexts. In clinical practice, a detailed medical history is commonly taken
with respect to symptoms and precipitants of angina, and often the first step in the
diagnosis is the exclusion of other differential causes of the symptoms. For
epidemiological purposes, however, a clinical diagnosis of angina may not be
reliable because of the subjectivity of symptom reporting. The application of
electrocardiograph (ECG) at both rest and during exercise has been attempted in
making the diagnosis of transient ischaemia more objective. Unfortunately, whereas
a resting ECG may turn out to be normal, the use of exercise ECG is both risky and
time-consuming and may not be suitable for population research. Moreover, ECG
changes frequently observed in patients with angina have been found to be of limited
diagnostic value (Chun and McGee, 2004). Other attempts to objectively diagnose
the condition in population studies resulted in the development of a standardized,
symptom-based angina questionnaire (Rose, 1962).
Myocardial Infarction
An MI occurs when prolonged ischaemia of a distinct segment of the cardiac
muscle results in necrosis of that part of the myocardium (Dawber, 1980). Without
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exception, an MI is the consequence of atherothrombotic disease in the coronary
circulation, and as already discussed, only a minimal arterial narrowing due to
atherosclerosis may be present at autopsy (Dawber, 1980). Clinically, MI is
characterized by the sudden onset of a severe substernal or epigastric pain which may
radiate to the neck, jaws, and down the arms. In contrast to angina symptoms, the
discomfort following an MI persists (or even becomes progressively more severe)
and is neither relieved by rest nor administration of glyceryl trinitrate. In a small
proportion of patients, no symptoms may have been experienced despite ECG
evidence of a previous MI (Tunstall-Pedoe, 1997).
Alterations in ECG, including the presence of diagnostic Q waves and ST
elevation, may be found during an MI, or alternatively, changes in ECG may evolve
over hours and days following the event. As a result, recording of serial ECGs has
proved to be valuable in the diagnosis ofMl (Pope and Selker, 2005). The use of
sensitive and specific biomarkers has also aided in the diagnosis ofMI (Rajappa and
Sharma, 2005). In particular, when necrosis of cardiac muscle cells occurs, several
enzymes that are normally present in such cells are released into the blood. Tests
have been developed to detect serum concentrations of different enzymes and an MI
may be diagnosed when these are increased in the clinical context of acute
ischaemia. While the enzyme concentrations are considered to reflect the extent of
damage to the myocardium, they are unable to reveal the underlying cause (Alpert et
al., 2000).
Chronic Heart Failure
Despite considerable aetiological heterogeneity, congestive cardiac failure is
most commonly the result ofCHD. The term refers to the inadequacy of the heart in
maintaining the systemic blood circulation through its pump function (Crouch,
2005). Reduced cardiac output may lead to hypoperfusion of body tissues and
organs. A number of different symptoms may be suggestive of congestive heart
failure but most are non-specific to the disease (Khunti et al., 2000). In its most
severe form, heart failure may lead to pulmonary edema which develops when
inadequate cardiac pumping results in an increase in lung fluid secondary to leakage
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from capillaries in the lung into the pulmonary alveoli. An enlargement of the heart
may also occur. In the Framingham Heart Study, the presence of pulmonary
congestion and cardiomegaly by chest radiography, as well as ECG evidence of left
ventricular hypertrophy, formed the basis for the diagnosis of congestive heart failure
(Dawber, 1980).
Sudden Death
In Western countries, sudden death is most commonly a consequence of acute
MI which may produce dangerous cardiac arrhythmia, such as ventricular fibrillation
or asystole (Henkel et al., 2006). Although a majority of individuals who suddenly
die have some evidence of CHD, such unexpected death frequently occurs in persons
without previously-known coronary disease. Despite no standard definition of the
term exists, the current practice of considering all such deaths as cardiovascular
unless otherwise shown may be warranted (Dawber, 1980). On rare occasions,
sudden death has seemingly occurred in the absence of CHD pathology. These are,
however, found to be infrequent and unlikely to invalidate the classification of
sudden death as a syndrome of atherosclerotic coronary disease.
1.4.4. Prevalence and Incidence
Population estimates of the prevalence of CHD have widely been collected.
In data from the USA, age and sex-specific analyses showed significant differences
in CHD prevalence rates between men and women and according to age (Thorn et
al., 2006). In both men and women, the prevalence rate rose steadily with every 10-
year increase in age from the age of 35 years. However, at every age, the rates in
men were up to three times as high as that for women. The highest rates for both
sexes were seen among those aged 75 years and older, 16.8% for men and 10.3% for
women, respectively. Substantially greater age-specific prevalence was noted in the
annual Health Survey for England in 2003 (Joint Health Surveys Unit, 2003). In
total, 6.4% of men and 4.1% ofwomen reported having CHD (angina or MI). When
broken down by age, those aged between 55 and 64 years of age (11.1% in men and
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5.8% in women) had approximately three times higher prevalence of CHD than
subjects aged 45-54 years (3.4% in men and 1.9% in women). In those aged 75 years
and older, the prevalence increased to as much as 26.5% in men and 18.1% in
women. Still higher rates of CHD were observed in the Scottish Health Survey,
which found up to 31.7% ofmen and 22.9% ofwomen aged 75 years or more to self-
report either angina or MI (Scottish Executive Department of Health, 2005).
Regarding specific CHD manifestations, 6.6% ofmen and 5.6% ofwomen in total
reported doctor-diagnosed angina whereas 4.2% ofmen and 2.4% ofwomen had
suffered an MI. Self-reported prevalence of both angina and MI increased steadily
with age. Other manifestations ofCHD, including congestive heart failure, have been
found to follow a similar pattern as noted above with regard to age and sex despite
evidence showing that elderly women may actually have higher prevalence of heart
failure relative to men (Thorn et ah, 2006).
Incidence data of CHD tends to be based predominantly on the ascertainment
of new cases ofMI. Population estimates of event rates in different countries and
regions have revealed vast geographical differences in the incidence ofMI (Tunstall-
Pedoe et ah, 1999). In all countries, however, men are relatively more affected than
women. Within the UK, large differences have been observed in incidence rates.
Among the highest are those that have been observed in the Glasgow area, whereby
an incidence of 777 per 100.000 population in men and 265 per 100.000 population
in women, aged 35 to 64 years, was observed. In comparison, the rates in men and
women of the same age in Oxfordshire were 273 and 66 per 100.000 population
(Volmink et ah, 1998).
Relative to MI, limited incidence data exists for other CHD syndromes. As
expected, however, based on the few available studies in the UK, the incidence of
angina has been found to increase with age and be higher in men compared to
women (Petersen et ah, 2004; Ghandi et ah, 1995). Moreover, vast differences in
incidence estimates exist across studies, possibly because of differences in
populations or in methods for diagnosing angina. Similarly, few studies have
investigated the incidence of cardiac failure, but in one UK-based study, the rate per
100.000 population was found to be approximately 50% greater in men compared to
women at every age level over age 45 to 55 years (Cowie et ah, 1999).
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1.5. PERIPHERAL ARTERIAL DISEASE
1.5.1. Definition
The concept 'peripheral arterial disease', which is synonymous with that of
'peripheral vascular disease', mainly refers to atherosclerotic disease in the arteries
supplying the upper and the lower extremities, and is much more rarely used to
denote atherosclerotic disease in the carotid arteries of the neck. However, since
disease in the upper extremities is proportionately rare, PAD is generally used to
indicate atherosclerosis of the arteries supplying the lower limbs. In more precise
terms, PAD refers to atherosclerotic disease of the distal aorta and the lower
extremity arteries that induces lumen narrowing and disruption of blood flow in the
legs (Fowkes, 2004).
Only when the atherosclerotic disease is relatively advanced, symptoms of
ischaemia may appear. The most common clinical presentation of transient ischaemia
in the lower limbs is intermittent claudication (sometimes referred to as angina of the
legs), which is manifested as pain or tightness in the calf, or the thigh, on physical
exertion and is relieved by rest (Dawber, 1980; Fowkes, 2004). Whereas most
patients either improve with the disappearance of symptoms or stay about the same,
comparatively few progress to more severe forms of the disease.
The clinical diagnosis ofPAD is usually made on the basis of presenting
symptoms (Fowkes, 2004). Similarly, self-reporting of symptoms has been used for
epidemiological purposes in detecting atherosclerotic disease in the lower extremities
(Dawber, 1980). For example, the WHO Intermittent Claudication Questionnaire has
been widely used for the identification of symptomatic PAD in the general
population (Rose, 1962). More recently, the Edinburgh Claudication Questionnaire
was constructed with the aim of improving the validity of the WHO questionnaire
(Leng and Fowkes, 1992). Further attempts have been made to provide more
objective methods of diagnosing lower-limb atherosclerotic disease and several non¬
invasive tests may be used for confirming the clinical history. In this respect,
measurement of the ratio of systolic blood pressure in the ankle to the upper arm
(termed the ankle-brachial pressure index or ABPI), has commonly been used for the
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non-invasive assessment of PAD (Fowkes, 1991). Whereas an ABPI of less than 0.9
has been shown to be 95% sensitive and 100% specific in identifying angiogram
positive disease in selective clinic samples, it may be less valid in establishing the
presence of asymptomatic PAD in community-based studies. Other techniques have
included palpitation of peripheral pulses, the use of stress tests, and Doppler
ultrasonography (Fowkes, 1991). Moreover, arteriography, in which specific arterial
segments can be directly visualized in living subjects, is currently the best objective
method of quantifying atherosclerotic disease and is used as reference against which
non-invasive techniques of existing disease are validated. However, apart from the
ABPI, important limitations regarding validity, costs, and patient tolerance, have
precluded most of these other methods from being widely used in population
research.
1.5.2. Pathophysiology
The gradual progression of atherosclerotic disease from an early age in the
distal aorta, the iliac, femoral, and popliteal arteries, may eventually lead to stenosis
and ischaemia of the lower extremities (Dawber, 1980). As discussed earlier, at an
advanced stage of atherosclerosis, ischaemic infarction may occur as a result of
vessel occlusion, leading to tissue gangrene and necessitating amputation. There is
evidence that atherosclerotic lesions at high risk of producing such acute ischaemic
syndromes in the lower extremities may both be greatly stenotic and fibrotic (Vilcs-
Gonzales et al., 2004). Further insights suggest that plaque stenosis, associated with a
hyperthrombotic state of the systemic blood, plays a key role in inducing acute
ischaemia of the lower limbs. Indeed, patients with advanced PAD have been found
to have a high prevalence of vascular risk factors, such as smoking, dyslipidaemia,
and diabetes, which increase the thrombotic potential of the blood (Willeit and
Kiechl, 2000).
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1.5.3. Prevalence and Incidence
A number of large-scale epidemiological studies have collected data on the
prevalence of symptomatic PAD in different populations (Diehm et al., 2004). On
many occasions, the WHO questionnaire has been administered for the purpose of
determining prevalence rates of intermittent claudication. Prevalence estimates have
been found to differ widely across studies, which in addition to true differences in
levels of disease, might be explained by varying age distributions and other
population characteristics (Vogt et al., 1992). Prevalence of intermittent claudication
has been noted to increase with age in both sexes, and even though not always found,
more men seem to be affected by the disease. In UK-based population studies,
intermittent claudication was relatively rare among both sexes under the age of 55
but increased steadily thereafter (Bainton et al., 1994; Fowkes et al., 1991; Smith et
al., 1991). Moreover, any male predominance observed in prevalence was found to
decrease with increasing age. Whereas the WHO questionnaire has been found to
underestimate the prevalence of PAD in the population, the Scottish Health Survey
administered the Edinburgh Claudication Questionnaire which may be of better
validity (Fowkes, 2004; Scottish Executive Department of Health, 2005). Overall,
2.8% ofmen and 3.5% ofwomen were found to have PAD. In the oldest age
category, among those aged 75 years and older, the prevalence was 8.9% in men and
6.9% in women.
The use of non-invasive measures has resulted in prevalence rates
approximately 2-5 times higher than that observed using a symptom-based
questionnaire (Vogt et al., 1992). Despite differences in absolute levels across
studies, similar trends with respect to age and sex tend to be seen. In the Edinburgh
Artery Study (EAS), for example, 17.0% ofmen and women had an ABPI of less
than 0.9 (Fowkes et al., 1991). When a stress test was added, the prevalence rate of
PAD rose to 24.6% for both sexes.
Data on the incidence of PAD has been collected less frequently than
information on prevalence. Based on the available evidence, however, the incidence
of intermittent claudication seems to increase with age in both sexes, and may be
higher in men compared to women, although the gap narrows with greater age. For
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example, in the Speedwell Study in the UK, which only included men, 4.0% of
subjects aged between 45 and 63 years developed claudication over 10 years of
follow-up (Bainton et al., 1994). Moreover, in the EAS, substantially higher
incidence rates were reported but approximately 9.0% developed incident
intermittent claudication over five years of follow-up (Leng et ah, 1996). The higher
incidence rate in the latter study may be explained by the older study subjects as well
as the inclusion of subjects having 'probable' intermittent claudication.
1.6. THE HUMAN BRAIN AND BEHAVIOUR
1.6.1. The Neuronal Basis of Brain Structure and Function
The central nervous system's (CNS) fundamental role is to receive, process,
store, and communicate information (Lezak, 1983; Afifi and Bergman, 1998).
Adequate exchange of information with the external environment is vital for normal
functioning and survival. At the most basic level, the CNS comprises two distinct
classes of cells: neurons and glial cells (Mitchell and Mayor, 1983). Whereas the role
of glial cells is to provide support to neurons, the neurons themselves are responsible
for information processing and communication. Despite many different types of
neurons, all share common morphological features such as a cell body, single or
multiple dendrites, and an axon (Kolb and Whishaw, 1996). The cell body, which
contains the cell's nucleus and a number of intracellular organelles, is the centre of
synthesis and transportation of proteins (called neurotransmitters) necessary for
intercellular communication. The dendrites constitute extensions of the cell body,
specialized in receiving information from other neurons in the form of
electrochemical signals. The axon on the other hand, which frequently is wrapped in
an insulating layer termed myelin sheath, represents the conduction component of the
cell.
A small space or cleft, called a synapse, physically separates one neuron from
another. When sufficiently stimulated, resulting in change in voltage charge across
the neural membrane, a nerve impulse rapidly travels from the receiving sites of the
neuron (mainly the dendrites but also the cell body) down along the axon. The
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propagation of the signal to other neurons is based on the release of neurotransmitters
from the axonal terminal into the synaptic cleft. Consequently, these bind to specific
receptors on the receiving neuron, and depending on the type of neurotransmitter,
alter the post-synaptic neuron's behaviour in various ways. In addition to the
unidirectional signal transmission across the synaptic cleft, other modes of
information transfer exist, whereby neurotransmitters freely diffuse through the
extracellular fluid from points that may be remote from the target cells (Coggan et al,
2005). It is thought that most cerebral functions use combinations of synaptic and
'extra-synaptic' transmission; whereas the former is fundamental to processes relying
on great selectivity, rapid initiation, and quick termination (e.g. selective movements
of the organism), the latter is likely to mediate general states of the organism such as
sleep, arousal, and mood, that require both widespread and sustained neural activity
(Kopanitsa, 1997).
The interaction of a single neural cell with other neurons (either across the
synapse or through extra-synaptic transmission) forms the basis of all
communication between neurons throughout the nervous system (Kolb and
Whishaw, 1996; Afifi and Bergman, 1998). Despite their autonomy, however,
neurons tend to operate collectively as assemblies or networks within the CNS, each
ofwhich makes a special contribution to brain functioning. Indeed, the vast number
and heterogeneity of neuronal interactions is sufficient to provide the structural
potential underlying the most complex and versatile aspects of human behaviour
(Lezak, 1983).
1.6.2. Macroanatomical Features of the Brain
At the earliest stage in its development, the human brain may be divided into
three anatomical structures: the hindbrain, the midbrain, and the forebrain (Gilman
and Newman, 1992). In structural terms, the brain areas farthest back on the
developing nervous system (the embryonic neural tube) are the most simply
organized (Lezak, 1983). Moreover, with regard to their functional role in the
nervous system, these are associated with the more primitive and often life-
maintaining functions of the brain.
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In the adult brain, the hindbrain represents the medulla oblongata (the centre
responsible for the nervous control of respiration, blood pressure, and heart beat), the
pons, and the cerebellum (together these other structures correlate information on
physical posture and body movement). Located forward of the hindbrain, the
midbrain contains further neural centres involved in the processing of sensory and
motor (movement) information. Situated frontal to the midbrain, the forebrain
presents a neural structure of vast anatomical complexity and versatility. The
forebrain, which may be divided into two large cerebral hemispheres and other
structures embedded deep within them (in particular, the thalamus and the
hypothalamus), forms the functionally most advanced as well as the most recently
developed part of the human brain (Gilman and Newman, 1992; Kolb and Whishaw,
1996). In contrast to the more primary functions mediated by the components of the
hind -and midbrain, the forebrain is the centre of the highest functions underlying
human behaviour (Lezak, 1983).
Collectively, the two cerebral hemispheres comprise by far the largest regions
of the adult brain, amounting to approximately 80% of the total brain volume (Kolb
and Whishaw, 1996). These are further made up of three principal features: the
cortex, the white matter underlying the cortex, and several deeply-located neural
centres called the basal ganglia, the hippocampus, and the amygdala (Mitchell and
Mayor, 1983). The deep centres, or nuclei, as such collections of neuronal cell bodies
deep within the brain are sometimes termed, serve important functions ranging from
the regulation ofmovement (the basal ganglia) to memory processing (the
hippocampus). The white matter under the cerebral cortex is made up ofmyelinated
axons which look white or pale yellow on visual inspection and extensively traverse
the brain. More specifically, these axonal projections (often in the form of bundles of
many axons grouped together) are found to carry nerve impulses between neurons
located in different cortical areas within the same hemisphere, between neurons in
the cortex and the deep nuclei, or between the two hemispheres. As a result, the
white matter may be seen as being responsible for the transmission of information
between different areas of the brain.
In the cerebral hemispheres, the cortex represents the outermost layer of the
brain. It is made up of four to six layers of neuronal cell bodies and their synaptic
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connections, and can be visually identified by its grey colour (often termed the grey
matter) (Mitchell and Mayor, 1983). In humans, the external surface of the cortex is
found to be highly convoluted, whereby grooves (sulci) separate the more elevated
ridges (gyri). Even though the exact location of specific gyri and sulci may vary
between the two hemispheres within the same individual, and between the brains of
different individuals, consistently present sulci have been used in dividing the cortex
into four areas or lobes that are named after the overlying cranial bones. Thus, the
cortex is frequently subdivided into the frontal, temporal, parietal, and the occipital
lobe (Kolb and Whishaw, 1996). The relationship of these regions with the
functional output of the brain is discussed in detail in section 1.6.4.
1.6.3. The Arterial Vasculature of the Brain
Due to its vast metabolic demand, the brain depends on an uninterrupted
blood supply which it receives from three major arterial systems: the right and left
internal carotid arteries and the vertebrobasilar system (Waxman, 1996). More
specifically, the vertebral arteries run upwards through the cervical vertebrae on each
side of the neck and enter the skull through the skull-base opening where they
eventually join to form the basilar artery which provides blood supply to the neural
substrates of both the hindbrain (pons and cerebellum) and the midbrain. Further on,
the basilar artery divides into two posterior cerebral arteries which irrigate the middle
part of the temporal lobe, most of the occipital lobe, and deeper sub-cortical areas.
The two internal carotid arteries constitute major arteries of the neck and the
head (Mitchell and Mayor, 1983). These arteries branch off the common carotid
artery which, on each side of the body, directly leads off from the aortic arch. The
internal carotids then ascend and enter the skull whereby they trifurcate into the
anterior and middle cerebral, and posterior communicating arteries. While the
anterior cerebral artery supplies blood to the middle portions of the cerebral cortex as
well as to the anterior part of frontal lobe, the middle cerebral artery, found to be the
largest of the three cerebral arteries, irrigates most of the frontal, parietal, and
temporal lobes. Smaller arteries also branch off the middle cerebral artery to
perforate the subcortical areas of the brain. The role of the posterior communicating
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artery is to connect the internal carotid and the middle cerebral arteries with the
posterior cerebral artery.
1.6.4. The Brain and Cognitive Function
As suggested earlier, the division of the cerebral cortex into lobes is based on
the visual presence of certain anatomical landmarks rather than specific structural or
functional characteristics. At least in broad terms, however, this distinction has been
found to provide a useful frame of reference for the localization of specific functions
in the brain (Lezak, 1983). This is possible because in the cerebral cortex, certain
functions have a primary or significant representation with enough regularity to be of
value in clinical practice and research. For example, the frontal lobe is found to be
involved in regulating and controlling intentions, and in programming and
monitoring complex behaviour (Lezak, 1983). It can be further divided into three
major functional zones, the motor cortex, the pre-motor cortex, and pre-frontal
cortex. Each of these provides a neural substrate for distinct functions (Kolb and
Whishaw, 1996). Much of the temporal lobe is involved in the processing of auditory
and visual information, such as auditory memory storage and the organization of
complex visuoperceptual information (Lezak, 1983). Within the temporal lobes,
deeply-placed structures such as the hippocampus play a major role in specific types
ofmemory functioning. Similarly, the parietal lobe may be divided into two
functionally distinct areas, the anterior and the posterior parietal cortex (Kolb and
Whishaw, 1996). Whereas the anterior part comprises the somatosensory cortex,
which is responsible for sensations such as touch and pressure, the posterior part is
concerned with processes related to spatial recognition, arithmetic, and reading.
Finally, the most posterior part of the cerebral hemisphere is the occipital lobe, which
is the site of the primary visual cortex (Lezak, 1983). As the name implies, the main
function of the occipital lobe is vision, and within this region, specialised anatomical
areas exist that are involved in the perception of form, movement, and colour (Kolb
and Whishaw, 1996).
To reiterate, some cerebral lobes are mostly or entirely concerned with
specific types of activity within the brain. In addition, most may also be further sub-
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divided into smaller units or areas which may sub-serve different kinds of functions,
and yet, the same lobal area may be involved in the processing of different
information depending on whether it is on the right or the left side of the brain
(Waxman, 1996). On the other hand, many aspects of brain functioning do not lend
themselves to be identified within clearly demarcated neuroanatomical boundaries
(Lezak, 1983). This applies especially to a wide range of complex or 'higher' cortical
processes (cognitive functions), such as reasoning and judgment, abstracting,
organizing, and planning, as well as specific aspects of these functions, all of which
are likely to depend on the functional integrity of the entire neural substrate rather
than on the intactness of discrete anatomical areas. In contrast, so-called 'lower'
cognitive activities, an example being processes involved in the storage and
recollection of information may be more easily correlated with underlying
neuroanatomical structures.
1.6.5. Structural and Behavioural Consequences of Brain Damage
Injury to the brain may result from a number of different causes which may
lead to short-term, intermediate, and long-term alterations in both brain structure and
neurocognitive function (Kolb and Whishaw, 1996). Precisely what changes take
place is likely to depend on many different factors. At the most fundamental level,
however, there is likely to be immediate death of individual neurons which
eventually may be replaced by a glial/connective tissue scar. Delayed neuronal death
also occurs and is thought to involve different or additional pathophysiological
mechanisms, including programmed cell death or apoptosis, which may continue for
up to weeks following the initial insult (Mazarakis et al, 1997). Brain injury can also
produce widespread physiological responses, which depending on the type of injury,
may lead to brain swelling, changes in tissue metabolism and blood flow, and
alterations in neurotransmitter release (Hacke et al., 1991). As a result, damage in
one cortical area may not only lead to death of neurons locally but can result in
temporary functional depression of other related areas in the brain; indeed, apoptosis
has been described in sites distant from the initial focal damage (Mazarakis et al,
1997). As a consequence of neuronal death and axonal wasting, even very distal
27
areas can undergo degeneration if they no longer remain connected and properly
stimulated by the damaged area. Degenerative changes of distal areas may continue
for months or years following the original insult.
The behavioural repercussions of damage to the brain will depend on a
number of factors, including the nature, extent, and duration of the insult (Lezak,
1983). In addition, the individual's personal (e.g. age and educational level) and
physical characteristics may further influence the observed pattern of cognitive
impairment. As reviewed in later sections, the pattern of ischaemic structural damage
and functional deficits is also likely to depend on which arteries are critically
affected with atherothrombotic disease, or the final lodging site of embolic material.
1.6.6. Assessment of Brain Structure and Function
A number ofmethods are available for assessing brain structure and function.
Largely for ethical and practical purposes, indirect methods of investigation tend to
be used in studying the living human brain (Lezak, 1983). On occasions, direct brain
examinations have been performed, either with surgery of neurological patients, or
more commonly, by using animal models. However, given the limitations of such
methods in generating comprehensive knowledge relevant to the normal human
brain, this text emphasizes the more frequently used indirect methods.
Of the various techniques used in examining the structure of the brain,
traditional radiography of the skull has been widely applied in clinical practice but
less in the research setting. Employed in visualizing the structure and intactness of
the cranial bones, some information about the intracranial anatomy can also be
obtained (Bradshaw, 1989). Other useful neuroradiographic methods include
pneumoencephalography (visualization of the spaces around and within the brain)
and angiography (visualization of the blood vessels in the brain). However, given the
invasive nature of these techniques, and the potential risks or complications
associated with their use, their application in research has been limited.
As modern neuroimaging began to develop in the early 1970s, a whole new
era in the investigation of the human nervous system began (Kolb and Whishaw,
1996). With the wide and rapid adoption of neuroimaging methods in both clinical
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and research settings, some of the older radiographic techniques were quickly
replaced by these newer inventions. In particular, the computerised tomography (CT)
allowed for the first time the creation of a visual representation of the brain
(Hounsfield, 1973). The method involves a rotating x-ray source that takes multiple
readings in a short period of time which are then translated by a computer into a
transaxial photographic slice of the brain. The CT technique has a variety of
applications, including the diagnosis of stroke, and in research of brain-behaviour
relationships.
Despite being based on an entirely different principle, the invention of the CT
contributed to the development ofmagnetic resonance imaging (MRI) during the
1980s (Bradshaw, 1989). As the name implies, MRI is based on measured changes in
the resonance of hydrogen atoms in the brain under a magnetic field. The detection
of radio waves emitted from these atoms allows the computation of images (even
three-dimensional) of considerably better quality and detail than that produced by a
normal CT scan. For example, MRI can provide information on specific
neuroanatomical structures, including cerebral vasculature, far beyond what CT is
capable of generating (Bradshaw, 1989). Unfortunately, the prohibitive cost ofMRI
has limited the number of population studies using this technique (Bradshaw, 1989).
Early methods for examining brain functioning include those that build on the
brain's electrochemical activity (Kolb and Whishaw, 1996). As already mentioned,
the activity of neurons has an electrochemical basis which may be recorded using
specialised equipment. For example, by placing a number of electrodes across the
scalp, small electrical changes in the underlying brain can be recorded and amplified
to produce an electroencephalogram (EEG) (Afifi and Bergman, 1998). Clinically,
EEG may be used to identify areas of brain pathology which are manifested as areas
of localized slowing of EEG activity (Woodruff-Pak, 1997). Similarly, so-called
event-related potentials (ERPs) represent short-lived changes in EEG signals in
response to a specific sensory task or stimulus, such as a brief noise. Prolonged
decision or processing time of any given task manifests itself as longer latencies of
certain ERP waves (notably the so-called P300 wave) (Woodruff-Pak, 1997).
For a number of decades, positron emission tomography, or PET, has been
employed in assessing the physiological response of the brain as it engages in
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cognition (Ramsey, 1987). This method is based on the idea that brain areas that are
active will become more radioactive than less active areas and thus emit more
positrons from radioactive isotopes ingested by the subject under study. Despite
important shortcomings, including its invasive nature, studies have successfully used
PET in elucidating brain mechanisms involved in age differences in cognitive
function (Woodruff-Pak, 1997). Another technique, the single-photon emission
computerised tomography, or SPECT, is based on the use of radioactive tracers
which emit photons for determining in vivo body tissue function (Rahmim, 2006).
Advances in detector technology and computing power have resulted in
improvements in the spatial resolution obtained in SPECT imaging of the brain.
However, in comparison to PET, as a technique, the SPECT is both less sensitive and
has a lower spatial resolution (Spencer et al, 1995). A further elaboration of the MRI
technique mentioned above is functional MR! (fMRI), which now is favoured over
PET because of its patient safety and high resolution images (Woodruff-Pak, 1997).
By detecting functionally-induced changes in blood oxygenation in specific areas of
the brain, the fMRI can provide unique insights into cerebral functioning.
Standardised tests and questionnaires have been widely developed and used
throughout the 20th century for assessing dimensions of human behaviour, especially
those involved in the acquisition, processing, storage, organization, and
communication of information. The emphasis on human cognitive processes may be
attributed to the relative ease with which different aspects ofmental function can be
conceptualized, measured, and sometimes correlated with underlying
neuroanatomical systems (Lezak, 1983). Indeed, on several occasions, currently
available tests and measures (commonly referred to as neuropsychological, cognitive,
or mental tests) have been derived and validated using comparisons between patients
with circumscribed brain lesions and normal controls (Woodruff-Pak, 1997).
Neuropsychological tests have been applied in diverse settings for assessing
patterns ofmental function. In a clinical context, cognitive testing may be carried out
in order to identify areas of strengths and weaknesses in intellectual capacity, to aid
the diagnosis of underlying neurological pathology, or to make recommendations for
treatment and care (Woodruff-Pak, 1997). Similarly, the goal of research may be to
determine aspects of cognition that are disproportionately affected either by normal
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ageing or some pathological process. However, whatever the purpose, a
comprehensive cognitive examination is likely to require the administration of
multiple neuropsychological measures since individual tests are normally designed to
assess a single major aspect or 'domain' of intellectual function.
The near-universal empirical finding that most representative mental tests
tend to show a positive covariation may be considered as putative evidence of a
common factor in all of the measured cognitive abilities (Jensen, 1998). In the early
20th century, Charles Spearman suggested the term g (short for general intelligence)
for this common factor (Spearman, 1904). His invention of the factor analytic
method allowed the determination of the degree to which each of the cognitive
measures correlated with (or loaded on) the general cognitive factor. More
specifically, the general intelligence factor may be defined as the first unrotated
principal component (or factor) from a battery of cognitive tests given to a study
sample (Deary and Batty, in press).
The subsequent accumulation of cognitive test data as well as further
sophistication of analytical techniques have preserved the central role of the general
intelligence factor but also resulted in its modern conception (Detterman, 2006). For
example, a hierarchy with the general factor at its apex and group factors (different
groups ofmental tests, each with similar task demands, may have these in common)
at successively lower levels is at present the most widely accepted model of human
cognitive abilities (Carroll, 1993). Further elaboration of the theoretical notion of the
hierarchical structure of cognitive abilities led to the proposal of two yet substantially
correlated aspects of general intelligence: fluid and crystallised abilities (Horn,
1994).
1.6.6. Structural and Functional Changes in Normal Ageing
Diverse changes in brain structure and function are thought to accompany
normal ageing. In older persons, these are reflected in a number of measurable
alterations in cerebral anatomy, physiology, and cognition (Raz, 2000). Although not
firmly established, influences of both hereditary and environmental factors are likely
to contribute to such observations. In particular, two major trends of structural and
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functional changes are commonly seen in the ageing brain: a selective preservation
and decline against a background of global changes (Raz, 2000).
Generalised alterations in brain structure are found at both the macro -and
microanatomical level (Duckett, 1991). For example, as people get older, the brain
decreases in both weight and volume. The latter is demonstrated by an expansion of
the spaces within the brain (ventricles) and an enlargement of cerebral sulci. The
reasons for these structural alterations are not clear but may possibly reflect changes
at the neuronal level, including reduction in the size and number of individual cells,
and in the number of connections with other neurons (a process termed dendritic
debranching) (Raz et al, 2005). Whereas it has been proposed that neuronal
shrinkage may be a more decisive age-related change than actual cell loss, alterations
in neuronal metabolism may also pose as a threat to the ageing brain (Stuart-
Hamilton, 1991).
As mentioned above, some areas of the brain may be relatively more affected
by the ageing process than others. For example, the cerebral cortex, and the
prefrontal cortex in particular, may be especially vulnerable to the effects of
biological ageing (Stuart-Hamilton, 1991; Raz, 2000). In comparison, age-related
influence on other neural structures may only be mild (e.g. the hippocampus) or all
together absent (i.e. parts of the hindbrain) (Raz, 2000). Further to changes in the
brain's grey matter, the underlying white matter may also undergo both a decrease in
total volume, which may be attributed to loss of neurons and demyelination. As with
the grey matter, however, the white matter changes are unlikely to be equally
distributed throughout the brain, and may in fact be restricted to certain cerebral
circuits and axonal sizes.
Further to leading to macroanatomical alterations in the brain, the changes
neurons go through as a part of biological ageing are also likely to be manifested in
altered physiological functioning (Duckett, 1991). For example, a slowing of the
dominant EEG wave rhythm with age is a well-documented finding even though it is
not clear what it means in behavioural terms (Woodruff-Pak, 1997). Similarly, P300
latencies also tend to increase with age, suggesting information processing time may
be slower in older persons (Stuart-Hamilton, 1991; Woodruff-Pak, 1997). More
specifically, however, slowing in processing speed may be attributed to the time
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taken for the person to respond to a given stimulus (reaction time) rather than
recognising it. This indicates that even within the domain of information processing
speed, not all components may be affected equally or in a global fashion by the
ageing process.
One fundamental reason for investigating age-related changes in brain
structure and physiology is to shed further light on the similarly-occurring alterations
in intellectual function (Raz, 2000). Thus, further to the relatively non-specific, age-
related slowing of reaction times, three major patterns are found to characterise the
process of cognitive ageing (see Salthouse, 1991 for review). First, supported by
abundant empirical evidence, it has been pointed out that different types of mental
functions may actually have different developmental trajectories which manifests as
a pattern of differential decline on neuropsychological measures (Baltes, 1987).
Indeed, specific cognitive processes, including reasoning, processing speed, working
memory, and spatial ability, collectively referred to as 'fluid' abilities, may be
particularly vulnerable to the effects of biological ageing but also neurological
damage (Anstey and Christensen, 2000). However, findings from studies on the
pattern of relations between age and cognitive measures representing distinct or
separate 'fluid' mental functions suggest that most of the age effects may in fact be
on the common factor or g and only a little on the factors specific to each of the
'fluid' cognitive tests (Salthouse, 2001). In other words, broad and relatively high-
order influences appear to play a major role in the age-related effects on a wide
variety of cognitive test variables. Although still open to debate, the commonality or
generality of neuropsychological processing represented by the common cognitive
factor may to a certain extent reflect the functional coordination and collaboration of
multiple higher cortical networks that depend on the total integrity of white matter
pathways linking diverse cortical and subcortical neuroanatomical regions (Newman
and Just, 2005). In this regard, general cognitive function as captured by g is unlikely
to be a single property of the underlying neural substratum (Detterman, 2006).
In contrast to the above, 'crystallised' functions, including general
knowledge, vocabulary, and arithmetic, may remain stable, or even improve, through
the influences of education and acculturation. Second, many of the intellectual
abilities that decline with age seem to do so in a gradual, linear manner, and there is
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in fact little indication of abrupt transitions from stable to declining cognitive
performance (Salthouse, 1991). Also, the process of cognitive ageing is marked by
significant individual differences in both the level of cognitive ability and rate of
decline. Indeed, depending on the cognitive outcome, chronological age has
generally been found to explain less than one sixth of the total variance in cognitive
test performance (which still may be substantial relative to the effects ofmany other
factors) (Salthouse, 1991). Recent empirical data have further demonstrated a
remarkable stability in individual differences in general intellectual ability over most
of the lifespan (Deary et al., 2000).
1.6.7. Subclinical Cognitive Impairment
As discussed above, vast individual differences in levels of intellectual ability
seem to accompany ageing. Characteristic of this spectrum of cognitive function in
old age is that fact that, whereas some elderly experience no or only minimal change,
others may deteriorate dramatically (Christensen, 2001). Moreover, in those who go
on to develop dementia, there is likely to be a long pre-clinical or transitional phase
of deterioration, which if amenable to intervention, may form a target for strategies
aimed at either delaying or even preventing further decline and cognitive impairment
(Bischkopf et ah, 2002).
Over the past decades, several attempts have been made to describe the pre¬
clinical stage between normal cognitive ageing and dementia, which among other
things, is reflected in the use of a somewhat confusing terminology. Thus, among the
earliest descriptions of this intermediate period was 'Benign Senescent
Forgetfulncss' (BSF), which in fact was thought to be a variant of normal ageing
rather than a distinct pathological entity (Petersen, 2004). This term was later
followed by other but related concepts, including 'Age-Associated Memory
Impairment' (AAMI), 'Age-Consistent Memory Impairment' (ACMI), and 'Ageing-
Associated Cognitive Decline' (AACD), all of which tend to view cognitive
impairment short of dementia to fall within the range of normal ageing (Bischkopf et
al., 2002; Ritchie et al., 2001). Further conceptualizations of dementing disorders as
disease processes, rather than the consequence of biological ageing, have stimulated
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the development of other categories, including 'Mild Cognitive Disorder' (MCD),
'Mild Neurocognitive Disorder' (MND), 'Cognitive Impairment, No Dementia'
(CIND), and 'Mild Cognitive Impairment' (MCI) (Davis and Rockwood, 2004). In
contrast to the previous concepts, these latter categories are assumed to be pathology-
based and therefore amenable to treatment or prevention (Ritchie et al., 2001).
Relative to the other descriptions proposed above, MCI has widely been
favoured as a diagnostic entity of subclinical cognitive impairment (Davis and
Rockwood, 2004). Whereas the concept assumes a continuum between normal
cognitive function and dementia of Alzheimer's type (AD) in particular, no single
definition currently exists for MCI. In general, MCI is thought to refer to a group of
individuals who have some cognitive impairment but of inadequate severity to meet
diagnostic criteria for dementia (Petersen, 2004). Specifically, MCI was originally
proposed if the following were present: 1) a memory complaint, preferably
confirmed by an informant; 2) an objective memory impairment for age; 3) a relative
preservation of other cognitive functions; 4) intact activities of daily living; and 5) no
dementia (Petersen, 2004). Even though further expansions and refinements of the
original diagnostic criteria have subsequently been undertaken (Portet et al., 2006),
resulting in a shift from an emphasis on memory deficits to a focus on the general
impact ofmild dysfunction, the modified version continues to highlight the role of
neuropsychological testing in the diagnosis ofMCI.
As a part of the refinement of the original MCI concept, further sub-
classification of the term has been carried out. The main reason for this breakdown in
MCI is the fact that, whereas an increased progression to AD in MCI has been
acknowledged, a substantial heterogeneity with respect to progression (not all MCI
patients actually go on to develop AD) can be observed in many individuals with
MCI (Davis and Rockwood, 2004). Thus, based on the type of neuropsychological
profile, the following three clinical subsets ofMCI, each of which may have different
aetiological origins (and thus paths of progression), have subsequently been
generated: 1) Amnestic MCI, which predominantly may lead to AD; 2) MCI with
slight impairment in multiple domains, which may represent normal ageing, or
progress to either AD or vascular dementia (VaD); and 3) MCI with impairment of a
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single cognitive domain other than memory, which may progress to various
outcomes other than specifically AD (Petersen, 2004; Portet et al., 2006).
More recently, the term 'vascular cognitive impairment' was proposed to
refer to all forms of mild to severe cognitive impairment associated with and
presumed to be the result of cerebrovascular morbidity (O'Brien et al., 2003). The
concept is, however, broad and there is much need for further refinement and
identification of appropriate subtypes of vascular-based cognitive dysfunction.
Reviewers of studies of the prevalence and incidence of subclinical cognitive
impairment have noted vast inconsistencies in findings across reports (Bischkopf et
al., 2002). In particular, prevalence estimates differ greatly between studies due to
different definitional criteria as well as different sampling and assessment
procedures. As a result, findings are conflicting with respect to whether there is a
continuous increase in the prevalence of cognitive impairment with age, and whether
the estimates vary according to sex. Similarly, a comparison of incidence rates across
studies is challenging due to an overall paucity of studies, differences in diagnostic
criteria, sample structure, length of follow-up and cognitive measures. Thus, a
steadily higher incidence of subclinical cognitive dysfunction with age, and among
men, has been reported in some investigations (Bischkopf et al., 2002) but not others
(Solfrizzi et al., 2004).
In an identical manner, data on the rate of conversion to dementia have been
found to vary substantially between studies for similar reasons as above (Bischkopf
et al., 2002). Of note is that the conversion rates to dementia seem to depend more on
the diagnostic constructs used for subclinical cognitive impairment than any other
factor, including the patient's age. For example, whereas studies using diagnostic
criteria for BSF, AAMI, or MCD, have generally reported annual conversion rates to
dementia or AD of less than 10%, somewhat higher rates have been observed in
investigations where criteria for either AACD or MCI have been applied.
1.6.8. Dementia
Further deterioration in cognitive function may lead to dementia, which
relative to normal levels of intellectual function, may be placed on the opposite end
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of the cognitive continuum. Dementia is not a single disease but refers to a syndrome
that is characterized by a chronic or progressive deterioration in cortical and
subcortical function that results in complex cognitive impairment (Ritchie and
Lovestone, 2002; van der Flier and Scheltens, 2005). Moreover, diverse disturbances
ofmood, behaviour, and personality both frequently accompany as well as contribute
to the dementia syndrome (Ritchie and Lovestone, 2002). Dementia is found to be of
major public health importance as it is one of the most common diseases in the
elderly and a major cause of disability, increased dependency, and death (Berr et ah,
2005).
A wide variety of disease states may give rise to the clinical characteristics of
dementia (Graves, 2004). Traditionally, the most common cause of dementia is AD,
which typically begins with difficulty recalling recently learned material only to
progress on to further loss ofmemory and decrements in various other cognitive and
functional abilities. Although validated criteria have been developed for the clinical
diagnosis ofAD, the clinical evaluation is not definitive and needs to be
supplemented with evidence of neuropathologic signs (the presence of neuritic
plaques and neurofibrillary tangles in the brain is thought to be the hallmark of the
AD pathology) at autopsy (Graves, 2004). In general, however, the accuracy
(positive predictive value) of different clinical criteria for AD is found to be
reasonably high (above 80%) when compared to a neuropathologic diagnosis
(Graves, 2004).
A major form of non-AD type dementia is that of vascular origin. Possibly
being an underestimation, the high prevalence ofVaD in the older population is
thought to be a reflection of the vast burden of cardiovascular disease in the elderly
(Roman, 2002). In particular, VaD was originally considered to arise from a series of
discrete cerebral infarcts (the term multi-infarct dementia had been proposed),
leading to a stepwise deterioration and deficits in frontal lobe executive function
rather than predominantly in memory (Looi and Sachdev, 1999; Rockwood, 2002).
However, it has become increasingly recognized that VaD may result from a wide
variety of vascular lesions, including large -and small-vessel disease of extra -and
intra-cranial arteries (van der Flier and Scheltens, 2005). Because of the
heterogeneous nature of the vascular pathology underlying VaD, no single set of
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clinical criteria have become universally accepted for its diagnosis (Graves, 2004).
Currently, the clinical diagnosis ofVaD is based on patients having to fulfill criteria
for 'dementia' and present evidence of cerebrovascular disease. Whilst this approach
to the diagnosis of VaD is likely to be overly biased towards AD, emphasizing
memory loss and progressive, irreversible decline as the primary symptoms
(Rockwood, 2002), a clear separation between AD and VaD may not be possible in
epidemiological investigations (van der Flier and Schcltens, 2005). A further
complication to the study of specific dementia subtypes is the fact that different
forms of the disease, such as AD and VaD, frequently co-exist in the same patient
(referred to as mixed dementia) and possibly also sharing underlying risk factors and
neuropathological features (Ritchie and Lovestone, 2002).
A number of studies have reported on the prevalence and incidence of AD
and VaD according to clinical criteria alone and without neuropathologic
confirmation. On other occasions, dementia as a whole has been the main focus of
study. Based on such data, and despite the use of different methodologies for case
identification and definition between studies, the prevalence and incidence of
dementia has generally been found to increase steeply with age (Graves, 2004). For
example, in an analysis of data from several European countries, the prevalence of
dementia ranged from 1.2% to 4.7% among those 65-74 years of age, between 4.5%
and 18.3% among those 75-84 years of age, and from 11.5% to 39.0% in those aged
85 years or above (Berr et al., 2005). An age-related trend in dementia prevalence
was observed for both sexes. Similarly, among participants in the Cardiovascular
Health Study, a steady increase in the incidence of dementia with age was noted in
both men and women (Fitzpatrick et ah, 2004). Whereas further analyses
demonstrated a steep increase in the incidence of both AD and VaD with age, the
incidence rates varied neither with sex or race. As discussed by Graves (2004),
although several studies have similarly failed to find any gender differences in AD
risk, there is evidence that women may be at an increased risk ofAD. Even though
the two genders may be at equal risk for developing AD pathology, generally lower
education, social status, smaller head circumference and lower circulating levels of




Cardiovascular Diseases, Risk Factors and Cognitive Function
2.1. LITERATURE SEARCH STRATEGY
For the purpose of the present study the following bibliographic databases
were comprehensively searched for relevant studies: MEDLINE (is the U.S. National
Library of Medicine's premier bibliographic database that contains over 12 million
references to journal articles in life sciences with a concentration on biomedicine
dating back to 1966), EMBASE (a bibliographic database covering the worldwide
literature on biomedical and pharmaceutical fields. It is published by Elsevier
Science NY, the world's largest publisher of scientific information and its content
covers information from 1974 to the present), and psycINFO (contains citations and
summaries in the field of psychology and psychological aspects of medicine,
psychiatry etc. Journal coverage, from 1887 to the present, includes international
material selected from more than 1,300 journals written in over 25 languages. Over
55,000 references are added annually through regular updates). In addition, the
following sources were used for identifying further research material: a) reference
sections of studies identified through bibliographic search of the above databases, b)
reference sections of relevant book chapters in Neuropsychology of Cardiovascular
Disease (Waldstein SR and Elias MF (Eds). New Jersey: Lawrence Erlbaum
Associates, Publishers, 2001), c) reference sections of relevant book chapters in
Medical Neuropsychology (Tarter RE, Butters M and Beers SR (Eds). Luwer
Academic/Plenum, Publishers, 2001), d) the reference section ofNeuropsychological
Function in Patients with Peripheral Vascular Disease (Unpublished doctoral
dissertation, Dalhousie University, Halifax, Nova Scotia, Canada), and e) the
reference section of Risk Factors for Dementia and Cognitive Decline (NHS Health
of Scotland source document compiled by Gow J and Gilhooly M, October 2003).
In particular, MEDLINE was searched from 1966 to present (September
2005). Similarly, EMBASE was searched from 1980 to present. The psycINFO
database was searched from 1990 to present. The literature search was limited to
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research material published in the English language. As an example of the search
terms and combination of terms used, the following search string was generated for
identifying published studies in MEDLINE on the association between CHD and
cognitive function:
("coronary heart disease " OR "coronary artery disease " OR "heart disease " OR
"anginapectoris" OR "myocardial infarction" OR "heart attack") AND
("neuropsycholog$ " OR "cognitivefunctions " OR "cognitive performance " OR
"cognitive decline" OR "cognitive change" OR "cognitive impairment").
All studies identified through the above methods were entered and stored
using bibliographic computer software. Given the relative scarcity of studies in this
field, criteria for the inclusion/exclusion of studies were kept necessarily broad. As a
result, the following prc-determined criteria had to be met in order for the CVD and
vascular risk factor-based studies to be included in the present review: a)
observational epidemiological design (i.e. cross-sectional, case-control, cohort), b)
structured neuropsychological test (rather than solely clinical evaluation of cognitive
impairment/dementia), c) sample based on adult subjects (middle-aged or older) at
the time of (follow-up) cognitive testing. The subsequent appraisal (particularly that
focusing on the potential validity of the reported results and the role of chance, bias,
and confounding as alternative explanations) of individual reports was in line with
suggested criteria for the evaluation of published epidemiological studies (Fowkes
and Fulton, 1991).
2.2. COGNITIVE FUNCTION AND STROKE
2.2.1. Introduction
Diverse neurological symptoms may occur following the cessation of blood
flow to the brain. Specifically, both long-lasting sensorimotor and behavioural (e.g.
language) disturbances are frequently observed in the aftermath of acute cerebral
ischaemia. Moreover, it is well recognised that either a single major or repeated
strokes may increase the risk of mild to severe cognitive impairment, hence the term
multi-infarct or vascular dementia. In contrast, until recently, reviewers have noted a
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relative paucity of research into the frequency, severity, and patterns, of
neuropsychological deficits in relation to stroke as a clinical entity.
The present chapter provides a review of studies investigating the relationship
between stroke and cognitive function. In particular, an attempt is made to answer
the following questions: is stroke negatively associated with performance on
neuropsychological tests? If so, do stroke patients show a generalised pattern of
cognitive impairment or are certain aspects of cognition more affected than others?
Also, does stroke predict decline in cognitive test performance? In recognition of the
pathological and clinical diversity of stroke, a further review is offered on findings
from studies examining the influence of these and specific patient characteristics on
post-stroke cognitive function. Lastly, a methodological discussion of current studies
is provided. An overview of the reports reviewed in the text is provided in appendix
A-l.
2.2.2. Mechanisms ofNeurocognitive Dysfunction and Stroke
As already highlighted in the text, the behavioural sequelae of stroke are
likely to be associated with many factors, not least its location within the nervous
system. In the brain, ischaemic stroke may be confined to the cerebral cortex, the
underlying white matter, or both (Merino and Hachinski, 2001). Large-vessel
atherosclerosis of intra and extracranial arteries may lead to cerebral hypoperfusion
and commonly results in artery-to-artery embolic stroke. Even though the
differentiation between an embolic and non-embolic ischaemic stroke may be
difficult, embolism may be inferred where, in the absence of an identifiable
cardiogenic source and complete carotid occlusion, there is onset of non-progressive,
rapid symptoms of cortical dysfunction that depend on the area affected (depressed
consciousness may also occur). For instance, infarction of the area supplied by the
anterior cerebral artery may result in defects in prefrontal lobe function, including
perseveration and disturbed temporal memory (Kolb and Whishaw, 1996). Similarly,
an ischaemic injury to the territory supplied by the middle cerebral artery, the largest
of the three cerebral arteries, may present as deficits in frontal, temporal, or parietal
lobe function. Thus, very heterogeneous behavioural effects may be seen, ranging
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from contralateral disturbances in sensorimotor functioning, impairment in language
ability (left-sided lesions), to apraxia and impaired spatial ability. Finally, ischaemia
in the area supplied by the posterior cerebral artery may manifest as inability in
reading and in naming objects.
Ischaemic damage to the sub-cortical white matter may arise from
atherosclerotic occlusion of the origin of small perforator vessels of the brain
(Merino and Hachinski, 2001). Without intact white matter connections, cortical as
well as deeply-located neural areas are unlikely to fulfil their functional role.
2.2.3. Frequency of Cognitive Impairment, Patterns of Cognitive Function, and Stroke
Evidence from clinic-based samples
To date, the majority of reports of the association of stroke with cognitive
function in older adults have been based on samples of consecutively admitted
hospital patients. In different studies, the cognitive assessment has been carried out at
variable time-points following the event. On a number of occasions, performance on
global cognitive tasks has been used in estimating the degree of generalised cognitive
dysfunction in these patients. Alternatively, established diagnostic criteria or
composite test scores have been employed, whereby performance below a certain
cut-off level has been used to denote cognitive impairment. Based on such data, there
is evidence to suggest that as much as over one third of patients may experience
deficits in global cognitive function at various time points after stroke. For example,
Ballard et al. (2002) found approximately 32% of 150 elderly stroke patients, aged
75 years and older, to meet diagnostic criteria for "Cognitive Impairment No
Dementia (CIND) three months after stroke. All patients, who were recruited from a
hospital-based stroke register, were considered free of dementia at the time of
cognitive testing (according to DSM-IV criteria), as well as without disabilities such
as aphasia and hemiparesis. In an early study by Tatemichi and colleagues (1994),
over 35% of elderly patients were found cognitively impaired at three months, based
on their performance below the fifth percentile of the residual scores of controls on
four or more cognitive measures. In comparison, only 3.8% of controls were
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cognitively impaired when age, sex, race, and education, were statistically controlled
for. Importantly, in the light of the fact that a number of abilities, including vigilance,
language, attention, and sensory and motor skills, may be acutely depressed
following stroke, and thus potentially affecting patients' early cognitive test
performance, both studies used an interval of three months from the onset of stroke
to the time of cognitive assessment.
The timing of cognitive assessment may have implications for the
longitudinal study of cognitive function after stroke, since by testing patients early
post-stroke, greater improvements in global function may be observed over time. In a
report by Rasquin et al. (2004), 44.3% of 196 elderly patients (mean age of 68.5
years) were defined as cognitively impaired one month after a first-ever stroke.
Cognitive impairment was defined as a baseline CAMCOG score below the 10th
percentile of the performance of a population-derived control group, matched on age,
sex, and level of education. At six months post-stroke, however, 33.5% of patients
still had cognitive impairment. Still later, at 12-month follow-up, an almost identical
proportion of patients (33.8%) were found to have global cognitive impairment.
Whereas selective participation at follow-up cannot be excluded, no baseline
differences in mean MMSE (Mini-Mental State Examination) scores were found
between subjects who continued in the study and those who did not (about 20% of
patients).
Further evidence was provided in a study by Ballard and colleagues (2003).
In contrast to the previous one, which examined the proportion showing impairment
at different time points, this study analysed the actual intra-individual change in test
scores over the follow-up period. Based on a sample of 115 very old stroke patients,
recruited from a hospital-based stroke register, the investigators showed that 31% of
patients experienced a drop in mean MMSE scores, from 26.6 to 24.1. Conversely,
57% had an increase in MMSE scores (mean increase of 2.2 points, from 24.6 to
26.8). Moreover, of those who demonstrated an increase, 18 subjects actually had an
increase ofmore than 2.2 points. However, the remaining 36 subjects had modest
increases of 1 or 2 points. All in all, 76% of these very old stroke patients remained
stable over the follow-up period, that is, neither improved nor declined.
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The use of specific cognitive tests has provided data on the pattern of
neuropsychology in stroke patients. Particularly in the early stages after acute stroke,
very high rates of impairment have been observed across different cognitive
domains. For example, in a study by Riepe et al. (2004), approximately 77% of 209
elderly ischaemic stroke patients, who were tested within 24 hours of admission,
were found to be impaired in concentration and working memory, while 73% scored
below the cut-off score for impairment in total memory (both free and cued recall of
four items was assessed). Moreover, about 45% had impairment in the ability to
name objects presented on pictures (11 of 12 items was defined as cut-off); 25%
were impaired on the 'orientation subscale' (patients needed to answer at least 7 of 8
questions regarding person, time, and place) of the Alzheimer's Disease Assessment
Scale (ADAScog). Thus, early in the aftermath of stroke, a high percentage of
patients may fall below defined criteria for impairment on apparently simple
cognitive tasks, taking only a few minutes to complete. However, since patients were
assessed within hours of stroke onset, potential confounding by acute post-stroke
confusional state or sensorimotor deficits cannot be ruled out. Even though a further
three-month examination suggested the persistence of cognitive deficits across all
domains apart from orientation, the validity of the data may be questioned since
complete data were available for less than 25% of the baseline sample.
In another study, Hochstenbach et al. (1998) found up to 70% of 229
consecutively admitted elderly stroke patients to be impaired in attention and
information processing ability when clinical criteria for impairment were used
(defined as a score below the 15th percentile of the performance score of a group of
33 healthy controls, comprising the patients' spouses and community recruits). With
respect to attention, these are substantially higher rates than in the study reviewed
previously, and may partly depend on the more sensitive instruments used in this
analysis. In addition, when more rigorous statistical criteria were applied (defined as
performance greater or less than 2 standard deviations of that of controls), almost
50% of patients still had impairment in these same functions. Similar rates of
impairment were observed for visuospatial and constructive skills, but memory
functions, and particularly those involving short-term recall of verbal material,
seemed to be less affected.
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Even though a majority of stroke patients may show impairment across
cognitive domains, some functions may be relatively less affected than others.
Moreover, this pattern may become more evident as the time interval between the
onset of stroke and cognitive testing increases. In this respect, the two studies above
were found to differ substantially. Whereas in the former study patients were
cognitively tested within 24 hours of admission for acute stroke, in the latter, in
which relatively few stroke patients had impaired memory, the average interval
between stroke and cognitive testing was approximately two months. Further
supporting evidence come from a recent analysis of the Goteborg 70+ Stroke Study
in which 149 non-demented elderly participants were cognitively assessed 20 months
after an index stroke (Linden et al., 2004). In comparison to age-matched community
controls, approximately 17% of patients were found to be impaired in non-verbal
mental abilities as assessed by the ADAScog. In comparison, less than 9.0% of
controls had deficits in these domains. However, whereas more stroke patients
(5.6%) than controls (2.2%) had impaired memory (based on items assessing short,
intermediate, and long-term memory), the proportion having impairment in memory
function was substantially lower than that noted for the other cognitive domains.
The collection of longitudinal data on neuropsychological test performance
has provided valuable insights into the long-term cognitive outcomes following
stroke. However, so far, these have both been limited in number and resulted in
mixed findings. For example, Rasquin et al. (2002) showed how 52.1% of 139
elderly first-ever stroke patients, cognitively assessed one and six months post-
stroke, improved by more than 10 points in total verbal memory score over the five-
month study period. In comparison, 37.6% remained stable and 10.3% declined by
the same amount. Importantly, only 22.2% of the patients were considered impaired
in memory at baseline, a substantially lower proportion than was found to be
impaired in either information processing speed or cognitive flexibility (49.6% and
45.8%, respectively). Moreover, relative to those with memory deficits, fewer
patients who were impaired in these functions improved (37.2% and 41.8%,
respectively) and more declined (12.4% and 13.6%, respectively).
In a subsequent study by Rasquin et al. (2004), already described earlier in
the text, similar patterns as above were observed. In this study, the proportion of
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patients showing impairment in verbal memory was reduced by 36.9% over the one-
year study period. In comparison, the proportion of patients having deficits in
executive functions, non-verbal ability, cognitive speed, and attention, decreased by
30.8%, 28.2%, 17.9%, and 4.4%, respectively. In stark contrast to these findings,
Sachdev et al. (2004) failed to find any evidence in support of preservation of
memory functions in a sample of 123 elderly stroke/TIA patients. In fact, by
examining the one-year individual change in cognitive scores, stroke patients were
found to have significantly steeper decline in both verbal memory and
visuoconstructive ability scores relative to 78 community controls. Importantly, the
analysis controlled for age, education, and MMSE score at baseline, and the size of
effects was found to be equivalent to that of 14 and 21% of a standard deviation,
respectively. However, perhaps somewhat surprisingly, and in further contrast to
previous findings, stroke patients did not decline at a greater in information
processing speed, attention, non-verbal reasoning, or executive control function,
compared to healthy controls.
Evidence from population samples
Studies of the cognitive performance of community-recruited stroke survivors
suggest impairment may be frequent in individuals who generally may be considered
as having milder stroke pathology compared to hospitalised patients. Thus, Patel et
al. (2002) found 38% of 248 elderly patients to score less than 24 on the MMSE
three months after a first-ever stroke. Zhu and associates (1998) had shown earlier
that the presence of stroke was associated with significantly increased odds of
cognitive impairment, also defined as an MMSE score less than 24, in a study of
1810 community-based residents, aged 75 years and older. Specifically, when
statistically controlling for potential confounding by age, sex, education, systolic
blood pressure, antihypertensive use, and heart disease (ICD-8 codes 390-429), the
association between stroke and global cognitive impairment persisted (OR=2.4). In
approximately 58% of stroke patients, the index event had occurred more than three
years prior to cognitive testing (in 37.9% and 14.4% of patients, the index stroke had
taken place more than five and 10 years earlier, respectively).
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In addition to reduced performance levels, stroke subjects may also be at an
increased risk of decline in global cognitive function as demonstrated by Kalmijn et
al. (1996), who found elderly male stroke subjects in the Zutphen Elderly Study at
4.3 times increased odds of having declined over three years (1990 to 1993). The
effects were independent of age, education, and baseline MMSE test scores. These
results are probably an underestimation of the true effect size because of the selective
follow-up participation of subjects who both had higher MMSE scores and were less
likely to report history of stroke at baseline. Further underestimation of the true
effects is likely to stem from the fact that non-stroke TIA subjects, as opposed to
stroke survivors only, were included in the study. In the Framingham Study (Kase et
al., 1998), a group of 74 first-ever incident stroke patients was found to score slightly
less on the MMSE at baseline relative to stroke-free controls (mean MMSE score of
27.3 versus 28.1). At six months post-stroke, the differences between patients and
controls had become even more pronounced (those with stroke had a mean score of
23.6 compared to 28.3 of controls). Whereas the comparison was matched for age
and education, the study did not control for either baseline differences in baseline
MMSE performance or risk factors for stroke. This would, however, have been
necessary in order to accurately assess differences in rates of decline, particularly
given the fact that the patients' cognition levels were already compromised at
baseline (pre-stroke). Moreover, by this time, the stroke subjects also possessed a
significantly more unfavourable 'stroke risk profile', expressed as the 10-year
probability of having stroke.
In most of the population-based stroke studies to date, there has been a trade¬
off between using a large sample size, and thus providing adequate statistical power,
and the ability to gather comprehensive neuropsychological test data. Limited
empirical information currently exists with respect to the extent and patterns of
domain-specific cognitive impairment in survivors of stroke. Moreover, on several
occasions, these have proved to be contradictory across studies. Specifically, whereas
some studies have shown greater levels of deficits in specific cognitive domains in
subjects with stroke, other investigations have failed to provide evidence in support
of this. For example, a cross-sectional study by Srikanth and colleagues (2003) found
no statistically significant differences in mean cognitive test scores at three months,
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when 99 non-aphasic, first-ever stroke survivors were compared to 99 age -and sex-
matched community-derived stroke-free subjects. This was despite the inclusion of
people with both definite ischaemic and haemorrhagic stroke (those with
TIA/possible stroke were excluded). Relative to controls, however, the stroke
patients had 50% increased odds of impairment in any cognitive domain (defined as
a more than one domain-specific test score below one standard deviation of the
performance of controls), which was primarily attributed to deficits in a single, rather
than multiple, cognitive function.
Similar findings were reported for 1224 older adults in the Longitudinal
Aging Study Amsterdam (LASA), who were cognitively tested on two separate
occasions, at baseline and three years later (Dik et al., 2000). When compared to
stroke-free subjects, and adjusting for age, sex, education, and baseline test
performance, patients with stroke did not show on average a faster decline in either
immediate or delayed verbal memory, or information processing speed. Identical
results were observed when the odds of three-year decline in the above functions
were compared in patients and controls.
Particularly with respect to cognitive speed, the above results contrast with
that of an earlier report from the Cardiovascular Health Study (CHS) (Haan et ah,
1999). In this investigation, elderly subjects with prevalent stroke declined faster
over a period of seven years in mean Digit Symbol Test scores, relative to stroke-free
participants (-1.96 points compared to -0.28). This analysis controlled for age, sex,
race, education, and incident stroke, and similar effects of stroke were seen for the
MMSE (-4.47 points versus -0.64). Whereas the sample size of 5888 subjects was
considerably larger than that used in the studies described previously, the follow-up
period was also substantially longer. However, tasks assessing other cognitive
domains, including aspects ofmemory functions, were not administered in this study.
2.2.4. Stroke Characteristics and Cognitive Function
As reported in the previous section, impaired performance on both global and
domain-specific cognitive tasks may frequently be observed in stroke patients. Both
clinical and population-based investigations have, however, also demonstrated that
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not all patients are likely to show impairment in mental function. But even under
such circumstances, a substantial proportion of stroke patients may still experience
some recovery in neuropsychological function with time. In this respect, it is possible
that the pathological heterogeneity of the event may have important prognostic
implications regarding the level and progression of cognitive dysfunction following
acute stroke.
On the whole, relatively few reports have examined the prognostic impact of
different anatomical features of stroke on cognitive performance. Despite the
challenges in accurately classifying stroke according to subtype and pathological
characteristics, several studies have provided data on some aspects of the type of
stroke, its laterality, location, and/or lesion size. The overall scarcity of reports has
hindered the synthesis of findings from such studies, which in addition are frequently
found to contradict each other. In particular, it is not clear whether stroke type is
associated with greater or lesser degree of cognitive impairment following such an
event. For example, Patel and colleagues (2003) found no effects of stroke type,
based on the Oxfordshire Community Stroke Project (OCSP) Classification, on the
proportion of patients showing recovery from MMSE-based cognitive impairment
over a period from three months to one year post-stroke. Similarly, no differences
with regard to stroke type were reported in a clinic-based study of 237 stroke patients
(180 with ischaemic stroke and 57 with haemorrhagic stroke), in which those with
memory deficits were compared to those without such impairment (Madureira et al.,
2001). Moreover, when the analysis was extended to stroke patients with any
cognitive dysfunction, relative to those without such deficits, no differences with
regard to stroke type were noted. In contrast to these null findings, Zhou et al. (2005)
demonstrated that, compared to elderly stroke subjects who were found cognitively
intact at three-months post-stroke (based on MMSE performance), those with
impairment were more likely to have had embolic cerebral infarction. Of the 70
ischaemic stroke patients in the Framingham Study (Kase et al., 1998), those with
thrombotic non-lacunar or cardioembolic stroke were found to experience a faster
decline in MMSE scores relative to lacunar stroke patients (4.0 and 4.4 versus 1.4
MMSE points, respectively). The differences failed, however, to reach statistical
significance.
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Further to the above, Hochstenbach et al. (1998) divided cognitive tests into
two clusters according to whether a verbal or non-verbal response was needed in
order to complete the tasks. The verbal cluster contained tests such as the AVLT,
WAIS similarities, and a test of verbal fluency, while the non-verbal part included
the WAIS Digit Symbol Test, Digit Span, Block Design, and clock drawing. Using a
summary score for each data cluster, no multivariate effects of stroke type were
found for the verbal scores, whereas cerebral infarction, rather than haemorrhagic
stroke, was associated with a better non-verbal performance. However, since these
effects were attributed to better performance on only three out of 17 tests, further
research was suggested by the authors in order to clarify whether stroke type actually
makes a difference for the prognosis of post-stroke cognitive impairment.
Similarly, stroke laterality has been studied in relation to post-stroke
cognitive function in several investigations, and even though in a majority of
investigations dominant hemispheric stroke has been found to be associated with
poorer cognitive outcomes, not all studies have reached such a conclusion. Thus, in
the aforementioned study by Patel et al. (2002), both bilateral and left hemispheric
stroke was associated with greater prevalence of cognitive impairment three months
post-stroke. This was also demonstrated by Zhou et al. (2005), and in an earlier study
of 227 elderly stroke patients, left-sided stroke, relative to either non-dominant or
vertebrobasilar stroke, was related to greater impairment in cognitive function
(defined as a performance score on four or more cognitive tests below the fifth
percentile of that of demographically-matched controls) (Tatemichi et al., 1994).
Similarly, the Framingham study showed that patients with left-sided stroke declined
at a greater rate in global cognitive scores in comparison to non-dominant stroke
patients (4.38 versus 1.65 MMSE points), albeit the difference did not reach
statistical significance. Hochstenbach et al. (1998) noted moreover that left-sided
stroke was associated with worse performance in cognitive abilities requiring both
verbal as well as non-verbal response. This finding suggests that even though the left
hemisphere is considered dominant for language and intellectual functions, a wide
range of non-verbal disturbances in mental function can also arise from damage to
specific left-sided cerebral structures and associated neural connections.
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In contrast to these results, Desmond et al. (1996) compared ischaemic stroke
patients who had improved (defined as increase in composite cognitive score ofmore
than two standard deviations above the mean first annual control group change) to
those who had not shown improvement over a nine-month period following stroke.
In this study, improvement was found to be significantly related to left hemispheric
infarction relative to either right hemispheric or vertebrobasilar stroke. In a similar
vein, Patel et al. (2003) observed less cognitive recovery in left-sided stroke patients,
but a comparison with those with right hemispheric stroke turned out to be non¬
significant. In the study by Madureira and colleagues (2001), dominant hemispheric
stroke was found to be more common in stroke patients with memory deficits,
compared to those without, whereas any cognitive deficit was noted to be more
frequent in right hemispheric stroke patients.
In comparison to the data available on both stroke type and laterality,
substantially less information is available on other aspects of the event in studies of
cognitive function post-stroke. However, based on findings from only a few studies,
stroke severity seems to be associated with poorer cognitive outcomes. For example,
Tatemichi et al. (1994) found that large lesions, independent of laterality, were
associated with greater frequency of cognitive impairment three months post-stroke.
Also, anterior (frontal/medial lobes) and posterior (parietal/occipital/temporal lobes)
arterial infarcts were related to more global cognitive impairment than
vertebrobasilar (brain stem/cerebellum) arterial strokes. In the Framingham study,
Kase et al. (1998) observed steeper decline in global function in patients presenting
with large infarcts, involving more than one half of a cerebral lobe. In contrast,
neither the location nor severity, or the number of infarcts and the interval from
stroke to cognitive testing, were related to either verbal or non-verbal cognitive
abilities in the study by Hochstenbach et al. (1998). In another study, Madureira and
colleagues (2001) found cortical lesions to be more frequent in stroke patients
demonstrating any deficits in level of cognitive function.
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2.2.5. Personal Characteristics and Post-Stroke Cognitive Function
In addition to the impact of the pathological features of stroke, the cognitive
outcome following such an event may also depend on certain personal characteristics
of the individual in whom the stroke occurs. The identification of such patient-based
factors has been considered important because they indicate that particular traits or
health states present before the onset of stroke may affect a patient's susceptibility to
cognitive impairment when it eventually takes place (Elkins et al., 2005).
In this context, the patient's age at the time of stroke has been found to
influence both the likelihood of cognitive impairment and the degree of recovery
following such an event. For example, MMSE-defined cognitive impairment at three
months was more frequently observed in older stroke patients in univariate analyses
by Patel et al. (2002) and Zhou et al. (2005). However, whereas multivariate effects
of age on cognitive impairment were noted by Zhou and colleagues (2005), the
former study failed to demonstrate such effects (Patel et al., 2002). Moreover, in a
study by Tham et al. (2002), stroke patients showing global cognitive impairment six
months post-stroke were found to be significantly older at the time of stroke. When
the patients were further divided into those who had remained stable, those who had
improved, and those who had deteriorated from the time of baseline testing to one-
year follow-up, significant differences in mean age were observed. Higher mean age
was also related to less one-year global cognitive recovery in elderly stroke patients
in a subsequent study by Patel et al. (2003).
Relatively limited evidence exists on the effects of age at stroke onset on
outcomes across specific functions. However, in a study by Madureira et al. (2001),
memory-impaired stroke subjects were found to be older at the time of disease-onset
than those without memory deficits (62.9 versus 57.8 years, respectively). An
identical pattern was observed when patients with any cognitive deficit were
compared with cognitively intact subjects. Subsequently, older stroke patients were
found to be more impaired in global function (assessed by the CAMCOG), cognitive
speed, and memory, six months after the event, whereas no age effects were found on
cognitive flexibility (assessed by the Stroop Test and Concept Shifting Task)
(Rasquin et al., 2002).
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In comparison to the influence of age on subsequent cognitive function in
patients with stroke, findings regarding sex differences in post-stroke cognitive
performance have been less consistent. As an example, Rasquin et al. (2002) showed
that, compared to men, women were significantly more likely to be impaired six
months post-stroke in cognitive speed, while no sex differences were observed for
either global cognitive function, memory, or cognitive flexibility. Whereas similar
null findings with regard to global levels of cognition were also reported by other
researchers (Patel et al., 2003; Tham et al., 2002; Zhou et al., 2005), less cognitive
recovery over a period of one year was associated with female sex in another study
(Patel et al., 2003). However, in a study by Hochstenbach and colleagues (1998),
male and female stroke patients were found to perform differently on different
cognitive tasks requiring a verbal response; men performed better on visuospatial
tasks whereas women did better on tests ofmemory. In contrast, no gender effects
were observed on non-verbal cognitive tasks.
Further to the influence of patients' demographic characteristics,
socioeconomic status, education, and medical history, may play a role in modulating
the effects of stroke on cognitive outcomes. In the study by Patel et al. (2002), lower
socioeconomic status was associated with cognitive impairment at three months post-
stroke, and this was further shown by Zhou et al. (2005). Whereas Zhou et al. (2005)
and Tham et al. (2002) both noted lower education to be associated with greater
global cognitive impairment at three months as well as less one-year recovery,
Madureira et al. (2001) had previously found less years of schooling to be more
frequent in stroke subjects who either had specific memory deficits, or any cognitive
impairment, compared to intact patients. However, these differences failed to reach
statistical significance. Earlier, in an investigation by Tatemichi and associates
(1994), no effects of either education or race were observed on levels of cognitive
impairment three months after stroke.
Similar conflicting evidence has been reported with respect to both medical
history and stroke risk factor levels, underscoring the need for additional research.
For example, in an early report by Desmond et al. (1996), the presence of diabetes
mellitus was significantly associated with a failure to exhibit improvement in global
cognitive function. In contrast, no effects of either depression, medication use, or
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other influences were noted. Importantly, recurrent stroke during follow-up was not
associated with cognitive recovery. Similarly, no effects of each of a number of
stroke risk factors, such as heart disease, vascular disease, hypertension, smoking, or
diabetes, were observed on either verbal or non-verbal cognitive skills by
Hochstenbach et al. (1998).
This was, however, not found to be the case in several other studies which
demonstrated that, for cognitive outcomes in stroke patients, such risk factors may be
of importance. Thus, Madureira et al. (2001) found that, in comparison to stroke
patients without memory deficits, those with memory impairment were more likely
to consume alcohol. No such effects were, however, found for stroke patients
showing any cognitive impairment. Similar effects of alcohol were also found by
Zhou et al. (2005), but in addition, stroke subjects who demonstrated global
cognitive impairment were also more likely to have had prior stroke and atrial
fibrillation (no association with hypertension, diabetes, heart failure, myocardial
infarction, or smoking, were observed). In multivariate models, only alcohol
consumption was associated with cognitive impairment. Almost identical null-
findings with respect to prevalent cardiovascular disease and established risk factors
were reported by two other studies (Patel et al., 2002; Patel et al., 2003), whereas in a
recent longitudinal investigation by Elkins et al. (2005), involving elderly women in
the Study of Osteoporotic Fractures (SOF), pre-existing hypertension was associated
with a greater decline in measures of global cognition, executive functioning, and
attention, following the onset of incident stroke. These last results suggest that
hypertension-induced subclinical brain injury prior to stroke may decrease the
brain's ability to adapt or recover from acute ischaemia, thereby increasing
susceptibility to cognitive decline. In this context, hypertension-related cerebral
damage may act to decrease the brain's functional capacity (the brain's "cognitive
reserve" concept maintains there are aspects of brain structure and function that can
buffer the effects of neuropathology such that the greater the reserve, the more severe
the pathology must be to induce functional impairment) to recover or adapt following
the onset of an acute ischaemic episode (Richards and Deary, 2005).
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2.2.6. Study Limitations
As is evident from the previous review, the current literature on stroke and
cognitive function in old age comprises studies which frequently have generated
contradictory findings. Existing investigations vary greatly methodologically and a
majority of reports tends to suffer from any of a number of methodological
shortcomings regarding the study of the above association. In particular, both the
quality and validity of individual reports may be questioned on the basis of how
cognitive function has been assessed, the timing of cognitive testing relative to the
onset of stroke, the determination of stroke status, the selection of comparison
subjects, and handling of potential biases and confounding.
Data on cognitive function have only been collected at a single point in time
in most studies. This is an important limitation for three reasons. First, even though
cognitive test performance may be a valid endpoint in itself, it constitutes a less
direct measure of the pathological process under study which is characterised by
change in cognitive function over time. Second, as a result of the first point,
performance scores may not be a good indicator of change in cognitive performance
over time. Third, a number of factors other than the process under study may
influence cognitive test performance at a single point in time. Unless included in the
study protocol and measured, the effects of these cannot be accounted for in the
analysis. In contrast, only a few studies have provided longitudinal data on cognitive
performance over very modest follow-up periods. Moreover, still fewer have
collected longitudinal data on specific cognitive functions. Several studies have
reported on the proportion of subjects having cognitive impairment at different time-
points post-stroke, which on different occasions during follow-up, may in fact
comprise different individuals. Much fewer reports have actually examined intra-
individual change in cognitive performance over time in subjects with stroke.
Extensive domain-specific data have been gathered in several case-control
studies using cognitive test batteries. In comparison, cognitive functions have been
less thoroughly examined in population-based investigations. In fact, in several such
studies, only global cognitive measures have been administered. This is potentially
problematic since the most widely used global tests were not designed to study
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change in cognitive function. Moreover, global tests may not capture a wide
spectrum of cognitive abilities and may suffer from either floor or ceiling effects.
Most importantly, global tasks are likely to be insensitive to subtle changes in
cognitive performance and mask differences in rates of decline in different cognitive
functions.
The length of the time interval from the onset or diagnosis of stroke to the
assessment of cognitive function varies considerably across studies. The timing of
cognitive assessment may greatly influence the study results. For example,
particularly high rates of impairment may be observed where cognitive testing is
performed very early following the event, during which time acute confusional or
sensorimotor states may influence cognitive test performance.
Standardised diagnostic criteria for stroke, such as that from the WHO, have
usually been used despite not always being explicitly stated. In a majority of reports,
brain imaging has been available, but in some multi-centre investigations, a single
imaging protocol has not always been followed at different study sites. In other
contexts, imaging data have not been provided for all subjects, and in the case of
negative findings, repeat scanning has not been performed. On the whole, few studies
have provided detailed imaging data allowing an analysis of specific stroke
characteristics with patterns of cognitive function.
Case-control studies tend to recruit consecutively admitted hospital patients.
On several occasions, recruitment has been limited to patients with ischaemic stroke.
In other studies, mixed stroke subtypes have been included. It is possible that
different stroke types influence cognitive outcomes to a different extent. Moreover,
regarding stroke aetiology, different subtypes tend to overlap substantially but not
entirely, which may affect the analysis of the relationship with cognitive function. In
still other analyses, non-stroke TIA patients have been included, whereas elsewhere
these have been deliberately excluded. The result of their inclusion may be dilution
of any cognitive effects seen among cases. Recruitment of people with a first-in-a-
life-time stroke has been emphasised in some research contexts whereas in others
not. It is unclear whether multiple strokes are associated with progressively worse
cognitive function.
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A major challenge of case-control studies is the selection of suitable stroke-
free comparison subjects. In the current literature, a number of different paths have
been taken, including the use of published norms, non-stroke community-drawn
controls, and patients' spouses. The use of community-based controls has been
criticised for 'overmatching' and thus potentially overestimating the cognitive effects
of stroke. In addition, a number of biases may be introduced by using healthy
population controls in such case-control studies.
A number of potential confounding factors need to be considered in the study
of cognitive function in stroke. Sociodemographic factors have usually been taken
into account in a majority of studies but other factors less so. A major limitation of
most current studies is the inadequate control for confounding by vascular risk
factors. In a number of investigations, cases and controls differ significantly on such
factors. In particular, hypertension, smoking, diabetes, and atrial fibrillation may
independently affect cognitive function. Prior cognitive ability is associated with
cardiovascular disease (Hart et al, 2004) and later-life cognitive function (Deary et
al, 2000) but has rarely been considered. Few studies have directly estimated peak
cognitive levels. Whereas most studies have only used proxy measures, such as level
of education or socioeconomic status, residual confounding by prior ability is
difficult to rule out in most current reports.
Further to confounding, several other methodological challenges may
threaten study validity. In particular, case-control studies tend to be based on small,
selected patient samples which may not be representative of other patient
populations. Nor may the results from such samples be generalised to stroke
survivors in the community. Patient samples are likely to comprise more severe cases
that may be difficult to study longitudinally. In a number of studies, follow-up has
proved difficult due to high mortality or drop out rates which may jeopardise the
validity of the study. In contrast, population studies include elderly survivors of
stroke who are likely to have milder stroke pathology. However, the age range of
subjects tends to vary widely between studies. Whereas some have focused on the
very old, others have been based on much younger samples. Still other reports
comprise patient groups whose age range spans several decades. When very old
subjects are included, in whom cognitive impairment and decline is most prominent,
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it is possible that in some patients stroke simply coincides with pre-existing
Alzheimer's disease (AD) pathology as an underlying cause of incident cognitive
decline: indeed, mixed aetiology for cognitive decline may be common in the oldest
subjects. In several investigations the following have been excluded: patients with
possible or probable AD, those institutionalised or dependent pre-stroke, those with
low cognitive test scores pre-stroke, and those meeting dementia criteria according to
proxy. Whereas these approaches are likely to reduce the possibility of unrecognised,
concomitant cognitive impairment, they may not exclude it. In comparison, when
recruited to research, younger subjects may be more likely to be free of co-existing
neurological pathology but stroke events may be few and the outcome under study
difficult to detect (although the possibility of reduced cerebral blood flow relating to
cognitive decline before the onset of stroke must be considered).
2.2.7. Section Summary
Disruption of normal cognitive processes may be the outcome of
atherothrombotic disease that can lead to acute cerebral ischaemia through a number
of mechanisms. Over the past decade or so, there has been growth in the number of
empirical investigations examining neuropsychological functioning following stroke.
In both hospital -and community-based samples, a high frequency of post-stroke
cognitive impairment has been reported, the size of which may depend on the time
interval from the event onset to the assessment of cognitive function. Indeed, in
several studies, an improvement in intellectual functioning has been noted, as
evidenced by a reduction over time in the proportion of patients meeting criteria for
cognitive impairment. It is possible that various aspects of the acute event itself, such
as its type, laterality, and location, or patient characteristics present at the time of the
stroke, including the patient's age and medical profile, may influence the extent of
recovery in cognitive function following stroke. Further clarification of the role of
these in post-stroke mental performance may assist in the identification of stroke
patients at particular risk for further cognitive deterioration.
In several investigations, stroke patients have been noted to perform worse on
cognitive tests relative to stroke-free controls. For example, there is evidence of
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involvement of global cognitive ability as indexed by mental status tests, but the
administration of detailed neuropsychological batteries to hospital samples has
suggested more selective cognitive deficits, specifically on measures of attention and
processing speed. Whereas there has been some support from population studies
regarding the influence on global measures, findings are conflicting with respect to
the specificity of the effects. Additionally, there is an apparent lack of population-
based evidence regarding whether stroke may be associated with an increased decline
in cognitive function over time. A number of methodological issues are likely to
need attention in future studies examining the relationship between stroke and
intellectual functioning. Among the important ones are the timing and completeness
of the neuropsychological assessment, the selection of cases and controls, and
handling of potentially confounding factors.
2.3. COGNITIVE FUNCTION AND CORONARY HEART DISEASE
2.3.1. Introduction
Coronary heart disease is a major cause of death and disability. It is a
manifestation of atherosclerosis in the coronary circulation and may be considered as
a marker of systemic atherosclerosis. In comparison to other study endpoints,
measures of neuropsychological functioning have rarely been the principal outcome
in studies of CHD. It is possible that the overall paucity of studies in this area reflects
a general lack of appreciation for the systemic nature of the disease. However, as
discussed first in the present chapter, a number of mechanisms may lead to cognitive
dysfunction in patients with CHD, although in the absence of overt neurological
impairment, subtle cognitive deficits may not be expected in individuals suffering
predominantly from a disease of the heart. Furthermore, this chapter provides a
review of empirical studies examining patterns of cognitive function in patients with
CHD, which is followed by a methodological discussion of published reports. For
support, a methodological overview of the studies reviewed in this chapter is
presented in appendix A-2.
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2.3.2. Mechanisms ofNeurocognitive Dysfunction and Coronary Heart Disease
Cognitive impairment in atherosclerotic cardiac disease could reasonably be
attributed to several different underlying mechanisms. In particular, three major
explanations have been proposed (see Vingerhoets, 2001 for review). First, a
generalised systemic process may contribute both to the development of cardiac
disease as well as to cerebrovascular insufficiency. Indeed, there is ample evidence
showing that the development of atherosclerosis in one arterial territory is likely to
be but one manifestation of a widespread, systemic disease. Such a generalised
pattern of atherosclerosis is further reflected in the fact that either symptomatic or
significant but yet clinically unrecognised disease may co-exist within the same
individual, and that disease in one arterial bed should prompt investigation of
manifestations of disease in others (Phillips, 2001). Evidence of coronary
atherosclerosis has been found in up to a third of individuals with carotid artery
stenosis (Mathiesen et al., 2001), and is also frequently reported in patients who have
had transient ischaemic attacks (TIA) and cerebral stroke (Russell, 1983). Likewise,
asymptomatic carotid stenosis may predict cardiac infarctions as well as infarctions
in the brain.
Second, whereas TIAs and stroke in older cardiac patients are frequently the
result of concomitant intracerebral or carotid atherosclerosis, cardiogenic cerebral
emboli also constitute an important cause of acute cerebral ischaemia. Even though
these are hard to diagnose with certainty, it is thought that between 15% and 20% of
all ischaemic strokes are cardiogenic in nature (Vingerhoets, 2001). A common
source for such emboli is a thrombus lodged within the left auricle or on a
hypokinetic or aneurysmal endocardium following MI (de Bono, 1983; Nadareishvili
et al., 1999). Of the different substrates of cardiogenic brain embolism, non-
rheumatic atrial fibrillation may be most commonly encountered, followed by left
ventricular mural thrombi in acute MI. Even though findings are conflicting as to
whether cardiogenic emboli show lodging preferences, there is evidence to suggest
that the middle cerebral artery or its branches are more commonly involved than
other supra-aortal circulatory sites (Oder et al, 1991).
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Third, cognitive impairment in cardiac disease may result from either acute or
chronic hypoxic brain damage due to cardiac failure. In this context, myocardial
infarction constitutes an important cause of congestive heart failure, which is
associated with reduced cardiac ejection fraction as a consequence of left ventricle
dysfunction. As well as predisposing to thromboembolism, cardiac failure may lead
to decreased cerebral blood flow (Pullicino and Hart, 2001). The brain, being a
highly metabolically active organ, is depended on adequate blood supply. As a result,
cerebral blood flow is autoregulated by intracranial mechanisms but if systemic
blood pressure levels fall below the autoregulative window, hypoxia may occur
(Vingerhoets, 2001). Impaired autoregulation and failing compensatory mechanisms
in advanced cardiac disease could lead to chronic hypoxia, potentially impacting
normal brain structure and cognitive processes, but both the rapidity and the extent to
which cerebral blood flow is reduced is likely to be of importance for the these
outcomes.
2.3.3. Frequency of Cognitive Impairment, Patterns of Cognitive Function, and Coronary
Heart Disease
Evidence from clinic-based samples
The overall growing interest in the relation of cardiovascular disease with
cognitive function has seen a slow but steady accumulation of studies examining
patients with coronary artery disease. In early investigations, where the focus had
exclusively been on small samples of cardiac patients with advanced disease,
researchers had noticed an increased risk of cerebral infarction and haemorrhage (for
discussion see Barclay et al., 1988). In many instances, the infarcts were thought not
to result from an in situ thrombosis of cerebral arteries but rather from
thromboembolism of an extracranial source. Whether patients with cardiac disease
also demonstrate poor cognitive function has been somewhat contradictory.
Barclay and colleagues (1988) examined 20 clinically stable cardiac
rehabilitation patients aged between 47 and 85 years. Whereas all were considered
free of dementia, seven had had an MI while the rest were recovering from various
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cardiac surgeries. Subjects with previous stroke were excluded. Cognitive deficits in
fine motor coordination (Pegboard Test), memory (Mattis Dementia Rating Scale,
MMSE, Mental Status Questionnaire), and initiation and perseveration (Mattis
Dementia Rating Scale), were observed in 40% to 60% of the sample. Between 10
and 30% of patients had impairment in naming objects (Confrontation naming),
psychomotor speed (Digit Symbol Test), abstract reasoning (WAIS similarities),
attention (Digit Span Test), and visuospatial ability (WAIS Block Design). However,
when the MI and surgical patients were compared on cognitive tests performance, no
statistically significant difference in either global or domain-specific functioning was
found. Importantly, whereas three patients had unifocal neurocognitve deficits, 15
showed multifocal findings, suggesting multi-domain cognitive impairment in this
population. Whereas the authors did not exclude the possibility that the observed
cognitive deficits were in some way related to the underlying cardiovascular disease,
they emphasised the need for further studies using non-vascular controls as well as
the collection of pre-operative cognitive data from surgical samples.
Perhaps partly in response to the above, Seines et al. (2003) provided further
data on the pre-operative cognitive test performance of 140 elderly patients
scheduled for coronary artery bypass grafting (CABG). In addition, 92
catheterisation-diagnosed coronary artery disease control subjects, similar in
sociodemographic structure to the patient group, also underwent detailed cognitive
assessment. When cases and controls were compared at baseline, using measures of
attention, language, verbal and visual memory, visuoconstruction, executive
function, and psychomotor and motor speed, no statistically significant differences in
test scores were found. This may not be surprising given that cases and controls both
had advanced cardiovascular disease at the time of cognitive testing, and in fact were
not observed to differ with respect to baseline prevalence of hypertension, diabetes,
history ofMI, TIA, cardiac arrhythmia, or medication use.
Even though the main objective of the last study was to evaluate the effects of
cardiac surgery on cognitive processes the authors noted that, in comparison to
published norms, not only the cases but the control subjects also performed relatively
worse on tests of verbal memory and timed tasks ofmotor speed and executive
function. In investigations where cognitive performance of severe cardiac disease
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patients has been compared with that of non-vascular controls, similar patterns of
cognitive impairment to that above have been observed. For example, Putzke et al.
(2000) administered a comprehensive cognitive test battery to a group of 44 cardiac
patients with end-stage disease undergoing routine evaluation for heart
transplantation. An equal number of subjects recruited from the community, and
without self-reported history ofCVD and stroke, comprised the control group.
Importantly, cases and controls were matched on age, sex, education, and race. The
study showed that, in comparison to controls, the transplant candidates displayed a
statistically worse performance on tasks of non-verbal reasoning (The Shipley
Institute of Living Scale) and timed tests of psychomotor speed and mental flexibility
(Trail Making Test). Moreover, cases were significantly slower on timed measures of
fine motor-speed and dexterity (Peg Board Test). In contrast, neither immediate nor
delayed recall of verbal material (Logical Memory Test) was affected. It is possible
that the discrepancy between these results and that reported above by Seines et al.
(2003) may be explained by the use of different tasks used in the measure of verbal
memory.
Finally, Moser et al., (1999) studied a group of 93 cardiac rehabilitation
patients whose cognitive test performance was compared to 36 age-matched
outpatients attending the same medical facility. Around 55% of cases were found to
have had MI, 50% had a history of poorly controlled systolic hypertension, and 41%
had undergone CABG surgery. Relative to controls, cases obtained lower mean
scores on all cognitive tasks in an unadjusted analysis. In particular, measures of
verbal learning and recognition (Recognition Memory Test-Words), psychomotor
speed (Digit Symbol Test), and executive functions (Category Fluency), were
moderately but significantly affected. In contrast, no statistically significant group
differences were observed for either the WAIS-similarities subtest or MMSE-
estimated levels of global cognitive function. Furthermore, in an analysis involving
only the rehabilitation patients, no differences in cognitive function were observed
between those with and without prior MI. Overall, however, these findings suggest
mild cognitive deficits on several specific cognitive abilities in patients with
advanced cardiac disease.
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Evidence from population samples
Some of the methodological challenges faced by clinical studies have partly
been overcome in investigations based on community-derived samples. In such
studies, information on a number of important confounding factors is usually
available and selection bias is less likely to distort the results. On several occasions,
cognitive assessment has been carried out on large numbers of individuals whereby
the cognitive test performance of diseased individuals is compared to that of healthy
subjects selected from the same population. In particular, they have provided greater
insight into cognitive function in relation to cardiac disease per se as distinct from
the potential influences of concomitant morbidity, previous cardiac surgery, or both.
Despite such methodological advances, findings from community-based studies have
been somewhat contradictory. For example, negative effects of cardiac disease on
global cognitive function were observed by Breteler and colleagues (1994) who
found ECG-diagnosed MI to be associated with poorer performance on the MMSE,
independently of age and education. Despite only modest differences in mean levels,
the total distribution ofMMSE scores was found to have shifted towards lower
values, thus increasing the proportion of participants with scores indicative of
cognitive impairment. In the Caerphilly study, elderly stroke-free men with CHD had
statistically lower age and social class-adjusted mean scores on two global cognitive
measures relative to men without vascular disease (Elwood et ah, 2002). Specifically,
the presence ofCHD was associated with lower MMSE and CAMCOG scores
equivalent to that of 13% and 14% of a standard deviation, respectively. Negative
effects of similar magnitude were also observed in men diagnosed as having either
ECG ischaemia or angina, but previous MI was not related to poorer global
performance. Whether these diagnostic categories were mutually exclusive is not
clear, however.
In other cross-sectional analyses, an association of cardiac disease with
inferior performance on global cognitive tasks has not been supported. For example,
Ahto et al. (1999) found no statistically significant association ofCHD, defined
either as the presence of angina or a previous MI, with MMSE performance in a
study of 486 community-resident Finnish elderly persons. However, for both men
64
and women, cases scored slightly lower compared to controls. In another Finnish
study involving 629 elderly subjects, no differences in age and sex-adjusted baseline
MMSE scores were observed between subjects with and without a history ofMI
(Tilvis et al., 2004). However, whereas no data were provided on history ofMI, heart
failure was implicated in a significantly greater five-year decline in global cognitive
performance as well as higher mortality rate over the same study period. Petrovitch
and associates (1998) also failed to associate previous MI with poorer performance
on the CASI instrument after controlling for age and level of formal education in
their study of over 3700 Japanese-American men. This null-finding is of interest in
the light of the fact that men with previous stroke or history ofCABG surgery,
overrepresented among those with history ofMI, were not excluded from the
analysis. Moreover, neither the number ofCHD events nor the time between last
event and cognitive assessment were found to be related to performance on the
CASI. Even though a single explanation is unlikely to exist, differences in study
populations, methods of assessment of cardiac disease as well as cognitive function,
are likely to contribute to such discrepancies.
Inconsistent findings have also been produced in several population-based
studies that have collected longitudinal data on performance on neuropsychological
tests. For example, Zhu et al. (1998) provided three-year follow-up data on 924 men
and women aged 75 years and older at baseline. Whereas an average yearly decline
of 0.4 MMSE points was observed for the sample as a whole, the rate of decline was
not found to be associated with either baseline CHD or heart failure. An adjustment
for potential confounders did not change the results. However, since relatively milder
cases of cardiac disease were included in this study, the authors did not exclude the
possibility that more severe forms of cardiac disease could be associated with
impaired cognitive function. Using a longer follow-up, Eslinger et al. (2003)
followed 287 elderly men participating in the Western Collaborative Group Study for
six years. The results showed that approximately 15% of subjects declined by three
or more points on the MMSE. In comparison, over 80% did not decline by the same
degree. When decliners and non-decliners were compared, no statistically significant
differences were observed with respect to the proportion of subjects having a positive
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history of CHD (based either on medical review showing the presence of angina, MI,
or congestive heart failure, or on ECG evidence of coronary heart disease).
Furthermore, Piguet et al. (2003) examined 377 non-demented (baseline
MMSE score of >25) community-dwelling subjects aged 75 years and over for a
period of six years. Whereas both subjects with and without heart disease at baseline
declined over the follow-up period, those with heart disease did not decline at a
steeper rate compared to the non-diseased participants. Identical results were found
when the analysis was confined to subjects having a baseline MMSE score of less
than 25.
In contrast to these findings, Haan et al. (1999) noted an increased seven-year
rate of decline in MMSE scores in subjects with either major ECG abnormalities or
congestive cardiac failure at baseline. Statistical control was made for both
sociodemographic confounders as well as incident stroke.
Information on the relationship of CHD with performance on domain-specific
tests has come from several studies. In particular, Elwood and colleagues (2002)
found men with any manifestation of CHD to score less on a task of verbal and
mathematical reasoning, relative to non-vascular controls. Also, diseased subjects
tended to demonstrate slower mental speed, as measured by a choice reaction task.
Moreover, a lower verbal and mathematical test score was observed in relation to
angina and history ofMI, but not ECG-determined ischaemia. Previous MI was also
related to significantly slower reaction times. Overall, the presence of disease was
associated with negative effects on verbal and mathematical reasoning, equivalent to
that ranging from 12 to 21% of a standard deviation, and that of 17 to 21% of a
standard deviation for choice reaction time. Similarly, a regression analysis adjusting
for age, sex, and socioeconomic status found history of CHD to be predominantly
associated with worse performance on measures of executive control functions in a
still older sample from the Berlin Aging Study (Verhaeghen et ah, 2003). Severe
cardiac disease, evident as congestive heart failure, was in addition associated with
worse perceptual speed. When added to the same multivariate model, only heart
failure, but not CHD, predicted reduced levels of executive control functioning.
Finally, using some of the same cognitive measures as above, Singh-Manoux
et al. (2003) demonstrated how different diagnostic indexes of CHD, estimated from
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several sources, were related to worse cognitive performance in a large sample,
comprising subjects of a relatively younger age to that described in the
aforementioned investigations. Interestingly, mean scores on tasks assessing both
fluid and crystallised functions, as well as some aspects ofmemory, were
significantly lower in those with disease than those without. Specifically, whereas
this was the case for both angina and an all-inclusive category CHD, the MI group
exhibited more selective difficulties on tests of verbal reasoning, crystallised ability,
and some indices of executive control (Semantic Fluency Test), but neither
immediate recall of verbal material nor other aspects of executive control functioning
(Lexical Fluency Test). This pattern was observed in both men and women. Similar
to the Caerphilly study (Elwood et al., 2002), the size of effects of cardiac disease on
particular cognitive measures in this study were found to range from 7 to 34% of a
standard deviation.
Limited longitudinal data have been collected on performance on specific
cognitive tasks in patients with CHD. In fact, two published studies have produced
mixed findings as to whether such patients may be relatively more prone to
intellectual decline. In the earlier report, which already has been mentioned, Haan et
al. (1999) observed a steeper 7-year decline in psychomotor performance, as assessed
by the Digit Symbol Test, in the presence of baseline cardiac disease (either major
ECG abnormalities or congestive heart failure). In contrast, neither clinically verified
baseline CHD nor congestive heart failure were found to be associated with a greater
4-year decline in domain-specific measures of fluid and crystallised intelligence,
memory functioning, and executive control functions (Verhaeghen et al., 2003).
Although both cases and control subjects demonstrated some decrease in
performance levels over the study period, the investigation failed to implicate CHD
in later-life cognitive decline.
2.3.4. Study Limitations
Relatively few studies have examined cognitive function in the context of
cardiac disease. Apparent conflicting findings from both clinic and community-based
investigations are likely to be attributable to any of a number ofmethodological
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shortcomings. Moreover, comparing studies is challenging given their
methodological heterogeneity.
Similarly with respect to investigations examining post-stroke mental
functioning, the majority of cardiac studies have only provided data on cognitive test
performance at a single point in time. In fact, very few population studies, and no
clinic-based investigations, have collected longitudinal data on cognitive function.
The implications of this have already been discussed in the context of stroke.
Furthermore, in most of such follow-up studies, cognitive assessment has been based
on global cognitive measures, such as the MMSE. As a result, it is currently not
known whether cardiac disease is associated with deficits or decline in all cognitive
functions, reflecting a generalised pattern of dysfunctioning, or is confined to some
functions and not others. In fact, only two studies, which actually produced
conflicting findings, have collected longitudinal data on various functions using a
battery of cognitive tests.
Current studies tend to differ significantly with respect to the methods and
criteria used in determining cardiac disease. The result is that largely non-equal
cardiac problems are often being compared. In clinic-based studies, patients with
very advanced disease, such as those attending cardiac rehabilitation or undergoing
surgery, are often recruited. On a number of occasions, cases are found to comprise
patients with mixed cardiac aetiology, suffering from other systemic diseases, or
having undergone surgery. In such circumstances, it may be impossible to identify
the exact causes responsible for the observed impairment in cognitive function.
Similarly, across population studies based on survivors of cardiac disease,
diverse methods have been used for detecting disease. In a few studies, multiple
sources, including past medical history and hospital discharge data, have been used
in identifying cases. In others, direct assessments have been carried out, using
symptom-based questionnaires or ECG. Often, however, the exact diagnostic criteria
have not been explicitly stated. The reliance on a single method only, such as ECG,
may result in some true cases being classified as not having disease given the
relatively low sensitivity of ECG in detecting previous MI. Further to this, most
population studies have collected data on cardiac disease at a single point in time
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(prevalence) rather than over time (incidence). In this context, some asymptomatic
cases, for example, could be wrongly considered being free of cardiac disease.
As mentioned above, clinic-based studies tend to include patients with mixed,
advanced cardiovascular problems. Even though the majority of patients have
significant underlying CHD, this disease heterogeneity makes the study of specific
CHD syndromes difficult. On the other hand, most population studies have either
relied on a single all-inclusive CHD category or on one prominent manifestation of
the disease (for example, MI). Only few studies have cross-sectionally investigated
cognitive function in relation to different CHD syndromes. In particular, limited data
have been collected from individuals with subjective or mild CHD, such as angina
pectoris. No studies to date have examined function-specific change in relation to
different CHD syndromes. In addition, it is of note that few studies have adequately
taken into account the potential overlap between different CHD syndrome groups or
between subjects with other manifestations of atherosclerotic disease. Specifically,
the possibility of confounding by previous stroke has not always been sufficiently
excluded in investigations of cognitive function in cardiac disease.
A major problem with clinic-based investigations is that, even though data on
cognitive function have widely been provided, the aim of these has not been the
study of the cognitive effects ofCHD per se. As discussed above, this is reflected in
the selection of cases but has also affected the choice of controls. In particular,
control subjects have frequently been drawn from other clinical populations,
including non-surgical vascular populations. In many instances, these also suffered
from advanced vascular disease. On other occasions, relatively healthy, community-
based volunteers have also been recruited using various methods. It is likely that the
choice of controls exerts major influence on any findings reported from such studies.
In population investigations, the choice of control subjects has been less of a problem
since both cases and controls are drawn from the same population and undergo
identical examination procedures. However, on several occasions, these have not
been entirely free of clinical vascular disease. This is reflected in the fact that, cases
and controls have been found to comprise subjects with and without a particular
CHD syndrome, such as MI, rather than the controls being free of any known
vascular disease. As discussed in the context of research of post-stroke cognitive
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function, confounding by vascular risk factors is also likely to be a problem in
studies of cardiac disease and cognitive function.
Population studies are relatively few and some have been confined to men or
specific ethnic groups. The findings from these may not apply to either women or
other populations. To date, the majority of studies has predominantly been cross-
sectional and longitudinal reports on cognitive function are still scarce. As a result,
little is known about the directionality of the relationship of cardiac disease with
cognitive function. Secondary changes due to cognitive impairment and its sequelae
may occur that can affect the development of vascular disease. Moreover, a few
studies have collected longitudinal data on cognitive change from very old subjects
but these may be biased if the subjects with both the exposure and outcome are
disproportionately lost to follow-up. For example, true cognitive effects ofMI could
be missed if individuals with post-MI cognitive impairment died before being
cognitively assessed at follow-up.
2.3.5. Section Summary
As is evident from the discussion above, several pathways exist through
which patients with clinically overt CHD may be at risk of cognitive impairment. As
a marker of atherosclerosis, CHD may be associated with clinically unrecognised
cerebrovascular disease. Moreover, atherosclerosis-induced cardiac pathology may
predispose to cardiogenic emboli and possibly reduced ventricular function which
may lead to a state of either acute or chronic cerebral hypoperfusion. So far,
however, this potential source of variance in cognitive ability has generated
somewhat limited empirical interest. Even though some early investigations
demonstrated both frequent and widespread deficits across mental abilities in
samples of cardiac rehabilitation or surgical patients, these studies were limited in
several ways. Most importantly, since the findings are generally based on individuals
both with highly advanced cardiac disease as well as multiple other illnesses, the
value of these studies in shedding light on patterns of cognitive function in relation to
CHD may be questioned. In population samples, different indices of CHD have been
associated with worse performance on measures of global cognitive ability. In
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addition, there is limited evidence in support of an effect ofCHD on longitudinal
decline in general mental ability. Interestingly, however, several population-based
studies have failed to confirm the above finding despite potential confounding by
either prior ability level or stroke. Possibly, global cognitive measures may not be
suitable for capturing subtle cognitive deficits in patients with CHD. The use of
neuropsychological tests has provided data that suggest measures of fluid ability,
including abstract reasoning, executive function, and information processing speed,
may be disproportionately affected in CHD patients. However, longitudinal data on
specific cognitive abilities in population samples is both scarce and conflicting,
highlighting the need for further research in this area. In particular, additional
population-based studies are required for outlining the pattern of change in specific
cognitive domains in relation to different CHD syndromes, taking into account
potential confounding by co-existing atherosclerotic risk factors.
2,4. COGNITIVE FUNCTION AND ATHEROSCLEROTIC DISEASE
2.4.1. Introduction
The aim of the present section is to provide an overview of current
investigations of the neuropsychological profile of patients with atherosclerotic
disease of the carotid and lower-extremity arteries, which is followed by a
methodological critique of published reports. On the whole, relatively few studies
have systematically examined cognitive function as a primary outcome in relation to
these manifestations of atherosclerosis despite the considerable burden ofmorbidity
they are associated with. Carotid artery disease constitutes a major risk factor for
cerebral ischaemia and the risk of both fatal and non-fatal cardiovascular events is
substantially increased in patients with peripheral leg disease. From this perspective,
disruption of normal neurocognitive processes might be expected in individuals with
generalised atherosclerotic disease. As a result, the potential mechanisms leading to
cognitive impairment in these patients will first be described. A methodological
summary of the studies reviewed in this chapter is supplied in appendix A-3.
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2.4.2. Mechanisms ofNeurocognitive Dysfunction and Peripheral Atherosclerotic Disease
As already pointed out, atherosclerosis is a chronic, systemic disease of large
and medium-sized arteries. There is widespread agreement that atherosclerosis in the
carotid and the lower extremity-arterial tree, represent just one manifestation of
similar pathology in other arterial systems (Drouet, 2002). In fact, it has been
suggested that the presence of atherosclerotic disease in the periphery should prompt
an inquiry into ischaemic manifestations in other major organs in the individual,
particularly the brain and the heart (Phillips, 2001).
Whereas severe narrowing of either carotid or cerebral arteries could obstruct
blood perfusion to the brain, thereby increasing the possibility of cognitive
dysfunctioning, atherosclerosis in the carotid tree is also associated with a
substantially elevated risk of acute thromboembolic cerebral events. For each 10%
increase in the degree of arterial stenosis, the risk may be increased by as much as
26% (Mathiesen et al., 2001). Depending on their size, shape, and the artery in which
they will ultimately lodge, the effects of circulating emboli on neurologic functioning
vary widely. Even in the absence of clinical stroke, cerebral microemboli (detected
using transcranial Doppler ultrasound) from ulcerous atheromatous lesions in the
carotid arteries may frequently be observed over time in most, if not all, patients with
significant stenosis (Hutchinson et ah, 2002). Whereas it has been hypothesised that
large numbers of such clinically silent emboli may potentially lead to progressive
cognitive dysfunctioning (Russell, 2002), they also strongly predict both TIAs and
ischaemic brain infarction (Molloy and Markus, 1999).
Despite the low prevalence of ultrasound-determined carotid stenosis in the
general population, its frequency has been found to rise steeply after 60 years of age
(Mathiesen et ah, 2001). In populations of patients with signs of atherosclerosis in
other arterial beds, including the lower extremities, the prevalence of carotid
atherosclerosis is increased several fold (Cheng et ah, 1999). Furthermore,
angiographically-assessed coronary artery disease may be evident in up to 90% of
individuals with symptomatic peripheral arterial disease, while cerebrovascular
disease may be present in as many as one half of patients (Vogt et ah, 1992). The
systemic nature of atherosclerosis is further reflected in the elevated risk individuals
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with symptomatic arterial narrowing in the lower extremities have of both fatal and
non-fatal vascular events (Dormandy and Murray, 1991). Moreover, an association
of low ABPI, indicating increased lower-extremity arterial stenosis, with an
increased risk of both non-fatal MI and stroke in the general population has been
demonstrated (Leng et al., 1996).
2.4.3. Frequency of Cognitive Impairment, Patterns of Cognitive Function, and Carotid
Disease
Evidence from clinic-based samples
Few studies have been published on the relationship of carotid atherosclerosis
with performance on neuropsychological measures. So far, our knowledge of this
association has largely come from small-scale clinical investigations based on
patients undergoing carotid endarterectomy (CEA), which now has become a routine
surgical procedure for the prevention of cerebrovascular insults in individuals with
advanced atherosclerotic disease in the carotid arteries. As the number of patients
undergoing such an operation has increased, there has been a growing interest in the
effects of CEA on cognitive function. In evaluating the cognitive effects of carotid
surgery, studies have normally collected detailed cognitive data both before and after
the operation. However, from the pre-operative cognitive performance levels, some
insight into the neuropsychological profile of patients with severe carotid
atherosclerotic disease may be gained.
In the light ofwhat has already been discussed, it may not be surprising that
relative to controls, CEA patients have generally been found to exhibit deficits in
multiple cognitive domains. Thus, for example, a sample of 36 CEA patients (mean
age 63.3 years) was found to have statistically significantly lower mean scores on
tasks (selected to represent both left and right hemispheric functions) assessing
auditory information processing (Dichotic Listening), psychomotor speed (Finger
Tapping Test), measured reaction and movement times (Motor Planning Test),
executive functioning (Verbal Fluency), and visuospatial ability and memory
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(Complex Figure Test Copy), compared to age and education-matched norms (Brand
et al., 2004). In this study, in which pre-operative cognitive testing was carried out
the day before operation, 26 of the 36 patients had more than 75% carotid stenosis as
determined by ultrasonography, whereas the rest had unilateral carotid occlusion.
Although not accounted for in the analysis, only seven CEA patients were found to
be asymptomatic, while 19 had experienced TIA, and 8 had suffered stroke.
Moreover, 14 had either hypertension or history of heart disease, and 17 were either
current smokers or recent quitters.
Kishikawa et al. (2003) also found lower mean scores on both global
cognitive measures (MMSE) and domain-specific tests (Verbal Memory, Benton
Visual Retention Test) in 23 elderly CEA patients who were compared to age and
education-matched hospital controls without carotid stenosis. Cognitive assessment
of cases was performed two weeks prior to surgery. As in the previous study, cases
had more often had TIA and stroke as well as higher pre-surgery levels of several
cardiovascular risk factors. Moreover, the differences between cases and control
were not assessed statistically.
A third study compared the pre-operative cognitive performance of older
CEA patients to that of two selected groups of controls (Aharon-Peretz et al. (2003).
In contrast to the two previous reports, cases were found to be asymptomatic despite
having carotid stenosis ofmore than 70%. Whereas one group consisted of non-
demented volunteers with no evidence of carotid stenosis (n=14), and matched with
the patient group on major risk factors, the other control group comprised 24 healthy
age and education matched volunteers. When compared to the former control group,
few differences in pre-operative performance levels were observed. Cases and
controls differed only with respect to attention and mental processing speed (assessed
with part A of the Trails Making Test). The patient group neither performed worse
on the MMSE nor tasks of immediate and delayed verbal memory. Relative to the
healthy group, however, CEA patients had poorer performance on several measures,
most notably on those relying on attention, visual searching and processing speed,
verbal learning abilities, and other frontal lobe functions. Again, no statistically
significant differences were observed in either MMSE scores or in performance on
tests of verbal memory.
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Findings of no differences in pre-surgery levels of cognitive function between
CEA patients and controls have also been reported (Fearn et al., 2003; Iddon et al.,
1997). This is surprising given that in both cases, symptomatic CEA patients were
compared to non-vascular controls. However, only in the latter report where the
differences formally assessed using statistical methods (Iddon et ah, 1997). In the
former study (Feam et ah, 2003), 159 CEA patients (mean age of 68.0 years) with
carotid stenosis of 70% or more, were found to have similar reaction times, attention
speed times, levels of accuracy in word and picture recognition, and in memory, as
20 elderly urological surgical control subjects. Although the control subjects were all
free of clinical cerebrovascular disease, approximately 65% of the CEA patients had
a past history of TIA and 35% had suffered clinical stroke. Earlier, Iddon and
colleagues (1997) had failed to observe differences in cognitive performance
between 30 elderly CEA patients and controls on a number of neuropsychological
measures, indicative of either frontal or temporal lobe damage (e.g. tasks involving
spatial recognition, short-term memory for spatial information, pattern-location
associations, verbal fluency etc.). The lack of association with pre-operative
cognitive performance is of interest given that, among cases, patients with history of
TIA were included in the study.
Evidence from population samples
Limited community-based evidence exists of the association between markers
of carotid atherosclerosis and global cognitive function. Moreover, with respect to
particular cognitive functions, evidence suggests tasks assessing fluid abilities,
including attention skills and psychomotor speed, may be disproportionately
affected. For example, in an early cross-sectional analysis of the Rotterdam study, a
study of 4971 institutionalised and non-institutionalised subjects aged 55 to 94 years,
the presence of ultrasonographically-determined internal carotid plaques was
associated with a shift in the distribution ofMMSE scores towards lower values after
potential confounding by age, sex, and education, was taken into account (Breteler et
al., 1994). However, whereas the difference in mean scores (0.4 MMSE points)
between those with and without plaques was found unlikely to be of clinical
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importance, the authors emphasised the contribution of atherosclerosis to cognition at
the population level. Importantly though, neither confounding by prior stroke nor
cardiovascular risk factors was taken into account in the analysis.
Auperin and colleagues (1996) showed subsequently that higher prevalence
of carotid plaques was associated with lower MMSE scores in a community sample
of stroke-free men, aged 59 to 71 years. This finding was further supported in a
multivariate analysis, adjusting for demographic, lifestyle, and some medical
variables. Identical patterns were observed for psychomotor speed (Digit Symbol
Test), but not for tasks requiring attention, non-verbal reasoning, visuospatial
perception, and memory. Furthermore, negligible or non-existent effects of intima-
media thickness (IMT) with cognitive function were observed (a weak, inverse
relation was found with verbal fluency in men with plaques only). In contrast, carotid
disease had no influence on cognitive performance in women.
Some evidence in support of a causal role of carotid disease in cognitive
impairment was provided in a recent report from the Cardiovascular Health Study
(Johnston et al., 2004). Few studies have attempted to distinguish between the role of
carotid stenosis as a marker of underlying systemic disease and vascular risk factors,
and its causal role in brain ischaemia. In this inquiry, all subjects with either
prevalent or incident stroke, TIA, or history of CEA were excluded. A cross-
sectional analysis revealed that, those with high-grade left-sided carotid stenosis
(>75%) had both lower mean modified MMSE (mMMSE) scores and greater global
cognitive impairment (an mMMSE score less than 80 out of 100) compared to
subjects without left-sided stenosis. Identical findings were observed for
psychomotor speed (Digit Symbol Test). However, when five-year decline in
cognitive scores was compared in these two groups, only an association with
mMMSE scores was noted. A greater annual decline in scores was found in those
with high-grade left-sided stenosis relative to the comparison group (-2.12 points per
year versus -0.44 points per year). Similarly, 50% of the diseased subjects compared
to 19% of controls declined by more the one mMMSE point a year on average. These
associations persisted after demographic and vascular risk factors as well as right-
sided stenosis where controlled for. Relative to subjects without left-sided stenosis,
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higher rates of decline were also seen in subjects with milder degrees of the disease
(l%-74% stenosis).
In contrast, substantially less, or non-significant, associations were found
with either cognitive test when subjects with right-sided stenosis (>75%) were
compared to those free of right-sided stenosis. These results were found to confirm
the main study hypothesis which had stated that high-grade stenosis of the left, rather
than the right, internal carotid artery would be associated with greater mMMSE
deficits and decline, since in right-handed persons this measure primarily tests left
hemisphere functions. Moreover, if causal in nature, such an association would
persist after adjusting for right-sided stenosis and vascular disease. The authors had
also assumed that IMT, rather than being a direct cause of cognitive impairment like
carotid stenosis, constituted a marker of generalised atherosclerosis and concomitant
risk factors. In this context, relative to subjects in the lowest quartile of IMT, those in
the highest quartile had lower global and psychomotor speed test scores at baseline,
and steeper five-year decline in mMMSE scores. However, no side-preference of
effects was observed. In addition, the associations were greatly attenuated when
adjusted for vascular risk factors, thus further supporting the notion of IMT as an
indicator of the burden of underlying vascular disease.
So far little is known about the mechanisms behind cognitive impairment in
carotid atherosclerotic disease, even though several explanations have been
proposed. For example, if causal, the effects of carotid disease could potentially be
attributed to clinically silent microembolic infarcts, arising from atherosclerotic
lesions. On the other hand, haemodynamic disturbances, resulting from severe
carotid stenosis, might also interrupt normal brain and cognitive processes. It is
therefore of interest that, in the only population-based investigation to empirically
test these hypotheses, neither in fact received empirical support (Mathiesen et al.,
2004). In this cross-sectional analysis of elderly stroke-free individuals, subjects with
carotid stenosis (>35%) scored significantly lower on tests of attention and
psychomotor speed, sustained attention, memory, and motor functioning. These
effects were found to be independent of age, sex, and level of education. When
further adjusted for MRI-determined subcortical white matter lesions, and lacunar
(lesions 5-15 mm in size) and cortical (lesions >15 mm in size) infarcts, most of the
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associations still remained. This suggested that the association of carotid disease with
cognitive test performance was unlikely to be accounted for by the presence of
clinically unrecognised brain infarcts. Interestingly, similar results were found when
the analysis was limited to subjects without any visible structural MRI lesions.
Furthermore, the authors considered cerebral hypoperfusion to be an unlikely
explanation since the majority of carotid patients had relatively low-grade stenosis.
Therefore, they postulated that carotid disease, rather than being a direct cause of
cognitive impairment, constituted a marker of either intracerebral or systemic
atherosclerosis, an explanation that Johnston et al. (2004) had refuted in their study.
2.4.4. Frequency of Cognitive Impairment, Patterns of Cognitive Function, and Peripheral
Arterial Disease
Evidence from clinic-based samples
As in carotid disease, patients suffering from atherosclerotic narrowing of the
arteries in the legs tend to have high levels of cardiovascular risk factors and may be
at an increased risk of cerebrovascular disease. Whether cognitive function is also
affected in such patients has only been investigated in a limited number of studies.
Moreover, a further limitation of some of the earlier studies was reflected in the fact
that these were not designed to evaluate the relationship of lower extremity
atherosclerosis with cognitive function. Nevertheless, some insight into the extent of
cognitive impairment in such patient samples can be gained from these reports. For
example, in a sample of 60 leg amputees undergoing evaluation for prosthetic limb
fitting and rehabilitation, 10% were found to have severe deficits in multiple
cognitive domains, including memory, orientation, and attention and concentration
(Pinzur et al., 1986). This impairment was considered severe enough to limit the
patients' capacity to learn to use a prosthetic limb successfully. The study, which was
restricted to male patients (some as young as 34 years of age), was found to be
methodologically limited in several ways. Apart from not using a control group, the
patient sample included subjects of different aetiological backgrounds. Thus, even
78
though the majority of amputees had peripheral vascular insufficiency, six subjects
had been amputated as a result of trauma or other reasons. Moreover, not all patients
received the same set of cognitive function tests, and whereas those below 60 years
of age were administered the WAIS instrument, older subjects were tested using the
Test ofMental Functions for the Elderly, the Auditory Verbal Learning Task, and the
Rey's Complex Figure Task. Unfortunately, since no data on actual test outcomes
were provided in the report, no firm conclusions about the level of cognitive
performance can be drawn from this study.
In a second report, where the aim was to investigate neuropsychological
functioning following major surgery in 312 CABG electives, a sample of 50 PAD
surgical candidates was included as a control group (Shaw et ah, 1987). When
compared on a standard cognitive test battery, comprising the Trail Making Test B
and the WAIS-subtests, no differences in mean pre-surgery test scores were observed
between the two groups. Although the PAD group was older and included relatively
more women, as expected, the CABG patients showed greater prevalence of pre¬
operative coronary heart disease. Moreover, the proportion of cases and controls with
hypertension, diabetes, previous TIA, or clinical stroke, did not differ significantly
but the PAD patients had more evidence of carotid arterial disease. Whilst not
confirming the intactness ofmental processes, these results rather suggest that the
level of cognitive impairment of patients with peripheral arterial disease may be at a
par with that in individuals showing advanced atherosclerotic disease in the coronary
circulation.
The purpose of the publication of two more recent clinic-based studies was
partly to address two major limitations with respect to the investigation of cognitive
function in PAD patients; firstly to add to the almost non-existing literature in this
area of research, and second; to improve the methodological quality of existing
studies. In the former investigation, Phillips et al. (1993) administered a
comprehensive cognitive test battery to 14 stroke-free PAD amputees, recruited from
a rehabilitation centre, and 14 community-drawn control subjects. Whereas only
slight groups differences were found regarding age at cognitive testing (mean age
69.9 versus 67.4 years), the patients were more likely to smoke, have diabetes, suffer
from hypertension, and be obese, relative to controls. This observation is likely to
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influence any conclusions drawn from the study, particularly in the light of the fact
that these differences were not statistically controlled for when the groups were
compared on tests of cognitive function. As expected, the comparison showed that
the amputees scored significantly worse on measures of psychomotor speed (Digit
Symbol Test) and problem solving and abstract reasoning (the Modified Card Sorting
Test). Moreover, there were trends towards worse performance on measures of
verbal fluency, concentration, and visuoperceptual skills. In their discussion, the
authors attributed this pattern of dysfunction to concomitant yet clinically
unrecognised cerebrovascular disease in the PAD patients. However, as a result of
the analytical approach used, the associations with cognitive function could equally
have been accounted for by the presence of vascular risk factors, such as high blood
pressure or diabetes.
The methodological weaknesses of this former study were partly addressed in
a subsequent investigation by Phillips and Mate-Kole (1997). Here, the authors
compared cognitive performance across three study groups: a patient group which
included both PAD amputees (n=13) and non-amputees (n=16), an atherothrombotic
stroke control group (n=29), and 30 community controls. Both control groups were
matched with PAD patients on age and education. By employing two control groups,
the authors set out to determine whether PAD patients would perform cognitively
worse than healthy controls, and moreover, if the pattern of cognitive deficits
observed in such patients would be similar to that seen in clinical stroke. The results
from the comparison to the healthy controls were in support of the study hypothesis.
In fact, PAD patients performed significantly worse on tasks of attention and
psychomotor speed, executive function, visuospatial ability, and visual memory. In
contrast, no differences were found on tests of language ability or verbal memory.
Furthermore, compared to stroke subjects, PAD patients showed very similar
patterns of deficits across cognitive domains, but of less severity. In fact, the
performance of the two groups was comparable on six out of the eight cognitive tests
used in the study. Also, when the analysis was restricted to the PAD sample, only
PAD clinical severity and history of ischaemic heart disease were found as predictors
of cognitive dysfunction in a multivariate model. In contrast, none of the
conventional atherosclerotic risk factors that were measured exerted independent
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effects on cognitive outcomes once disease severity was included. Although type 2
statistical error can not be ruled out as an explanation for the null findings, the study
provides further cross-sectional data in support of the presence of widespread
cognitive deficits in patients with PAD. In addition, it suggests that, in such patients,
the cognitive effects of various vascular risk factors may be mediated through the
role of the former in the development of generalised atherosclerotic vascular disease.
Evidence from population samples
In several community-based investigations, the presence of atherosclerosis
has been determined from clinical symptoms of arterial narrowing in the legs
(intermittent claudication). In other contexts, the ABPI has been directly measured
and used to indicate arterial stenosis. In relation to the former, Tilvis et al. (2004)
found elderly claudicants in the Helsinki Aging Study to perform significantly worse
on the MMSE at baseline compared to subjects without intermittent claudication.
However, even though the analysis adjusted for baseline age and level of education,
it neither controlled for concomitant stroke nor other vascular disease and risk
factors. Moreover, intermittent claudication was related to an increased risk (RR=2.2,
95%CI=1.4-3.2) of cognitive decline during the first follow-up year, whereby decline
was defined as either an increase in Clinical Dementia Rating (CDR) class or at least
a four-point decrease in MMSE score. On the other hand, baseline PAD was not
found to be associated with greater risk of cognitive decline at five-year follow-up,
but a significant relation with longitudinal mortality was observed. Thus, the lack of
association with long-term cognitive decline in this study could have occurred
because of selective mortality among PAD patients over the study period.
Similarly, no significant differences were found between subjects with and
without claudication at baseline with regard to the rate of decline in MMSE
performance over a six-year follow-up in the Sydney Older Persons Study (Piguet et
al., 2003). Whereas these findings were based on individuals scoring at least 25 or
more on the MMSE at baseline, identical results were noted when the analysis was
restricted to subjects having a baseline score of less than 25. In response to these
results, the authors pointed out that the role ofPAD was possibly to increase the risk
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ofmortality early in life, but in older survivors, atherosclerotic disease might have
no, or only limited, specific contribution to cognitive decline.
The use of domain-specific cognitive tests in population studies has
contributed further to the study of cognitive function in systemic atherosclerotic
disease by providing domain-specific information. However, so far findings have
been somewhat conflicting. For example, both stroke-free men and women (aged 46-
68 years) with intermittent claudication were found to perform significantly more
poorly when administered cognitive function tests for the first time 11 years post-
baseline by Singh-Manoux et al. (2003). In men with symptomatic PAD, tasks
assessing short-term memory, verbal and mathematical reasoning, word recognition
and knowledge, and executive function, were particularly affected. When expressed
as a proportion of the standard deviation for individual tests, effect sizes ranged from
0.17 (knowledge and recognition) to 0.65 (semantic fluency test). Whereas no effects
on either short-term memory or semantic fluency were observed in women with
PAD, relative to men, weaker effects were seen on lexical fluency (0.11% of a
standard deviation) but stronger on measures of knowledge and word recognition
(0.33% of a standard deviation).
In contrast, Elwood and colleagues (2002) failed to show significant effects
of intermittent claudication on cognitive test scores in another cross-sectional report
based on elderly stroke-free men in the Caerphilly study. However, since diseased
subjects were found to obtain lower scores on measures of mental speed, global
functioning, and non-verbal and verbal reasoning, the null findings may simply be
attributed to a lack of statistical power given that men with peripheral vascular
disease were relatively few (n ranged from 31 to 38 depending on cognitive
outcome).
Limited longitudinal data still exist on change in specific cognitive functions
over time in patients with symptomatic PAD, highlighting the need for further
longitudinal investigations in this area. Similarly, longitudinal research of the
association ofAPBI and domain-specific cognitive decline is greatly lacking. This
would constitute a valuable addition to the current cross-sectional findings which
point to an inverse association between APBI and cognitive performance. In an early
study by Breteler et al. (1994), the presence of a low APBI (less than 0.9) was
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associated with moderately lower MMSE scores, and a shift in the total distribution
ofMMSE scores, independent of the effects of age and education. Moreover, a low
baseline APBI was associated with a steeper decline in MMSE scores over a follow-
up period of seven years in a longitudinal study by Haan et al. (1999). These effects
were found to be independently of potential confounding by sociodemographic
factors and incident stroke. More recently, Price and colleagues (2006) analysed data
from 717 older men and women in the Edinburgh Artery Study. The ABPI was
measured at baseline and a battery of cognitive tests was administered after 10-years
of follow-up. In an age and sex-adjusted model, significant, but modest, positive
associations ofABPI were found with scores on measures of non-verbal intelligence
(Raven's Progressive Matrices), executive function (Lexical Verbal Fluency Test),
and information processing speed (Digit Symbol Test). Although it was not reported
whether estimated pre-morbid ability (National Adult Reading Test) was associated
with each cognitive outcome, when further controlled for, all associations apart from
that with the Digit Symbol Test were attenuated beyond statistical significance.
Despite its cross-sectional nature, the authors did not exclude the possibility that
atherosclerotic disease in the lower extremities might be associated with steeper
decline in cognitive function over time. Clearly, further research is needed to
establish such a relationship, and also with other cognitive abilities.
2.4.5. Study Limitations
Similar to that of stroke and CHD, studies of cognitive function in either
carotid atherosclerosis or PAD are limited in number as well methodologically. So
far, most have been cross-sectional in nature and longitudinal cognitive data have
rarely been collected. Moreover, longitudinal data on different cognitive functions
are greatly lacking. In fact, some areas of investigation, such as the study of change
in different cognitive functions in PAD patients, have been more or less unexplored.
Clinic-based studies of carotid disease tend to be based on highly-diseased
individuals, normally undergoing CEA. As with other vascular patients, extensive
co-existing disease may be present. These studies have provided some insight into
cognitive function in carotid disease even though the aim has been to estimate the
83
effects of surgery rather than atherosclerosis per se on cognition. Regarding lower-
extremity disease, some clinic-based studies have included leg amputees, who are
unlikely to be representative of the general PAD population. On occasions, cases
have been heterogeneous with respect to the underlying aetiology. In other
circumstances, PAD patients have been recruited as controls. In several population
investigations, PAD has been determined on a single occasion using questions
concerning the presence of disease symptoms. As a result, it is possible that some
true cases may go unnoticed because of remission of symptoms due to formation of a
collateral circulation. Moreover, the use of standard instruments in detecting disease
symptoms has not always been ensured.
Confounding by concomitant vascular risk factors as well as other
confounders is a major general shortcoming of the studies reviewed above. In
particular, disease categories have been found to be non-mutually exclusive of other
manifestations of atherosclerotic disease, including stroke. Only on rare occasions
have control subjects been free of any clinical cardiovascular disease. In population
studies, inadequate control for confounding is reflected in part in the limited use of
multivariate statistical methods across studies. Specifically, few attempts have been
made to examine cognitive function in lower-extremity atherosclerosis independent
of vascular risk factors.
2.4.6. Section Summary
The current literature of the relationship between peripheral markers of
atherosclerosis and cognitive function has until now been based on a relatively
limited and often contradicting body of evidence. So far, most studies have focused
on symptomatic and sub-clinical disease in two arterial beds in particular: the carotid
system and in the lower extremities. There is ample evidence showing that
atherosclerotic lesions of the carotid arteries constitute an important source of
cerebral emboli. Many may be clinically silent. Similarly, individuals with leg
disease are likely to have significant changes in other arterial beds and are at an
increased risk ofmajor vascular events. Concomitant, yet asymptomatic, cerebral and
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carotid atherosclerosis may be frequent in such individuals, predisposing them to
brain ischaemia and possibly cognitive impairment.
Based on the findings from a few clinical studies, carotid surgical candidates
are found to show generalised cognitive impairment relative to controls. Some data
in support of this have come from population cohorts but there is also a lack of
evidence for such as association. Other reports have found effects on a more
restricted set of functions. Clinic-based investigations of patients with leg disease
have been few and most of the early studies were often not designed to study
cognitive function in relation to PAD per se. Subsequent studies which have been
carried out have demonstrated intellectual deficits at a comparable level to that seen
following stroke. These studies have, however, been limited in number and based on
selected patient samples. Confounding by co-existing atherosclerotic risk factors has
also precluded an evaluation of the independent effects of atherosclerotic disease on
aspects of cognitive function. Rather than relying solely on global tasks, the use of
neuropsychological tests in population samples has provided insights into the pattern
of cognitive dysfunction in patients with symptomatic and asymptomatic PAD.
However, whereas cross-sectional data are abundant, so far there is a noticeable lack
of data linking atherosclerotic disease to change in domain-specific cognitive
abilities over time, independently of atherosclerotic risk factors and prior to clinical
cerebrovascular disease.
2.5. ATHEROSCLEROTIC RISK FACTORS AND COGNITIVE FUNCTION
2.5.1. Introduction
The prevalence of established risk factors for atherosclerotic vascular disease
increases with age in the general population. Specifically, a significant proportion of
the risk for stroke and CVDs can be attributed to factors such as high blood pressure,
smoking, diabetes, and abnormal circulating lipids. Over the past decades, there has
been intense interest in the epidemiological association of these risk factors with both
levels of normal neuropsychological functioning and cognitive impairment, not least
because of the possibility that these may be amenable to treatment or prevention.
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Furthermore, the contribution of other more recently investigated vascular risk
factors to adult cognitive function is being examined in a growing number of reports.
A major objective of the current chapter is to present findings from published
epidemiological studies of the relation of established and novel atherosclerotic risk
factors with neuropsychological function. Secondly, wherever possible, a reflection
on the potential mechanisms through which these factors may exert influence on
normal cognitive processes is provided.
2.5.2. Non-Modifiable Risk Factors
Age
As suggested elsewhere in the text, the cognitive changes observed in normal
ageing may be substantial and have attracted much attention. Data on the relation of
chronological age and cognitive function in elderly cohorts have been provided by a
number of recent, population-based, epidemiological studies (Anonymous, 1998;
Brayne et ah, 1995; Comijs et ah, 2004; Starr et ah, 1997). In cross-sectional
analyses, an inverse relation between scores on measures of global cognitive ability,
such as the MMSE, and age tends to be noted (Brayne et ah, 1995; Anonymous,
1998). Higher age has moreover been associated with a downward shift in the
distribution ofMMSE scores (Anonymous, 1998). Similar findings have been
reported in longitudinal studies which have examined change in cognitive function
over time. In the Hughes Hall Project for Later Life, a Cambridge-based dementia
prevalence study of individuals aged 75 years and older, the oldest age group
(subjects 90 years and older) declined by 3.0 points on the MMSE over a period of
two and a half years compared to that of 0.9 points in subjects aged 75 to 79 years
(Brayne et ah, 1995). Furthermore, by using various MMSE cut-off points in order to
assess the two and a half-year incidence of cognitive impairment, similar patterns
were found, with an increase in new impairment at each age level in the study
population irrespective of the cut-off point chosen.
Further recent data came from the Longitudinal Aging Study Amsterdam
which found the risk of progressive cognitive decline on the MMSE over a period of
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six years to be strongly but inversely related to baseline age (Comijs et al., 2004). An
administration of a cognitive test battery in the Massachusetts Male Aging Study
further demonstrated an inverse, linear association between chronological age and
performance on measures of working memory, speed and attention, and spatial
relations, in 981 middle-aged to older men (Fonda et al., 2005). Moreover, in a study
of 102 high-functioning professional men and women, notable age differences were
observed on a number of different cognitive tasks after differences in level of
education were controlled for (Compton et al., 2000). Thus, for example, older
subjects tended to perform relatively poorly on the Digit Symbol and the Trails A
and B tests. In contrast, older subjects obtained higher scores on the WAIS-R subtest
of similarities.
These findings, and those of numerous other studies (Gregoire and Van der
Linden, 1997; Schaie, 1996), lend further support to the well-known pattern of
differential effects seen in cognitive ageing, whereby tasks of crystallised functions
seem quite resistant to the ageing process, while those acquired as a result of genetic
factors (fluid abilities) may be particularly vulnerable (Compton et al., 2000; Deary
and Batty, in press). Despite the correlation with age, however, it is still open to
debate whether the observed patterns of cognitive decline occur as a result of ageing
per se, stem from the effects of concomitant age-associated pathologies, or both
(Hedden and Gabrieli, 2004; Starr et al., 1997). Whereas it has been proposed that
specific developmental changes in neural structure and function may underlie age-
associated cognitive decline (Bartzokis, 2004; Hedden and Gabrieli, 2004), the
incidence of diseases with long and progressive preclinical phases also rises with
age. Failure to adequately control for such age-associated pathologies, which are
likely to affect cognitive function even at subclinical levels, can falsely lead to the
assumption that the ageing process itself is the underlying cause of the observed
cognitive decline. In particular, this may pose as major challenge when investigating
cognitive processes in old age.
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Sex
The hypothesis of sex differences in later-life cognitive function has been
investigated in a series of recent population-based epidemiological studies. A general
lack of studies in this area has, however, been noted (Barrett-Connor and Kritz-
Silverstein, 1999), and somewhat conflicting findings exist. In particular, cross-
sectional studies have reported mixed results regarding sex differences in cognitive
performance of older people. For example, men were found to obtain higher mean
MMSE scores at baseline in both the Hughes Hall Project for Later Life (Brayne et
al., 1995) and the MRC CFA Study (Anonymous, 1998). In contrast, no sex
differences were observed in general ability as indexed by either the sum of the
WAIS-R subtests (Portin et ah, 1995) or the CAMCOG instrument (Cullum et ah,
2000).
Even though inherent weaknesses in the cross-sectional study design have
been mentioned as possible explanations for these null findings, similar contradictory
findings have also been noted in longitudinal studies. As an example, in addition to
having a higher mean MMSE score at baseline, male subjects in the Hughes Hall
Project for Later Life further experienced less (1.56 points) 2.5-year decline in
mental status (adjusted for age and baseline performance) compared to women (2.19
points) (Brayne et ah, 1995). These findings were, however, not replicated in two
recent studies of longer follow-up periods, applying either the MMSE (Comijs et ah,
2004) or a measure of global cognitive function based on 19 different cognitive tests
(Barnes et ah, 2003). Moreover, there is no indication that men and women perform
differently at different ages in old age.
Some evidence in support of sex effects on cognitive function in elderly
persons comes from studies that have administered neuropsychological test batteries.
In sum, cross-sectional analyses have suggested that women may outperform men on
memory (Aartsen et ah, 2004; Barrett-Connor and Kritz-Silverstein, 1999; Portin et
ah, 1995) and vocabulary tasks (Barrett-Connor and Kritz-Silverstein, 1999). In a
Finnish study, elderly women performed better than men on tests of visuomotor and
reciting speed and verbal and object memory (Portin et ah, 1995). In contrast, men
scored higher on measures of visuospatial speed and visuoconstructive performance.
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Whereas more recent (Aartsen et al., 2004; van Exel et al., 2001) cross-sectional
work has further replicated the above pattern, results from longitudinal analyses have
been less suggestive. For example, no sex differences in 4-year risk of decline on any
of the eight CAMCOG subscales in the CC75C study were noted (Cullum et al.,
2000). Neither were there any differences between men and women with regard to
the rate of decline on several measures of speeded tasks over a period of six years in
the Longitudinal Aging Study Amsterdam (Aartsen et al., 2004).
Several explanations have been proposed in order to account for sex
differences in cognitive function in old people, among them male-female differences
in brain reserve (van Exel et al., 2001) and differential susceptibility to normal or
pathological age-associated changes (Barrett-Connor and Kritz-Silverstein, 1999;
van Exel et al., 2001). Based on the current evidence, however, it is clear that more
work is needed in order to verify the similarities and differences in cognitive function
between men and women. That work would begin by properly addressing the
methodological limitations of existing studies, such as excluding potential
confounding by diverse health and lifestyle factors, before moving on to speculations
about causal mechanisms.
2.5.3. Major Modifiable Risk Factors
Blood Pressure
One of the most studied risk factors for cognitive decline is high blood
pressure. Blood pressure is easily measured, potentially modifiable, and a strong
predictor of cerebrovascular disease. As a result, it has been a candidate variable in a
number of epidemiological studies probing into the aetiology of individual
differences in cognitive function in later life. So far, however, somewhat mixed
results have been produced. In an early study carried out on 202 non-institutionalised
subjects aged 60-79 years at baseline, Wilkie and Eisdorfer (1971) examined the
relationship of diastolic blood pressure (DBP) with WAIS scale scores at baseline
and 10 years later. The results showed that hypertensives (DBP >105 mmHg) had a
lowerWAIS score than either normotensives or borderline subjects (DBP 96-105
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mmHg). Also, over the 10-year follow-up, only the hypertensive group declined in
the full WAIS scale score. These findings were only seen in those aged 60-69 years
at baseline as opposed to 70-79 years old subjects, none of whom classified as having
hypertension at baseline returned for post-testing. When the data were pooled, DBP
was negatively related to the majority ofWAIS verbal and performance scale sub¬
tests at follow-up in the younger age-band only. Importantly, even though subjects
with a history of cerebrovascular disease were excluded, the study was based on few
subjects who might or might not have been treated with antihypertensive agents.
Confounding by medication was taken into account in two subsequent cross-
sectional analyses based on the Framingham (Fanner et al., 1987) and the East
Boston Study (Scherr et al., 1991) cohorts. In short, both studies failed to find any
convincing evidence of a relationship, in either direction, between systolic blood
pressure (SBP) and DBP, when determined on a single occasion in old age, and
performance on a series of cognitive tests. Excluding those taking antihypertensives
was not found to alter the results (Farmer et al., 1987). Moreover, in a third study
(Herbert et al., 2004), largely composed of older African-Americans who have been
found to be at an increased risk of hypertension, no relation of either SBP or DBP
with 6-year change in MMSE scores was noted. Approximately 50% of study
participants were receiving antihypertensive medication. While the exact reasons for
these null findings remain speculative, it has been argued, that in older cohorts, other
pathological factors than blood pressure may be operating concomitantly to
compromise mental processes (Wilkie and Eisdorfer, 1971).
The timing of blood pressure measurement relative to the cognitive
assessment may therefore prove to be fundamental to the investigation of this
association. Moreover, nowadays it can be anticipated that a substantial proportion of
elderly individuals may be receiving treatment for hypertension. It is, however,
unclear how accurately the measured blood pressure values in these elderly actually
reflect long-term exposure levels (Herbert et al., 2004). These problems have been
dealt with in a series of large-scale epidemiological studies where cognitive tests
were administered to untreated hypertensive patients, and test scores were related to
blood pressure levels determined in mid-life. In the Framingham Study, blood
pressure values were averaged over five biennial examinations during the period
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1956-1964 when few hypertensive participants received antihypertensive treatment
(Elias et al., 1993). With cognitive function assessed 12 to 14 years later, the results
for the total sample showed a negative, linear relationship between both SBP and
DBP and performance on a global composite score as well as on several WAIS
subtests (the Logical Memory immediate and delayed recall, the Visual
Reproductions, and the Digits Backward). Specifically, every 10 mmHg increase in
blood pressure was associated with a decline of 0.04 to 0.07 standard deviations in
the composite score. Identical results were obtained in sub-analyses of participants
who were untreated at the time of blood pressure measurement or throughout the
entire study period.
Subsequent studies using data from midlife blood pressure assessments have
reported similar findings. For example, an analysis based on old Japanese-American
men in the Honolulu-Asia Aging Study observed a nine percent increase in risk of
poor cognitive function (a CASI score of <82) for every 10 mmHg increase in SBP
levels determined approximately 25 years earlier (Launer et ah, 1995). Another
study, involving 999 elderly Swedish men, linked cognitive performance at age 70 to
blood pressure levels assessed 20 years earlier (Kilander et ah, 1998). Levels of
DBP, rather than SBP, were found to be inversely associated with composite test
scores obtained in old age. Stronger associations were observed in men who, at the
time of blood pressure assessment, were not taking antihypertensive medication. In
contrast, another population-based study failed to find evidence of an association
between either SBP or DBP (assessed either at baseline or nine years before
cognitive testing) and scores on two brief, global cognitive measures (Glynn et ah,
1999).
Collectively, the pattern of findings from the studies described above
suggests, that whereas blood pressure in old age may contribute relatively weakly to
cognitive impairment over and above that of other morbidity, midlife levels short of
hypertension may result in trajectories which, lasting throughout the adult life, may
contribute to individual differences in cognitive function in late adulthood (Swan et
ah, 1998).On the other hand, evidence shows that the association between blood
pressure and cognitive function in old age may be to some extent be accounted for by
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individual differences in childhood mental ability (Starr et al, 2004), which needs to
be acknowledged as a potential confounding factor in such studies.
Blood Lipids
The current literature of the relationship between blood lipid levels and
neuropsychological function has been limited to relatively few reports. Based on
these studies, results have been mixed as to whether blood lipid concentrations are
positively, negatively, or indeed at all, associated with adult cognition. As early as in
1963, beneficial effects on cognitive performance were demonstrated by actively
lowering the level of total serum cholesterol (TC) in 174 healthy, male management
and scientific employees (Reitan and Shipley, 1963). Of particular interest was the
finding that, in comparison to men (above 40 years of age) who did not experience a
reduction in TC levels by either sitosterols or diet, those whose TC concentration
was decreased by at least 10% had better cognitive scores on problem-solving and
reasoning tasks after 12 months of follow-up. Unfortunately, however, the validity of
these results may be questioned given that treatment was not randomised, the
comparison groups differed in baseline TC levels, and blinding with respect to
treatment was not applied (Muldoon et al., 1997).
Subsequent clinical trials have not corroborated the early results reported
above. For example, in the Cholesterol Reduction in Seniors Program (CRISP), a
small-scale trial of elderly men and women with elevated LDL-cholesterol levels
who were randomised to lovastatin treatment, no differences in Digit Symbol scores
were found between two treatment groups and a placebo group after six months of
follow-up (Santanello et al., 1997). This was despite large reductions in TC and LDL
levels in both treatment groups. In another recent randomised clinical trial involving
young to middle-aged adults, a battery of cognitive tests was administered in order to
assess patients' tolerance of lipid-lowering treatment (Muldoon et al., 2000). The
results from this trial showed an improvement in memory performance over a six-
month follow-up among subjects in the treatment arm. Similarly, the placebo group's
performance on several cognitive measures, such as on tasks of attention and
psychomotor speed, also improved significantly over the same period. Despite being
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'gold standard', it is possible that the small samples and short follow-ups of these
trials contributed to these somewhat disappointing results.
In a similar manner, an even larger body of observational data has neither
been able to shed light on the direction of the blood lipid-cognition relationship in
any consistent way. In fact, any meaningful synthesis of the literature has proved to
be difficult due to vast methodological differences across studies. For example, a
positive association was reported between TC levels and both P300 latency (Wada et
al., 1997) and steeper 3-year decline in MMSE scores (Wada et al., 1997) in two
small-scale studies on Japanese elderly. Similar findings came from a recent analysis
based on the Framingham cohort (Elias et al., 2005), in which multiple measures of
TC were used and cognitive function was assessed on a single occasion. In
comparison to subjects with high (>240 mm/dL) and borderline-high (200-239
mg/dL) TC concentrations, subjects with low or 'desirable' values (<200 mg/dL)
scored lower on the WAIS similarities test, and tasks based on word fluency and
attention. In contrast, however, no relationship was noted between TC levels and
cognitive performance in Leiden 85+ data (van Exel et al., 2002), although low high-
density lipoprotein (HDL) levels were associated with poorer mental status scores
(but unlikely of clinical relevance). Neither LDL-cholesterol nor triglyceride levels
were related to cognitive function. Still further, two other population-based studies
also failed to demonstrate a relationship between blood lipid parameters and scores
on several neuropsychological tests (Reitz et al., 2005; Sarti et al., 2001).
Despite the inconsistency in epidemiological findings, a positive association
between blood lipids and intellectual functioning may have biologic plausibility. For
instance, the brain has a high lipid content, and low circulating lipid levels, perhaps
resulting from chronic morbidity and/or poor nutrition intake or absorption in old
age, may directly affect neuronal metabolism, neurotransmitter synthesis, and
cognitive processes. In the light of this possibility, it is intriguing to consider the
findings from two studies demonstrating a negative association between blood lipid
concentrations and cognition. In the earlier report, Yaffe et al. (2002) examined the
development of blood lipid levels over a 4-year period in more than 1000
postmenopausal women with CHD who participated in the Heart and
Estrogen/progestin Replacement Study. Administering the MMSE at the end of the
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follow-up, the investigators first showed that higher levels of TC and LDL, but
neither HDL nor triglycerides, were associated with lower MMSE scores and
increased odds of impairment (more than 1.5 SD below the cohort mean). Moreover,
reductions in both TC and LDL over the 4-year period were associated with better
MMSE scores and lower odds of impairment. In addition, statin use, although not
randomised, was also associated with better cognitive performance. Beneficial
effects of statin use on IQ change from childhood to old age in dementia-free older
survivors of the Scottish Mental Health Survey were also noted by Starr et al (2004).
In the latter of the two investigations mentioned above, an inverse
relationship between performance on different cognitive task and serum levels of
various precursors and metabolites of cholesterol metabolism was observed, even
though no relation with TC was found (Teunissen et al., 2003). In this analysis based
on data from the Maastricht Aging Study cohort, higher concentrations of lanosterol
and lathosterol, which may be suggestive of greater rates of cholesterol synthesis,
were related to poorer performance on verbal learning and memory tasks,
independently of age, sex, and education. Whereas not examined in these
investigations, it is possible that the inverse relationship of blood lipid levels with
cognitive outcomes may be fully or partly mediated through atherosclerosis-based
co-morbidity.
Smoking
Smoking is a major modifiable risk factor for vascular and pulmonary
diseases, and there has been interest in the possibility that smoking may be
associated with poor cognitive function. So far, however, findings have been
inconclusive (Elwood et al., 1999; Richards et al., 2003). Results from the
population-based Zutphen study of elderly men demonstrated 20% more errors on
the MMSE in current smokers compared to never-smokers (Launer et al., 1996).
Level of disagreement between current smoking status and reported smoking history
five years earlier was assessed, and found to be independent of cognitive function
and disease. However, in a subsequent report based on the Caerphilly cohort
(Elwood et al., 1999), no differences in MMSE performance were observed between
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current and never-smokers. Whereas not assessed in the former study, no clear
evidence of an association between the amount and duration smoked and cognitive
test performance was found in the latter investigation. Such a null result had also
been reported earlier by Galanis and colleagues (1997) who examined performance
on global cognitive tasks in relation to pack-years of smoking in elderly Japanese-
American men. In all the studies, smoking was assessed by self-report which may
invite recall bias to the data. Even though smoking status may be relatively well
reported, self-report of exposure levels by older people may be influenced by
cognitive status at the time of assessment (Woodward, 2002).
The above issues have partly been addressed in other studies. For example, in
one recent investigation, 9209 participants aged 65 years and older were followed
over a mean period of 2.3 years (Ott et al., 2004). Administering the MMSE, the
study showed that both male and female current smokers declined at a greater rate
compared to those who had never smoked. In addition, a weak but statistically
significant inverse relationship was found between the rate of cognitive decline and
the number of pack-years of smoking, thereby providing further evidence of a
deleterious influence of smoking on cognitive processes in older people. However,
whereas potential confounding by any of a number of disease and psychological
factors could have accounted for these findings, this was unlikely to be the case in an
earlier analysis based on the British 1946 birth cohort study (Richards et al., 2003).
Adjusting for a range of possible confounders, among them an estimate of early-life
cognitive ability, the investigators studied change in cognitive functions from age 43
to 53 in both men and women. Despite the young age of the sample, a significant
trend was noted between the number of cigarettes smoked at age 43 and the rate of
10-year change in performance on a memory task. Based on such findings, the
effects of smoking on cognitive function may seem at least partly direct rather than
being totally mediated through either vascular or pulmonary pathology (a notion
empirically demonstrated later by Whalley et al. (2005) in an investigation based on
survivors of the Scottish Mental Health Survey). For example, it is possible that
smoking may upset various cerebral blood flow parameters. On the other hand, the
effects of smoking could be accounted for by other unknown mechanisms.
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The value of giving up smoking for mental functioning in old age has been
the focus of several epidemiological studies and an important line of research in this
field. In the Caerphilly cohort (Elwood et ah, 1999), no differences in cognitive
performance were found between former smokers and never-smokers, and in the
MORGEN study in the Netherlands (Kalmijn et ah, 2002), scores on the Verbal
Learning Test and the Stroop were found to be between those of current and never-
smokers. Whereas Galanis et al. (1997) noted that the likelihood of scoring poorly on
the CASI instrument was inversely related to the time since quitting smoking in
elderly Japanese-American men, it has also been pointed out that giving up smoking
may be related to a reduced rate of decline in specific cognitive functions (Richards
et ah, 2003).
Body Weight
Increased body weight is associated with elevated risk of premature
cardiovascular mortality and morbidity, including stroke. In particular, obesity is a
risk factor for hypertension and type II diabetes, and may be related to disturbed
blood lipid levels. In this context, a relationship might also exist between body
weight and cognitive function. For example, body weight may act as a moderator of
vascular risk factors, including hypertension (Elias et ah, 2001). However, it has also
been suggested that overweight might contribute more directly to impairment in
cognitive function, perhaps through its pro-inflammatory potential (Jeong et ah,
2005), eventually leading to structural brain changes (Jagust et ah, 2005). Despite the
biological plausibility of such an association, a recent review of the epidemiological
literature underscored the relative paucity of studies in this area (Elias et ah, 2001).
In an early population-based study of older men, an absence of a linear
association between the body mass index (BMI) and performance on a global
cognitive task was noted (Kilander et ah, 1997). However, a high BMI (>28.6) was
moderately associated with lower performance, independently of age, education,
occupation, and history of stroke. Similarly, a sex-specific analysis based on data
from the Framingham Study demonstrated poorer mental ability in obese individuals
(BMI > 30) (Elias et ah, 2005). After control for sociodemographic and vascular risk
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factors, obese men scored relatively worse on a global composite score, and on the
WAIS visual reproductions and digit span backwards subtests. Relative to subjects
with a BMI of less than 23, those with a BMI equal or greater than 25 had poorer
mental status scores, but these results were limited to participants with a waist
circumference ofmore than either 80 (women) or 90 cm (men) (Jeong et al., 2005).
In subjects with low abdominal obesity, a BMI level between 23 and 25 was
associated with lower global ability scores. In contrast to these findings, a study
involving community-resident older men failed to establish an association between
BMI and measures of global ability and information processing speed after
controlling for multiple confounders (Alemann et al., 2005).
Physical Inactivity
Whether physical inactivity is associated with impairment in cognitive
function in old age has been the focus of study in a number of investigations. In an
early observational study by Rogers et al. (1990), a greater 4-year decline in bi-
hemispheric cerebral blood flow was observed in physically inactive retired, elderly
subjects after annual blood flow measurements. In contrast, subjects who maintained
a high level of physical activity over the study interval experienced no decline in
cerebral blood flow. Moreover, performance on a global cognitive task, the
Cognitive Capacity Screening Examination, was significantly worse in the physically
inactive group. In a study by Hultsch et al. (1993) cognitive function was examined
in 484 men and women aged 55-86 years who self-reported participation in physical
activities. Using linear regression analysis, a positive, statistically significant
association was found between levels of physical activity and performance on
measures of verbal fluency, word recall, and text recall. In other words, more
exercise was associated with better cognitive performance. In addition, exercise
levels were inversely associated with performance on tasks assessing semantic
processing time and comprehension time.
In another investigation, in which 858 Australian community-resident elderly
subjects were administered a cognitive test battery, moderate positive associations
were observed between self-reported and informant-reported activity levels and
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performance on both global and domain-specific cognitive tests (Christensen et al.,
1996). In particular, for certain timed tasks, a significant interaction between level of
activity and age were found, suggesting that participation in physical activities may
offset the effects of age on these cognitive measures. In doing so, it has been
suggested that greater exercise may lower vascular risk and/or directly stimulate the
growth of neurons and prolong their survival (Yaffe et ah, 2001). It must be noted,
however, that in all these studies, a single summary score capturing a large number
of different leisure activities was used for the computation of exposure status. In
some instances, other activities than those strictly physical in nature were included.
As a result, important aspects of the assessment of the level of exercise, including its
type, intensity, and duration, were unavailable to these analyses.
Perhaps in response to the limitations experienced by the studies above, a
series of recent reports have investigated the above relationship in more detail, and
what is likely to be of importance for health promotion strategies, the impact of
commonly performed everyday activities on mental performance. For example, in
the Study ofOsteoporotic Fractures (SOF) (Yaffe et ah, 2001), cognitive function
was assessed with the MMSE at baseline and follow-up six to eight years later in
5925 community resident women. A major objective of the study was to examine the
relationship between performance and decline on the MMSE and baseline physical
activity levels (blocks walked and total kilocalories expended per week). The results
demonstrated a significant trend whereby greater levels of exercise were associated
with less risk of cognitive decline. Moreover, for every mile (approximately 1.6
kilometres) walked per day, women had a 13% lower risk of decline. Similar levels
of reduced risk were associated with every standard deviation of total kilocalories
expended per week.
Pignatti et ah (2002) also noted that high baseline levels of physical activity
(walking at least two kilometres a day) were associated with decreased decline on the
Mental Status Questionnaire over 12 years of follow up in elderly Italian women.
Lastly, in a large sample of over 16000 women recruited to the Nurses' Health
Study, in which physical activity was based on a series ofmeasures prior to cognitive
testing, a positive association between the two was observed (Weuve et ah, 2004).
Specifically, a significant relationship across quintiles of physical activity was noted
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for both measures of global cognitive ability and specific cognitive functions. The
mean differences across quintiles of exposure were equivalent to the mean
differences that were observed for women two to three years apart in age. With
respect to walking, differences in cognitive scores associated with walking at an easy
pace for at least one and a half hour a week (compared to less than 38 minutes a
week) were equivalent to those that were observed for women approximately one
and a half years apart in age. Multivariate adjustment did not materially affect the
findings which also were observed when subjects with extreme values were excluded
from the analyses. Whether the above observations are also applicable to men
remains to be tested. In sum, however, these results do strongly point to the role of
low-intensity everyday exercise levels in the preservation of intellectual processes of
elderly people.
Diabetes
Diabetes mellitus is characterised by elevated circulating blood glucose levels
(hyperglycaemia), which through damage to small and large blood vessel, may lead
to premature vascular and neurological complications. The adverse influence of type
I diabetes on cognitive function in adults has been well established (Ryan, 2001). In
contrast, the relationship of type II diabetes with neuropsychological processes has
only been investigated more recently. Whereas the focus of studies of type I diabetes
has mostly been on the cognitive effects of intensive glycaemic control
(hypoglycaemia and/or hyperinsulinaemia), type II diabetes studies have largely
concentrated on the role of the disease itself (Asimakopoulou et ah, 2002). With
respect to the latter, contradictory findings regarding an association with cognition
have widely been found (Kalmijn et ah, 1995; Perlmuter et ah, 1984; Robertson-
Tchabo et ah, 1986). A recent review which was based on over 20 studies
highlighted a number ofmethodological shortcomings of published reports (Strachan
et ah, 1997). Despite this, in a majority of studies, type II diabetes was found to be
negatively associated with at least one aspect of cognition in middle-aged and older
individuals. Accordingly, the most consistent association reported was with tasks of
verbal memory, but also with measures of global or other domain-specific abilities.
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Cognitive deficits in relation to type II diabetes have further been shown in
subsequent reports, some of which have addressed the methodological limitations of
earlier investigations. For example, an analysis based on the Framingham Study
found diabetic subjects more likely to perform poorly (below the 25th percentile) on
the delayed recall component of the WAIS logical memory test (Elias et al., 1997).
Performance on the other WAIS subtests did not vary with disease status. Small but
significant differences in verbal memory (immediate recall only) and mental
flexibility were also reported in a methodologically rigorous comparison of subjects
with and without type II diabetes, matched on age, sex, IQ, morbidity, and
medication use (Asimakopoulou et al., 2002). Moreover, in a large-scale study of
elderly women, the largest effects of diabetes were observed on immediate and
delayed word recall (Crooks et al., 2003).
In contrast to the above, the finding of a selective deficit in memory
associated with type II diabetes was not corroborated in a large sample of middle-
aged male and female civil servants (Kumari and Marmot, 2005). It was noted,
however, that the absence of an association with memory might be due to the
relatively young age of the cohort. Possibly, the negative effects of diabetes on
memory might not be sufficiently manifest at this age level. Alternatively, memory
might predominantly be affected by medical comorbidity rather than diabetes per se,
and if so, the relatively low prevalence of diabetes complications in middle-age may
partly be responsible for these results. With respect to this latter point, there is some
evidence suggesting that the effects of type II diabetes-associated vascular
complications on cognitive performance in elderly people may actually be less
detrimental than those related to poor glycaemic control (Gradman et al., 1993;
Sommerfield et al., 2004; Gallacher et al., 2005).
2.5.4. Other Modifiable Risk Factors
Peak Prior Cognitive Ability
In addition to influence of adult social circumstances on cognitive function
(reviewed in a later section), a growing body of evidence suggests socioeconomic
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conditions in early life may also be important for subsequent intellectual
development and levels of functioning in adulthood (Luo and Waite, 2005; Singh-
Manoux et al., 2005). In a series of recently published reports, markers of childhood
socioeconomic circumstances have been positively associated with indicators of
childhood health (Luo and Waite, 2005), adult educational attainment (Richards and
Wadsworth, 2004), and socioeconomic status (Singh-Manoux et al., 2005), all of
which may act as major determinants of physical and psychological functioning in
old age. In other words, childhood socioeconomic conditions may greatly influence
adult living and working conditions, and it could be through such circumstances that
social inequalities in old-age levels of functioning and health are realised.
There is also, however, evidence ofmore direct effects of poor childhood
conditions, such as low socioeconomic status (Kaplan et al., 2001; Luo and Waite,
2005) and adverse home conditions (Richards and Wadsworth, 2004) on both levels
of performance and the rate of decline on global and domain-specific cognitive
measures in middle-aged and older adults. Despite some contradictory evidence
(Singh-Manoux et al., 2005), these findings are in support of the perspective that
childhood socioeconomic status may have long lasting imprint on cognitive functions
irrespective of other experiences over the intervening years. In these terms, a more
advantageous socioeconomic environment in early life may directly affect cognitive
development, possibly through a greater exposure to cognitive stimuli (Everson-Rose
et al., 2003), thus providing a buffer against cognitive deterioration in later life. On
the other hand, childhood socioeconomic status may act as a proxy for 'cognitive
reserve' or pre-morbid cognitive ability (as discussed by Richards and Deary (2005),
and already mentioned herein, the brain's "cognitive reserve" concept maintains
there are aspects of brain structure and function that can buffer the effects of
neuropathology such that the greater the reserve, the more severe the pathology must
be to induce functional impairment).
Employing more proximal indicators of cognitive reserve, several studies
have demonstrated a relation of levels of childhood ability, as estimated from
performance on mental ability tests, with diverse health outcomes in later life. For
example, lower ability levels are related to an increased risk of all-cause and cause-
specific mortality and morbidity (Batty et al., 2005; Deary et al., 2004; Hart et al.,
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2003; Hart et al., 2004), greater frailty (Deary et al., 2004), and poorer quality of life
(Bain et al., 2003). In contrast, higher ability is associated with less cognitive decline
in adult life (Richards et al., 2004), even though an earlier study, using less precise
methods, failed to confirm this (Rabbitt et al., 2003). In a study ofmen and women
born in 1946, Richards et al. (2004) noted an inverse relationship between measured
ability levels at age 15 and the rate of decline on tasks ofmemory and search speed
from age 43 to 53 years. More importantly, these results were observed after later-
life educational and occupational attainment as well as several health indicators were
statistically controlled for.
In sum, these findings suggest that childhood cognitive ability, vastly shaped
by early-life socioeconomic conditions, exerts important influence on adult
intellectual capacity, possibly through its relation with adult socioeconomic
attainment and associated exposures, but also independently, by providing greater
resistance to the effects of diverse pathological insults.
Educational Level
A substantial body of literature now exists on the relationship between early-
age educational attainment and cognitive function in later life. The finding of a
strong positive association between years of formal education and better cognitive
performance, and less decline, has almost been the norm across various population-
based epidemiological studies (Lee et al., 2003; Seeman et al., 2005; Wight et al.,
2002). Moreover, such an association has been noted in both representative (Cagney
and Lauderdale, 2002) and selected (Lee et al., 2003; Seeman et al., 2005) study
populations, in men (Wight et al., 2002) and women (Lee et al., 2003), and in
different ethnic groups (Cagney and Lauderdale, 2002).
In several cross-sectional reports, higher scores on global measures of
cognition were found to be positively related to level of education. In the MRC CFS
Study (Anonymous, 1998), baseline MMSE scores increased as the number of years
of full-time education completed increased. Time spent in full-time education was
negatively associated with the proportion of subjects showing cognitive impairment.
Similar cross-sectional findings were demonstrated in the MacArthur Studies of
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Successful Aging (Seeman, 2005), the Nurses' Health Study (Lee et al., 2003), and
in the National Longitudinal Surveys of Older Men (Wight et ah, 2002). Findings
from studies that have collected longitudinal data on specific cognitive abilities have
lent further support to the above results, even though differences in study populations
and cognitive tasks may be the underlying reason for the observed heterogeneity
regarding what aspects of cognition may be involved. For example, formal
educational attainment was highly positively associated with performance on all five
measures of both crystallised and fluid abilities in elderly men and women in the
MacArthur Studies of Successful Aging (Seeman et ah, 2005), but only with
measures of psychomotor speed in the Leiden 85-plus Study (and not with memory
functions) (van Exel et ah, 2001).
On the other hand, in the CC75C study (Cullum et al., 2000), an inverse
association between the rate of 4-year decline and level of education was only
observed for the CAMCOG Memory subscale. Despite such inconsistencies, the
mere fact that an association is consistently found between education level and
cognition has prompted an inquiry into the potential mechanisms for this
relationship.
Several hypotheses have been proposed to account for the relationship
between education and cognitive function (Lee et al., 2003; Seeman et al., 2005). For
example, one explanation states that education may serve as a marker for other
education-related factors, including health status and lifestyle choices (Seeman et al.,
2005). In most studies, however, an education-cognition association has been found
after the statistical control of numerous health and lifestyle-related indicators. In a
second hypothesis, it is postulated that the relation of education with cognitive
function is in fact artefactual, perhaps due to a cultural bias in the assessment of
neuropsychological function or better test-taking ability of individuals with more
formal education. Given that this association has been found in different ethnic
cohorts, where access to formal education may vary substantially according to
subjects' ethnicity, makes this an unlikely explanation (Cagney and Lauderdale,
2002). A third perspective, consistent with the 'use it or lose it' hypothesis, suggests
that education may lead to occupations or personal and social environments which
are more likely to include mental stimulation throughout the life-course. In fact, there
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is evidence for better cognitive ability in mid to late life in individuals who engage in
leisure activities (Singh-Manoux et al., 2003) and continued education (Wight et al.,
2002), even though the cognitive benefits of such activities may be most evident in
those with the least formal education (Wight et al., 2002). Finally, it is possible that
education may be associated with more direct influence on cognitive processes,
perhaps through greater dendritic branching, ultimately resulting in more brain
'reserve' capacity. Despite the challenges involved in testing this last hypothesis,
based on the current empirical evidence, the first two seem unlikely explanations for
the widely observed association between level of formal educational attainment
during the formative years and cognitive function in later life (Cagney and
Lauderdale, 2002; Seeman et al., 2005).
Socioeconomic Status
Socioeconomic variability in adult health has been well established and
recently has the association with levels of cognitive ability gained interest. A
prominent feature of the growing body of literature in this area is the use of
heterogeneous indicators of socioeconomic status across studies, among them being
level of education (Cagney and Lauderdale, 2002; Turrell et al., 2002), type of
occupation (Cullum et al., 2000; Jorm et al., 1998), household income (Cagney and
Lauderdale, 2002; Richards, 2004), and personal wealth (Cagney and Lauderdale,
2002). In this discussion, the focus is exclusively on non-educational indicators of
socioeconomic status. Cross-sectional studies, investigating cognitive performance in
relation to occupational social class, have found class level to be inversely associated
with scores on measures of global ability, such as the MMSE (Anonymous, 1998;
Gallacher et al., 1999). For example, lower occupational class was associated with a
greater 4-year decline on the CAMCOG Attention/ Calculation subscale in the
CC75C study of elderly people (Cullum et al., 2000).
A similar association to the above was noted with respect to the rate of 10-
year decline on tasks assessing memory and search speed (in men only) in middle-
aged adults (Richards et al., 2004). In this latter study, the association with social
class was relatively weak. It is therefore possible, that the lifetime impact of
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occupation, and associated exposures, on cognitive processes in these middle-aged
individuals may not have been fully realised at the time they underwent
neuropsychological assessment. In a related enquiry carried out by Jorm et al. (1998),
the cognitive effects of lifetime occupational activity rather than job-associated
hazardous exposures, health behaviours, or access to medical care, were studied in a
sample ofmen aged 70 years and more. Using a classification of occupations based
on their psychological demand, an age and education-adjusted cross-sectional
analysis demonstrated that the poorest relative performance on the MMSE, the
Episodic Memory Test, and the Symbol-Letter Modalities Test, was in men who had
worked for most of their lives in skilled trade, technical, and service occupations.
The use of occupation as an indicator of socioeconomic status has important
limitations, particularly in studies involving people of retirement age (Cagney and
Lauderdale, 2002). For example, commonly used scales based on salaried lifetime
occupation may not rank women's occupations as appropriately as they do men's.
Moreover, the most recent, or current, occupation of older people may itself reflect
poor health and diminished levels of functioning. In response, more direct measures
of socioeconomic status have been advocated. For example, positive associations
were found between current household income and performance on a cognitive test
battery in a cross-sectional analysis of the AHEAD survey of older people (Cagney
and Lauderdale, 2002). Similar findings were reported for older Finnish men in the
Kuopio Ischaemic Heart Disease Risk Factor Study (Turrell et al., 2002).
The above finding was not, however, corroborated in a more homogeneous
sample of elderly women in the Nurses' Health Study (Lee et al., 2003). The lack of
association in the last study may reflect the inherent limitations involved in using
current household income as a measure of socioeconomic status of old people since it
does not reveal significant income disparities that may have prevailed before
retirement. This may be of particular relevance to elderly women whose
socioeconomic status is closely tied in with their husband's occupation (Cagney and
Lauderdale, 2002). Moreover, current household income does not reflect the value of
accumulated assets, such as property and personal savings, which may act as a better
indicator of cumulative socioeconomic influence over a person's lifespan (Cagney
and Lauderdale, 2002). Turrell and colleagues (2002), who advocated a life-course
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perspective in the study of cognitive ability in adulthood, reported on the consistent
impact of socioeconomic mobility over the life-course on late-life mental
functioning: better cognitive performance was observed for men who occupied a
disadvantaged childhood status and then demonstrated upward mobility over the life-
course than those of similar status in childhood but did not show such upward
change. Similarly, subjects of high childhood socioeconomic status but who later
experienced downward mobility were cognitively worse off in later life than those
who maintained a similar position throughout life. Also, the number of times
subject's found themselves in a low socioeconomic position over the life-course was
strongly and inversely related to performance on both global and domain-specific
cognitive tasks.
Although the exact mechanisms of such an association has yet to be
identified, these findings are in support of a general hypothesis which proposes that
cognitive ability in late adulthood may be shaped through the positive or negative
influence of exposures over time, including those that are associated with
socioeconomic status at different stages during the person's lifespan (Richards and
Deary, 2005; Turrell et al., 2002).
Alcohol Consumption
In early investigations of the relationship of alcohol with mental outcomes,
heavy drinking was found to be associated with an increased risk of cognitive
impairment (Saunders et al., 1991). In more recent studies, the interest has been on
the long-term effects of regular, moderate alcohol intake on cognitive processes. So
far, however, findings have been mixed. For example, in the Zutphen Elderly Study
(Launer et al., 1996), moderate drinking (<26.4 grams of alcohol) per day in the
preceding month) was associated with a lower risk of poor performance on a global
ability test. In contrast, no relationship was found between the amount of alcohol
consumed and performance on several cognitive tests, including the MMSE, in the
Caerphilly cohort study (Elwood et al., 1999). One possible explanation for this
discrepancy may be that, in the former analysis, the comparison group included both
lifetime abstainers as well as ex-drinkers. Indeed, the lowest intake category was
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preferred as the reference level in the Caerphilly study since former drinkers were
found to have both worse cognitive function and more co-morbidity. However, in a
third study, essentially no change in results was observed when abstainers were
excluded and the analysis repeated using the lowest drinking category as reference
(Kalmijn et ah, 2002). In this cohort of elderly Dutch men and women, a U-shaped
association was noted between the level of alcohol consumed and cognitive
performance. Subjects who had either 1-2 or 2-4 drinks a day scored relatively better
on timed tasks assessing psychomotor speed and flexibility. Interestingly, a linear
relationship was only observed in women, none ofwhom was in the heaviest
drinking category (more than eight drinks a day).
Given that the pattern of alcohol use is likely to differ for men and women,
sex-specific analyses of the association with cognitive function have been
encouraged (Elias et ah, 1999). Based on such recommendations, the MORGEN
study demonstrated better cognitive function in relation to moderate alcohol
consumption in women but not in men (Kalmijn et ah, 2002). Moreover, in a French
study based on 1389 elderly men and women (Dufouil et ah, 1997), low to moderate
alcohol levels (less than five drinks a day) were cross-sectionally associated with
better overall cognitive performance in women; a positive, linear association was
also reported with scores on six out of the 10 tests used, including the MMSE and the
Digit Symbol Test. In contrast, no association was found in men.
Several hypotheses have been proposed in order to account for the sex
differences in the relation of alcohol with cognitive function, most ofwhich focus on
sex differences in alcohol metabolism and alcohol-related risk behaviours. However,
a more recent study found both male and female current drinkers to perform better on
a task of global cognitive ability relative to abstainers and former drinkers (Bond et
ah, 2004). In addition, current drinking at baseline was associated with less 4-year
decline in global cognitive performance. It is likely that the discrepancy between
these and the findings reported above can be attributed in part to differences across
studies with respect to the population examined, methods of assessing exposure to
alcohol, neuropsychological tests, and handling of potential confounding factors.
Before embarking on a search for causal mechanisms, future research needs to
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adequately address these methodological challenges associated with the problem
under study.
Anxiety
The understanding of the importance of mood for normal cognition has
greatly increased through decades of research. Specifically, it has been postulated
that anxiety, which is characterised by feelings of apprehension, fear or nervousness,
may interfere with cognitive processes by producing worry and other intrusive
thoughts that compete for resources associated with the efficiency of processing,
rather than storing, information (Eysenck and Calvo, 1992).
The empirical data of an association between anxiety and neuropsychological
function in adulthood largely comes from cross-sectional studies, and only recently
has anxiety been investigated as a predictor of cognitive decline for the first time. In
a large, prospective study of elderly Swedish subjects, Wetherell et al. (2002)
demonstrated an inverse association between baseline anxiety levels (based on
performance on the State Anxiety subscale of the State-Trait Personality Inventory,
STPI) and performance on tests assessing visual learning (Names and Faces, and
Thurstone's Picture Memory), forced-choice vocabulary (Synonyms), verbal
reasoning (Analogies), and visuospatial ability (Block Design). Tasks based on
pattern matching (e.g. Digit Symbol), visual reasoning (Figure Logic), or general
knowledge were not affected by greater anxiety. In contrast, the study failed to link
neuroticism (based on the Eysenck Personality Inventory Neuroticism scale), which
was used as a proxy for anxiety trait or proneness rather than current anxiety, with
the rate of decline in cognitive test performance over a six-year interval when control
for multiple covariates was made. Even though the study was limited in its approach
to assessing anxiety and neuroticism, its findings suggests that anxiety may not be a
long-term predictor of cognitive decline in elderly people. Rather, the presence of
anxiety may simply affect test performance on specific cognitive tasks which require
complex attention and coordination skills.
Results from a subsequent clinic-based study, which followed a group of
cognitively-intact elderly people for a mean of 3.2 years, are somewhat in conflict
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with the assumptions raised above (Sinoff and Werner, 2003). Using a path analysis,
the interaction between complaint of loss ofmemory, anxiety, depression, and
cognitive decline on the MMSE, was examined. Excluding cognitively impaired
participants (MMSE score <24), the study demonstrated independent effects of
baseline anxiety levels on the rate of decline in global cognitive performance. In
addition, anxiety was also found to affect cognitive decline indirectly, through
greater levels of depression. Interestingly, the effects of subjective memory loss, as
assessed by self-report at baseline, on cognitive function were entirely mediated by
anxiety in these models. Despite the inherent difficulty in determining the direction
of the anxiety-cognition association, the case has been made that anxiety may occur
as a result of early cognitive changes, and therefore act as an early predictor of future
cognitive decline. However, more prospective evidence is greatly needed where, for
instance, both the characteristics and duration of anxiety are carefully assessed at
different points in time.
Depression
Depression, which may be defined as the inability to experience pleasure, is
likely to be both under-diagnosed and insufficiently managed in older people
(American Psychiatric Association, 1994; Patemiti et ah, 2002; Stewart, 2005).
There is, however, increasing evidence suggesting it may be an important and
treatable risk factor for cognitive dysfunction in the elderly. It has been pointed out
that depression may comprise subtypes that differ by diagnostic criteria as well as by
their response to treatment, even though few studies have systematically examined
these in relation to neuropsychological function (Airaksinen et al., 2004; Willner,
1984). Different depression subcategories are, however, all likely to share the main
symptoms of depressed mood, including difficulty in initiating responses and in
sustaining effort or concentration, which may be of particular relevance to
performance on cognitive tasks involving psychomotor speed, learning, and memory.
It is also possible that impaired cognitive function in depressed individuals
may be directly related to the disease itself and its neuropathological aspects. This
hypothesis received support in a small-scale study where in the first instance, the
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neuropsychological test performance of cognitively-intact (CAMCOG score of 92 or
more) patients with clinical depression was compared to that of healthy controls
(Brown et al., 1994). In comparison to controls, depressed patients performed more
poorly on a number of tasks assessing language, memory recall and recognition,
attention, and behavioural regulation. In a subsequent step, which was based on
comparing borderline (CAMCOG score between 82 and 91) and cognitively-
impaired (CAMCOG less than 81) depressed patients to a group ofunimpaired
depressed subjects, both patient groups showed significant deficits on tests involving
immediate recall and attention. In this analysis, the poorest relative performance was
seen in depressed subjects who were classified as being cognitively impaired.
Disease severity, symptomatology, or treatment, did not have an effect on cognitive
performance in depressed subjects.
Although a negative cross-sectional association between depression and
cognitive function has consistently been observed in large population-based studies
(Fuhrer et ah, 1992), it remains to be determined whether depression has a role in
predicting later-life intellectual decline. In an early study based on community-
resident elderly men and women, self-reported depressive symptoms at baseline did
not predict risk of decline in SPMSQ performance over a period of 12 years (Bassuk
et ah, 1998), although an association was noted in subjects who experienced mental
decrements post-baseline. Similarly, Major Depressive disorder was not associated
with the rate of decline in MMSE performance over an 11-year period in young to
middle-aged participants in the Epidemiologic Catchment Area Study (Rosenblatt et
ah, 2003).
Whereas the findings reported above seem to go against the notion that
depression may precede cognitive decline in time, evidence from other investigations
have been more supportive. For example, Yaffe and associates (1999) found a
significant dose-related association between the number of self-reported depressive
symptoms and the rate of 4-year decline in performance on three cognitive tasks (the
modified MMSE, the WAIS Digit Symbol, and the Trails B) in non-demented
elderly women. Importantly, the association remained when baseline cognitive
ability, health, and functional status, were controlled for in multivariate models. Self-
reported depressive symptoms were also related to cognitive decline in both the EVA
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study cohort (Paterniti et al., 2002) and in a prospective study involving a bi-racial
population (Wilson et ah, 2005). In the earlier study, an association with 4-year
decline in global cognitive performance was only found in those subjects who
reported persistent (depressed at baseline and follow-up), rather than episodic
(depressed only at baseline), depressive symptoms. These analyses were based on
subjects who were considered cognitively-intact based on their baseline MMSE
performance (score of 26 or greater).
Although it is likely that methodological differences may be the cause of the
inconsistency found between published studies, and particularly with respect to the
assessment of depressive symptoms (Stewart, 2005; Wilson et al., 2005), little is still
known about the basis of this relationship. As a result, three possible explanations
have been proposed (Comijs et ah, 2001). Whilst the first suggests depression may
be a psychological reaction to early subclinical cognitive decline, the second
emphasises a shared nervous system pathology underlying depression and cognitive
dysfunction, possibly one which has a predilection for either subcortical and/or
prefrontal cortical structures (Butters et ah, 2000). Lastly, it has been pointed out that
depression may be associated with elevated levels of Cortisol which may lead to
dysregulation of the hypothalamic-pituitary-adrenal axis (HPA). Judging from the
available empirical evidence, however, the first of these is unlikely to be the sole
explanation.
2.5.5. Novel Risk Factors
Homocysteine
The past decade has seen a growth in the number of studies of the
relationship between plasma concentrations of homocysteine and performance on
cognitive tasks in adulthood. Homocysteine is an amino acid that is generated in the
metabolism ofmethionine, a sulfur-containing amino acid, a process dependent on
particular vitamin B fractions (folic acid and cobalamin). In this respect, plasma
homocysteine levels are considered to be a good marker of the functional status of
cobalamin and folic acid in body tissues (Nilsson et ah, 2001). An elevation in
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homocysteine levels is frequently observed in patients with deficiency in one or more
of these vitamins. Accumulation of homocysteine in the plasma may exert direct
neurotoxic effects and/or induce atherogenesis in vascular structures (Garcia and
Zanibbi, 2004).
Early population-based studies relating homocysteine levels with cognitive
function were small and based on cross-sectional analyses. Mixed results were
frequently reported. For example, no association with performance on global (the
MMSE) and domain-specific tasks was found in an Italian study involving 54
subjects aged 65 years and older (Ravaglia et al., 2000). On the other hand, a small-
scale study based on 156 community-dwelling UK elderly showed an inverse, linear
association between homocysteine levels and CAMCOG test scores (Budge et ah,
2000). These analyses, which controlled for age, sex, pre-morbid ability, and
depressed mood, suggested a 3-point decrease in CAMCOG scores for every 10
pmol/L increase in plasma homocysteine levels. In contrast, no relationship with
MMSE scores was observed. Similar findings of an inverse cross-sectional
relationship between homocysteine levels and performance on global (Ravaglia et
ah, 2003; Wright et ah 2004) and domain-specific (Schafer et ah, 2005) tasks have
been reported in subsequent publications. In the last of these, the Baltimore Memory
Study, the homocysteine effects on cognitive performance were large: on average, an
increase in homocysteine from 7.6 pmol/L (25th percentile) to 11.3 pmol/L (75
percentile) was equivalent to an increase of 4.2 years in baseline age (Schafer et ah,
2005).
In order to verify the direction of the relationship of homocysteine with
cognitive function, large-scale, prospective epidemiological studies need to be
carried out. To date, however, few exist. Moreover, it is not clear whether it is
through neurotoxicity, vascular effects, or folic acid and/or cobalamin insufficiency
that elevated homocysteine levels are negatively related to intellectual performance.
However, based on data from 70 male participants in the Normative Aging Study, an
inverse association between plasma homocysteine levels and spatial copying skills
was observed (Riggs et ah, 1996). Whereas the results were not accounted for by
clinical diagnosis of CVD, the association no longer remained once blood levels of
both folic acid and cobalamin were statistically controlled for. Similar findings were
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observed in the MacArthur Studies of Successful Aging cohort (Kado et ah, 2005).
In both cross-sectional and a 7-year longitudinal analyses of cognitive ability, no
association with baseline homocysteine levels was found when vitamin B status was
taken into account. In other words, the effects of homocysteine levels on cognition
were largely explained by low folic acid levels. Identical findings had been replicated
by some researchers (Almeida et ah, 2004) but not others (McCaddon et ah, 2001;
Miller et ah, 2003; Wright et ah, 2004). This inconsistency in findings across studies
is likely to be in part due to differences in study populations, methods of assessment
of homocysteine and vitamin B levels, the overall lack of serial blood level measures,
handling of potential confounders, and differences in neuropsychological tasks.
Inflammatory Markers
A limited but growing body of published work currently exists on the relation
of plasma and serum markers of inflammation and haemostasis with
neuropsychological function in the elderly. Inflammation is central to atherosclerosis
and elevated blood levels of inflammatory markers have been associated with an
increased risk of acute coronary disease and stroke (see section Risk Factors for
Atherosclerosis). In addition, it has been suggested that pro-inflammatory proteins in
the periphery may directly promote neuroinflammation, ultimately leading to
cognitive impairment.
Further evidence in support of a relationship between inflammatory activity
and cognitive function has come from epidemiological studies. For example, in a
cross-sectional analysis of data from the Conselice Study of Brain Aging, a
community-based study of Italian elderly, subjects with MMSE scores of 24-25 and
26-28 had significantly increased odds (relative to subjects with an MMSE score of
29-30) of baseline serum CRP levels greater than 0.7 mg/dL (highest decile of CRP)
(Ravaglia et ah, 2005). Despite the low numbers of low-scoring subjects with high
levels of CRP, these analyses controlled for age, sex, education, fibrinogen,
leukocyte count, albumin, BMI, edentulism, and co-morbidity. These findings are
further supported by data from the Longitudinal Aging Study Amsterdam (LASA)
(Dik et ah, 2005). A cross-sectional analysis adjusting for age, sex, and education
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revealed less verbal items recalled in subjects falling into the middle (141-172 %
normal human plasma, NHP) and highest tertile (173-437 % NHP) of baseline levels
of the inflammatory marker ai-antichymotrypsin. However, no relation with other
cognitive measures was noted, including the MMSE. High levels of the pro¬
inflammatory cytokine IL-6 (IL-6) (5.0-76.0 pg/mL) and CRP (5.3-171.0 pg/mL)
were not associated with performance on any of the cognitive tasks used.
On the basis of longitudinally-collected data on cognitive function,
inflammatory processes have further been associated with an increased decline in
cognitive test performance. In the MacArthur Study of Successful Aging, both the
largest 2.5-year and 7-year shift towards lower values in median cognitive test scores
(a single score was used which was based on several cognitive tests that were
combined in order to indicate the highest cognitive function possible in the
individual) occurred in subjects with the highest baseline values of IL-6 (highest
tertile) (Weaver et al., 2002). Further analyses showed that in the final fully-adjusted
model, the 2.5-year risk of decline (defined as having a change score in the bottom
tertile of the overall change distribution for the full sample) was significantly
elevated in subjects in the highest (OR=2.03; 95% 0=1.30-3.19) and the middle
(OR=2.21; 95% 0=1.44-3.42) tertiles. A significantly higher 7-year risk was only
observed in the highest IL-6 tertile (OR=1.90; 95% 0=1.14-3.18).
Similarly to the above, a linear regression analysis (controlling for age, sex,
and education) based on data from 92 subjects in the Maastricht Aging Study
demonstrated how baseline levels of the serum inflammatory markers haptoglobin
and CRP predicted steeper six-year decline in performance on mental tests assessing
attention and executive function (Stroop test), immediate (CRP only), and delayed
recall of verbal material, in persons 50 years and older (Teunissen et al., 2003).
Additional work has provided evidence of an inverse relation of baseline levels of
IL-6 and CRP (Yaffe et al., 2003), D-dimer (Wilson et al., 2003), and ai-




Diverse changes in vascular and haemorheological properties accompany
ageing which may affect the flow of blood in vessels. In addition to alterations of the
blood vessel walls themselves, as indicated by greater arterial stiffening, decreased
vascular tone, and decreased vessel diameter, changes in rheological parameters
include increases in blood viscosity, the intrinsic resistance of blood to flow, and its
major determinants (haematocrit, plasma viscosity, and red cell
deformability/aggregation) (Ajmani et al., 2000). Additional negative influence on
blood viscosity could come from exposures to cigarette smoking, high blood
pressure, and elevated levels of circulating plasma lipids/lipoproteins. Possibly
through the rheological effects of high blood viscosity on atherothrombogenesis or
ischaemia distal to atherothrombotic stenosis (Lowe, 2003/2004), elevated levels of
haematocrit, plasma viscosity, and erythrocyte sedimentation, have been positively
associated with the degree of carotid artery atherosclerosis (Lee et al., 1998), the risk
of coronary events (Lowe et al., 1997; Yarnell et al., 2004), and stroke (Lowe et al.,
1997). In addition, erythrocyte deformability is a major determinant ofblood flow in
the microcirculation and, if reduced as is in sickle-cell disease, has been implicated
in the aetiology of MRI-determined cerebral infarctions/ischaemia (Moser et al,
1996; Simchon et al, 1987).
With respect to the aforementioned, a link between blood rheology and
cognitive function may seem plausible. For example, relative to age-matched
controls, more errors associated with maze learning have been noted in rats treated
with erythropoietin, resulting in large increases in haematocrit levels (Ajmani et al.,
2000). The effects may be age-dependent, suggesting more susceptibility to
haemorheological stress in older age. Unfortunately, few published accounts exist on
the relationship between rheological factors and cognitive function in elderly people.
In fact, only in the Caerphilly study has this association been investigated in a
population context (Elwood et al., 2001). A cross-sectional analysis was carried out
on the association between haematocrit, fibrinogen, plasma viscosity, and
performance on tests assessing verbal and mathematical reasoning (AH4) and choice
reaction time. The study demonstrated that, whereas no association was observed
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between haematocrit and AH4 test performance, a U-shaped relationship existed with
reaction time. Specifically, reaction time improved with increasing haematocrit
levels (up to 46%) and then decreased with any further increase. In addition,
statistically significant linear trends, adjusted for age and social class, were also
observed for both tests across quartiles of plasma viscosity. A difference of
approximately 23% (AH4) and 12% (choice reaction time) of a standard deviation
was found between men in the highest and lowest quartile of plasma viscosity,
respectively. In contrast, fibrinogen levels were not related to performance on either
task.
2.5.6. Section Summary
A large and growing part of the research in the area of cardiovascular disease
and cognitive function has been dedicated to investigating the role of atherosclerotic
risk factors in intellectual dysfunction. Over recent decades, and despite conflicting
results at times, a number of studies have convincingly demonstrated the contribution
of such factors to reduced levels of cognitive function in middle-aged and elderly
people. There is also evidence that several potentially modifiable vascular risk
factors may be associated with an increased decline in cognitive ability over time,
which may have implications for strategies aimed at delaying or preventing cognitive
deterioration in the population. Another outcome of this research effort has been the
increase in studies suggesting that physical activity and smoking cessation, among
other things, may have beneficial effects on adult cognitive function. However,
further interventional studies which build on existing observational data are greatly
needed.
Despite being studied separately, many atherosclerotic risk factors, as well as
those exerting a positive influence on cognitive function, are likely to co-exist within
the same individual. Few studies have examined the combined effects of several risk
factors on cognitive processes. Whereas each of the major risk factors, including
blood pressure, smoking, blood lipids, and diabetes, may independently be associated
with intellectual impairment, the cognitive effects of these are also likely to be
mediated in part through their influence on atherosclerotic vascular pathology. As a
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consequence, targeting such factors through appropriate interventions may possibly
be the single most important step towards halting or delaying cognitive decline. On
the other hand, in investigations of cognitive functions in patients with vascular
disease, most if not all of the factors reviewed in this chapter are likely to operate as
potential confounders of the association under study.
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CHAPTER THREE
Aims and Objectives of Study
3.1. STUDY BACKGROUND
Human cognitive ageing is characterized by large inter-individual differences
in the rate of intellectual change. Although many individuals maintain their prior
levels of cognitive ability well into the last decades of life, some may even
experience an improvement in specific skills. On the other hand, deterioration in
cognitive processes frequently accompanies ageing. Intact mental function in old age
is fundamental to normal physical self-maintenance, successful social interactions,
and performance of everyday tasks (Bell-McGinty et al., 2002). As a result, even
mild intellectual deficits may induce functional impairment (Plehn et al., 2004).
Progressive decline in cognitive function may also lead to dementia which is a major
cause of increased dependency and institutionalisation of elderly people (Melzer et
al., 1997; Neale et al., 2001). Treatment options for cognitive impairment are limited
at present and finding ways to prevent or delay its onset in old age is regarded as a
public health priority (Purandare et al., 2005; Roman, 2003). Linking potentially
amenable predictors to early markers of cognitive impairment is likely to be an
important part of such a strategy. Specifically, performance on cognitive measures
may be predictive of intellectual impairment by up to a decade later (Cervilla et al.,
2004; Grober et al., 2000). Acting as possible markers of sub-clinical impairment,
neuropsychological tests have a key role to play in assessing the effects of diverse
exposures on brain functioning in elderly people.
The pattern of individual differences in mental ability in old age underscores
the importance of person-specific factors in its aetiology. In recent years, there has
been a growing interest in the investigation of the contribution of atherosclerotic
vascular disease to patterns of adult cognitive function. A finely tuned relationship
exists between the brain and the circulatory system, which if upset by vascular
pathology, may disrupt normal neurocognitive processes (Tarter, Edwards, Van
Thiel, 1988). Further to the biological plausibility of an association with cognitive
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function, the interest taken in vascular diseases is also likely to reflect their general
importance in adult morbidity and mortality, their high prevalence in the older
population, the possibility of their modification and prevention, and the clarity with
which they may be conceptualised, detected, and diagnosed, in the research setting.
Based on the present review of published investigations, it is apparent that
several important gaps exist in our current understanding of the relationships
between CVDs, vascular risk factors and adult cognitive function. Specifically, there
is a need to quantify the effects of clinical vascular disease on cognitive decline in
population-based samples of older people where cognitive performance of those with
disease is compared with that of non-vascular controls. Also, from both an
epidemiological and clinical point of view, it is of inherent interest to examine
whether the pattern of intellectual ability varies with type ofmanifestation of
atherosclerotic vascular disease and whether vascular disease predicts decline over
time in different mental functions. With respect to the latter, few studies examining
vascular-related decline in mental function have acknowledged current theoretical
notions of the hierarchical structure of human cognitive abilities. A further major
issue in the study of cognitive decline in individuals with clinical CVDs is whether
any observed associations are either wholly or partly the result of influences exerted
by concomitant vascular risk factors on cognitive processes. Similar challenges are
likely to apply to findings from investigations of the relationships between vascular
risk factors and cognitive outcomes in older people.
3.2. RESEARCH AIM AND QUESTIONS
The principal objective of the present study is to examine the relationship
between clinical CVD, vascular risk factors, and cognitive function in older people.
In particular, the EAS provides a suitable ground for addressing some of the
fundamental shortcomings of previous investigations since its features:
1) A random sample from the elderly general population. The data are therefore
based on survivors with CVDs who in addition are likely to differ substantially in
both mental ability as well as risk factor profile.
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2) Data on longitudinal change across different intellectual functions over a period of
four years as well as on a validated estimate of peak prior cognitive ability allowing
the further exploration of the putative decline in cognitive function from 'best-ever'
level.
3) Data collected from various sources on the prevalence and incidence of different
indexes of atherosclerotic CVD using validated objective methods and standard
diagnostic criteria.
4) Data on a number of potential confounding factors of the associations under study.
The specific research questions underpinning the present study are listed below:
1) As a group, do older people with any major symptomatic (non-stroke)
cardiovascular disease experience more cognitive decline than those without clinical
vascular disease?
2) Do older people with major symptomatic cardiovascular disease in specific arterial
sites (e.g. CHD, PAD, and stroke) show on average an increased cognitive decline
relative to those without any major vascular disease?
3) Is clinical vascular disease associated with individual differences in decline in
cognitive function when individual variation in demographic characteristics and prior
cognitive ability is taken into account?
4) Is symptomatic cardiovascular disease further related to individual differences in
cognitive decline independently of established and novel vascular risk factors?
5) Do vascular risk factors contribute to individual differences in cognitive decline
independently of concomitant clinical cardiovascular disease?
6) What aspects of cognitive function (i.e. general ability versus specific functions)





This chapter describes the baseline methodology and follow-up procedures
employed by the EAS, which is the first population-based cardiovascular
epidemiological study in the United Kingdom to principally focus on peripheral
arterial disease in the lower extremities. Specifically, the chapter provides detailed
information on the EAS study population, the procedures of recruitment at baseline,
the layout of the baseline and follow-up clinical examinations, as well as on the
measures taken in order to continuously monitor the occurrence of new
cardiovascular events. In addition, the cognitive function testing that was carried out
in 1998/9 and 2002/3 is discussed in depth, with a special emphasis on subject
recruitment procedures, the measures taken in order to ensure consistency in the
administration and scoring of cognitive function tests, and the description of the
cognitive function test battery. Finally, the chapter draws to a close with a section
discussing the ways data were stored, manipulated, transformed, and statistically
described for the purposes of the present study. Moreover, the section provides an
insight into the approach of the multivariate data analysis and the adoption of
specific statistical techniques.
4.2. THE EDINBURGH ARTERY STUDY: BASELINE SURVEY
4.2.1. Study Design
The original aim of the EAS was to describe the distribution and determinants
of symptomatic and asymptomatic PAD in the general population. A further
objective was to investigate the relationship between PAD and ischaemic cardiac
disease in the study sample. As a result, the first part of the study was a cross-
sectional survey, subsequently followed by two follow-up clinical examinations (see
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appendix B for a diagram of study design). The study participants, recruitment
procedures, and measurements at each stage of the study are described throughout
subsequent sections.
4.2.2. Study Population
The study population of the EAS comprised 55-74 years old residents of the
City of Edinburgh. A random sample of participants was selected from age-sex
registers of 11 Edinburgh general practices representing the whole spectrum of
socioeconomic strata in all parts of the city. Based on sample size calculations (see
below) approximately 272 subjects were randomly selected from each general
practice in age-sex specific, five-year age bands in order to generate equal numbers
in each age group (34 males and females from each age band). Lists with 2720
patient names were obtained from the general practices which were scrutinised by
general practitioners (GPs) for exclusion of subjects considered unsuitable for
participation (for example, because of advanced mental or physical illness), who had
changed general practice, or had died. Excluded subjects were replaced by other
randomly selected participants (n=353; 13.0%).
4.2.3. Subject Recruitment
All eligible subjects were approached about attending an Edinburgh
University clinic for medical examination (n=2709). Following publicity in the
media, participants were sent a letter of invitation signed by the director of the study
and by a partner in the relevant general practice. Subjects unable to attend the clinic
were offered either free of charge transportation to the clinic or to be visited at home.
Any travel expenses incurred by the participants were fully reimbursed. On receipt of
an affirmative reply, subjects were mailed an appointment date, a map of the
University area, and detailed description of the clinical examination. Those whose
letters of invitation were returned by the post office were subsequently replaced by
other randomly selected subjects (n=163; 6.0%). Non-repliers to the first invitation
were sent a second invitation letter, and those who had confirmed participation but
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were unable to attend the examination were offered a new appointment at a
subsequent date.
4.2.4. Sample Size Determination
Sample size calculations undertaken in preparation for the EAS revealed that
approximately 1500 subjects would be required for the baseline cross-sectional
survey carried out in 1987/8. This decision was made on the basis of the number
needed to conduct a subsequent follow-up study (prospective cohort study) with a
sufficient statistical power to detect differences in the incidence of vascular events in
relation to baseline characteristics.
4.2.5. Ethical Approval
An ethical approval for the conduct of the EAS baseline clinical examination,
and the subsequent follow-up study, was granted by the Lothian Health Board Ethics
ofMedical Research Sub-Committee for Medicine and Clinical Oncology. In
addition, an informed signed consent was requested from each participant before
undergoing clinical examination.
4.2.6. Baseline Examination
All eligible subjects were invited to a baseline examination which involved a
detailed collection of sociodemographic information, medical history, and clinical




Clinical examinations were conducted during mornings, each weekday from
August 1987 to September 1988 at an Edinburgh University clinic. Occasional out-
of-hours clinic sessions were also held as required. Approximately ten participants
were invited to each clinic session. All subjects were asked to fast from 11 pm the
previous evening (only if they were not diabetic) and refrain from smoking for at
least two hours prior to the examination. Each participant had two sets of clinical
procedures undertaken by one of two teams, each comprising a nurse and a trained
technician. Before the clinical examination, a self-administered questionnaire was
fdled in by each participant and read over for completeness by a member of the clinic
team.
Baseline Questionnaire
The self-administered questionnaire consisted of multiple questions enquiring
about personal characteristics (age, sex, and marital status), level of education
(highest completed), occupational social class, smoking history, medical history,
history of angina pectoris and intermittent claudication, exercise, diet, and alcohol
consumption.
Coding of social class was made according to the Registrar General's
classification, with female married subjects classified by their husband's occupation
(OPCS, 1980). Retired and currently unemployed participants were coded according
to their longest held employment. Furthermore, a Carstairs deprivation score was
assigned to each subject, based on the postcode district classification from the 1981
census (Carstairs and Morris, 1989).
Smoking habits were based on self-report and items regarding information on
both current and lifetime smoking status were included. Alcohol intake was also
assessed by self-report, and participants were asked to record their intake over the
past week by indicating the number of drinks they had consumed in each of three
categories: beer, wine, and spirits. One unit of alcohol was defined as a half a pint of
beer, one glass of wine or a single measure of spirits. This allowed the assessment of
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a typical week's alcohol consumption (units of alcohol consumed per week). The
above measures were judged to be sufficiently accurate since the self-reported levels
of both smoking and alcohol intake correlated with the mean thiocyanate
concentrations and gammaglutamyl transferase activities in the blood (Fowkes et ah,
1992).
Information on the presence of angina, MI and stroke was obtained by
requiring subjects to recall a doctor's diagnosis of the condition. Assessment of
current medical treatment was also made through direct questioning. The WHO's
angina and intermittent claudication questionnaire was used to enquire about the
presence and characteristics of pain in the chest and legs (Rose, 1962). Subjects were
also asked about ever having had a doctor's diagnosis of diabetes and the use of
injections or tablets for its treatment.
Clinical Measurements
Of the inflammatory and haemostatic markers examined, serum CRP was
assessed immunologically with a high-sensitivity assay in a BN ProSpec
nephelometer (Dade Behring, Milton Keynes, UK). Similarly, plasma levels of IL-6,
intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-
1), E-selectin, and D-dimer, were measured with high-sensitivity ELISA kits (R&D
Systems, Oxford, UK; and for D-dimer AGEN (Parsippany, NJ, USA). Lastly,
fibrinogen was assessed by a thrombin-clotting turbidometric method in a centrifugal
analyzer. Intra -and inter-assay variability coefficients were CRP, 4.7% and 8.3%;
IL-6, 7.4% and 8.8%; ICAM-1, 4.8% and 7.4%; VCAM-1, 4.3% and 8.5%; E-
selectin 4.8% and 5.7%; D-dimer 10.0% and 12.0%; and fibrinogen, 5.0% and 7.0%.
The measures undertaken in order to ensure quality of the analyses included
repeating values outside the 95% normal range and using internal quality control
plasma with each marker assay.
Whole-blood and plasma viscosities were measured in EDTA-anticoagulated
blood at high shear rates (over 300/s) in a Coulter-Harkness viscometer at 37 °C.
Haematocrit was measured using a Hawksley microcentifuge and reader. Serum total
and HDL cholesterol and triglycerides were performed on a Roche Cobas
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Bioanalyser. LDL cholesterol was calculated using the formula: LDL
cholesterol=total cholesterol-HDL cholesterol-triglycerides/5.
Following blood sampling, subjects' standing height was measured once to
the nearest 5 mm with a free-standing metal ruler on a heavy base, and weight,
without shoes and outer clothing, was measured to the nearest lOOg on a Sochnle
digital scale. A 12-lead electrocardiograph (ECG) and rhythm strip were then taken
using a Hewlett Packard 'pagewriter' electrocardiograph. The ECGs were
independently coded at a later date by two trained staff using the Minnesota code
(Prineas et al., 1982). A third member of staff checked the two results. In the event of
disparity, the ECGs were coded for the third time. If the third code agreed with
neither of the other two coders, the ECG was checked by a consultant cardiologist
and a final code assigned following a discussion between the coders.
In the second set ofprocedures, participants were asked to rest for ten
minutes in the supine position before their systolic and diastolic blood pressure was
taken in the right arm using a Hawksley random zero sphygmomanometer. The
femoral, posterior tibial, and dorsalis pedis arteries were palpated in both legs for
peripheral pulses. Ankle systolic blood pressure was measured in each leg (in the
posterior tibial artery) using a random zero sphygmomanometer and a Sonicaid
Doppler probe. Finally, in the reactive hyperaemia test which followed, ankle
systolic blood pressure was assessed in each leg 15 seconds after the release of a cuff
occluding arterial flow just above the knee for four minutes at approximately 50 mm
Hg above systolic blood pressure. An electronic timer was used for standardising the
timing of the procedure. Subjects not known to have diabetes underwent an oral
glucose tolerance test (GTT) whereby a blood sample was analysed for circulating
glucose levels before and 2 hours after an oral administration of a glucose load,
consisting of 335 mL Solripe Gluctoza Health Drink containing 75 g of glucose
(Strathmore Mineral Water Company).
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4.3. THE EDINBURGH ARTERY STUDY: FIVE-YEAR FOLLOW-UP
EXAMINATION
Approximately five years after the baseline clinical examination in 1987/8, all
surviving and eligible subjects (and still residing in Edinburgh City) were invited to
attend a follow-up clinical examination. The procedures of the five-year follow-up
examination are detailed below.
4.3.1. Invitation to Study
Each subject was sent an invitation letter and offered either to come to the
study clinic or have the medical procedures performed at home. All travel expenses
incurred were fully reimbursed, and subjects who lived outside the City of Edinburgh
were offered overnight accommodation but not a home visit. Subjects who did not
attend the clinic, missed their appointment, or did not respond to three letters of
invitation, were sent a self-administered questionnaire to fill in (the same was
administered to clinic attenders). Those not returning the questionnaire were
telephoned in the first instance, then visited at home and asked to complete it.
Participants whose invitation letter was returned by the post office were traced
through the Primary Care Division of Lothian Health Board, and the invitation
procedure repeated.
4.3.2. Clinical Examination
Medical examinations were carried out by a team of three specially trained
nurses between November 1992 and March 1994. Before the clinical procedures
were performed, subjects completed a self-administered questionnaire which was
comprised of, in addition to the annual questions about cardiovascular events,
questions concerning sociodemographic characteristics, smoking history,
medications (including aspirin), age at menopause, and the WHO angina and
intermittent claudication questionnaire (Rose, 1962).
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After a rest of five minutes, systolic and diastolic blood pressure was
measured in the right arm using a Hawksley random zero sphygmomanometer. In
each leg, the femoral, posterior tibial, and dorsalis pedis arteries were palpated for
peripheral pulses. Ankle systolic blood pressure was assessed using a Sonicaid
Doppler ultrasound probe. Standing height was measured to the nearest 5 mm
without shoes, using a free-standing metal ruler on a heavy base, while weight was
measured to the nearest 100 g on a digital Soehnle scale. The above measurements
were made using the same equipment that was used in the baseline clinical
examination.
Carotid artery scanning was carried out using an ATL UM9, HDI Duplex
Scanner. The carotid arteries were first examined in a transverse plane and then
longitudinally. The following arterial sites were examined bilaterally: the internal
carotid artery, the external carotid artery, the common carotid artery, and bulb. An
assessment of the intima-media thickness was made at the far wall of the common
carotid artery, 2 cm proximal to the arterial bifurcation. All scan images were
videotaped and those in which measurements were not made but suggested
significant disease were reviewed by a consultant radiologist and a member of the
study team. A decision was then made as to whether the subject should be re¬
examined by the consultant.
An ECG was taken from each participant using a Hewlett Packard 12 lead
portable 'pagewriter' and later on coded independently by two raters using the
Minnesota code system (Prineas et ah, 1982). In the event of a non-agreement
between the two coders, the ECGs were read over by a consultant cardiologist who
made the final decision. Lastly, a sample of 30 ml of venous blood was taken and
stored for a subsequent examination of haemostatic, rheological, and genetic factors.
4.4. THE EDINBURGH ARTERY STUDY: TWELVE-YEAR FOLLOW-UP
EXAMINATION
A second follow-up clinical examination was held in 1999 (12-year follow-
up) to which all eligible subjects were invited. The recruitment procedures and the
methods of the clinical examination are discussed below.
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4.4.1. Invitation to Study
All eligible EAS subjects (alive at the time of testing, still willing to
participate, and had not been excluded by their GPs) were invited to the follow-up
examination. Invitation letters were sent by post and subjects offered to come to a
study clinic or to be seen at home. All travel expenses incurred were fully
reimbursed. Subjects residing outside the City of Edinburgh were offered an
overnight accommodation. Subjects not responding to the first invitation letter were
telephoned and offered another appointment. Non-contactable subjects were sent a
second letter of invitation, and a questionnaire (see below) was mailed out to all non-
responders. Subjects whose invitation letter was returned by the post office were re-
invited after the Primary Care Division of Lothian Health Board was contacted for
the subject's new place of residence.
4.4.2. Clinical Examination
Comprehensive clinical examinations were held during 1999 and testing was
carried out by a team of three staff: a research fellow, a physiological technician, and
a nurse. Before undergoing physical testing, all subjects were asked to complete a
questionnaire enquiring about personal characteristics, angina, intermittent
claudication and previous MI, in addition to smoking history, and respiratory
symptoms.
Height was measured without shoes to the nearest 5 mm using a stadiometer:
weight was measured without outer clothing to the nearest 100 g using a digital scale
(Soehnle). After a few minutes rest, systolic and diastolic blood pressure was taken
in the right arm using a Hawksley random zero sphygmomanometer. In each leg,
peripheral pulses were palpated and ankle systolic blood pressure was measured
using a Sonicaid Doppler ultrasound probe. All measurements were made using the
same equipment that was used at the previous clinical examinations.
Scanning of the carotid arteries was performed using an ATL UM9, HDI
Duplex Scanner. The following arterial sites were inspected, first in a transverse
plane and then longitudinally: internal and external carotid arteries, common carotid
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artery, and bulb. An assessment of IMT was made at the far wall of the common
carotid artery, 2 cm proximal to the arterial bifurcation. In addition, estimation was
made of both peak systolic velocity and plaque size. All scan images were
videotaped, and those suggesting disease but in which no measurements were made,
were reviewed by specialized members of the study team.
The diameter of the abdominal aorta was measured by ultrasound scan using
a 3 MHz transducer and an ATL UM9, HDI system. The maximum of three readings
was taken as the diameter. For a few subjects unable to attend the clinic, an Aloka
500 portable scanner was used on a visit to their home.
A 12 lead ECG was taken from each subject using a Hewlett Packard portable
'pagewriter' and later coded by two raters according to the Minnesota code system
(Prineas et al., 1982). A consultant cardiologist was consulted in the event of non-
agreement by the two raters. Finally, a 20 ml venous blood sample was drawn from
each subject without tourniquet, centrifuged and aliquots of citrated plasma stored at
-40 °C.
4.5. IDENTIFICATION OF CARDIOVASCULAR EVENTS
Every effort was made to ensure the detection of new (incident) fatal and
non-fatal cardiovascular disease events in the EAS cohort during follow-up.
Information on the development of new events was obtained from a number of
different sources. These, and the methods used in locating EAS subjects in relevant
health records, are described in the following sections.
4.5.1. Non-Fatal Events: General Practitioners
At the beginning of the EAS, all general practices participating in the study
were visited and permission was granted to flag relevant patient records with plastic
envelopes containing pink cards and prepaid envelopes. A pink card containing
subjects' details (name, address, city of residence, patient study number, date of
birth, and general practice code number) was attached to the front of patients' GP
records to be returned following a cardiovascular event. General practitioners were
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provided with new cards and envelopes to replace the ones sent. The pink card was
also returned in the event of patients changing an address or a GP, in which case they
were traced through the Lothian Health Primary Care Division.
4.5.2. Non-Fatal Events: Information and Statistics Division of the Scottish Office Home and
Health Department
Annual computer printouts of all hospital discharges occurring for subjects in
Scotland for the previous year were provided by the Information and Statistics
Division (ISD). First, a list with all discharges with the following ICD-9 codes was
provided: 410-414; 430-438; 440-444; 785; 250.6; 342, 344.3, 344.4; 781.2, 781.4;
784.3, 784.5; 798, 798.1, 798.2, and 798.9. The list was then checked to identify
EAS subjects. Following a systems change in 1991 it became possible to link the
EAS participant list to the database of hospital discharges. All subsequent lists were
classified by subject's name rather than by ICD code. These were matched with the
ISD file on name, date of birth, sex, and study members. In the former system, once
subjects were identified, their records were obtained at the relevant hospital and
checked for details regarding admission and progress. An event was recorded only if
study criteria were met. Under the latter system, discharges with relevant ICD codes
were identified and followed up at the hospital. Hospital records were reviewed and
events noted if study criteria were fulfilled.
4.5.3. Non-Fatal Events: The Royal Infirmary of Edinburgh
Lists with information on new referrals to the peripheral vascular clinic with
relevant ICD codes were supplied by the Royal Infirmary of Edinburgh. In addition,
a list of vascular operations, coded using a coding system for surgical operations
developed by the Surgical Audit Committee, was provided. The lists were read over
by the study coordinator who identified EAS subjects and appropriate follow up of
medical records was carried out as required.
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4.5.4. Non-Fatal Events: Annual Questionnaires
Each participant in the study was sent an annual questionnaire enquiring
about the development of the following conditions in the previous year: heart attack,
stroke, chest and leg pain, loss of power in arms or legs, and hardening of arteries.
Participants were also asked about any hospital attendances or visits to a GP. Those
who answered positively to any of the above, or were unsure in their reply, were
followed up with the WHO angina and intermittent claudication questionnaire which
they were asked to complete and return in a prepaid envelope. If the participants had
consulted their GP for any of the above, the GP was sent a short questionnaire to fill
in, in order to clarify the diagnosis. In the event of a hospital attendance or
admission, medical records were examined to determine whether study criteria for
the event were fulfilled.
4.5.5. Fatal Events: United Kingdom National Health Service Central Registry
Each participant's record at the National Health Service Central Registry
(NHSCR) was flagged in order to ensure that death certificates would be
automatically forwarded for all study participants dying in the United Kingdom. In
addition, cases ofmortality from cardiovascular causes were further examined using
hospital or GP records in order to determine that the study protocol criteria were
appropriately fulfilled.
4.6. METHODS OF COGNITIVE FUNCTION TESTING
4.6.1. First Round of Cognitive Function Testing
The 'Cognitive Function Project' of the EAS was launched with the first
round of cognitive function testing in 1998/9. A range of cognitive abilities was
assessed in the study subjects attending cognitive function testing. The results from
the first round of cognitive testing are described below while a more detailed
discussion on the subject recruitment, the procedures of cognitive testing, and the
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cognitive test battery that was used on both occasions is provided in the subsection
on the second round of cognitive testing.
Subject Recruitment
Over the 11 years since the baseline examination in 1987/8, approximately
380 study subjects were reported to have died. Inevitably, this left 1209 subjects
available for cognitive testing. Further reductions in the number of subjects eligible
for participation resulted from 61 withdrawals from the EAS, reports of 19 additional
deaths occurring during the one-year study period, and 28 exclusions made by GPs.
In total, 1103 subjects were sent a letter of invitation to attend cognitive function
testing. Of these, 933 (84.5%) replied to the invitation, while 151 (13.7%) subjects
did not reply, and 19 (1.7%) letters were returned by the post. Of those who replied
to the invitation letter, 740 (67.0%) accepted the invitation while 193 (17.4%)
subjects declined. Of the 740 subjects who accepted to be tested, 717 attended
testing, 22 did not attend, and one subject refused consent when visited at home.
Complete data on at least one cognitive function measure are available for 698
(97.3%) out of the 717 subjects who attended cognitive testing.
Cognitive Testing Procedures
The cognitive function testing, which began in March 1998 and was
completed in April 1999, was carried out by two trained members of staff (a research
nurse and a psychologist). Approximately two-thirds of the subjects attended a
University clinic, while the remaining one-third was tested at home.
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4.6.2. Second Round of Cognitive Function Testing: Subject Recruitment
The recruitment of EAS subjects to follow-up cognitive testing (second
round) began in early July 2002. Subjects who had participated in the first round of
cognitive testing in 1998/9 were potentially eligible for participation in the study.
The procedures used in selecting and inviting subjects to the study are described
below. Documents relating to the recruitment of subjects are provided in appendices
C-l through C-4.
Eligibility for Participation
All subjects who had undergone cognitive testing in 1998/9 were considered
as potential candidates for participation in the study. However, recruitment of
subjects, whose compromised physical or mental health status (for example, sight or
hearing problems, or dementia) might have limited their capability to undergo
cognitive testing, was discouraged. All general practices (letters were addressed to a
contact GP in each practice) were sent a complete list with the names of subjects to
be recruited from the respective practice by the study team, which was to be notified
about anyone considered unfit to participate for any of the reasons above. As a result,
all surviving subjects, whose participation in the cognitive testing was approved of
by their GPs, were considered eligible to take part in the study.
In the instance where a subject had moved and registered with a new general
practice (information supplied by a contact GP in response to the letter sent for the
purpose described above) the subject's new address was requested from the previous
practice. In response, a letter with the subject's name and date of birth was sent to the
manager in charge of the practice the subject was currently registered with. In the
letter the study team requested a permission to approach the subject and anyone
deemed unsuitable to participate in the cognitive testing for health reasons or
otherwise, was excluded from participation. On the rare occasion when the previous
general practice was unable to provide the study team with data on the subject's new
place of residence, Lothian Health Board was able to provide the necessary
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information. No further attempts were made in order to obtain information on new
addresses if the above routes available to the study team proved unsuccessful.
Invitation to Participate
Letters of invitation to participate in the second round of cognitive function
testing were mailed to all eligible EAS subjects. The subject invitation letter had
enclosed an information sheet describing the purpose of the study, a reply slip which
also requested the subject's current contact details, and a pre-paid envelope. Those
willing to participate in the study were given the option to be cognitively tested at a
University of Edinburgh clinic or at home. Subjects were allowed approximately 3-4
weeks to reply to the initial invitation letter before they were re-contacted by the
study team.
Subjects who answered positively (ticking the 'yes' box on the reply slip) to
the initial invitation letter were contacted by phone shortly after the study team
received their reply form. Those to be tested at the University clinic were given an
appointment through the phone and subsequently mailed a reminder and a map of the
University clinic and surrounding area. Subjects requesting a home visit were only
given a date to be tested by phone. In the case where a subject did not have a phone,
but had expressed a willingness to participate, a letter with a provisional appointment
was sent out. Subjects replying 'yes' to the first invitation letter but wishing not to
take part when subsequently contacted by phone were asked if they could be re-
contacted at a later date in case their personal circumstances might change. Those
subjects who were willing to undergo testing but could then not be reached by phone
(no answer or answering machine constantly connected) were repeatedly phoned at
different days and hours. If, despite repeated attempts, there was still no answer, a
letter with a pre-arranged appointment at the University clinic and a map was mailed
to the subjects. Subjects not turning up at the clinic for their provisional appointment
were categorised as 'non-responders'.
All subjects rejecting the invitation (ticking the 'no' box on the reply slip) to
cognitive testing were given a second opportunity to participate in the study in case
they had changed their mind about taking part. At a later date a second invitation
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letter was mailed out, and while subjects who accepted the invitation were given an
appointment, no further attempts were made to recruit those still refusing to undergo
testing (categorised as 'refusal to participation').
Any subject not replying to the first invitation was followed up with a second
copy of the invitation letter. Depending on the type of response to the second
invitation, either an appointment was made or subjects were classified as 'non-
responders' or those who refused participation. However, subjects not responding to
the second invitation were labelled as 'non-repliers'.
4.6.3. Second Round of Cognitive Function Testing: Cognitive Testing Procedures
The follow-up phase of the cognitive function testing took place from
September 2002 to December 2003. The following sections describe in detail the
settings of the testing and the specific measures taken in order to ensure the quality
of the cognitive test data.
Training ofInvestigators
Before the initiation of the cognitive function testing, an appropriate training
in the administration of cognitive function tests was provided to the study team. The
two investigators who carried out the testing were informed about the basic cognitive
test procedures by two senior members of academic staff (psychology consultants on
the EAS) from the Department ofPsychology at the University of Edinburgh.
Subsequently, one of the investigators was trained to the necessary level for testing
through practice on fellow co-workers and then on study subjects attending the
University clinic. The second investigator was then trained by the first by sitting in
on several clinic test sessions and monitoring the process of test administration. After
several sessions, the second investigator applied the tests with either the first
investigator or a study psychologist monitoring the performance. Any issues or
problems regarding the administration of the tests arising during the training sessions
or at any point during the cognitive testing were thoroughly discussed and led to
conclusion within the study team.
136
Cognitive Function Testing Sessions
Subjects either attended a University clinic for cognitive function testing or
were visited at home. Testing at the clinic was carried out in a moderately warm,
quiet and well-lit room in the Department of Public Health Sciences at the Edinburgh
University Medical School. Subjects attending the clinic were usually tested between
10:00 am and 4:00 pm during normal working days. All travel expenses (including
parking cost) were fully reimbursed. Subjects seen at home were normally tested
between 10:30 am and 3:00 pm, Monday through Friday.
Inter-Rater Consistency in Cognitive Function Test Administration
In order to ensure consistency in the administration and scoring of the
cognitive function tests, a 'quality control' exercise was carried out during the period
from January 13 to May 23 2003. The procedure involved the two investigators
undertaking 15 duplicate cognitive function test sessions in which one or the other
would carry out the testing while the second investigator simultaneously observed
and scored the cognitive test battery. In this way, both investigators registered the
subject's answers (item by item) on each of the following cognitive measures (see
next section for description of individual cognitive tests): The Mini-Mental State
Examination; The National Adult Reading Test; The Logical Memory Test
(Immediate and Delayed); The Verbal Fluency Test (letters C, F, and L). Since both
the Ravens Progressive Matrices and the Digit Symbol Test require the subject to fill
in a standard scoring sheet (tick boxes), they were not scored simultaneously by the
two investigators as the verbal tests were. Rather, after each session, the answering
forms for these two tests were photocopied and scored individually by the
investigators (see appendix D). Any discrepancies relating to the administration and
marking of the cognitive function test battery (or any aspect of it) were properly
addressed by the study team.
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4.6.4. Second Round of Cognitive Function Testing: Cognitive Function Test Battery
The cognitive function test battery used in the first and second rounds of
testing in the EAS was comprised of six neuropsychological tests, a test assessing
subjects' pre-morbid ability and a scale aimed at determining anxiety and depression
levels. The test administration time was approximately one hour. The individual
components of the test battery are described below in the order they were presented
to the participants. Copies of each of these are supplied in secions 1 to 9 ofAppendix
D.
Consent Form
In line with ethical rules, the study subjects agreed to participate in the
cognitive testing by signing a consent form after having been made clear that they
could withdraw from the study at any time without giving a reason, that such a
decision would in no way affect their standing with their GP, and that personally they
would derive no direct benefit from the study. Also, participants were offered to read
over the subject information sheet (had they not brought with them the copy mailed
out to them accompanying the invitation letter) and encouraged to ask questions and
discuss the study before signing the consent form.
Medical Questionnaire
In order to rule out any physical medical conditions interfering with subjects'
performance on the cognitive tests, a medical questionnaire was administered. In a
dichotomous manner, the subjects were asked whether or not they suffered, or had
ever suffered, from any of several conditions, such as Parkinson's disease, stroke,
sensory problems, arthritis, or were on any medications at the time of testing.
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The Hospital Anxiety andDepression Scale
The Hospital Anxiety and Depression Scale (HADS) is a brief self-
administered instrument designed for detecting mood disorder in non-psychiatric
patients, and has also been found to be a valid measure of the severity of both anxiety
and depression (Zigmond and Snaith, 1983).
The HADS consists of two sub-scales that reflect subjects' anxiety and depression
levels over the past few days before completing the scale (examinees were
encouraged to note down their immediate reaction to each item rather than taking too
long time to think about what to reply). Each sub-scale is comprised of 7 items or
statements that are based solely on the psychic symptoms of anxiety and depression
(items relating to both physical and emotional disorder e.g. dizziness or headaches
are not included). Each item is rated on a four-point scale (0-3) and the highest total
score on both scales is 21. Non-cases and possible cases fall into the range 0-7 and 8-
10, while a total score of 11 or more indicates a probable case (the HADS has good
sensitivity and specificity for determining whether a particular patient is probably a
psychiatric case of anxiety or depression although it does not allow a definite
diagnoses, and only gives a dimensional rather than a categorical representation of
mood (Herrmann, 1996)).
The Mini-Mental State Examination
The Mini-Mental State Examination (MMSE) is a brief cognitive measure
that is widely used for evaluation of a restricted set of cognitive functions in both
clinical practice and research (Folstein et al., 1975).
The MMSE is comprised of 20 questions and tasks that fall into the following
domains: orientation-time, orientation-place, memory-registration, attention and
calculation, memory-recall, praxis-ideational, praxis-copying and drawing, and
spontaneous praxis-writing. As an example of a question from the orientation-time
domain, the examinee is asked to tell the examiner what time it is in terms of day,
month and year at the time of testing, while in the attention-calculation domain, the
subject is asked to spell the word 'world' backwards. Before administering the
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MMSE, examinees were told that they were going to be asked a series of relatively
simple questions about the day they had their test, about their location and so on. One
point is awarded for each correct answer and the points of correctly answered
questions are summed for each domain. The maximum score obtainable on the test is
30 (range 0-30).
The National Adult Reading Test
The National Adult Reading Test (NART) is a briefly administered reading
test which is frequently encountered in both clinical and research settings as a
measure of pre-morbid intellectual ability (Nelson and Willison, 1991). The NART is
comprised of a list of 50 single words that are irregular with respect to common rules
of pronunciation in order to minimise the possibility of reading by lexical decoding
rather than word recognition. The word order on the list is of graded difficulty and
the test is assumed to make minimal demands on current cognitive abilities because it
only requires the examinee to read out loud one short single word at a time. Among
the words included in the NART test are ache, nausea, radix, and beatify.
The number of correctly and incorrectly pronounced words is noted by the
examiner as the test progresses. Slight variations in pronunciation are allowed when
these are due to regional accents. Overall, however, the accuracy of the scoring of the
NART depends solely on the examiner's accuracy in interpreting the examinee's
responses and his/her adherence to the appropriate pronunciation of the words as set
out by the test instructions (both in print and audio format). A maximum score of 50
(range 0-50) indicates all words correctly pronounced.
The Wechsler Memory Scale-Revised: Logical Memory Test (Immediate Recall)
The Wechsler Memory Scale-Revised (WMS-R) is a revised version of the
Wechsler Memory Scale which is a widely used clinical instrument designed for
evaluation ofmajor dimensions ofmemory functions in adolescents and adults
(Wechsler, 1987). The test is both used as a diagnostic and screening tool for use as a
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part of a general neuropsychological examination or a clinical examination where
assessment ofmemory functions is required.
The Logical Memory (LMT) test is one of eight sub-test of the WMS-R test
battery and assesses immediate or short-term memory for verbal material. The test is
comprised of two short stories (A and B) of almost equal difficulty that are read to
the examinee. The examinee is told to pay a close attention to the two stories and the
words they use, and after hearing each story, asked to retell the two stories to the
examiner. The examinee is given one point for every idea of the story correctly
recalled and the points are summed for each story. The total score is comprised of the
total ideas produced for both stories.
The Raven 's Standard Progressive Matrices
The Raven's Standard Progressive Matrices (RPM) constitute a measure of
eductive or non-verbal ability which refers to the process of educing new insights
and information out of that which is perceived or already known by the individual
(Raven et ah, 1977). More specifically, the RPM set out to measure a person's ability
to make sense of complex situations and identify relationships between apparently
unrelated structures. The processes underlying this sort of cognitive ability have been
described as being largely non-verbal, depending on flashes of insight too rapid for
assimilation into language.
The RPM comprises 60 items grouped in five sets (12 in each set). Each item
contains a pattern problem where a part or a piece has been removed and six to eight
pictured inserts of which only one contains the correct pattern. The examinee is
asked to identify the piece that correctly completes the pattern and write the number
of the piece they choose on an answer sheet. Items increase in difficulty across each
of the five sets (item one least demanding, item 12 most demanding), and between
sets (set A least demanding, set E most demanding). One point is given for each
correct answer and the maximum score given for each of the five sets is 12. The
maximum test score is 60 (range 0-60). In the EAS, examinees were given 20
minutes to complete the test after having had a short practice trial involving the first
three test items.
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The Lexical Verbal Fluency Test
The Lexical Verbal Fluency Test (VFT) is based on the quantity of words
produced orally by an individual in response to a stimulus (letter of the alphabet)
within given time limits (Lezak, 1995). Neural imaging studies, and studies of brain
lesions, have demonstrated how lexical fluency tasks seem to place a high demand
on strategic search processes (divergent thinking) involving specific regions of the
left and right frontal lobes.
The VFT test consists of three one-minute word-naming trials. Examinees are
asked to name as many words as they can think of beginning with a particular letter
of the alphabet (the letters C, F, and L were used in the EAS). The total score is
based on the total number of acceptable words produced. The letters are chosen on
the basis of the frequency of English words beginning with these letters. Thus, words
beginning with the letter C have relatively high frequency, while the frequency of
words beginning with the letter F is relatively lower, and words beginning with L
have still lower frequency. Names of persons and places (proper nouns), numbers
and the same words with different suffices (e.g. sing and singing) are not allowed,
and in order to familiarize the examinee with the task a practice trial involving the
high frequency letter 'S' is provided. The examinee is expected to provide two or
three words beginning with the letter 'S' before moving on to the timed trials.
The Wechsler Adult Intelligence Scale-Revised: The Digit Symbol-Coding Test
The Digit Symbol-Coding Test (DST), a measure of psychomotor
performance, is one of several subtests of the Wechsler Adult Intelligence Scale
(WAIS-R) which is a clinical instrument designed for evaluating the intellectual
ability of adults 16 to 89 years of age (Wechsler, 1981).
The DST is composed of four rows containing 100 blank boxes, each paired
with a number from one to nine that have been randomly ordered. Above these rows
is a key that pairs each number with a unique symbol. Before doing the actual test,
the examinee briefly practices on the first seven boxes which do not count towards
the final score. The main test requires the examinee to fill in as many blank boxes
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with the corresponding symbols as possible in 90 seconds (the examinee is closely
monitored during the testing and a stopwatch is used for time taking). The final test
score is based on how many boxes the examinee correctly managed to fill in within
the given time limits. The maximum score obtainable is 93.
Wechsler Memory Scale-Revised: Logical Memory Test (Delayed Recall)
Following an approximately 25-30 minutes delay since the two stories (A and
B) were read to them, examinees are prompted to recall the stories and tell the
examiner everything they can remember about them (a process called 'delayed
recall' which denotes the examinee's ability to retrieve stored verbal material from
long-term memory) (Wechsler, 1987). In the instance where examinees have no
recollection of the two stories whatsoever, a brief reminder of the stories is read to
them in order to enable retrieval from memory.
4.7. DATA HANDLING AND ANALYSIS
4.7.1. Entry of Cognitive Data
Data from the second round of cognitive function testing were entered into a
computer using EpiData, a software package which has proved to be compatible with
a number of statistical programmes (Lauritsen et al., 2001). Data entry (undertaken
by the author) commenced on January 20 2004 and finished on January 28 2004. The
data entry was repeated by a departmental technician who began the data entry on
January 29 2004 and completed the task on February 6 2004. The two independent
data files thus generated were then compared with regard to each of the 22 numerical
variables for each patient using the 'Validate Duplicate Files' command of the
EpiData software which resulted in flagging of any non-matching records. In the
event of non-matching records, the original paper questionnaires were consulted, and
any discrepancies arising during the data entry process were corrected.
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4.7.2. Data Handling and Variable Computation
The cognitive data set from the second round of cognitive testing was
exported from EpiData into SPSS version 12.0 which was used for statistical
description and analysis (SPSS, 2004). Study numbers (a unique five digit number
assigned to each patient) were used to match the cognitive data set with data
collected previously from the baseline examination and during follow-up.
The complete data set was inspected for errors (for example, values outside
the possible range for a given variable) and missing values. In the case ofmissing
values on the cognitive tests, the original paper questionnaires were consulted and
checked with regard to whether study subjects had left out individual items (and the
corresponding test scored as missing) or refrained from doing the test. This resulted
in re-scoring of several more tests leading to an increase in the number of valid cases
for analysis. Further investigation of the data showed no consistent pattern with
regard to missing values on the cognitive tests. For instance, having missing data
(any missing versus none) was not related to having cardiovascular disease, nor was
having missing data on any particular cognitive outcome.
Cardiovascular Disease Categories
As previously described, extensive information on the prevalence and
incidence ofCVDs has been amassed following the baseline examination in 1987/8.
Moreover, a number of different sources were used in order to ascertain the
occurrence of new cardiovascular events. A diagnosis of CVD was assigned to those
subjects found to meet predetermined study criteria at baseline or any time during
follow-up (see appendix E for diagnostic criteria). A cut-off date for diagnosis of
CVD was set at six months prior to the beginning of the second round of cognitive
function testing. This was decided mainly in order to minimise the possibility of
including in our analyses those subjects, if any, who might have been suffering from
acute post-CVD confusional state or sensory-motor deficits when cognitively tested
in 2002/3. Also, since a major objective of the current study was to examine CVD in
relation to change in cognitive performance between two test occasions, separated by
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four years, a decision was taken to have the cut-off date prior to the second rather
than the first round ofmental testing.
The data collected at each of the three clinical examinations were stored in a
central database. An event file containing information from the continuous follow-up
(based on annual questionnaires, flagging of GP records, and hospital discharge
records) was matched with the central data base using patient study numbers.
Inspection of the combined data set revealed a number of duplicate events indicating
an overlap between the different sources of data. In one instance, intermittent
claudication noted at the five-year follow-up examination had been entered in the
event file a year earlier (reported in an annual questionnaire). As a result, the
respective date of diagnosis was identified for each subject reporting a major
cardiovascular event at any time over the study period. Then, the earliest date was
chosen for those subjects who had dates for both non-fatal events and dates from
either of the two follow-up clinical examinations. In the case of multiple events of
the same type, the earliest event based on the date it was first reported was taken as
the index event.
For the purpose of the present investigation, a major objective of which was
to examine cognitive outcomes in relation to different clinical manifestations of
atherosclerotic disease, the following six CVD exposure groups were created: any
CVD with the exclusion of subjects with stroke, angina pectoris, intermittent
claudication, MI, stroke, and a single comparison group comprising subjects
considered free ofCVD since they did not meet the study criteria for any of the
above vascular conditions during the study period. Assignment to any of the CVD
groups was based on the presence of the most severe manifestation of atherosclerotic
disease noted for each case, yet acknowledging the co-existence of multiple events in
a substantial number of subjects ever reporting symptomatic CVD. In the light of
this, and with regard to the total number of cases available for each CVD category
among those who underwent cognitive assessment in 2002/3, a considerable overlap
between some CVD exposure groups was inevitable. An exception was the category
for subjects with angina, which was kept distinct from that ofmore severe CVD
conditions, such as intermittent claudication and stroke, allowing the study of
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cognitive function in relation to a relatively mild, non-acute form of atherosclerotic
CVD.
Cognitive Outcomes
Given the high correlation (r=0.89 for the 1998/9 data and r=0.92 for the
2002/3 data) between the immediate and delayed components of the LMT (these are
essentially based on the same test material) they were combined to form a total LMT
score which was used in all statistical analyses. Moreover, the letters 'C\ 'F', and
'L' of the VFT were combined into one test score representing the total number of
words produced. Again, the total score was used throughout.
In order to compute a general cognitive factor representing the variance
common to all the cognitive tests, the following measures were subjected to a
principal components analysis (PCA): LMT (immediate and delayed recall
combined), RPM, VFT (all three letters combined), and DST. The data were found to
adequately meet the necessary criteria for PCA (the sample size was substantially
greater than the necessary minimum; factorability of the correlation matrix measure
of sampling adequacy and Bartlett's test of sphericity indicated the adequacy of the
intercorrelations amongst the cognitive outcomes; scatter plots of all cognitive
outcome combinations revealed no non-linear relationships; the data did not violate
the assumptions regarding no outliers). Scores were saved on the first unrotated
principal component. Each cognitive test loaded strongly on this component which
accounted for 57.1% of the variance, thus validating the use of a general factor (a
scree plot was also inspected in order to confirm the results from the PCA factor
extraction).
In addition, given the high loading of each of the tests on the general factor,
further outcome variables were computed in order to examine any non-general factor
cognitive elements associated with CVD. This was carried out using multiple linear
regression whereby each of the cognitive tests (LMT, RPM, VFT, and DST) were
regressed on the general cognitive factor each at a time. The new outcome variables
comprised the general factor-adjusted standardised residuals for each cognitive test.
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Putative Confounding Variables
The following variables, based on their associations with both CVD and
cognitive outcomes, were considered as possible confounders in the current study: 1)
Age at the time of cognitive testing in 2002/3 and sex; 2) Baseline level of education
which was categorised as a four-level variable (university, post school training,
secondary, primary); 3) Baseline level of occupational social class which was
grouped as a five-level variable (social class IV and V were combined; 4) Mood
levels at the time of cognitive assessment in 2002/3 as assessed by the HADS scale;
5) Prior cognitive ability level, which was based either on the actual cognitive test
scores in 1998/9 or estimated using the NART; 6) Baseline (in 1987/8) levels of
smoking, alcohol intake, and physical activity. Pack-years of smoking were
estimated by multiplying the number of 20-cigarette packs smoked per day with the
number of years as a smoker. A zero value was entered for life-long non-smokers.
Alcohol intake was based on the number of alcohol units consumed in a typical week
at baseline. Physical activity was grouped into four levels of intensity according to
type of activity (ranging from none to strenuous); 7) Baseline body mass index was
defined as weight in kilograms divided by the square of the height in meters; 8)
Diabetes at baseline was based on subject's recall of doctor's diagnosis of diabetes,
current treatment for diabetes, or 2-hour blood glucose concentration equal or greater
than 11.1 mmol/L. Glucose levels ranging from 7.8-11.0 mmol/L were used to
denote impaired glucose tolerance; 9) DBP and SBP at baseline; 10) Baseline serum
levels of total, LDL, and HDL cholesterol, and serum triglyceride levels; 11) Plasma
homocysteine levels measured at the five-year clinical examination; 12) Baseline
levels of circulating markers of inflammation and haemostasis, and baseline
indicators of blood rheology; 13) Place of cognitive testing (clinic versus home).
4.7.3. Data Description and Bivariate Statistical Analysis
Each of the CVD groups, cognitive outcomes, and potential confounders
were examined and described. Categorical variables were described with regard to
the frequency (percentage/number) at each level of the variable. The distribution of
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continuous variables was explored using both statistics (the mean and standard
deviation) and visually inspecting histograms. Any outliers were checked and
corrected if necessary. Distributions of all continuous variables apart from the
following approximated normality: the HADS anxiety and depression scores, total
units of alcohol, pack-years of smoking, serum lipoprotein levels, and levels of
serum CRP and IL-6. Therefore, for descriptive purposes, the median and the
interquartile range of each of these factors were used. Statistical transformations
were also carried out and used in all multivariate analyses. A square root
transformation of the raw values of pack-years of smoking was performed and the
HADS anxiety and depression scores were transformed using the logarithm of n+1
scores in order to avoid the logarithmic transformation of a score of zero. The
logarithmically transformed form of the remaining variables above was used in all
subsequent analyses.
Bivariate analyses preceded testing specific hypotheses using multivariate
methods. Rank correlations amongst cognitive tests were computed, first by using the
data from the first and second rounds of cognitive testing separately, and then by
calculating the correlations between the two data sets. Pearson's r correlation
coefficients were calculated for each pair of linear correlations in order to estimate
both the direction and the strength of the relationship between any two variables.
Scatter plots were also produced and visually inspected for linearity. Levels of CVD
risk factors were compared bivariately in subjects with and without CVD. The
statistical significance of differences in categorical CVD risk factors was determined
using the Chi-square test (Chi-square test for trend in the case of ordinal variables).
Differences in median levels of risk factors by cardiovascular disease status were
assessed using the Mann-Whitney U Test. Moreover, mean levels of each cognitive
function test variable and other normally distributed CVD risk factors were
compared using the t-test after ensuring assumptions concerning the normality of the
distribution and homogeneity of the variance were met. Lastly, the general cognitive
factor scores were not included in the examination of the four-year change in mean
cognitive test scores since the general factor represents a standardised variable, with
a mean of zero and standard deviation of one on each occasion of cognitive testing.
However, the general factor scores are valuable when it comes to examining the
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contributions to individual differences. Therefore, it was employed as a dependent
variable in the multivariate analyses which are described next.
4.7.4. Multivariate Statistical Analysis
Analysis of covariance (ANCOVA) was applied for assessing the statistical
significance of any mean differences in both general cognitive function and specific
mental functions among subjects with and without CVD while adjusting for potential
confounding factors (see below). Multiple linear regression analysis was used for
examining the independent contribution ofCVD and any vascular risk factors to
change in general and domain-specific cognitive abilities while adjusting for possible
confounders. In a further set of examinations, the multiple linear regression-based
analyses above were repeated using the general cognitive factor-adjusted
standardised residuals of each cognitive test as dependent variable.
In the modelling approach used (the same method was applied in both the
ANCOVA and multiple linear regression analyses), potential confounding variables
were introduced into the models in three cumulative steps. In the first, age and sex
were controlled for. Then, in subsequent steps, two different types of adjustment
were made for prior mental ability level. In one set of models, the 1998/9
performance score for the respective dependent cognitive variable in 2002/3 was
used as a covariable. This adjustment for earlier test performance allowed
determining the level of actual change in specific cognitive abilities in relation to
CVD over a time frame of approximately four years. In another set of models, peak
prior cognitive ability as indexed by the NART was used as a covariable. By
controlling for a well-validated estimate ofpeak ability, it was possible to assess the
impact of vascular disease on the imputed decline from best-ever level of cognitive
function to that actually measured here in old age (in 2002/3) (Deary et al., 2004).
Using regression in this way with prior scores as covariables is considered superior
to using change scores; for example, it prevents the spurious correlation between the
baseline and change scores found (Campbell and Kenny, 1999).
Further adjustment for potential confounding by vascular risk factors was
made for those variables only, which in unadjusted comparisons, differed
149
significantly between subjects with and without CVD. These were incorporated into
the age, sex, and cognitive ability-adjusted models each at a time. The most distal
factors on the hypothesised causal pathway were added first and then all other factors
(Victoria et al., 1997). Only those confounders which exerted independent effects in
the age, sex, and cognitive ability-adjusted multiple linear regression models were
retained for further analyses, which were based on examining their individual and
cumulative effects on the cognitive outcomes, as well as the effects of their control
on the association between CVD and cognitive change.
Prior to the above analyses, the data were checked with regard to whether
basic assumptions for using multiple linear regression methods were met (the sample
size was considered to be adequate; an inspection of a correlation matrix
demonstrated that none of the variables were too highly correlated (r>0.9); none of
the variables constituted a combination of other independent variables; the data were
visually inspected for outliers as a part of the univariate description of the data;
standardised residual scatter plots were visually inspected for violations of normality,
linearity, and homoscedasticity.
A statistical power analysis was conducted using nQuery version 4.0 on the
sample of survivors participating in the follow-up cognitive function testing in
2002/3. In one sample calculation, the following conditions were applied: a (two-
tailed significance level)=0.05, n=279 (the average effective sample size available
for the regression analyses) and the inclusion of three covariates ( age, sex, and prior
cognitive ability) which, on average, accounted for approximately 45.0% of the total
variance in the outcome variable (R2=0.45) in the multiple linear regression analyses.
Based on the above, the results from the analysis demonstrated 80% statistical power
for detecting an increase of 0.015 in R2 following the addition of a further covariate
to the model (i.e. there was adequate power for detecting relatively small effects that
any additional predictor variables might have exert when added to the core model.
4.8. CHAPTER SUMMARY
The aim of the present chapter was to describe the methods of the EAS and
the spectrum of data which have been gathered from baseline onwards through more
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than a decade of follow-up. More specifically, a major goal of the text was to provide
a detailed discussion of the routes taken in the collection and analysis of data on
cognitive outcomes and CVD for meeting the particular objectives of the current
study. As highlighted earlier, the EAS may be considered well suited for addressing
some of the fundamental shortcomings of prior reports examining the relationship
under study, given it is based on a random sample from the elderly general
population, and has collected longitudinal data on different cognitive abilities,
information on both prevalent and incident vascular disease, and data on a number of





The present chapter discusses the results from the current study of the
relationships between CVDs, vascular risk factors and neuropsychological outcomes
in elderly participants in the EAS. In doing so, it first presents results from a sample
of subjects who participated in the assessment of cognitive function in 2002/3. This
is followed by findings from a comparison of cognitively tested subjects with the
total number of survivors as well as subjects eligible for neuropsychological
assessment. Subsequently, data on the frequency of non-fatal CVD events, vascular
risk factors, and neuropsychological outcomes in 1998/9 and 2002/3 are provided for
the cognitively tested sample. Finally, a major goal of the chapter is to report on
findings relating to the stated research objectives of the present investigation. These
are predominantly based on a series ofmultivariate analyses which are discussed in
the text under separate headings throughout the latter part of the chapter.
5.2. SECOND ROUND OF COGNITIVE FUNCTION TESTING:
PARTICIPATION RATES
5.2.1. Number of Eligible Subjects
By mid-year 2002, EAS records revealed that 617 subjects who had provided
cognitive data in 1998/9 were still alive and available for recruitment to the second
round of cognitive testing. However, as a result of letters mailed out to all general
practices (asking about subjects' suitability to take part in cognitive testing) 23
subjects were deemed unfit to participate by their GP for health or personal reasons.
Moreover, four more subjects were excluded from participation since they had
moved away and neither the general practice nor Lothian Health Board was able to
provide the study team with information about their new whereabouts. As a
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consequence, 590 (95.6%) subjects were deemed eligible to undergo cognitive
assessment.
5.2.2. Number of Subjects Invited to Participate
Invitation letters were mailed out to the 590 EAS subjects who had attended
cognitive testing in 1998/9, were still alive by mid-year 2002, were considered fit to
undergo cognitive testing in 2002/3, and whose address was known to the study team
(figure 1). In total, 460 subjects (74.6%) accepted the invitation whereas 114 did not:
101 refused participation and 13 subjects did not reply to two letters of invitation. In
addition, 16 deaths occurred over the study period. As a result, 460 subjects were
contacted for appointment but before attending cognitive testing, seven subjects
withdrew from the study: six refused when asked whether they could be contacted
again at a later date and one subject could not be reached despite being telephoned
repeatedly at different dates and hours. As a last resort, a letter with a pre-arranged
clinic appointment was mailed out to the subject but without success (a reply was
never obtained).
In total, 452 (73.3%) subjects attended cognitive testing in 2002/3: 280
(61.9%) were tested at the University clinic and 172 (38.1 %) subjects were tested at
home. Of the two investigators performing cognitive testing, the author tested 278
(61.5%) subjects in total, whereas 174 (38.5%) subjects were tested by a senior
research fellow in the Department of Public Health Sciences at the University of
Edinburgh. Of the 278 subjects tested by the author, 122 were seen at the University
clinic (43.5% of all subjects tested at the University) and 156 at home (90.7% of all
subjects tested at home).
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5.3. COMPARISON OF COGNITIVELY TESTED AND NON-TESTED
SUBJECTS
5.3.1. Baseline Cardiovascular Diseases and Sociodemographic Characteristics
Baseline levels of lifestyle and sociodemographic factors, and frequency of
CVD, in cognitively tested (n=452) compared to non-tested (n=138) subjects are
shown in table 1. The mean age at baseline of tested subjects was 62.6 years
compared to 64.0 years of non-tested subjects. Moreover, the proportion ofmen in
the tested group was 49.8% versus 46.4% in the non-tested group. In comparison to
non-tested subjects (13.9%), 22.2% of those who were cognitively tested had
finished university or some kind of post school training (24.8% versus 12.4%),
whereas secondary school was the highest education level completed by 73.0% of
non-tested and 51.7% of tested subjects. Approximately 1.3% of tested versus 0.7%
of non-tested subjects had completed primary level of education. More tested than
non-tested subjects came from social classes I and II (based on current occupation
when interviewed at baseline or longest held occupation in the case of retired or
unemployed subjects; married women were classified according to husband's
occupation). The converse was true for social classes III-VI.
Baseline frequency of both vascular risk factors and disease was compared in
cognitively tested and non-tested subjects. For instance, in non-tested subjects, the
median level of pack-years of smoking was 10.0, the mean level of systolic blood
pressure 144.5, and the percentage of participants with impaired glucose tolerance
and diabetes was 19.3 and 3.0% (the tested group had median pack-years of 2.7,
mean systolic blood pressure of 138.8, and 9.9 and 2.7% had impaired glucose
intolerance or diabetes, respectively). In contrast, body weight (assessed with the
body mass index) did not differ between tested and non-tested subjects (25.6 in both
groups). Furthermore, with respect to vascular disease, 2.2% of non-tested subjects
met baseline criteria for MI and stroke (compared to 2.0 and 1.3% of tested subjects,
respectively).
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5.3.2. Results from the First Round of Cognitive Testing
Table 2 presents the results from the cognitive assessment performed in
1998/9 among subjects attending or not cognitive testing in 2002/3. For example, the
tested group obtained a mean NART score (the mean number of correctly
pronounced words) of 33.2 compared to 22.3 in the non-tested group. With regard to
specific cognitive outcomes, tested subjects obtained a mean general cognitive factor
score of 0.20 whereas the non-tested group obtained a mean score of-0.38 (more
than half a standard deviation less). The mean number of items recalled on the LMT
was 37.0 in the tested group compared to 31.0 in the non-tested group, and the mean
number of problems correctly completed in 20 minutes on the RPM was 35.2 versus
30.0, respectively. On the VFT, the tested group obtained a mean score of 39.5
compared to a mean score of 36.0 in the non-tested group (higher score indicates
more words produced during a timed trial). Lastly, the mean DST score (indicating
the number of correctly filled-in boxes in 90 seconds) in the tested group was 41.6
compared to a mean score of 35.5 among non-tested subjects.
5.4. NON-FATAL CARDIOVASCULAR DISEASES IN PARTICIPANTS IN
THE SECOND ROUND OF COGNITIVE TESTING
5.4.1. Angina Pectoris
Angina pectoris was recorded at baseline if there was a) positive WHO
questionnaire and positive ECG or b) positive WHO questionnaire and a recall of a
doctor's diagnosis of angina. At follow-up, angina was noted if either of the above
was present or a clinical diagnosis of angina was confirmed by either a GP or a
hospital. Approximately 5.0 % (n=23) of subjects who underwent cognitive testing in
2002/3 met diagnostic criteria for angina at baseline in 1987/8. By February 2002
(the cut-off date for diagnosis of CVD in the current study), 25.0% (n=l 13) of
subjects had accumulated a diagnosis of angina since baseline (see appendix F-l for
the number of subjects meeting individual confirmatory criteria).
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A further comparison of subjects who were tested at the University clinic
compared to those tested at home revealed no significant differences with respect to
the numbers with angina. The results showed that 15.7% (n=34) of clinic subjects
versus 20.0% (n=25) of those who were seen at home had history of angina
(P=0.307).
5.4.2. Intermittent Claudication
Intermittent claudication was recorded if there was a positive response on the
WHO questionnaire at baseline or during follow-up. Approximately 1.5% (n=7) of
the cognitively tested subjects had reported intermittent claudication at baseline. By
February 2002, the total number of subjects meeting criteria for claudication had
increased to 13.7% (n=62) (see appendix F-2 for the number of subjects meeting
individual confirmatory criteria).
The proportion ever having met criteria for intermittent claudication was
compared in subjects cognitively tested at the clinic versus at home. The comparison
revealed that 16.8% (n=37) of those tested at the clinic and 16.7% (n=20) of those
tested at home had ever had intermittent claudication (P=0.971).
5.4.3. Myocardial Infarction
Myocardial infarction was noted if the following two out of three
confirmatory criteria were met at baseline or during follow-up. At baseline the three
criteria were: a) positive WHO questionnaire, b) ECG evidence ofMI, and c) a recall
of a doctor's diagnosis of the event. During follow-up, the three criteria were: a)
elevated cardiac enzymes, b) ECG evidence ofMI, and c) typical cardiac chest pain
for 20 minutes or more. Among those who participated in the cognitive testing in
2002/3, 2.0% (n=9) met study criteria for diagnosis ofMI at baseline. By the cut-off
date for diagnosis ofCVD, 11.7% (n=53) of subjects had either met baseline or
follow-up criteria for MI (see appendix F-3 for the number of subjects meeting
individual confirmatory criteria).
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A further analysis involved comparing the number of subjects who had ever
met study criteria for MI among those who were tested at the clinic versus at home.
The results showed that 15.3% (n=33) to clinic subjects compared to 14.5% (n== 17)
of subjects tested at home had history ofMI (P=0.855).
5.4.4. Stroke
Stroke was recorded at baseline or at a follow-up examination if there was a
subject's recall of a doctor's diagnosis of the event, or on the presence of either of
the following at any point during follow-up: a) history of onset of symptoms of less
than 48 hours plus clinical confirmation of a focal or global disturbance of cerebral
function lasting for more than 24 hours, or b) computerised scan (CT) showing
evidence of cerebral infarction or haemorrhage. A history of stroke at baseline was
confirmed in 1.3% (n=6) of subjects cognitively tested in 2002/3. By February 2002,
4.4% (n=20) of the sample had met either baseline or follow-up study criteria for
stroke (see appendix F-4 for the number of subjects meeting individual confirmatory
criteria).
An additional analysis focused on assessing the number of subjects meeting
stroke criteria among those cognitively tested at the University clinic versus at home.
The results revealed that, among those attending the clinic, only 1.6% (n=3) had ever
had stroke compared to 12.3% (n=14) of subjects visited at home. The difference
turned out to be statistically significant (PO.OOl).
5.5. LEVELS OF CARDIOVASCULAR RISK FACTORS IN PARTICIPANTS
IN THE SECOND ROUND OF COGNITIVE TESTING
Of the 452 subjects who were cognitively assessed in 2002/3, 32.7% were
less than 75 years of age at the time of testing: 29.4% were aged between 75 and 79
years; 27.9% came from the 80-84 years age band; and 10.0% were 85 years or
older. Approximately 50.0% of the sample were women (n=227). Baseline
information on the highest level of education completed was available for 451
subjects (data missing for one subject). In total, 22.2% had completed University and
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24.8% had finished post school training of some kind. Approximately 51.5% had
completed secondary school and 1.3% had finished primary school. Most social
classes were well represented in the sample. Based on the current, or the longest
held, occupation when interviewed at baseline (or husband's occupation in the case
ofmarried women), 14.6% and 40.9% of subjects came from social classes I and II,
respectively. Social class IIIN (non-manual) was represented by 21.0% of subjects,
15.7% came from social class IIIM (manual), and 7.5% of subjects belonged to
social classes IV and V (these were combined due to small numbers).
Levels of several lifestyle variables were assessed at baseline according
subjects' self-report. Physical activity levels were based on questions regarding
current and past leisure activities. Complete data were available for all cognitively
tested subjects and the following pattern was observed: 7.1% of subjects were
physically inactive; 31.4% were engaged in light physical activity at most; 50.2%
were engaged in moderate activity at most; and 11.3% were engaged in strenuous
activity at most.
Assessment of alcohol intake referred to a typical week's alcohol
consumption (units of alcohol consumed in a typical week). At baseline, 7.8% of
subjects reported not having consumed any alcohol in the week prior to the baseline
interview, 56.1% had consumed 1-2 units, 21.5% had had three units, and 14.6% had
consumed four or more units of alcohol.
As above, self-reported data on smoking habits at baseline were available for
a total of 446 cognitively tested subjects. Based on these, 14.9% and 40.9% of
subjects were either current or former smokers, whereas 44.1% of subjects had never
smoked.
5.6. UNIVARIATE DESCRIPTION OF COGNITIVE OUTCOMES
5.6.1. First Round of Cognitive Testing
As an early step in the statistical analysis of the cognitive test data, the central
tendency and score distribution of each of the cognitive outcomes from 1998/9 was
determined in the 452 subjects who were cognitively tested in 2002/3 (table 2). As
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defined, the mean general cognitive factor score for the sample was 0.00 (SD=1.00)
and valid results were available for 411 subjects (41 missing). With regard to the
individual cognitive tests, the mean LMT score (immediate and delayed recall
combined) was 37.0 (SD=13.4) with valid data obtained from 447 subjects; the mean
RPM score in the sample was 35.2 (SD=9.1) and complete data were available for
439 subjects; a mean score of 39.5 (SD=12.8) on the VFT (letters C, F, and L
combined) was based on 447 subjects; and 417 subjects provided valid data on the
DST (mean score=41.6; SD=10.8).
5.6.2. Second Round of Cognitive Testing
A similar data description to that above was carried out on the cognitive
outcomes from the second round of cognitive testing. The mean general cognitive
factor score of 0.00 (SD=1.00) was based on data from 424 subjects (data from 28
subjects were missing). Complete data on the LMT was obtained from 445 subjects
(mean score of 38.5; SD=15.8) whereas 433 subjects provided valid data on the RPM
(mean score of 32.5; SD=10.1). The mean total number of words produced on the
VFT was 37.7 (SD=12.9) and valid data were available for 446 subjects. Lastly, 433
subjects had complete data on the DST (mean score of 36.2; SD=11.7).
5.7. BIVARIATE CORRELATIONS AMONGST COGNITIVE OUTCOMES
5.7.1. Outcomes from the Second Round of Cognitive Function Testing
Pearson's r product moment correlation coefficients were computed for all
combinations of bivariate associations between the individual cognitive tests in
2002/3 in order to assess the direction and strength of their relationships. Overall, all
the cognitive tests correlated at least moderately positively with each other. More
specifically, the following was observed: The LMT correlated 0.46 with the RPM
(PO.OOl), 0.21 with the VFT (P0.001), and 0.37 with the DST (P0.001). The
correlation coefficient for the relationship between the RPM and the VFT was 0.37
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(P<0.001), and that between the RPM and the DST was 0.65 (PO.OOl). The VFT
and the DST also correlated positively (r=0.45; PO.OOl).
5.7.2. Outcomes from First and Second Rounds of Cognitive Function Testing
Pearson's r correlation coefficients were also computed in order to assess the
level of stability in individual differences in cognitive test performance over the four-
year study interval. For each cognitive outcome, 1998/9 scores were correlated with
the 2002/3 scores with missing values deleted on a listwise basis. The correlation
coefficient for the 1998/9 and 2002/3 general cognitive factor scores measured 0.87
(PO.OOl). Of the individual tests, the earlier and the latter LMT scores had a
correlation coefficient of 0.71 (PO.OOl), whereas that for the RPM scores was 0.77
(PO.OOl). The earlier and the latter VFT and DST scores correlated still higher, 0.82
(PO.OOl) and 0.85 (PO.OOl), respectively.




Mean age at the time of cognitive testing in 2002/3 was assessed in each of
the CVD groups relative to that in non-diseased subjects (table 3). The mean age in
subjects with evidence of any major CVD apart from stroke was 78.4 years (SD=4.9)
compared to 77.1 years (SD=5.0) in subjects without CVD. The difference was
statistically significant (P=0.011). When age was examined in the individual CVD
categories, subjects with stroke had the highest mean age (79.5 years; SD=5.8) while
the next highest was among subjects with intermittent claudication (78.7 years;
SD=4.9). Subjects with angina had a mean age of 78.4 years (SD=5.0) and the mean
age among those with MI was 78.3 years (SD=4.9). Only subjects with intermittent
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claudication had a statistically higher mean age relative to subjects without any CVD
(P=0.033).
Sex
Relative to subjects without CVD, men were overrepresented (although non-
significantly so) in all disease categories (table 3). As an example, men made up
55.0% of subjects with any CVD compared to 46.6% in the healthy group. Men
represented 54.2% of subjects with angina, 49.1% of subjects with intermittent
claudication, 62.0% of subjects with MI and 47.1% of subjects in the stroke group.
Only the proportion ofmen with MI differed statistically from that in the group of
healthy subjects (P=0.045).
Educational Level
Common to most of the vascular groups, diseased subjects were relatively
less likely to have completed higher education (University or post school training)
(table 3). For instance, among subjects with any CVD, the proportion having
completed University was 16.8% compared to 25.5% in healthy subjects. The
equivalent proportion among those with angina was 13.6%; 17.5% in the intermittent
claudication group; 16.0% in those with MI; and 17.6% in stroke subjects. Likewise,
relatively more diseased subjects had only completed primary or secondary
education when interviewed at baseline. When evaluated statistically, the above trend
turned out to be significant for subjects with any CVD (P=0.010), and those with
intermittent claudication (P=0.022) and MI (P=0.016).
Occupational Social Class
Similar to that above, the association between social class and CVD was
assessed by examining social class trends in relation to CVD status (table 3). In
subjects having any CVD apart from stroke, a relatively lower proportion of subjects
came from social classes I and II. For instance, 9.4% and 35.6% of subjects with any
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CVD came from social classes I and II compared to 16.6% and 44.5% in the group of
healthy subjects. These trends were statistically significant (P=0.001). Similar pattern
was observed for the other vascular categories, yet only the trend among subjects
with angina (P=0.002), intermittent claudication (P=0.041), and MI (P=0.024) was
statistically significant.
5.8.2. Mood, Cognitive Status, and Prior Ability Level
Anxiety
Anxiety levels at the time of assessment of cognition in 2002/3 were
evaluated using the HADS (table 4). Depending on the magnitude of the anxiety
score for any given subject, individual case status was also estimated. Both median
levels of anxiety and anxiety caseness were examined in relation to CVD status. The
median anxiety score for subjects showing evidence of any CVD was 5.0 (IQR=3.0-
8.0) relative to a score of 4.0 (IQR=2.0-6.0) in healthy subjects. The difference tested
statistically significant (P0.001). Higher median anxiety levels were also observed
in subjects with angina (P=0.006) and MI (P=0.001). Moreover, elevated anxiety
scores were found in subjects with intermittent claudication and stroke but the
differences between these subjects and those without CVD failed to reach statistical
significance.
In comparison to healthy subjects, relatively more of those with vascular
disease had high enough scores on the anxiety sub-scale to suggest the presence of
either possible or probable clinical anxiety. For instance, 18.1% of subjects with any
CVD had scores indicating possible anxiety whereas 7.4% probably had anxiety
around the time of testing (the equivalent proportions of subjects without CVD were
8.9% and 3.9%). The above trend tested statistically significant (P=0.002). Similar
results were obtained for the individual CVD groups. Diseased subjects were in all




In comparison to scores on the anxiety sub-scale (see above) HADS
depression scores were generally lower in CVD subjects even though the same trends
were more or less observed (table 4). As an example, the median depression score in
subjects with any CVD was 4.0 (IQR=2.0-6.0) compared to a median score of 2.0
(IQR= 1.0-4.0) in those without CVD (PO.OOl). The median scores for the other
CVD categories ranged from 3.5 in subjects with MI to 5.0 in those with intermittent
claudication. Subjects with CVD had in all instances statistically elevated median
depression scores relative to subjects without CVD. Leading on from these results,
proportionately more diseased subjects had depression scores indicating possible or
probable clinical depression.
Mini-Mental Status
Cognitive screening at the time of cognitive function testing in 2002/3 was
performed using the MMSE. Due to the positive skewness of the MMSE scores,
median levels were compared in diseased and healthy subjects using appropriate
statistical methods (table 4). Overall, no statistically significant differences were
observed between subjects with and without vascular disease despite comparatively
lower median MMSE scores in all CVD groups. Due to the skewness in the data
distribution, scores on the MMSE were generally very high and close to the upper
limits of the scale (the median ranged from 28.0 to 28.5 across the CVD groups).
Peak Prior Cognitive Ability
Peak prior cognitive ability was estimated using the NART (table 4). A
comparison of diseased and healthy subjects revealed marked differences in mean
performance on the NART, which was based on the total number of correctly
pronounced words. Specifically, subjects with CVD had significantly lower mean
NART scores (the mean scores ranged from 29.8 in those with MI to 31.3 in the any
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CVD group, all at least P<0.01) compared to those without any vascular disease




Physical activity levels at baseline were assessed in each CVD group relative
to the group of healthy subjects (table 5). In general, relative to the comparison
group, diseased subjects were less likely to be physically active at baseline (the
opposite was true for the healthy group) even though most subjects (diseased and
healthy) were engaged in some kind of exercise. No statistically significant trends
were, however, observed for any of the exposure groups.
Alcohol Consumption
Median levels of self-reported intake of units alcohol consumed in a typical
week were slightly elevated in subjects with CVD compared to healthy subjects
(table 5). However, no statistically significant differences were observed. As an
example, the median alcohol level in subjects with any CVD was 5.0 (IQR=1.0-15.0)
compared to a median total units of alcohol of 4.0 (1.0-11.0) in the healthy group.
Median levels in the other CVD groups ranged from 4.0 to 5.0. When divided into
categories of total units alcohol consumed over the past week, no meaningful trends
were observed.
Smoking
An analysis of baseline data on smoking revealed that, in general, subjects
with CVD were more likely to smoke, and less likely to have never smoked, relative
to those without CVD (table 5). Statistically elevated levels were, however, only
164
noted in subjects with intermittent claudication (P=0.047). Approximately 27.8% of
these subjects smoked at baseline, whereas only 11.7% of healthy subjects did;
42.6% of subjects with intermittent claudication had never smoked versus 47.6% of
healthy subjects.
Reflecting the above pattern, median pack-years of smoking were normally
higher in diseased subjects relative to those without CVD. As an example, the
median pack-years in subjects with any CVD were statistically elevated (P=0.046),
and of the individual disease groups, the highest median levels of pack-years were




Calculation of the BMI at baseline was based on the measured height and
weight of any given subject (table 6). The observed mean BMI score for subjects
without CVD was 25.1 kg/m2 (SD=3.3) whereas mean BMI values for diseased
subjects ranged from 26.1 kg/m2 (stroke) to 26.6 kg/m2 (angina). In each of the CVD
categories, subjects with stroke being the only exception, the mean BMI was
statistically elevated relative to that of healthy subjects.
Glucose Tolerance
The majority of both diseased and healthy subjects had baseline blood
glucose levels within normal limits (table 6). Overall, however, diseased subjects
were more likely to have either impaired glucose tolerance, or clinical diabetes, in
comparison to healthy subjects (the proportion with impaired glucose tolerance
ranged from 8.9% to 15.5% across the CVD categories compared to 8.6% in subjects
without CVD). Moreover, mean blood glucose levels (fasting blood glucose was
assessed in non-diabetic subjects only) were elevated in most CVD groups (mean
values ranged from 5.6-5.9 mmol/L) relative to healthy subjects (mean value equal to
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5.6 mmol/L) even though none of the differences turned out to be statistically
significant.
Blood Pressure
Mean baseline levels of both SBP and DBP were substantially higher in
diseased subjects compared to those without CVD (table 6). Mean levels of SBP and
DBP in healthy subjects measured 134.9 mmHg (SD=20.3) and 74.9 mmHg
(SD=11.2), respectively. SBP levels in diseased subjects were on average 8.6 to 12.1
mmHg higher than in no CVD subjects (values ranged from 143.5 mmHg to 147.0
mmHg across CVD categories); mean DBP levels were on average 3.3 to 5.1 mmHg
higher (values ranged from 78.2 mmHg to 80.0 mmHg). For the majority ofCVD
groups, the elevated blood pressure levels differed statistically from that in healthy
subjects.
Blood Lipids
Mean total cholesterol levels at baseline were elevated across most disease
groups and ranged from 6.9 to 7.4 mmol/L (table 6). In comparison, healthy subjects
had a mean level of 7.0 mmol/L. Similarly, mean LDL levels were generally higher
in diseased subjects (levels ranged from 5.2 to 5.7 mmol/L) compared to those
without CVD (5.2 mmol/L). In contrast, mean levels ofHDL were statistically
significantly reduced in most groups of subjects with CVD (levels ranged from 1.3 to
1.6 mmol/L compared to a mean value of 1.5 mmol/L in subjects without CVD).
In a similar manner, both median levels of lipoprotein (a) and mean
triglyceride levels were comparatively higher across most of the CVD categories.
Overall, however, no statistically significant differences in baseline levels of these
factors were observed between diseased and healthy subjects.
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Homocysteine
Mean plasma levels of homocysteine (measured at 5-year follow-up) were
elevated in subjects with any CVD, and in those with intermittent claudication and
MI, relative to healthy subjects (table 6). The observed mean levels were 11.9
(P=0.077), 12.8 (P=0.029), and 13.0 pmol/L (P=0.020) versus 11.2 pmol/L in the
group of subjects without CVD, respectively. Comparatively lower mean levels of
homocysteine were observed in both subjects with angina and stroke but not to a
statistically significant degree.
5.8.5. Levels of Haemostatic, Inflammatory and Rheological Factors
Fibrinogen
Mean plasma fibrinogen levels were elevated in all groups of diseased
subjects relative to healthy subjects (2.6 to 2.8 g/L versus 2.5 g/L) (table 7).
Statistically higher levels were observed in subjects with any CVD (P=0.003) and in
those with intermittent claudication (P<0.001).
D-Dimer
Mean levels of the fibrinogen degradation product D-dimer ranged from 82.9
to 95.5 pg/mL in subjects with CVD compared to 78.7 pg/mL in subjects without
CVD (table 7). Only in subjects with any CVD (P=0.015) and those with intermittent
claudication (P=0.022) were the mean levels statistically elevated.
C-Reactive Protein
Median baseline levels of CRP were statistically significantly raised in all
CVD categories relative to healthy subjects (median level of 1.1 mg/L) (table 7).
Median levels ranged from 1.5 to 2.5 mg/L in those with evidence ofCVD and the
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highest comparative levels were observed in subjects with intermittent claudication
(P=0.002) and stroke (P=0.018).
Interleukin-6
In comparison to subjects without CVD, baseline median levels of IL-6 were
elevated across all CVD categories (table 7). Median levels ranged from 1.8 to 3.4
pg/mL in subjects with CVD (statistically raised levels were observed in subjects
with any CVD and in those with intermittent claudication and MI) versus a median
level of 1.6 pg/mL in the comparison group.
Cellular Adhesion Molecules
Baseline serum levels of three types of cellular adhesion molecules were
determined and compared in diseased and healthy subjects: ICAM-1, VCAM-1, and
E-selectin (table 7). Overall, mean levels of these factors were elevated across all
CVD groups. Mean levels of ICAM-1 were, however, only statistically significantly
raised in subjects with any CVD (P=0.029) and in those with intermittent
claudication (P=0.011); mean E-selectin levels were only statistically higher in
subjects with any CVD (P=4).032). No statistically significant associations between
CVD status and VCAM-1 levels were observed.
Blood Viscosity
Whole blood viscosity levels varied between healthy and diseased subjects
(table 7). Mean levels were statistically significantly elevated across all CVD groups
relative to that in subjects without CVD (values ranged from 3.6 to 3.7 mPa/sec
versus 3.4 mPa/sec in the comparison group). Similar results were obtained for




Mean levels of percentage haematocrit were found to be comparatively
higher across all CVD groups (table 7). Mean values ranged from 45.8% in subjects
with intermittent claudication and MI to as high as 46.5% in subjects with stroke. In
comparison, the mean haematocrit level in healthy subjects was 45.1%. Statistically
elevated levels were only observed in subjects with any CVD and in those with
angina.
5.9. FOUR-YEAR CHANGE IN MEAN COGNITIVE TEST SCORES BY
CARDIOVASCULAR STATUS: UNADJUSTED BIVARIATE ANALYSES
5.9.1. Logical Memory
Data on LMT performance in 1998/9 were available for 279 healthy and 148
diseased subjects (any CVD) (figure 2). Whereas healthy subjects had a mean score
of 37.0 (SD=13.0), the diseased group obtained a mean of 37.5 (SD=13.9). Over the
four-year interval, mean scores improved in the healthy group (mean score=40.0;
SD=15.1; N=277) but declined slightly in subjects with any vascular disease (mean
score=37.3; SD=16.2; N=148). In contrast, subjects with angina had a mean score of
37.9 (SD=13.4; N=59) in 1998/9 but a higher mean score of 39.0 (SD=16.8; N=58)
in 2002/3. Whereas subjects with intermittent claudication, MI, and stroke all
showed a four-year decline in mean LMT scores, the decrease was relatively greatest
in the stroke group. Thus, in 1998/9, the following results were obtained for the three
groups: intermittent claudication (mean score=36.7; SD=14.8; N=57), MI (mean
score=35.5; SD=13.4; N=49), stroke (mean score=33.5; SD=16.2; N=17). The
2002/3 results revealed the following: intermittent claudication (mean score=35.2;
SD=15.5; N=57), MI (mean score=35.2; SD=15.9; N=50), stroke (mean score=29.5;
SD=18.9; N=17).
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5.9.2. Raven's Standard Progressive Matrices
In contrast to that above, a more distinctive pattern of four-year decline in
RPM performance was observed across all groups of healthy and diseased subjects
(figure 3). In 1998/9, subjects without CVD had a mean RPM score of 36.1 (SD=9.2;
N=276) whereas subjects with any CVD had a mean of 33.7 (SD=8.6; N=144). In
2002/3, a lower mean RPM score was observed in both groups: 274 healthy subjects
obtained a mean of 33.8 (SD=10.0) while 141 subjects with any CVD had a mean
score of 30.5 (SD=9.8). In subjects with angina, the mean RPM score in 1998/9 was
33.9 (SD=9.6; N=55) and 32.3 (SD=10.4; N=53) in 2002/3. The mean score in
subjects with intermittent claudication declined by almost four points over the four
years (the mean score in 1998/9 was 32.9; SD=8.1; N=57 and in 2002/3 it was 29.0;
SD=9.1; N=55). In the group of subjects with MI, the mean score decline from 33.8
(SD=8.2; N=49) in 1998/9 to 28.8 (SD=9.3; N=50) in 2002/3. A slightly less decline
was observed among those with stroke; the mean decreased from 32.2 (SD=11.9;
N=16) in 1998/9 to 28.6 (SD=12.0; N=15) in 2002/3.
5.9.3. Verbal Fluency
An overall decline in mean VFT scores over the four years was observed in
both healthy subjects and across all CVD groups (figure 4). Subjects without CVD
had a mean score of 40.9 (SD=12.5; N=282) in 1998/9, whereas a mean score of 37.7
(SD=12.7; N=146) was reported in subjects with any CVD. In 2002/3, the mean
score in the former group had decreased to 39.2 (SD=12.9; N=280), while that in the
latter was 36.3 (SD=12.3; N=146). In subjects with angina, a mean score of 38.9
(SD=11.6; N=58) was observed in 1998/9 whereas in 2002/3 the mean score was
37.1 (SD=11.1; N=57). In subjects with intermittent claudication, MI, and stroke, the
following was noted: in 1998/9, subjects with intermittent claudication had a mean
score of 34.6 (SD=12.1; N=56), those with MI had a mean of 36.8 (SD=14.2; N=49),
and the stroke group had a mean of 32.1 (SD=14.1; N=16); in 2002/3, the mean score
in those with intermittent claudication had decreased to 34.3 (SD=11.5; N=56),
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whereas that in subjects with MI was 36.1 (SD=14.2; N=50), and 29.6 among
subjects with stroke (SD=13.3; N=17).
5.9.4. Digit Symbol-Coding
In general, mean DST scores declined over time in both subjects with and
without CVD (figure 5). In healthy subjects, the mean score in 1998/9 was 43.5
(SD=10.8) and valid data were obtained for 267 subjects. Equivalently, the mean
score in diseased subjects (any CVD) was 38.7 (SD=9.9; N= 135). In 2002/3, the
mean scores had decreased for both groups: the mean score for subjects without
CVD was 38.3 (SD=11.6) whereas that for subjects with any CVD was 33.1
(SD=11.0; N=143), or almost five points lower. In subjects with angina, the mean
DST score had decreased by more than five points over the four-year interval (the
mean score in 1998/9 was 40.2; SD=10.9; N=50, while in 2002/3 it was 34.4;
SD=12.9; N=54). The four-year decline in mean scores among subjects with
intermittent claudication was slightly lower than that in angina subjects: the mean
score in 1998/9 was 36.0 (SD=9.4; N=54), whereas the mean score in 2002/3 was
31.6 (SD=8.9; N=56). A larger decline of almost six points was observed in subjects
with MI who had a mean score of 37.8 (SD=8.9; N=47) in 1998/9 and a mean of 32.0
(SD=10.2; N=50) in 2002/3. In stroke patients, however, a decline of almost seven
points was observed over the four-year period (the stroke group had a mean score of
35.2; SD=9.9; N=12 in 1998/9 and of 29.4; SD=10.8; N=15 in 2002/3).
5.10. COGNITIVE PERFORMANCE IN 2002/3 BY CARDIOVASCULAR
STATUS: MULTIVARIATE ANALYSIS
5.10.1. General Factor Scores
Baseline Performance-AdjustedAnalysis
Adjusting for baseline differences in general cognition (in addition to age and
sex), attenuated the mean differences in general factor scores at follow-up between
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subjects with any CVD and those without vascular disease so they no longer
remained statistically significant (tables 8-12). Similar patterns were noted for the
individual CVD categories as well. However, angina was not significantly associated
with general cognition either before or after control for baseline factor scores. The
mean differences between subjects with intermittent claudication and those without
CVD decreased (the change in significance level was from P=0.001 to P=0.028) after
adjustment for baseline general factor levels; for the MI group, the difference was
attenuated beyond statistical significance. Subjects with stroke had a borderline
statistically (P=0.047) lower age, sex, and 1998/9 score adjusted mean general
cognitive factor score relative to healthy subjects.
Results from the regression analysis of the relationship between intermittent
claudication and general cognitive factor scores are presented in table 13. In addition
to age, sex, and earlier general cognitive factor scores, only BMI turned out to be
independently related to the dependent variable when included with these core
factors (factors that were examined but did not contribute independently to the model
included: education, depression, SBP, DBP, HDL, LDL, homocysteine, fibrinogen,
D-dimer, CRP, IL-6, ICAM-1, blood and plasma viscosity). Essentially no change
occurred in the intermittent claudication - general cognitive factor association (B
decreased from -0.15 to -0.14) when BMI was added (model 3). In the final model,
which accounted for approximately 79.7% (adjusted R2) of the variance in the
outcome variable (F(5,300)=240.80; P<0.001), the following terms made an
independent contribution: intermittent claudication (B=-0.14/standardized beta=-
0.05; t(300)=-2.06; P=0.040), which explained about 0.29% of the variance in
general cognitive factor, earlier general cognitive factor scores (B=0.84/standardized
beta=0.86; t(300)=31.13; P0.001), and BMI (B=-0.01/standardized beta=-0.05;
t(300)=-2.03; P=0.043).
Similar to above, the association between stroke and the general cognitive
factor were further examined using multiple regression (table 14). The analysis
showed that none of the CVD risk factors investigated for inclusion in the analysis
(place of cognitive testing, depression, pack-years of smoking, SBP, CRP, and blood
viscosity) contributed independently when added to the model containing the core
adjustment variables (age, sex, and 1998/9 general cognitive factor scores). As a
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result, the final model contained these core variables in addition to the stroke term.
Only stroke (B—0.29/ standardized beta=-0.06; t(261 )=-1.99; P=0.047), which
explained about 0.32% in the variance of the outcome variable, and earlier general
cognitive factor scores (B=0.84/standardized beta=0.86; t(261)=28.41; P<0.001)
contributed independently in the final model (adjusted R2= 78.8%; F(4,261)=247.23;
PO.OOl).
Peak Prior Cognitive Ability-AdjustedAnalysis
Initially, age and sex-adjusted mean general cognitive factor scores were
compared in healthy and diseased subjects, examining first subjects with any CVD
(tables 15-19). A statistically significant difference in age and sex adjusted mean
scores was observed between these subjects and those without CVD (P=0.002).
Further adjustment for peak prior ability as estimated by performance on the NART
attenuated the difference so it no longer remained significant. No statistically
significant differences were detected in mean general cognitive factor scores between
subjects with angina and those without CVD, either before or after adjusting for peak
prior ability level. A mean difference in age and sex-adjusted means between
subjects with intermittent claudication and those without CVD decreased when
adjustment for prior ability was made so it no longer remained significant. An even
greater attenuation in mean general cognitive factor scores was observed when peak
prior ability was adjusted for in a comparison of subjects with MI and those without
CVD. Finally, stroke subjects had statistically lower age and sex-adjusted mean
general cognitive factor score than subjects without CVD; further adjustment for
peak prior ability led to a slight increase in the observed difference which also
became more statistically significant (change in P from 0.009 to <0.001).
Further analysis of general cognitive factor scores in subjects with stroke was
carried out using multiple linear regression (table 20). The following were
considered for inclusion in the regression analysis, in addition to age, sex, and prior
ability: place of cognitive testing, depression, smoking, systolic blood pressure, C-
reactive protein, and blood viscosity. Significantly elevated levels of these factors
were found in stroke subjects compared to subjects without CVD. Only blood
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viscosity was independently associated with the general cognitive factor when added
to a regression model controlling for age, sex, and prior ability. The incorporation of
blood viscosity led to a slight attenuation (the unstandardised B coefficient decreased
from -0.70 to -0.59) in the association of stroke with the general cognitive factor
(model 3). In this final model, stroke remained independently associated with the
outcome variable (B=-0.59/standardized beta=-0.11; t(232)=-2.33; P=0.021),
accounting for 1.25% of the variance, along with age (B=-0.07/standardized beta=-
0.36; t(232)=-7.60; PO.OOl), prior ability (B=0.06/standardized beta=0.55;
t(232)=l 1.44; PO.OOl), and blood viscosity (B=-0.22/standardized beta=-0.11;
t(232)=-2.29; P=0.023). Taken together, approximately 47% of the variance (based
on the adjusted R2) in the general cognitive factor was explained by the final
regression model (F(5,232)=43.57; P<0.001).
5.10.2. Logical Memory
Baseline Performance-Adjusted Analysis
A comparison of age and sex adjusted mean LMT scores across CVD
categories (tables 8-12) revealed that only in subjects with stroke was the mean score
statistically lower than in healthy subjects. Subjects with MI had, on average, a lower
mean LMT score but the difference from that of healthy subjects failed to reach
statistical significance. When further adjustment involving performance on the LMT
in 1998/9 was performed, the mean differences between healthy and diseased
subjects became more exacerbated. For example, a statistically lower mean score was
observed for the group of subjects with any CVD. Moreover, subjects with
intermittent claudication, MI, and stroke all performed significantly worse than those
without CVD.
Further analysis initially focused on the association of any CVD with 2002/3
LMT scores (table 21). Of the individual CVD risk factors that were considered for
inclusion in the model (putative confounding factors that failed to contribute
independently in the model included social class, anxiety, depression, pack-years of
smoking, BMI, SBP, DBP, HDL, LDL, D-dimer, CRP, IL-6, ICAM-1, E-Selectin,
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haematocrit, and blood and plasma viscosity) containing the core adjustment
variables (age, sex, and 1998/9 LMT scores), education was first entered alone
(model 3), and then fibrinogen was entered separately (model 4). The final model
(model 5) included both these factors in addition to age, sex, and 1998/9 LMT
scores. Addition of education led to attenuation in the association of any CVD with
LMT scores (increase in B from -2.67 to -2.19), whereas incorporation of fibrinogen
strengthened the association (B decreased from -2.67 to -3.04). A slight reduction in
the main association occurred when both factors were included (B=-2.56 in model 5).
As a result, the final model included the following independent factors: any CVD
(B=-2.56/standardized beta=-0.08; t(402)=-2.22; P=0.027), age (B=-0.23/
standardized beta=-0.07; t(402)=-2.03; P=0.043), 1998/9 LMT scores (B=0.77/
standardized beta=0.67; t(402)=18.46; P<0.001), education (B=-1.95/standardized
beta=-0.11; t(402)=-2.88; P=0.004), and fibrinogen (B=2.25/standardized beta=0.09;
t(402)=2.47; P=0.014). Around 0.62% of the variance in 2002/3 LMT scores was
explained by the any CVD term whereas the proportion accounted for by the model
as a whole was approximately 51% (adjusted R2=51.3%; F(6,402)=72.56; PO.OOl).
Identical approaches were used in the regression analysis of the relationship
of the other CVD categories with 2002/3 LMT scores. For example, a series of
regression models were created for the purpose of investigating the relation of
intermittent claudication with LMT scores (table 22). In addition to the core
confounders, the following were included in the models (factors that were examined
but did not contribute independently to the model included: depression, SBP, HDL,
LDL, homocysteine, D-dimer, CRP, IL-6, ICAM-1, blood and plasma viscosity),
first each on its own in addition to the basic confounders, and then cumulatively:
education, diastolic blood pressure, and fibrinogen. Inclusion of education (model 3)
attenuated the intermittent claudication-LMT association somewhat (change in B
from -4.01 to -3.29), as did adjustment for diastolic blood pressure (B increased from
-4.01 to -3.68) (model 4). Adjusting for fibrinogen strengthened the intermittent
claudication-LMT association (B decreased from -4.01 to -4.78) (model 5).
Cumulatively, adjusting for education and diastolic blood pressure led to an even
further attenuation in the intermittent claudication-LMT association (B increased
from -4.01 to -2.92), whereas adding fibrinogen to this model increased the strength
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of the association so that it became statistically significant. Therefore, in the final
model (model 7), the following made an independent contribution to the variance in
2002/3 LMT scores: intermittent claudication (B=-3.72/standardized beta=-0.09;
t(315)=-2.35; P=0.020), 1998/9 LMT scores (B=0.74/standardized beta=0.66;
t(315)= 16.34; PO.OOl), education (B=-2.56/standardized beta=-0.143; t(315)=-3.53;
PO.OOl), diastolic blood pressure (B=-0.10/standardized beta=-0.08; t(315)=-2.00;
P=0.047), and fibrinogen (B=2.71/standardized beta=0.11; t(315)=2.62; P=0.009).
The intermittent claudication term was found to contribute approximately 0.88% to
the variance in the dependent variable whereas just over 50% of the variance was
explained by the model as a whole (adjusted R2=52.3%; F(7,315)=51.42; PO.OOl).
In the analysis of the association ofMI with LMT scores in 2002/3, education
(other putative confounding factors that failed to contribute independently in the
model included social class, anxiety, depression, pack-years of smoking, BMI, SBP,
DBP, HDL, homocysteine, CRP, IL-6, and blood viscosity) was added to the model
containing age, sex, and 1998/9 LMT scores (table 23). This attenuated the MI-LMT
association so that it no longer remained statistically significant (B increased from -
3.36 to -2.80). This final model (model 3) accounted for almost 50% of the total
variance in 2002/3 LMT scores (adjusted R2=49.9%; F(5,316)=64.90; PO.OOl). The
following were independently related to the outcome variable: 1998/9 LMT scores
(B=0.76/standardizcd beta=0.66; t(316)= 15.99; PO.OOl) and education (B=-1.71/
standardized beta=-0.10; t(316)=-2.29; P=0.023).
An even simpler final model was obtained as a result of a regression analysis
of the stroke-LMT association which consisted solely of the core adjustment
variables (table 24). None of the CVD risk factors evaluated contributed
independently when added to the basic model (these included place of cognitive
testing, depression, pack-years of smoking, SBP, CRP, and blood viscosity). In this
final model, stroke was independently related to 2002/3 LMT scores (B=-
7.17/standardized beta=-0.11; t(286)=-2.61; P=0.010) and accounted for 1.21% of
the total variance. Earlier LMT scores also made an independent contribution
(B=0.77/standardized beta=0.67; t(286)=l 5.46; P<0.001), whereas the model as a
whole explained around 49% of the total variance (adjusted R2=49.1%;
F(4,286)=70.98; PO.OOl).
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Peak Prior Cognitive Ability-Adjusted Analysis
With the exception of stroke, no statistical differences were observed in age
and sex adjusted mean LMT scores between healthy and diseased subjects (tables 15-
19). Non-significant differences were further attenuated when peak prior ability was
adjusted for. Stroke subjects had an age and sex adjusted mean score which, on
average, was 8.9 points lower than in healthy subjects. When peak prior ability was
adjusted for, the mean difference still remained significant (P-0.028).
As shown in table 25, a regression analysis of the relationship of stroke with
LMT scores which led to the inclusion of C-reactive protein (other factors considered
but did not contribute independently to the model included place of cognitive testing,
depression, pack-years of smoking, SBP, and blood viscosity) resulted in a slightly
stronger association which, however, remained non-significant (change in B from -
3.25 (model 2) to -5.78 (model 3)). In the final model, which accounted for
approximately 25% of the variance in 2002/3 LMT scores (adjusted R2=24.6%;
F(5,199)= 14.28; PO.OOl), the following factors were independently related to the
outcome variable: age (B=-0.91/ standardized beta=-0.30; t(199)=-4.63; PO.OOl),
peak prior ability (B=0.77/ standardized beta=0.42; t( 199)=12.94; PO.OOl), and C-
reactive protein (B=1.36/ standardized beta=0.24; t(199)=2.94; PO.OOl).
5.10.3. Raven's Standard Progressive Matrices
Baseline Performance-Adjusted Analysis
Adjusting for 1998/9 RPM scores resulted in a substantial reduction in the
differences in mean RPM scores in 2002/3 between diseased and healthy subjects
(tables 8-12). Whereas differences in mean scores were no longer observed between
healthy subjects and those with any CVD, angina, or stroke, subjects with MI had
statistically lower scores and those with intermittent claudication had a lower score
of borderline significance.
Table 26 presents the results from the regression analysis of the association of
intermittent claudication with 2002/3 RPM scores. Separate models were computed
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for each CVD risk factor (along with the core adjustment variables) in order to
demonstrate both the effects each had on the intermittent claudication-RPM
association, as well as their cumulative impact. The factors that were included
(factors that were examined but did not contribute independently to the model
included: depression, SBP, DBP, HDL, LDL, homocysteine, D-dimer, CRP, IL-6
and plasma viscosity) in the analysis were: education, fibrinogen, ICAM-1, and
blood viscosity. The analysis revealed that separately, each CVD risk factor led to a
modest attenuation in the intermittent claudication-RPM association: addition of
education increased B from -1.39 to -1.06 (model 3), addition of fibrinogen increased
B from -1.39 to -1.28 (model 4), inclusion of ICAM-1 resulted in an increase in B
from -1.39 to -1.23 (model 5), and adding blood viscosity increased B from -1.39 to -
1.24 (model 5). In none of these analyses did the intermittent claudication-RPM
association become statistically significant. When added cumulatively, each factor
resulted in an even greater attenuation in the strength of the relationship of
intermittent claudication with RPM scores. An increase in B from -1.39 to -0.98 was
observed in model 7 (with education and fibrinogen in addition to core adjustment
variables), a change from -1.39 to -0.89 in B resulted when ICAM-1 was added
(model 8), and lastly in model 9, blood viscosity increased the value ofB even
further. In the final model, which was found to explain approximately 60% of the
total variance (adjusted R2=60.2%; F(8,208)=41.78; PO.OOl), only age (B=-0.27/
standardized beta=-0.13; t(208)=-2.90; P=0.004) and 1998/9 RPM scores (B=0.76/
standardized beta=0.66; t(208)=l3.55; PO.OOl) made an independent contribution.
The final MI model included only the core adjustment variables since none of
the CVD risk factors examined (social class, anxiety, depression, pack-years of
smoking, BMI, SBP, DBP, HDL, homocysteine, CRP, IL-6, and blood viscosity)
contributed independently when added to the model (table 27). In this model (model
2), MI was independently related to the dependent variable and contributed 0.90% to
the total variance (B=-2.65/standardized beta=-0.10; t(315)=-2.69; P=0.007) whereas
the model as a whole explained approximately 61% (adjusted R2=61.1%;
F(4,315)=T26.04; PO.OOl). Age (B=-0.22/standardized beta=-0.11; t(315)=-3.03;
P=0.003) and 1998/9 RPM scores (B=0.81/standardized beta=0.72; t(315)= 19.72;
PO.OOl) also contributed independently in the final model.
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Peak Prior Cognitive Ability-Adjusted Analysis
An analysis of age and sex adjusted mean RPM scores revealed statistically
lower scores in subjects with any CVD, intermittent claudication, and in those with
MI, relative to subjects without CVD (tables 15-19). Further adjustment for peak
prior ability resulted in a substantial attenuation in these associations. As a result,
statistically significant differences were no longer observed. As a consequence, no




Adjustment for performance on the VFT in 1998/9 substantially reduced the
magnitude of the age and sex adjusted mean VFT differences observed between
diseased and healthy subjects (tables 8-12). As an example, the mean difference
between healthy and subjects with intermittent claudication was reduced so it became
non-significant. A similar attenuation was seen for the mean difference between
subjects with stroke and those without CVD. Because CVD was no longer associated
with cognition in any of the comparisons ofmean scores, no further analyses were
carried out on the data.
Peak Prior Cognitive Ability-AdjustedAnalysis
Statistically lower age and sex adjusted mean VFT scores were observed in
subjects with intermittent claudication, and in those with stroke, compared to healthy
subjects (tables 15-19). Inclusion of peak prior ability attenuated these differences,
but whereas the mean score for subjects with stroke remained statistically lower
relative to that for healthy subjects, the difference between healthy and subjects with
intermittent claudication became non-significant.
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The association between stroke and 2002/3 VFT scores was further examined
using multiple regression (table 28). A final model explaining close to 26% of the
total variance in 2002/3 VFT scores (adjusted R2=25.6%; F(4,288)=26.17; P<0.001)
included only the stroke term in addition to the core adjustment variables (place of
cognitive testing, depression, pack-years of smoking, SBP, CRP, and blood viscosity
were examined as putative confounders but failed to contribute independently to the
model). The contribution of the stroke term to the total variance in the outcome
variable was 1.80% (B=-7.61/standardized beta=-0.13; t(288)=-2.62; P=0.009). Age
(B=-0.32/ standardized beta=-0.12; t(288)=-2.44; P=0.015) and NART
(B=0.71 /standardized beta=0.48; t(288)=9.46; P0.001) also made an independent
contribution in the final model.
5.10.5. Digit Symbol-Coding
Baseline Performance-AdjustedAnalysis
Adjusting for 1998/9 DST performance led to substantial attenuation of all
age and sex adjusted differences in the follow-up scores so that they no longer
remained significant (tables 8-12). It was therefore decided, that no further analyses
would be performed on the above data.
Peak Prior Cognitive Ability-AdjustedAnalysis
Relative to subjects without CVD, the mean age and sex adjusted 2002/3
DST scores were significantly lower in subjects with any CVD, and among those
with intermittent claudication, MI, and stroke (tables 15-19). A further adjustment
for peak prior ability reduced these differences so that, although the association of
any CVD, intermittent claudication, and stroke with DST scores remained
statistically significant, having MI was no longer associated with lower mean DST
scores.
Results based on a further examination of the relationship between any CVD
and DST are presented in table 29. The CVD risk factors included in the analysis
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were (other putative confounding factors that failed to contribute independently in
the model included social class, BMI, HDL, LDL, D-dimer, CRP, ICAM-1, E-
Selectin, and plasma viscosity): anxiety, depression, smoking, systolic and diastolic
blood pressure, interleukin-6, haematocrit, and blood viscosity. Adjusting for each of
these factors at a time led to a reduction in the magnitude of the any CVD-DST
association (models 3 through 10). Whereas inclusion of interleukin-6 resulted in the
largest relative reduction in the any CVD-DST relationship (B increased from -1.82
to -1.16) most of the other factors led to attenuation of similar size. In none of these
models did vascular disease exert independent influence on DST scores. When the
above factors were added in a cumulative fashion (models 11 through 17), there was
a progressive decrease in the strength of the any CVD-DST relationship which at no
point was found statistically significant. In the final model (model 17), which
accounted for approximately 38% of the variance in DST scores (ad justed
R2=38.3%; F(12,244)=14.23; PO.OOl), the following factors were found to
contribute independently to the outcome variable: age (B=-0.88/standardized beta—
0.37; t(244)=-6.37; PO.OOl), peak prior ability (B=0.41/standardized beta=0.31;
t(244)=6.01; P<0.001), smoking (B=-0.55/standardized beta—0.12; t(244)=-2.30;
P=0.022), and interleukin-6 (B—2.94/standardized beta=-0.15; t(244)—2.61;
P=0.010).
A regression analysis of the association of intermittent claudication with DST
scores resulted in the addition of interleukin-6 to the model (other factors that were
examined but did not contribute independently to the model included: education,
depression, SBP, DBP, HDL, LDL, homocysteine, fibrinogen, D-dimer, CRP,
ICAM-1, blood and plasma viscosity) consisting of the core adjustment variables
(table 30). The result was a slight reduction in the strength of the intermittent
claudication-DST relationship which remained non-significant (B increased from -
3.23 to -2.25). However, age (B=-0.91/standardized beta=-0.39; t(218)=-6.85;
PO.OOl), peak prior ability (B=0.45/standardized beta=0.34; t(218)=6.12; PO.OOl),
and IL-6 (B=-2.74/standardized beta=-0.14; t(218)=-2.29; P=0.023) all contributed
independently in the final model which accounted for close to 33% of the total
variance in DST (adjusted R2=32.7%; F(5,218)=22.65; PO.OOl).
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Finally, the relationship of stroke with DST scores is presented in a series of
regression models in table 31. Levels of smoking and blood viscosity were found to
be relatively elevated in stroke subjects and were considered for inclusion in the
analysis (other factors considered included place of cognitive testing, depression,
SBP, and CRP). Addition of smoking to model 2 (adjusting for age, sex, and peak
prior ability) resulted in a slight attenuation in the stroke-DST association which
remained non-significant (B increased from -6.61 to -5.26), and incorporation of
blood viscosity reduced the strength of the association somewhat more (an increase
in B from -6.61 to -4.88). In the final model, which in addition to the core variables
also included terms for both smoking (B=-0.59/standardized beta=-0.12; t(231)=-
2.26; P=0.025) and blood viscosity (B=-2.97/standardized beta=-0.13; t(231)=-2.31;
P=0.022), stroke did not make an independent contribution to DST performance. Age
(B=-0.99/standardized beta=-0.42; t(231)=-7.93; P<0.001) and peak prior ability
(B=0.45/standardized beta=0.34; t(231)=6.45; PO.OOl) were also independently
related to DST scores. As a whole, the final model accounted for around 35% of the
variance in DST scores (adjusted R2=34.7%; F(6,231 )=21.98; P<0.001).
5.11. GENERAL FACTOR-ADJUSTED RESIDUALS OF INDIVIDUAL




Rather than using the raw LMT scores as a dependent variable, the outcome
variable in the current analysis comprised the general factor-adjusted standardised
residuals of the LMT, which were computed by regressing the LMT on the general
factor. As shown in table 32, after adjustment for age and sex, any vascular disease
was not associated with the outcome (model 1). Further control for LMT
performance in 1998/9 and other potential confounders attenuated the relationship
between any CVD and the LMT residuals even further. However, in none of the
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models did the vascular term exert independent effects on the outcome. In the final
model, age (standardised beta=0.03; t(384)=3.15; P=0.002), LMT performance in
1998/9 (standardised beta=0.04; t(384)=l 1.9; P<0.001), and baseline fibrinogen
levels (standardised beta=0.23; t(384)=3.25; P=0.001) were significantly associated
with the LMT residual scores. The model as a whole explained approximately 28%
of the total variance in the dependent variable (R2=28.2%; F(6,384)=26.48;
PO.OOl).
Similar to above, the relation of intermittent claudication with LMT residuals
was examined and the results are presented in table 33. In the age and sex adjusted
model (model 1), intermittent claudication did not significantly predict the LMT
residual scores. Further adjustment for 1998/9 LMT performance and other potential
confounding factors led to further attenuation in the association of intermittent
claudication with the outcome variable. In the final model, age (standardised
beta=0.03; t(303)=2.59; P=0.010), prior LMT scores (standardised beta=0.04;
t(303)=9.43; PO.OOl), and fibrinogen levels (standardised beta=0.24; t(303)=2.77;
P=0.006) were independently associated with the dependent variable. The final
model, however, explained close to 23% of the total variance in the outcome variable
(R2=22.9%; F(7,303)—14.17; PO.OOl).
Lastly, the LMT residual scores were studied in relation to both MI and
stroke. Having MI was not related to the outcome variable when adjusted for age,
sex, 1998/9 LMT performance, and level of education (see table 34). In the final
model, which accounted for about 22% of the total variance in LMT residual scores
(R2=21.8%; F(5,308)=18.41; PO.OOl), only age (standardised beta=0.03;
t(308)=3.12; P=0.002) and 1998/9 performance (standardised beta=0.04;
t(308)=9.39; PO.OOl) remained independent predictors of LMT residual scores.
Identically, stroke neither significantly predicted LMT residual scores in models first
adjusted for age and sex, and then additionally for prior performance (see table 35).
Only age (standardised beta=0.02; t(275)=2.28; P=0.024) and 1998/9 LMT
performance (standardised bcta=0.03; t(275)=8.20; PO.OOl) significantly predicted
the outcome in a model which accounted for approximately 18% of the total variance
(R2=18.5%; F(4,275)=16.83; PO.OOl).
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Peak Prior Cognitive Ability-AdjustedAnalysis
As shown in table 36, stroke was not associated with the outcome in any of
the models (models 1 to 3). Further adjustment for peak prior ability did not change
the association of stroke with the LMT residual scores, but further addition of CRP
(model 3) led to a greater attenuation in the stroke-LMT association. In the final
model, which accounted for less than 4.0% of the total variance in the dependent
variable (R2=3.9%; F(5,193)=2.61; P=0.026), only CRP remained an independent
predictor of the outcome (standardised beta=0.23; t( 193)=3.25; P=0.001).
5.11.2. Raven's Standard Progressive Matrices
Baseline Performance-AdjustedAnalysis
Whereas no further peak prior cognitive ability-adjusted analysis of the
relation ofCVD with residuals of the RPM test was carried out, the association of
both intermittent claudication and MI with the RPM residual scores was performed,
controlling for RPM performance in 1998/9. The analysis of the intermittent
claudication-RPM residual association which is presented in table 37 failed to
establish a relationship between the two. More specifically, in none of the models
examined was having intermittent claudication related to the outcome variable.
Further addition of potential confounding factors to age, sex, and 1998/9 RPM
performance-adjusted models changed the intermittent claudication-RPM residual
score association only negligibly. The final model (model 9) was found highly
significant (R2=13.4%; F(8,202)=5.07; P<0.001) and the following contributed
independently to the outcome: sex (standardised beta=-0.43; t(202)=-3.09; P=0.002)
and 1998/9 RPM performance scores (standardised beta=0.04; t(202)=4.57;
P<0.001). Similarly, MI was not related to the RPM residual scores in two models,
one adjusting for age and sex, and another further controlling for RPM performance
in 1998/9 (see table 38). Again, however, only sex (standardised beta=-0.32; t(310)=-
3.13; P=0.002) and 1998/9 RPM performance (standardised beta=0.04; t(310)=6.63;
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PO.OOl) contributed significantly in a final model which as a whole accounted for
approximately 16% of the total variance (R2=16.1%; F(4,310)=16.07; P<0.001).
5.11.3. Verbal Fluency
Peak Prior Cognitive Ability-Adjusted Analysis
No analyses of the association between CVD and VFT residual scores were
performed, statistically taking VFT performance scores in 1998/9 into control.
Rather, the residual scores of the VFT in 2002/3 were examined in relation to stroke,
in models adjusting first for age and sex, and then additionally for an estimate of
peak prior cognitive ability (table 39). In neither model was stroke significantly
associated with the outcome variable. Adjusting the age and sex controlled models
further for peak prior ability did not have any impact on the relation between stroke
and the dependent variable. In this model, which contributed only about 3% to the
total variance (R2=2.7%; F(4,277)=2.97; P=0.020), both age (standardised beta=0.02;
t(277)=2.08; P=0.038) and prior ability (standardised beta=0.02; t(277)=2.08;
P=0.010) exerted independent effects on the outcome variable.
5.11.4. Digit Symbol-Coding
Peak Prior Cognitive Ability-Adjusted Analysis
Identically to above, our analysis of the residuals of the DST in relation to
CVD was limited to models adjusting for peak prior cognitive ability rather than
earlier performance on the DST. In the first of these, the dependent variable was
examined in relation to any CVD as well as potential confounders (see table 40). The
cumulative adjustment for these (models 1 to 3 and 11 to 17) led only to a slight
attenuation in the association of vascular disease with the cognitive outcome, but in
none of the models was having any CVD significantly related to the DST residual
scores. In the final model, which accounted for 18% of the total variance (R =18.0%;
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F(12,241)=5.63; PO.OOl), the following co-variates exerted independent influence:
age (standardised beta=-0.04; t(241)=-2.90; P=0.004), sex (standardised beta=0.31;
t(241)=2.27; P=0.024), scores on the estimate of peak prior ability (standardised
beta=-0.03; t(241)=-4.04; P<0.001), and baseline smoking (standardised beta—0.06;
t(241)—-2.67; P=0.008).
Similar results were obtained when the relationship between intermittent
claudication and the DST residual scores were studied (see table 41). In models
adjusting for age and sex, then additionally for prior ability, and then finally for
baseline interleukin-6 levels, intermittent claudication did not exert significant
influence on the outcome variable. However, in the final model, which explained
around 14% of the total variance (R2=13.9%; F(5,215)=8.08; PO.OOl), age
(standardised beta=-0.04; t(215)=-3.09; P=0.002), sex (standardised beta=0.40;
t(215)=3.15; P=0.002), and prior ability (standardised beta=-0.03; t(215)=-4.35;
PO.OOl), contributed independently to the DST residual scores.
Finally, as presented in table 42, the DST residual scores were regressed on
stroke and potential confounding factors in a series of models. However, in none of
the models did stroke emerge as an independent predictor of the DST residual scores.
In the final model, however, age (standardised beta=-0.04; t(229)=-3.33; PO.OOl),
sex (standardised betaO.28; t(229)=2.15; PO.032), peak prior ability (standardised
beta=-0.02; t(229)=-3.51; PO.OOl), and pack-years of smoking at baseline in 1987/8
(standardised beta=-0.06; t(229)=-2.54; PO.012), each contributed independently
(R203.4%; F(6,229)=7.09; PO.OOl).
5.12. CHAPTER SUMMARY
The main aim of this chapter was to present data from the sample of 452
Edinburgh Artery Study subjects who participated in assessment of cognitive
function in 2002/3 and on which the results discussed herein are based. In particular,
some modest differences in baseline sociodemographic and medical characteristics
were observed between participants considered eligible for cognitive testing in
2002/3 and those who were actually assessed. On the whole, the cognitively tested
subjects were relatively younger, comprised relatively more males, were more
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educated, and ofhigher social standing. In addition, they also had slightly more
favourable medical and lifestyle profiles. An examination of cognitive test
performance in relation to CVD status showed an overall decline in mean scores on
the majority of cognitive tests in both diseased and non-vascular subjects over
1998/9 to 2002/3.
In multivariate analyses, adjusting for age, sex, and prior ability, subjects
with stroke scored lower on most tests compared to non-vascular controls. Further
analyses demonstrated that stroke was associated with a progressive decline in
general ability, verbal memory and verbal fluency. Similarly, subjects with MI but
without a recognised previous stroke obtained lower scores on tests of verbal
memory and non-verbal reasoning. In linear regression analyses, MI independently
predicted steeper decline in non-verbal reasoning. In contrast to these findings,
angina was not significantly related to cognitive decline in any of the analyses.
Intermittent claudication was further associated with a significant progressive decline
in both general cognitive function and verbal memory after control for possible
confounders.
Several potentially modifiable vascular risk factors, including education,
body mass index, smoking, diastolic blood pressure, inflammatory markers and
blood viscosity were also related to decline in general and specific cognitive abilities,
independently of age, sex, prior cognitive ability and vascular disease. Further
analyses demonstrated that the associations with decline in specific cognitive
measures principally resulted from the relationship between vascular disease and risk
factors with general cognitive ability rather than the individual functions per se.
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FIGURE 1. Participation in the second round of cognitive function testing in 2002/3.
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AnxietvCasen ss%t1 Probable(>11) Possible(8-10) Non-cases(<7)
3.9(11) 8.9(25) 87.2(245)
7.4(11) 18.1(27) 74.5(111) (trend)**
3.4(2) 23.7(14) 72.9(43) (trend)*
8.8(5) 15.8(9) 75.4(43) (trend)*
14.0(7) 12.0(6) 74.0(37) (trend)**








DepressionCas ness%In) Probable(>11) Possible(8-10) Non-cases(<7)
0.7(2) 5.3(15) 94.0(264)
2.0(3) 9.4(14) 88.6(132) (trend)*
I.7(1) II.9(7) 86.4(51)
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TABLE 8. Mean differences (95% CI) in cognitive test scores in 2002/3 by CVD
status, adjusted for demographic factors and cognitive performance in 1998/9.





Age & sex adjusted 277 39.7(37.9-41.6) 148 37.6 (35.1-40.1)
Age, sex & 1998/9 score adjusted 274 40.0(38.7-41.3) 147 37.3 (35.5-39.0)*
Raven's Progressive Matrices
Age & sex adjusted 274 33.6 (32.4-34.7) 141 30.8 (29.2-32.3)**
Age, sex & 1998/9 score adjusted 271 33.2 (32.4-33.9) 138 32.2 (31.1-33.2)
Verbal Fluencv Test
Age & sex adjusted 280 39.0 (37.5-40.5) 146 36.6(34.5-38.6)
Age, sex & 1998/9 score adjusted 279 38.3 (37.4-39.2) 144 38.2 (37.0-39.4)
Digit Svmbol Test
Age & sex adjusted 272 37.9 (36.6-39.2) 143 33.9(32.1-35.6)***
Age, sex & 1998/9 score adjusted 262 37.3 (36.6-38.1) 131 36.8 (35.7-37.8)
General Cognitive Factor
Age & sex adjusted 269 0.13 (0.02-0.24) 138 -0.17 (-0.32 to-0.01)**
Age, sex & 1998/9 score adjusted 256 0.11 (0.06-0.17) 125 0.02 (-0.06-0.11)
Any CVD (n=149) excludes subjects with prevalent or incident stroke (n= 17).
*P<0.05; **P<0.01; ***P<0.001.
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TABLE 9. Mean differences (95% CI) in cognitive test scores in 2002/3 between
subjects with angina and no CVD, adjusted for demographic factors and cognitive
performance in 1998/9.





Age & sex adjusted 277 39.8 (38.0-41.6) 58 39.6 (35.7-43.6)
Age, sex & 1998/9 score adjusted 274 40.0(38.7-41.3) 58 38.6(35.8-41.5)
Raven's Progressive Matrices
Age & sex adjusted 274 33.7 (32.6-34.8) 53 32.7 (30.1-35.2)
Age, sex & 1998/9 score adjusted 271 33.7 (32.9-34.4) 51 34.2(32.4-35.9)
Verbal FluencvTest
Age & sex adjusted 280 39.1 (37.7-40.6) 57 37.5 (34.2-40.7)
Age, sex & 1998/9 score adjusted 279 39.0 (38.1-39.9) 56 38.3 (36.3-40.2)
Digit Svmbol Test
Age & sex adjusted 272 38.1 (36.8-39.4) 54 35.5 (32.6-38.4)
Age, sex & 1998/9 score adjusted 262 38.4 (37.6-39.1) 47 38.4 (36.7-40.1)
General Cognitive Factor
Age & sex adjusted 269 0.15 (0.04-0.26) 52 0.04 (-0.21-0.30)
Age, sex & 1998/9 score adjusted 256 0.18(0.12-0.23) 44 0.20 (0.07-0.34)




TABLE 10. Mean differences (95% CI) in cognitive test scores in 2002/3 between
subjects with intermittent claudication and no CVD, adjusted for demographic
factors and cognitive performance in 1998/9.





Age & sex adjusted 277 39.8 (38.0-41.6) 57 35.9 (32.0-39.9)
Age, sex & 1998/9 score adjusted 274 39.8 (38.6-41.1) 57 35.7 (32.9-38.5)**
Raven's Progressive Matrices
Age & sex adjusted 274 33.7 (32.5-34.8) 55 29.8 (27.3-32.3)**
Age, sex & 1998/9 score adjusted 271 33.4 (32.6-34.2) 55 31.5 (29.8-33.2)*
Verbal Fluency Test
Age & sex adjusted 280 39.1 (37.6-40.6) 56 34.9 (31.5-38.2)*
Age, sex & 1998/9 score adjusted 279 38.3 (37.4-39.1) 56 39.0(37.1-40.9)
Digit Symbol Test
Age & sex adjusted 272 38.1 (36.8-39.3) 56 32.7 (29.9-35.4)**
Age, sex & 1998/9 score adjusted 262 37.7 (37.0-38.4) 53 37.0 (35.4-38.6)
General Cognitive Factor
Age & sex adjusted 269 0.14(0.03-0.25) 53 -0.32 (-0.57 to-0.07)**
Age, sex & 1998/9 score adjusted 256 0.12(0.07-0.18) 50 -0.03 (-0.15-0.10)*
Intermittent claudication (n=57) includes subjects with intermittent claudication only (n=26),




TABLE 11. Mean differences (95% CI) in cognitive test scores in 2002/3 between
subjects with MI and no CVD, adjusted for demographic factors and cognitive
performance in 1998/9.





Age & sex adjusted 277 39.9 (38.1-41.7) 50 35.4 (31.1-39.6)
Age, sex & 1998/9 score adjusted 274 39.7 (38.5-41.0) 49 36.3 (33.2-39.4)*
Raven's Progressive Matrices
Age & sex adjusted 274 33.7 (32.6-34.8) 50 29.0 (26.4-31.7)**
Age, sex & 1998/9 score adjusted 271 33.5 (32.8-34.3) 49 30.9 (29.1-32.7)**
Verbal Fluency Test
Age & sex adjusted 280 39.2 (37.6-40.7) 50 36.3 (32.7-40.0)
Age, sex & 1998/9 score adjusted 279 38.7 (37.8-39.5) 49 39.6 (37.5-41.7)
Digit Symbol Test
Age & sex adjusted 272 38.1 (36.9-39.4) 50 33.1 (30.2-36.1)**
Age, sex & 1998/9 score adjusted 262 38.0 (37.2-38.7) 47 37.0 (35.3-38.7)
General Cognitive Factor
Age & sex adjusted 269 0.15(0.04-0.26) 50 -0.33 (-0.59 to-0.07)**
Age, sex & 1998/9 score adjusted 256 0.13 (0.08-0.19) 47 0.00 (-0.13-0.14)
Myocardial infarction (n=50) includes subjects with MI only (n=12), Ml and angina (n=21), MI and
intermittent claudication (n=2), MI, angina, and intermittent claudication (n= 15).
*P<0.05; **P<0.01; ***P<0.001.
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TABLE 12. Mean differences (95% CI) in cognitive test scores in 2002/3 between
subjects with stroke and no CVD, adjusted for demographic factors and cognitive
performance in 1998/9.





Age & sex adjusted 277 39.9 (38.1-41.7) 17 31.0 (23.8-38.3)*
Age, sex & 1998/9 score adjusted 274 39.8 (38.5-41.1) 17 32.6(27.3-37.8)*
Raven's Progressive Matrices
Age & sex adjusted 274 33.7 (32.6-34.9) 15 29.8 (25.0-34.7)
Age, sex & 1998/9 score adjusted 271 33.7(33.0-34.5) 15 31.5 (28.2-34.7)
Verbal FluencvTest
Age & sex adjusted 280 39.2 (37.7-40.7) 17 30.4 (24.2-36.6)**
Age, sex & 1998/9 score adjusted 279 38.8 (37.9-39.7) 16 37.6 (33.9-41.2)
Dieit Svmbol Test
Age & sex adjusted 272 38.2 (37.0-39.5) 15 30.5 (25.1-35.9)**
Age, sex & 1998/9 score adjusted 262 38.5 (37.8-39.2) 11 38.5 (35.0-42.0)
General Cognitive Factor
Age & sex adjusted 269 0.16(0.04-0.27) 14 -0.51 (-1.0 to -0.03)**
Age, sex & 1998/9 score adjusted 256 0.18 (0.13-0.24) 10 -0.10 (-0.38-0.18)*




TABLE 13. 1998/9 cognitive performance-adjusted regression analysis of general
cognitive factor scores in 2002/3 in relation to intermittent claudication (N=306).
Numbers are unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2 Model 3
B SE B SE B SE
Intermittent -0.47** 0.14 -0.15* 0.07 -0.15* 0.07
claudication
Age -0.06***0.01 -0.01 0.00 -0.01 0.00
Sex -0.10 0.10 -0.04 0.05 -0.04 0.05
GCF 0.83*** 0.03 0.84*** 0.03
(1998/9)
BM1 I ob * ob
R2 0.146 0.795 0.797
Df (3, 302) (4, 301) (5, 300)
F 18 44*** 296.88*** 240.80***
AR2 0.643 0.003
Df (1,301) (1,300)
F 957 11*** 4.12*
Intermittent claudication (n=57) includes subjects with intermittent claudication only (n=26),




TABLE 14. 1998/9 cognitive performance-adjusted regression analysis of general
cognitive factor scores in 2002/3 in relation to stroke (N=266). Numbers are
unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2
B SE B SE
Stroke -0.46 0.29 -0.29* 0.14
Age -0.07*** 0.01 -0.01 0.01













TABLE 15. Mean differences (95% CI) in cognitive test scores in 2002/3 by CVD
status, adjusted for demographic factors and peak prior cognitive ability.





Age & sex adjusted 277 39.7(37.9-41.6) 148 37.6(35.1-40.1)
Age, sex & NART adjusted 275 39.1 (37.3-40.8) 145 39.1 (36.7-41.6)
Raven's Progressive Matrices
Age & sex adjusted 274 33.6 (32.4-34.7) 141 30.8 (29.2-32.3)**
Age, sex & NART adjusted 273 33.0(32.0-33.9) 140 32.0(30.6-33.4)
Verbal Fluencv Test
Age & sex adjusted 280 39.0(37.5-40.5) 146 36.6 (34.5-38.6)
Age, sex & NART adjusted 277 38.3 (37.0-39.6) 144 38.1 (36.3-40.0)
Digit Svmbol Test
Age & sex adjusted 272 37.9 (36.6-39.2) 143 33.9 (32.1-35.6)***
Age, sex & NART adjusted 271 37.4 (36.2-38.5) 142 35.0(33.4-36.7)*
General Cognitive Factor
Age & sex adjusted 269 0.13 (0.02-0.24) 138 -0.17 (-0.32 to -0.01)**
Age, sex & NART adjusted 268 0.07 (-0.02-0.16) 138 -0.03 (-0.16-0.09)
Any CVD (n=149) excludes subjects with prevalent or incident stroke (n=17).
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 16. Mean differences (95% CI) in cognitive test scores in 2002/3 between
subjects with angina and no CVD, adjusted for demographic factors and peak prior
cognitive ability.





Age & sex adjusted 277 39.8(38.0-41.6) 58 39.6 (35.7-43.6)
Age, sex & NART adjusted 275 39.6 (37.9-41.3) 56 41.3 (37.5-45.1)
Raven's Progressive Matrices
Age & sex adjusted 274 33.7 (32.6-34.8) 53 32.7 (30.1-35.2)
Age, sex &NART adjusted 273 33.5 (32.5-34.5) 53 34.0(31.8-36.2)
Verbal Fluency Test
Age & sex adjusted 280 39.1 (37.7-40.6) 57 37.5 (34.2-40.7)
Age, sex & NART adjusted 277 39.0 (37.7-40.3) 55 38.8 (35.8-41.7)
Digit Svmbol Test
Age & sex adjusted 272 38.1 (36.8-39.4) 54 35.5 (32.6-38.4)
Age, sex & NART adjusted 271 37.9(36.7-39.1) 54 36.7 (34.0-39.4)
General Cognitive Factor
Age & sex adjusted 269 0.15(0.04-0.26) 52 0.04 (-0.21-0.30)
Age, sex & NART adjusted 268 0.13 (0.04-0.22) 52 0.16 (-0.04-0.37)
Angina (n=59) includes those with angina and no other known clinical manifestation of cardiovascular
disease.
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 17. Mean differences (95% CI) in cognitive test scores in 2002/3 between
subjects with intermittent claudication and no CVD, adjusted for demographic
factors and peak prior cognitive ability.





Age & sex adjusted 277 39.8 (38.0-41.6) 57 35.9 (32.0-39.9)
Age, sex & NART adjusted 275 39.3 (37.7-41.0) 56 38.6 (34.9-42.3)
Raven's Progressive Matrices
Age & sex adjusted 274 33.7 (32.5-34.8) 55 29.8 (27.3-32.3)**
Age, sex & NART adjusted 273 33.3 (32.4-34.2) 54 31.8 (29.7-33.9)
Verbal Fluencv Test
Age & sex adjusted 280 39.1 (37.6-40.6) 56 34.9 (31.5-38.2)*
Age, sex & NART adjusted 277 38.7 (37.4-40.0) 56 37.5 (34.6-40.5)
Digit Svmbol Test
Age & sex adjusted 272 38.1 (36.8-39.3) 56 32.7 (29.9-35.4)**
Age, sex & NART adjusted 271 37.8 (36.6-38.9) 55 34.5 (32.0-37.1)*
General Cognitive Factor
Age & sex adjusted 269 0.14(0.03-0.25) 53 -0.32 (-0.57 to -0.07)**
Age, sex & NART adjusted 268 0.10(0.02-0.19) 53 -0.08 (-0.28-0.11)
Intermittent claudication (n=57) includes subjects with intermittent claudication only (n=26),
intermittent claudication and angina (n=14), MI and intermittent claudication (n=2), MI, angina, and
intermittent claudication (n=l 5).
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 18. Mean differences (95% CI) in cognitive test scores in 2002/3 between
subjects with MI and no CVD, adjusted for demographic factors and peak prior
cognitive ability.





Age & sex adjusted 277 39.9 (38.1-41.7) 50 35.4 (31.1-39.6)
Age, sex & NART adjusted 275 39.5 (37.8-41.2) 50 38.1 (34.1-42.2)
Raven's Progressive Matrices
Age & sex adjusted 274 33.7 (32.6-34.8) 50 29.0(26.4-31.7)**
Age, sex & NART adjusted 273 33.3 (32.3-34.2) 50 31.6(29.3-33.8)
Verbal Fluency Test
Age & sex adjusted 280 39.2 (37.6-40.7) 50 36.3 (32.7-40.0)
Age, sex & NART adjusted 277 38.7 (37.4-40.0) 50 39.8 (36.6-43.0)
Digit Symbol Test
Age & sex adjusted 272 38.1 (36.9-39.4) 50 33.1 (30.2-36.1)**
Age, sex & NART adjusted 271 37.8 (36.6-38.9) 50 35.3 (32.5-38.0)
General Cognitive Factor
Age & sex adjusted 269 0.15 (0.04-0.26) 50 -0.33 (-0.59 to -0.07)**
Age, sex & NART adjusted 268 0.10(0.01-0.19) 50 -0.04 (-0.25-0.16)
Myocardial infarction (n=50) includes subjects with MI only (n= 12), MI and angina (n=21), Ml and
intermittent claudication (n=2), MI, angina, and intermittent claudication (n= 15).
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 19. Mean differences (95% CI) in cognitive test scores in 2002/3 between
subjects with stroke and no CVD, adjusted for demographic factors and peak prior
cognitive ability.





Age & sex adjusted 277 39.9 (38.1-41.7) 17 31.0 (23.8-38.3)*
Age, sex & NART adjusted 275 39.9 (38.3-41.6) 16 31.9 (24.9-38.9)*
Raven's Progressive Matrices
Age & sex adjusted 274 33.7 (32.6-34.9) 15 29.8 (25.0-34.7)
Age, sex & NART adjusted 273 33.8 (32.8-34.8) 15 29.8 (25.7-34.0)
Verbal Fluency Test
Age & sex adjusted 280 39.2 (37.7-40.7) 17 30.4 (24.2-36.6)**
Age, sex & NART adjusted 277 39.3 (38.0-40.7) 16 31.7 (26.2-37.3)**
WAIS-R Digit Svmbol Test
Age & sex adjusted 272 38.2 (37.0-39.5) 15 30.5 (25.1-35.9)**
Age, sex & NART adjusted 271 38.3 (37.1-39.4) 14 31.8 (26.7-36.8)*
General Cognitive Factor
Age & sex adjusted 269 0.16(0.04-0.27) 14 -0.51 (-1.0 to -0.03)**
Age, sex & NART adjusted 268 0.16 (0.08-0.25) 14 -0.54 (-0.9 to-0.16)***
Stroke (n=17) includes subjects with stroke only (n=l 1), stroke and angina (n=3), stroke and
intermittent claudication (n=3).
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 20. Peak prior cognitive ability-adjusted regression analysis of general
cognitive factor scores in 2002/3 in relation to stroke (N=238). Numbers are
unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2 Model 3
B SE B SE B SE
Stroke -0.52 0.32 -0.70** 0.25 -0.59* 0.25
Age -0.08***0.01 -0.07***0.01 -0.07***0.01
Sex -0.09 0.12 -0.07 0.10 -0.14 0.10
NART 0.06*** 0.00 0.06*** 0.00
Blood Viscosity -0.22* 0.10
R2 0.147 0.464 0.473
Df (3, 234) (4, 233) (5, 232)
F 14.61*** 52.20*** 43.57***
AR2 0.315 0.012
Df (1,233) (1,232)
F 139 11 *** 5.24*
Stroke (n=17) includes subjects with stroke only (n=l 1), stroke and angina (n=3), stroke and
intermittent claudication (n=3).
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 23. 1998/9 cognitive performance-adjusted regression analysis of Logical
Memory Test scores in 2002/3 in relation to MI (N=322). Numbers are
unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2 Model 3
B SE B SE B SE
MI -4.31 2.32 -3.36* 1.69 -2.80 1.69
Age -0.50** 0.17 -0.14 0.12 -0.17 0.12
Sex -2.65 1.67 -1.81 1.21 -1.34 1.22
LMT 0.79*** 0.05 0.76*** 0.05
(1998/9)
Education -1.71* 0.75
R2 0.036 0.492 0.499
Df (3, 318) (4,317) (5, 316)




Myocardial infarction (n=50) includes subjects with MI only (n=12), MI and angina (n=21), MI and
intermittent claudication (n=2), MI, angina, and intermittent claudication (n= 15).
*P<0.05; **P<0.01; ***P<0.001.
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TABLE 24. 1998/9 cognitive performance-adjusted regression analysis of Logical
Memory Test scores in 2002/3 in relation to stroke (N=291). Numbers are
unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2
B SE B SE
Stroke -8.74* 3.72 -7.17* 2.75
Age -0.70*** 0.17 -0.17 0.13













TABLE 25. Peak prior cognitive ability-adjusted regression analysis of Logical
Memory Test scores in 2002/3 in relation to stroke (N=205). Numbers are
unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2 Model 3
B SE B SE B SE
Stroke -2.43 5.01 -3.25 4.60 -5.78 4.51
Age -0.73***0.21 -0 78***0.19 -0.94***0.19
Sex -2.01 2.17 -2.22 1.99 -1.99 1.93
NART 0.70*** 0.11 0.76*** 0.11
CRP 3.84*** 1.03
R2 0.044 0.197 0.246
Df (3,201) (4, 200) (5, 199)
F 4.16** 13 49*** 14.28***
AR2 0.154 0.052
Df (1,200) (1, 199)
F 39.12*** 13.96***
Stroke (n=17) includes subjects with stroke only (n=l 1), stroke and angina (n=3), stroke and
intermittent claudication (n=3).
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability)
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TABLE 27. 1998/9 cognitive performance-adjusted regression analysis of Raven's
Progressive Matrices scores in 2002/3 in relation to MI (N=320). Numbers are
unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2
B SE B SE
MI -4.58** 1.46 -2.65** 0.98
Age -0.58*** 0.11 -0.22** 0.07









Myocardial infarction (n=50) includes subjects with MI only (n= 12), MI and angina (n=21), MI and
intermittent claudication (n=2), MI, angina, and intermittent claudication (n=15).
*P<0.05; **P<0.01; ***P<0.001.
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TABLE 28. Peak prior cognitive ability-adjusted regression analysis of Verbal
Fluency Test scores in 2002/3 in relation to stroke (N=293). Numbers are
unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2
B SE B SE
Stroke -7.28* 3.31 -7.61** 2.90
Age -0.34* 0.15 -0.32* 0.13
Sex -0.93 1.49 -0.36 1.31
NART 0.71*** 0.07
R2 0.029 0.256





Stroke (n=17) includes subjects with stroke only (n=l 1), stroke and angina (n=3), stroke and
intermittent claudication (n=3).
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 30. Peak prior cognitive ability-adjusted regression analysis of Digit Symbol
Test scores in 2002/3 in relation to intermittent claudication (N=224). Numbers are
unstandardised regression coefficients and standard errors.
Model Term Model 1 Model 2 Model 3
B SE B SE B SE
Intermittent -5.12** 1.88 -3.23 1.77 -2.25 1.80
claudication
Age -0.95***0.14 -0.98***0.13 -0.91***0.13
Sex 1.28 1.41 0.67 1.31 0.28 1.31
NART 0.45*** 0.07 0.45*** 0.07
Interleukin-6 -2.74* 1.20
(.Log transformed)
R2 0.198 0.314 0.327
Df (3, 220) (4,219) (5,218)




Intermittent claudication (n=57) includes subjects with intermittent claudication only (n=26),
intermittent claudication and angina (n=14), MI and intermittent claudication (n=2), MI, angina, and
intermittent claudication (n= 15).
*P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 34. 1998/9 cognitive performance-adjusted regression analysis of 2002/3
Logical Memory Test score residuals in relation to MI (N=314). Numbers are
standardised regression coefficients and standard errors.
Model Term Model 1 Model 2 Model 3
B SE B SE B SE
MI 0.03 0.15 0.08 0.13 0.05 0.14
Age 0.01 0.01 0.03** 0.01 0.03** 0.01
Sex -0.10 0.11 -0.05 0.10 -0.07 0.10
LMT 0.03*** 0.00 0.04*** 0.00
(1998/9)
Education 0.08 0.06
R2 0.003 0.216 0.218
Df (3, 310) (4, 309) (5, 308)
F 0.73 22.54*** 18.41***
AR2 0.219 0.004
Df (1, 309) (1, 308)
F 87 34*** 1.69
Myocardial infarction (n=50) includes subjects with MI only (n=12), MI and angina (n=21), MI and
intermittent claudication (n=2), MI, angina, and intermittent claudication (n=15).
*P<0.05; **P<0.01; ***P<0.001.
227
TABLE 35. 1998/9 cognitive performance-adjusted regression analysis of 2002/3
Logical Memory Test score residuals in relation to stroke (N=280). Numbers are
standardised regression coefficients and standard errors.
Model Term Model 1 Model 2
B SE B SE
Stroke 0.06 0.27 0.04 0.24
Age 0.00 0.01 0.02* 0.01













TABLE 36. Peak prior cognitive ability-adjusted regression analysis of 2002/3
Logical Memory Test score residuals in relation to stroke (N=T99). Numbers are
standardised regression coefficients and standard errors.
Model Term Model 1 Model 2 Model 3
B SE B SE B SE
Stroke 0.46 0.33 0.46 0.33 0.30 0.32
Age 0.00 0.01 0.00 0.01 -0.00 0.01
Sex -0.02 0.14 -0.02 0.14 -0.01 0.13
NART 0.00 0.00 0.01 0.01
CRP 0.23** 0.07
Rz 0.005 0.008 0.039
Df (3, 195) (4, 194) (5, 193)
F 0.70 0.60 2.61*
AR2 0.001 0.051
Df (1, 194) (1, 193)
F 0.29 10.55**
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TABLE 38. 1998/9 cognitive performance-adjusted regression analysis of 2002/3
Raven's Progressive Matrices score residuals in relation to MI (N=315). Numbers
are standardised regression coefficients and standard errors.
Model Term Model 1 Model 2
B SE B SE
MI -0.13 0.15 -0.04 0.14
Age -0.00 0.01 0.02 0.01









Myocardial infarction (n=50) includes subjects with MI only (n=12), MI and angina (n=21), MI and
intermittent claudication (n=2), MI, angina, and IC (n=15).
*P<0.05; **P<0.01; ***P<0.001.
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TABLE 39. Peak prior cognitive ability-adjusted regression analysis of 2002/3
Verbal Fluency Test score residuals in relation to stroke (N=282). Figures shown are
standardised regression coefficients and standard errors.
Model Term Model 1 Model 2
B SE B SE
Stroke -0.31 0.27 -0.32 0.27
Age -0.02* 0.01 0.02* 0.01
Sex 0.03 0.12 0.04 0.12
NART 0.02* 0.01
R2 0.007 0.027





Stroke (n= 17) includes subjects with stroke only (n=l 1), stroke and angina (n=3), stroke and
intermittent claudication (n=3). *P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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TABLE 41. Peak prior cognitive ability-adjusted regression analysis of 2002/3 Digit
Symbol Test score residuals in relation to intermittent claudication (N=221).
Numbers are standardised regression coefficients and standard errors.
Model Term Model 1 Model 2 Model 3
B SE B SE B SE
Intermittent -0.09 0.17 -0.21 0.17 -0.21 0.18
claudication
Age -0.04** 0.01 -0.04** 0.01 -0.04** 0.01




R2 0.07 0.143 0.139
Df (3,217) (4,216) (5,215)




Intermittent claudication (n=57) includes subjects with intermittent claudication only (n=26),
intermittent claudication and angina (n= 14), MI and intermittent claudication (n=2), MI, angina, and
intermittent claudication (n= 15). *P<0.05; **P<0.01; ***P<0.001.
NART=National Adult Reading Test (an estimate of peak prior cognitive ability).
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In this chapter the findings from the study are discussed. First, the results
from the analyses of the relationship between cognitive test performance and CVD
status are examined according to vascular morbidity type. Then, the associations
between vascular risk factors and neuropsychological functioning are considered.
Both sets of findings are examined in relation to results from published studies.
General aspects of the study's methodological and analytical approaches are also
discussed. Finally, the chapter concludes with an examination of the potential
neuropathological mechanisms underlying vascular cognitive decline.
6.2. SUMMARY OF MAIN FINDINGS
Cardiovascular diseases constitute a major determinant ofmorbidity and
mortality in the adult population. The present study further demonstrated that
vascular disease is associated with a progressively steeper decline in
neuropsychological functioning in older people. Specifically, subjects with stroke
performed worse on a majority of cognitive tests compared to those without major
clinical CVD. In multiple linear regression analyses, stroke was associated with a
significantly greater decline in general cognitive function (the proportion of the total
variance accounted by stroke ranged from 0.32 to 1.25%) as well as in verbal
memory (stroke explained 1.21% of the total variance) and word fluency (1.80% of
the total variance was attributed to stroke), independent of prior cognitive ability and
demographic and vascular risk factors.
Relative to subjects without symptomatic CVDs, there was evidence ofworse
general cognitive function and lower scores on most mental tests in those with
demonstrable vascular disease other than clinical stroke. In particular, participants
with MI but without a diagnosed stroke scored lower on most cognitive measures,
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although only significantly so on tests of verbal memory and non-verbal reasoning.
In multiple linear regression analyses, MI predicted greater decline in non-verbal
reasoning (0.90% of the total variance was attributed to MI) after adjustment for
possible confounding factors. In contrast, the study did not support an independent
association between angina pectoris and cognitive decline in elderly people.
The study further demonstrated worse performance on most cognitive tests in
participants with symptomatic PAD compared to subjects without major clinical
CVD. Multiple linear regression analyses showed PAD was notably associated with
a significantly greater decline in general cognitive function (accounting for 0.29% of
the total variance) as well as in verbal memory (0.88% of the total variance was
attributed to PAD) after possible confounding by demographic and vascular risk
factors was taken into account.
In a number ofmultivariate models, several potentially modifiable CVD risk
factors had measurable negative effects on cognitive function. Specifically, baseline
diastolic blood pressure predicted decline in verbal memory (0.61% in the total
variance was explained by blood pressure) and body mass index was negatively
associated with general cognitive decline (BMI accounted for 0.28% of the total
variance in general function). Both smoking and blood viscosity were also associated
with an increased decline in information processing speed (about 1.46% and 4.0% of
the total variance were explained by these, respectively), and in addition, blood
viscosity predicted steeper decline in general cognitive function (1.32% of the total
variance was accounted for by blood viscosity). Of the inflammatory and
haemostatic markers assessed in the study, IL-6 in particular was related to a
significantly steeper decline in information processing speed (IL-6 was related to
between 1.85 and 2.16% of the total variance). In contrast, level of formal education
was inversely associated with decline in verbal memory (education accounted for
between 0.92 and 2.04% of the total variance), independently ofprior cognitive
ability, demographic factors and vascular disease.
Further analyses of the data were performed where the associations of
vascular risk factors and diseases with change in individual mental tests were
examined after the simultaneous control for performance on the general cognitive
factor. These analyses revealed that the above relationships were largely explained
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by the relationship of vascular disease and risk factors with general mental ability
rather than with individual functions per se.
6.3. CARDIOVASCULAR DISEASES AND COGNITIVE DECLINE
6.3.1. Stroke
Any meaningful comparison of the present findings with published results is
challenging given the methodological heterogeneity (e.g. regarding the selection of
the population under study, the comparison group used, the choice of cognitive
measures, the approach to the control for potential confounding, data analysis etc.)
between studies. Also, as yet, few previous population studies have comprehensively
assessed longitudinal change across major cognitive domains in relation to stroke. In
the light of our approach to the examination of the association between stroke and
cognitive function, the present study is likely to add to the existing research base in
several different ways. For example, in the context of research of the impact of
stroke on general cognitive function, we employed a novel approach for assessing
general mental ability which is in line with current theoretical notions of the
hierarchical structure of human cognitive abilities (Carroll, 1993; Deary and Batty, in
press).
In contrast, the majority of previous studies have solely administered the
MMSE for assessing general mental ability in community samples but a single global
measure may be ill-suited for this purpose (Morris et al., 1999). Regarding the
current context, its validity in the study of cognitive function among subjects with
stroke has also been questioned (de Koning et al., 1998). As a summary measure of
general cognitive function, there is great potential for ceiling effects with respect to
performance on the MMSE in non-demented samples. Moreover, an important
limitation of the MMSE stems from its relative insensitivity to such subtle changes in
cognitive function which might be expected in studies of cognitively-intact elderly
people. In such circumstances, the use of the MMSE may result in an
underestimation of the true extent of cognitive decline.
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Similar to the above, we demonstrated that stroke, as a clinical entity, was
significantly related to worse general cognitive factor scores, representing the
variance common to the specific mental tests we used, when the performance of
people with stroke and non-vascular controls was compared (see tables 12 and 19).
Upon the investigation of individual change in general ability, stroke significantly
predicted steeper cognitive decline (see tables 14 and 20). Despite differences in
measures of general ability, our findings converge with those of previous population
studies where stroke has been associated with a worse cognitive outcome.
For example, in a considerably larger sample than ours, Zhu et al. (1998)
reported that Swedish stroke survivors aged 75 years and older were significantly
more likely to score below 24 on the MMSE. However, the analysis was cross-
sectional and change in MMSE performance over time was not assessed in relation to
stroke status. On the other hand, in the Zutphen Elderly Study, stroke was related to
more than a four-fold increased risk of three-year global cognitive decline (defined
as a change of at least two points on the MMSE) although, in contrast to the present
study, the findings were based on males (Kalmijn et al., 1996). Also, in the
Framingham study, stroke was linked to a subtly increased decline in mean MMSE
performance over a short period of only six months in elderly subjects (Kase et al.,
1998). Similarly, Haan et al. (1999) associated stroke with a steeper decline in
performance on the modified MMSE scale over a seven-year follow-up in the
Cardiovascular Health Study. Despite the length of the follow-up in this study which
was substantially greater than that available to us for the measurement of actual
change in general ability, the level of decline was only modest and unlikely to be of
clinical significance.
In contrast to the above, our results deviate from those reported by Srikanth et
al. (2003) who failed to find a significant difference in mean MMSE scores when
subjects with stroke and 99 age and sex-matched non-stroke controls were cross-
sectionally compared. Although the discrepancy between this and the present study
might in part be attributed to differences in measures of general cognitive ability, it is
also possible that the lack of difference between people with stroke and controls
observed by Srikanth et al. (2003) might have been caused by the recruitment of
control subjects who in fact did not differ from those with stroke regarding the extent
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of non-stroke vascular disease and atherosclerotic risk factors such as diabetes and
hyperlipidaemia. Similarly, stroke was not associated with a significantly steeper
three-year decline in mean performance on the MMSE in the Longitudinal Aging
Study Amsterdam (Dik et ah, 2000). However, relative to non-stroke elderly,
diseased subjects did demonstrate a greater change in global scores over the follow-
up. Therefore, the lack of statistical significance might have been the result of
inadequate statistical power to detect modest MMSE-based changes in general
cognition over a relatively short follow-up.
With respect to specific indices of cognitive function, our age and sex-
adjusted comparison of people with stroke and non-vascular subjects pointed to a
significantly worse performance by those with stroke on several tests, including
those assessing verbal memory, verbal fluency and information processing speed (see
tables 12 and 19). Upon further adjustment for baseline test performance, those with
stroke only differed from healthy subjects in mean verbal memory performance.
After similar control for performance on the NART, the diseased subjects performed
significantly worse on average on verbal memory, verbal fluency and information
processing speed tasks. Furthermore, we also demonstrated that stroke was
independently associated with an increased four-year decline in verbal memory (see
table 24). And when estimated from a pre-morbid level of cognitive function, stroke
also predicted a greater decline in verbal fluency (see table 28). Although Srikanth et
al. (2003) failed to find statistically significant differences between people with and
without stroke in mean cognitive test scores, the stroke group did perform less well
on several tests, including measures of information processing speed and components
of verbal memory. More specifically, subjects with stroke had slightly lower delayed
verbal memory scores compared to stroke-free controls but no differences were
found regarding immediate recall. It is unlikely that the differences in results
between this and the present study can entirely be attributed to the use of different
memory tasks. For example, in the present study verbal memory was assessed using
immediate and delayed recall of two stories (WMS-R Logical Memory Test) whereas
Srikanth et al. (2003) administered the Rey Auditory Verbal Learning Test, which is
based on recalling a list of 15 words. Although it is conceivable that recalling a list of
random words (free recall) might pose different challenges for memory functioning
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than memorising a story (which may contain some cues facilitating recall), the
significantly worse verbal memory performance among people with stroke in the
present investigation may also to some extent be explained by the use in the current
study of control subjects without any major vascular pathology rather than simply
free of clinical stroke.
In a similar research context, Dik et al. (2000) demonstrated an improvement
during follow-up in mean performance on both the immediate and delayed
components of the Rey Auditory Verbal Learning Test among people with and
without stroke, although to a slightly lesser degree in delayed functioning among the
former group. To the extent which practice effects affected the findings of the
present study, particularly the four-year change in verbal memory performance, the
associations reported herein are likely to be an underestimation of the true level of
change seen among both diseased and non-diseased participants. Such effects would,
however, not have affected the individual differences in memory change over time
which, in contrast to both the above studies, we examined as well.
The results of the present study are in further contrast with that of Srikanth et
al. (2003) who found no differences between subjects with stroke and controls with
respect to verbal fluency performance. It is possible that the short word-producing
task (Controlled Oral Word Association Test) used by Srikanth et al. (2003) simply
was not sensitive enough to separate between diseased and non-stroke subjects with
respect to potential deficits in frontal lobe executive functioning. Although similar
speculations are likely to apply to the present study given the similarities of the tasks
used in these two investigations, our findings of a relatively greater verbal fluency
dysfunction among those with stroke are also likely to have been influenced by our
selection of relatively less morbid control subjects than in the above study. However,
it is likely that future population studies examining stroke and cognitive function
need to comprehensively probe this cognitive domain through the administration of
multiple executive functioning tests.
In another set of analyses, stroke did not significantly predict decline in
information processing speed when estimated over the life-span. With respect to this
cognitive domain, the null-finding contradicts the results of Haan et al. (1999) who
associated baseline stroke with a modest but statistically significantly greater decline
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in information processing speed over a follow-up of seven years. Further to the fact
that both studies assessed information processing speed from performance on the
Digit Symbol Test, one might have expected a significant relation between stroke
and processing speed in the present context given our attempt to model this
relationship over an effectively much longer period of cognitive change (i.e. from
'best-ever' level) compared to that available to Haan and colleagues (1999). Indeed,
the negative coefficient for stroke in our regression model suggested a steeper
decline in relation to stroke although we were unable to demonstrate this statistically.
Whereas almost by definition stroke denotes a direct impact on the
underlying neural substrate, we demonstrated through a further novel analysis of the
data that the associations of stroke with decline in particular mental functions were
largely attributed to the relation of stroke with general cognitive ability rather than
the elements of the individual measures per se (although not shown here, preliminary
analyses demonstrated no significant differences in physical impairment between
people with and without stroke although in some instances individuals who had had
stroke clearly showed some sensorimotor difficulties which could have affected their
performance on the DST but, on the whole, these were unlikely to account for the
associations reported here). As discussed in detail in a later section, it is possible that
acute ischaemia may lead to disruption of complex, intricate neural networks
underlying general cognition by affecting the functional connectivity of diverse
cerebral regions (Duncan et ah, 2000; Newman and Just, 2005). Similarly or in
conjunction with the above, ischaemic alterations disrupting the structural integrity
of subcortical white matter tracts, essential to intact inter-regional communication of
cortical and subcortical grey matter areas, may affect not only the functional capacity
of the white matter but also the processing ability of neurocognitive networks
(Newman and Just, 2005).
Although our cut-off point for the diagnosis of stroke was approximately six
months prior to follow-up cognitive testing, for the majority of subjects, the
ischaemic event had been diagnosed prior to the baseline cognitive assessment. After
the exclusion of people with stroke occurring during cognitive follow-up, none of the
associations reported earlier with decline in cognitive performance over the four-year
study interval changed direction even though some became attenuated and no longer
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remained statistically significant. Thus, whereas people with stroke no longer
remained significantly more impaired in general cognitive ability when compared to
non-vascular controls, their average performance on verbal memory was still
significantly lower. Similarly, stroke continued to exert independent negative effects
on both general ability and verbal memory after our examination of the four-year
individual change in these cognitive functions.
A number of factors may act as possible confounders of the association
between stroke and cognitive decline which, if not adequately controlled, may give
rise to spurious results. In the present study, an effort was made to control for
potential confounding by prior cognitive ability further to any confounding arising
from differences in demographic composition between subjects with stroke and
controls. Although our approach is in line with that of some previous population
studies (e.g. Dik et al., 2000; Kalmijn et al., 1996) others have only taken into
account differences in education or social status between those with stroke and
healthy groups (Haan et al., 1999; Srikanth et ah, 2003; Zhu et ah, 1998). However,
given the wide variation of ability levels within the same education or social class
level, these factors are unlikely to fully control for subjects' prior level of mental
ability. As a result, residual confounding by prior cognitive ability may be difficult to
rule out as an alternative explanation for these findings.
In further contrast to most previous research, the present results are unlikely
to be explained away by confounding by differences in either levels of mood or
conventional and novel atherosclerotic risk factors. For example, we found that
subjects with stroke had elevated HADS-determined levels of anxiety compared to
the non-vascular controls but changes in mood may negatively affect cognitive test
performance (Morris et ah, 1999). The stroke subjects also had significantly higher
rates of smoking and greater values of systolic blood pressure, serum CRP, and
whole blood viscosity. Each of these may be independently associated with cognitive
outcomes. In this regard, only Zhu et ah (1998) demonstrated a greater risk of
general cognitive impairment in subjects with stroke after controlling for SBP and
ICD-classified CHD. Therefore, our findings suggest that the progressive decline in
cognitive function observed in people with stroke may in fact depend on those
mechanisms resulting in acute cerebral ischaemia rather than on any concomitant
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influences of atherosclerotic risk factors. Possibly, the continuing advancement of
large-vessel vascular pathology might induce progressively more hypoperfusion-
related injury to deeply-located cerebral areas (de la Torre, 2006). Also, progressive
cognitive decline in the absence of further clinical events might be attributed to the
cumulative impact of continuous, multiple, asymptomatic, cerebral microemboli
arising from extra -or intracranial atheromatous lesions (Russell, 2002). The fact that
the association between stroke and decline in specific cognitive tests was totally
mediated by the effects of stroke on the general cognitive factor might imply that
those neurocognitive processes represented by general ability would be particularly
vulnerable to any such vascular pathology.
In addition to the above, our findings are unlikely to be the result of stroke-
induced neurological deficits, including aphasic disabilities. Although mild disability
affecting some participants with stroke may not be excluded, the inclusion of
severely impaired subjects was improbable given these would not have been
forwarded by the GPs. Also, a signed informed consent was required from all
participants who subsequently were probed for any sensory-motor difficulties.
The present findings are based on study participants who at any point
throughout follow-up were found to meet pre-determined criteria for the diagnosis of
stroke. The comprehensive approach employed by the EAS for the detection of
clinical stroke is likely to have minimised the likelihood of inclusion of false-
negatives cases. However, given the use of different diagnostic criteria at different
points in the study, there might be potential for misclassification under certain
circumstances. For example, where the diagnosis was solely based on clinical
symptoms (but computerised tomography was not carried out or initial scan showed
negative findings and no follow-up scan performed) or on subject's recall of a
doctor's diagnosis of stroke, some subjects who did not have true acute
cerebrovascular disease despite symptoms might have been falsely identified as
cases. On the other hand, it is also possible that some persons falsely recalled having
ever been told by a doctor that they had suffered a stroke. In any case, any
misclassification whereby a truly healthy individual had been categorised as having
stroke would have lowered the overall morbidity level of the stroke group. As a
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result, such a bias would resulted in the findings reported here being an
underestimation of the true extent of stroke-induced cognitive deterioration.
Also, due to the lack of systematic scanning of participants with stroke,
information on the various pathological aspects of the event, including aetiological
type, lesion site, and severity were not available to us. However, on the basis of
published data, it is likely that the majority of subjects with stroke in our study had
suffered a thromboembolic infarct (Merino and Hachinski, 2001). In addition, since
stroke severity is strongly related to early mortality and non-participation (Srikanth et
ah, 2003), the current sample is likely to comprise survivors with mild to moderate
stroke pathology. The fact that we employed an interval of six months between the
diagnosis of stroke and follow-up cognitive testing may further have reduced the
possibility of people with severe stroke being included in the study.
In line with most previous studies, we did not have brain scan data on
subjects comprising our comparison group. Therefore, we can only speculate
whether any might have had clinically unrecognised cerebral lesions. Such silent
infarcts would have increased the morbidity level of the comparison group and
further attenuated any differences between these and the stroke group. Most previous
reports have compared the cognitive performance of people with stroke with that of
non-stroke controls, although on some occasions the controls have had a similar non-
stroke vascular burden as the disease group.
Evidence shows non-symptomatic cerebral infarcts may be a common finding
in non-stroke vascular patients (Pardo et al., 1998) and these may be negatively
associated with performance on cognitive tests, as will be discussed later. As
mentioned earlier, it is possible that the use of relatively morbid controls may have
contributed to the lack of significant findings reported in some studies. In contrast,
our comparison group comprised subjects without prospectively-determined clinical
CVD. Although we cannot rule out the possibility of sub-clinical atherosclerotic
pathology among some non-vascular controls, our comparison group is likely to be
both physically and cognitively healthier than those used in most previous
investigations.
246
6.3.2. Coronary Heart Disease
Cognitive function has been a relatively understudied outcome in population-
based epidemiological investigations of non-stroke vascular diseases. In the present
study, the focus was on the investigation of patterns of cognitive decline in both
general ability and specific functions in relation to two major CHD syndromes:
angina pectoris and MI.
With respect to general cognitive ability, as indexed in the current study by a
general factor computed from subjecting individual mental tests to a principal
components analysis, significant associations with MI were found in age and sex-
adjusted comparisons with subjects without major clinical CVD (see tables 11 and
18). After further control for prior cognitive ability, people with MI continued to
demonstrate lower yet non-significant mean general ability scores. On the other
hand, angina was not associated with general cognitive function in any of the
analyses performed (see tables 9 and 16). Despite differences in measures of general
cognition across investigations, our findings are in line with results from some but
not all previous population studies which have examined cognitive outcomes in
relation to these CHD syndromes separately. Thus, although using a somewhat larger
sample than available for the present analysis, Tilvis et al. (2003) failed to find
significant differences in average performance on the MMSE in a cross-sectional
comparison of elderly subjects with and without history ofMI. Identical null-
findings came from a very large cohort based on Japanese-American men, despite MI
subjects with a history of stroke were not excluded from the analysis (Petrovitch et
al., 1998). In yet another set of cross-sectional data, which also was restricted to
elderly males, Elwood et al. (2002) failed to associate prevalent MI with greater
global cognitive dysfunction when patients' test performance was compared to that
of subjects without any evidence of clinical vascular disease. In addition, although
few studies have examined longitudinal change in general cognitive function in
relation to specific coronary syndromes, most have failed in their attempt to
demonstrate a significant association between the presence of symptomatic CHD in
older people and MMSE-based global cognitive decline (e.g. Eslinger et al., 2003;
Piguet et al., 2003; Zhu et al., 1998).
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On the other hand, the fact that we did not find a significant relation of either
CHD syndrome with general ability is partly in conflict with other published
evidence, including that by Breteler et al. (1994) who demonstrated an overall shift
in the distribution ofMMSE scores in relation to MI in an early cross-sectional
analysis based on the Rotterdam Study cohort. Whereas significance testing was not
performed on the data, the actual mean difference in MMSE scores between subjects
with and withoutMI was only modest after correction for variation in age and level
of education. Although differences regarding how general ability was measured in
the two studies need to be bome in mind, on their own these may not fully account
for the discrepancy in findings. Indeed, whereas in the present study MI was
associated with significantly worse general cognitive function (the difference
between patients and healthy subjects amounted to approximately a third of a
standard deviation), the relationship did not hold after controlling for differences in
prior ability between cases and controls. Adjustment for differences regarding level
of education in the Rotterdam Study might not have provided adequate control for
prior ability differences between diseased and non-diseased subjects, given the
potentially wide range of cognitive ability levels among individuals within the same
education category. As a result, some residual confounding by prior ability cannot be
ruled out in the data by Breteler et al. (1994). In addition, other differences between
the two studies might also have played a role, such as the fact that the diagnosis of
MI in the Rotterdam Study was solely based on ECG changes whereas most events
in the current analysis were diagnosed on the basis of presenting chest pain and
elevated cardiac enzymes. In this regard, the clinical features ofMI in the Rotterdam
Study might be indicative ofmore severe coronary disease than that experienced by
the majority of cases in the current study. On the whole, however, our inability to
demonstrate significant differences in general ability between those with MI and
non-vascular controls needs to be viewed in the light of the relatively conservative
approach chosen for controlling for potential confounding.
In a similar manner, the absence of an association with angina in the current
study contradicts findings from the Caerphilly study where elderly males with angina
scored significantly worse on two measures of global mental ability (Elwood et al.,
2002). Although the two studies differed with respect to type ofmeasurement of
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general cognition, both administered a symptom-based questionnaire for the
assessment of angina. However, it is unclear whether the disease group used in the
Caerphilly study was mutually exclusive of other manifestations ofCVD. On the
other hand, given that we kept the angina category distinct ofmore severe vascular
morbidity in order to study cognitive function in relation to a relatively mild, non-
acute form of atherosclerotic vascular disease, the observed discrepancies in findings
might partly be attributed to differences regarding the vascular burden among
subjects comprising the exposure group.
Of the individual cognitive measures that were administered, diseased
subjects scored on average lower on tests of verbal memory, non-verbal cognitive
ability, and information processing speed relative to non-vascular subjects (see tables
11 and 18). After adjustment for demographic factors and prior cognitive ability,
diseased and healthy subjects differed significantly in mean performance on tests of
both verbal memory and non-verbal intelligence. No significant associations were
found with angina. Our findings are similar in part to those of Elwood et al. (2002)
who in an earlier analysis had reported significantly worse performance on a
combined task of verbal and non-verbal reasoning in elderly subjects with MI.
However, the administration of a more comprehensive battery of mental tests in the
current study allowed the examination ofmajor cognitive domains, including aspects
ofmemory, in relation to coronary disease. Our results are also in line with those
reported by Singh-Manoux et al. (2003) who noted that subjects with MI scored
modestly yet significantly lower on average on half of the tests that were
administered (verbal reasoning, general knowledge, and semantic fluency). Despite
differences in measures of cognitive function and sample structure, both our findings
and those by Singh-Manoux et al. (2003) suggest that MI may be associated with
deficits in a relatively restricted set of cognitive functions, compared to that seen for
either stroke or PAD. Importantly, whereas neither of the above studies examined
individual change in cognitive performance in relation to coronary disease, we
further demonstrated that MI independently predicted a progressively steeper decline
in non-verbal reasoning over the four-year cognitive follow-up (see table 27).
The absence of a relationship between angina and domain-specific test
performance in the current study is in conflict with findings from the Caerphilly
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study where significant differences in verbal and non-verbal reasoning were found
when subjects with angina and non-vascular controls were compared (Elwood et al
2002). Although difficult to ascertain, this discrepancy could have arisen from the
emphasis we placed on using a relatively homogeneous, mutually exclusive disease
category, as discussed previously in the text. Similarly, the inclusion of angina
subjects with other concomitant vascular morbidity might also have contributed to
the positive findings reported by Singh-Manoux et al. (2003) who demonstrated
significantly lower mean scores in participants with angina on tests of verbal
memory, verbal and non-verbal reasoning, knowledge, and verbal fluency.
A major limitation of previous studies examining the relationship ofCHD
with cognitive outcomes has been the inadequate control of potential confounding
factors. Specifically, in few of the above analyses was possible confounding by prior
cognitive ability sufficiently taken into account. When attempted, however, most
studies have either adjusted for highest level of education completed (e.g. Breteler et
al., 1994; Petrovitch et al., 1998) or occupational-based socioeconomic status (e.g.
Elwood et al., 2002; Singh-Manoux et al., 2003). As discussed already, statistical
adjustment for differences in these characteristics may not provide a full control for
any confounding assigned to prior cognitive ability. In contrast, our findings were
unlikely to be explained away by differences between diseased and non-diseased
subjects in prior ability.
The availability of data on several conventional and novel vascular risk
factors further allowed us to examine whether the association between CHD and
cognitive function existed independently of these parameters. In particular, subjects
with MI had significantly lower pre-morbid cognitive ability levels, were less
formally educated, and of lower social standing than the non-vascular controls. Also,
both anxiety and depression levels were significantly elevated in subjects with MI.
Moreover, these subjects also had greater smoking rates as well as higher levels of
BMI, blood pressure, IL-6, and blood viscosity. In contrast, those with MI had
significantly lower HDL cholesterol levels compared to subjects without any
vascular diseases. As a result, the fact that we found an independent relationship
between MI and progressive decline in non-verbal reasoning skills suggests that, at
least to a degree, the association may actually depend on the underlying vascular
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pathological processes and their continuing development. In this respect, CHD and
cognitive dysfunction may both be manifestations of systemic atherosclerosis.
Indeed, the diffuse nature of atherosclerosis is well recognised and both significant
intra -and extracranial disease may increase the risk of clinically silent cerebral
infarcts and other vascular-related cerebral pathology (Drouet et al., 2002; Mosley et
al., 2005). However, it has been pointed out that MI per se does not adequately
represent the level of systemic atherosclerosis in the body which possibly is reflected
in the generally weaker and more restricted cognitive effects found in such patients
relative to those with other CVD manifestations (Singh-Manoux et ah, 2003).
Therefore, on-going clinically unrecognised, cardiogenic brain embolism, rather than
silent infarcts arising from an in situ thrombosis of either cerebral or other
extracranial arteries, might be an important vascular mechanism associated with
progressive cognitive decline in MI patients (Vingerhoets, 2001). Indeed, it has been
pointed out that as many as 15-30% of all ischaemic strokes may be cardiogenic in
origin (Boden-Albala and Sacco, 2004). Similarly, it is also possible that, in some
patients with MI, reduced cardiac output in relation to chronic ischaemic cardiac
failure may lead to decreased cerebral perfusion and either recurrent or continuous
episodes of hypoxia (Vingerhoets, 2001). Given that the relationship between MI and
decline in performance on individual cognitive tests was fully mediated by the
effects ofMI on the general cognitive factor, these findings underscore the particular
vulnerability of the neuropsychological processes underlying general cognitive
ability in older subjects with ischaemic cardiac disease.
In the present study, diagnosis of angina was predominantly based on
information collected using the WHO Questionnaire. Although this questionnaire is
both a widely used and valid tool for classifying individuals with symptoms and
signs of transient cardiac ischaemia, there is evidence suggesting it may have low
overall specificity, and particularly so in women (Bowling, 1995). However, to the
extent that our angina category included false positive cases, any misclassification of
cases would have lowered the overall vascular morbidity level of our exposure
group. Therefore, further to the fact that our angina category was kept mutually
exclusive of other clinical CVD, our null-findings suggest that cognitive function
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may be relatively preserved in the context of relatively mild, non-acute coronary
disease.
Because of the proportionately few subjects diagnosed solely as having MI,
we were unable to preserve the mutual exclusiveness of the MI morbidity category.
More specifically, more than half of the MI subjects had also met study criteria for
either angina or lower-extremity arterial disease, or both (but not clinical stroke).
Although not ideal, few previous studies have investigated cognitive outcomes in
relation to a mutually exclusive MI category. However, in contrast to earlier studies,
our use of broad criteria for the diagnosis ofMI may have facilitated the inclusion of
participants with relatively mild to moderate myocardial ischaemia in the study. For
example, as mentioned briefly before, most events in the present study were
diagnosed during follow-up on the basis of chest symptoms and elevated enzyme
levels. In contrast, only a minority demonstrated diagnostic ECG alterations further
to clinical signs. Whether these patterns may partly be reflecting better survival
chances of patients with mild to moderately severe MI is difficult to ascertain.
However, we also included cases who did not meet diagnostic criteria for a definite
ischaemic event, although these have been deliberately excluded in other
investigations. Collectively, it is likely then that, in comparison to most published
results, our findings are based on the cognitive experience of relatively less morbid
survivors ofmyocardial ischaemia.
6.3.3. Peripheral Arterial Disease
The present analysis further adds to the relatively limited population-based
literature on cognitive function in elderly persons with symptomatic lower-extremity
arterial disease. Our results revealed significant differences between participants with
intermittent claudication and non-vascular controls in general cognitive function,
with the former showing greater deficits after adjustment for demographic factors
and prior mental ability (see tables 10 and 17). In addition, we further demonstrated
that symptomatic PAD was associated with a significantly accelerated decline in
general ability over the four-year cognitive follow-up (see table 13). Despite
methodological differences between studies, such as regarding the approach to
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assessment of general cognitive function and the analysis of the association under
study, on the whole, our findings point to the direction of those reported by some
although not all earlier investigations. For example, Tilvis et al. (2004) found a
significant cross-sectional association between the presence of intermittent
claudication at baseline and mean performance on the MMSE in elderly participants
in the Helsinki Aging Study. Moreover, claudication was related to an increased risk
of decline in global cognitive performance during the first year of cognitive follow-
up. Although unclear in the above study, the group of subjects with intermittent
claudication in the present analysis was mutually exclusive of clinical stroke. Also,
in addition to statistically adjusting for age and sex, we also paid attention to
potential confounding by prior cognitive function. Although Tilvis et al. (2004)
failed to make similar adjustments in their cross-sectional comparison, differences
between cases and non-cases in baseline performance on the MMSE were taken into
account in the longitudinal analysis. However, in contrast to the one-year follow-up
results, an association between intermittent claudication and five-year cognitive
decline was not found, which might have been due to the high selective mortality
among cases during follow-up (Tilvis et al., 2004). The discrepancy between our
longitudinal findings and these results might be attributed in part to the higher
baseline age of the above sample relative to that of our subjects. Indeed, the
possibility that Tilvis et al. (2004) examined not only older but relatively more
diseased subjects than we did could have contributed to the proportionately high
attrition of cases over the follow-up and the simultaneous disappearance of the
association with the five-year cognitive decline.
Further to the above, our findings also seem in conflict with results published
from two other population studies. In the first, Piguet et al. (2003) did not find any
significant differences between very old subjects with and without intermittent
claudication at baseline in the level of decline in performance on the MMSE over six
years of follow-up. Similar to that described for the study by Tilvis et al. (2004), it is
possible that the absence of a relation with intermittent claudication in these data
might have been induced by selective attrition of relatively older and more morbid
cases during follow-up. Also, it may be that the MMSE proved to be insensitive to
perhaps more subtle cognitive decline experienced by relatively milder cases
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surviving up to follow-up cognitive testing. Furthermore, in the second report,
Elwood et al. (2002) failed to detect a significant cross-sectional association between
intermittent claudication and performance on two measures of global cognitive
function. This was despite the authors compared test scores of cases to those of a
group of subjects without evidence of any clinical vascular disease, an approach also
undertaken in the present study. However, despite low numbers of diseased subjects,
they did perform worse than non-cases on both measures, suggesting that the lack of
significant difference might partly have been the result of insufficient statistical
power.
In addition to the relationship with general cognitive function, we also found
significant age and sex-adjusted differences between diseased and non-vascular
controls in the performance on tests of verbal memory, non-verbal reasoning skills
and information processing speed (see tables 10 and 17). After further adjustment for
prior cognitive ability, either measured at baseline or estimated 'best-ever' level, the
differences remained significant. The results from our mean comparison are in line
with those described by Singh-Manoux et al. (2003) who found scores on tests of
short-term memory, verbal and non-verbal reasoning, word recognition and
knowledge and executive functioning modestly but significantly lower in male
claudicants compared to non-vascular controls. Similar patterns were seen in female
patients with the exception of deficits in memory and aspects of executive function.
Also, although Elwood et al. (2002) failed to show a significant association of
claudication with performance on tests of verbal and non-verbal reasoning and
slower mental speed, the cases who were few in number actually did obtain lower
mean scores on all the measures. From the point of view that we found a relationship
with PAD using a different battery of cognitive measures to that administered in the
above studies, our findings lend additional weight to the existence of a relationship
between chronic vascular disease and cognitive deficits in adults. However, in further
contrast to the above studies, we demonstrated through an analysis of individual
change in cognitive performance that intermittent claudication was also associated
with an increased decline in verbal memory over the four-year study interval (see
table 22).
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Previous studies have documented high levels of diverse potentially
modifiable vascular risk factors in patients with symptomatic arterial leg disease
(Hooi et al., 1998). In our comparison of subjects with intermittent claudication and
non-vascular controls, several significant differences emerged with respect to levels
of particular vascular risk factors. As an example, the diseased subjects in our study
were more likely to show signs of anxiety and depression at the time of cognitive
testing in 2002/3 and have ever smoked when interviewed at baseline in 1987/8. In
addition, they reported having completed a lower level of formal education.
Importantly, the claudication group also had significantly raised levels of various
physiological variables, including body mass index, blood pressure and circulating
markers of inflammation and coagulation. Given our approach to control for
potential confounding differences between cases and controls in any of these
parameters, the present findings support the notion of a relationship between
intermittent claudication and cognitive decline which to some extent may be
attributed directly to the atherosclerotic process underlying PAD. As pointed out in
earlier sections, this would be physiologically plausible since lower-extremity
arterial disease is thought to constitute but one marker of chronic, systemic
atherosclerosis (Phillips, 2001). In individuals with symptomatic PAD, evidence of
atherosclerotic disease in both the coronary and cerebral circulation may be found in
as many as 50-90% of cases (Vogt et ah, 1992). In addition, the prevalence of carotid
atherosclerosis in PAD patients is increased several fold. Even in the absence of
overt stroke, atheromatous lesions in either the carotid or intracerebral arteries may
be the source ofmultiple, clinically silent emboli which could induce progressive
ischaemic changes in the neural tissue in patients with clinically-manifest
atherosclerotic disease. In these individuals, the neurocognitive processes giving rise
to general cognitive ability might be particularly sensitive to the influence of such
vascular pathological mechanisms. Our finding of a total mediation of the
relationship between PAD and decline in domain-specific tests by the general
intelligence factor would be supportive of this notion.
In the present study, approximately half of the participants with symptoms
indicative ofPAD did not have diagnosis of another manifestation of CVD. As a
result, our patient group was not mutually exclusive of other vascular conditions
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although subjects who had suffered a stroke at any point during follow-up were not
included. At the baseline and follow-up clinical examinations, the determination of
PAD was based on a subject's recall of a doctor's diagnosis of the condition as well
as on the administration of the WHO questionnaire. Registration of new vascular
events during follow-up was based exclusively on a positive WHO questionnaire
response. The WHO questionnaire has been found to lack sensitivity for detecting
symptomatic PAD (Fowkes, 1991). Therefore, it is possible that some true cases of
PAD went unnoticed in our study. Possibly, this might have occurred under the
circumstances where clinical symptoms resolved because of formation of a collateral
circulation or any other reason. However, any error whereby diseased subjects would
have been misclassified as healthy is likely to have been rare and would have had
limited influence on the findings reported here. On the other hand, the associations
observed in the present study are likely to reflect the cognitive experience of
survivors with mild to moderate vascular morbidity. Indeed, previous studies have
reported increased vascular-related mortality in patients with PAD (Dormandy and
Murray, 1991), and these may underlie the high attrition rate seen among these
patients during cognitive follow-up (Tilvis et al., 2004). The fact that the majority of
cases in our study only had probable symptomatic arterial disease might partly reflect
the proportionately greater mortality found in patients with more advanced disease.
Moreover, only approximately half of those who met the criteria for definite PAD
had grade 2 symptoms (onset of leg pain when walking on the level).
6.4. VASCULAR RISK FACTORS AND COGNITIVE DECLINE
6.4.1. Education
The analytical strategy employed in the present study allowed the
examination in the total sample of separate relationships of various potentially
modifiable CVD predisposing factors with cognitive outcomes, including level of
formal education. In several multivariate models, a significant, inverse, linear
association emerged between highest completed level of education reported at
baseline in 1987/8 and decline in verbal memory performance over the subsequent
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four-year cognitive follow-up (see tables 21-23) . A further analysis of the data
revealed total mediation of the education-verbal memory relationship by general
cognitive ability.
Our findings are largely consistent with those already forming a substantial
body of literature suggesting early-life educational attainment may be protective
against cognitive decline in later-life (Cagney and Lauderdale, 2002; Lee et ah, 2003;
Seeman et ah, 2005). In particular, Cullum et al. (2000) demonstrated that less
education was specifically associated with a significantly greater four-year decline in
the CAMCOG memory subscale. Other authors have reported significant negative
inverse relations of education with decline on multiple domain-specific cognitive
measures (Seeman et al., 2005).
Unfortunately, the method of data analysis we used prevented us from
examining the relationship between education and performance on the other mental
tests that were administered. As a result, we are unable to determine whether the
protective effects of education extended to additional cognitive functions in the
current sample. On the other hand, we further demonstrated that the association with
verbal memory was attenuated so that it no longer remained significant when a
general cognitive factor was included in the analysis. It is also possible that the
relationship with the cognitive measures could have been attributed to any beneficial
effects associated with education on more general or fundamental neurocognitive
processes.
Any attempt to account for the observed effects of education on cognitive
decline will pose challenges since several possible explanations may exist for such
an association. Importantly, our findings existed independently of differences by
educational level in demographic structure and baseline cognitive test performance.
Also, the multivariate models included terms for clinical CVD, objectively-assessed
at any point from baseline to six months prior to follow-up cognitive testing,
including PAD and MI as well as a combined category for any non-stroke vascular
disease. While an inverse association between education and both CVD mortality
(Kilander et al., 2001) and morbidity (Kuper et al., 2006) has been firmly established
in the adult general population, in most previous studies examining cognitive
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function as a primary outcome, CVD status has neither comprehensively nor
objectively been determined.
In contrast to these reports, our findings further support an association
between education and cognitive decline independently of concomitant CVD,
although possible confounding by previous stroke or even asymptomatic vascular
pathology cannot be ruled out. However, in this regard, the current results are more
in line with a hypothesis suggesting formal education may produce direct effects on
brain structure and functioning which, rather than altering the vulnerability to
pathological processes leading to cognitive decline, would delay the appearance of
clinically-apparent cognitive impairment by furthering the point at which a sufficient
amount ofpathology had accumulated for symptoms to appear (Albert, 1995).
6.4.2. Body Weight
In the present study, a significant, inverse association between BMI and four-
year decline in general cognitive function was found (see table 13). Importantly, the
effects ofBMI on cognitive decline were independent of differences in age, sex, and
prior level of cognitive function. Although significant relationships with body weight
have also been reported in a few previous studies, all have been cross-sectional in
design. Therefore, a direct comparison with the results reported here is difficult. In
particular, despite Kilander et al. (1997) did not find a significant linear association
between the BMI and a mean composite score of 13 cognitive function tests, a high
BMI was associated with a lower value independently of demographic and
socioeconomic factors as well as stroke. Similarly, obesity (BMI > 30) in male
subjects in the Framingham study was also significantly related to lower global
cognitive function (Elias et al., 2005). In addition, several domain-specific subtests
of the WAIS scale were also significantly affected. In contrast, any effects of body
weight on decline in the individual cognitive measures were not available for study
in the current investigation.
The relation between obesity and CVD morbidity is well established (Sacco
et al., 1997). However, the association we found with decline in general cognitive
ability existed independently of concomitant atherosclerotic vascular disease. Indeed,
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our multivariate model adjusted for prevalent intermittent claudication which may be
a good indicator of the level of systemic atherosclerosis in the body (Vogt et al.,
1992). Therefore, although the possibility of confounding by previous stroke cannot
be excluded, our findings do not rule out other explanations for our findings. For
example, obesity may act as a moderator of the effects of other more proximal
vascular risk factors, including high blood pressure (Elias et al., 2001). Indeed,
Aleman et al. (2005) failed to find any significant effects ofBMI on either mental
status or domain-specific tests when a number ofwell-established CVD risk factors
were also included in the multivariate model. Similarly, statistical adjustment for
major CVD risk factors attenuated several associations between obesity and
cognitive function in the Framingham study so that they no longer remained
statistically significant (Elias et al., 2005). However, other relations remained,
suggesting different mechanisms could be at work, including inflammatory processes
which might be directly related to the endocrine activity of the adipose tissue itself
(Jeong et al., 2005).
6.4.3. Smoking
By virtue of the well-established relation of smoking with both
cerebrovascular disease (Sacco et al., 1997) and peripheral markers of systemic
atherosclerosis (Vogt et al., 1992), the importance of investigations of the potential
effects of smoking on cognitive function has been pointed out (Elias et al., 2001). In
the current investigation, we found a significant, inverse relationship between pack-
years of smoking based on self-report at baseline in 1987/8 and decline in
information processing speed estimated from 'best-ever' level of cognitive function
to that actually measured in later-life (see tables 29 and 31). Further analyses
demonstrated large mediating effects of general cognitive ability on this association.
Although our results seem in conflict with some early cross-sectional reports
where cognitive function was examined in relation to smoking status (Elwood et al.,
1999), they are also in line with those produced by more recent prospective
investigations. For example, Ott et al. (2004) demonstrated that higher baseline pack-
year exposure of smoking was correlated with a significantly greater 2.3 year-decline
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in MMSE-based global cognition among persons aged 65 years and older. Similarly,
in a study examining the effects of smoking and midlife cognitive function,
associations with a faster decline in verbal memory, slower mental speed and worse
concentration were found (Richards et al., 2003). Importantly, these associations
proved to be independent of early-life cognitive ability, measured lung-functioning
and self-reported CVD. In a similar vein, our findings persisted further to the
simultaneous adjustment for demographic factors, estimated prior cognitive ability,
mood, blood pressure, and non-stroke CVD. Also, inclusion of inflammatory and
haemorheological parameters did not explain away the association.
Although potential confounding by either previous stroke or asymptomatic
vascular pathology is hard to rule out, our results raise the possibility of a more direct
effect of smoking on the underlying neural substrate. For example, clinical studies
have demonstrated smoking can induce a rapid diffuse decrease in cerebral blood
flow (Yamamoto et al., 2003). On the other hand, poor nutritional status of smokers
has been mentioned as another potential confounder of this association (Richards et
al., 2003).
6.4.4. Blood Pressure
It has been suggested that lifetime exposures to elevated blood pressure may
be a more important predictor of adverse cognitive outcomes in the elderly than
cross-sectionally measured blood pressure levels in old age (Waldstein and Katzel,
2001). Specifically, whereas late-onset high blood pressure may only contribute
relatively weakly to cognitive function over and above that of other age-associated
morbidity, blood pressure elevation of an earlier onset may result in long-term
trajectories contributing to individual differences in adult cognitive decline (Swan et
al., 1998; Waldstein and Katzel, 2001). Indeed, associations between blood pressure
levels determined in mid-life and poor old-age cognitive outcomes have been
reported in several studies (e.g. Kilander et al., 1998; Launer et al., 1995), including
the Framingham Study where a dose-response relationship was found between SBP
and DBP and performance on tests of both general and domain-specific cognitive
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functions 12-14 years later when the mean age of the sample was approximately 65
years (Elias et ah, 1993).
In a similar regard, the current findings also partly conform to this view given
that we found a significant, inverse, dose-response relationship between DBP
measured at a single occasion at baseline in 1987/8, when the mean age of the
cognitively-tested sample was approximately 62 years, and decline in verbal memory
skill over a four-year window of cognitive testing more than a decade later (see table
22). We further showed total mediation of this association by general cognitive
ability. Moreover, in another series of analyses, negative yet non-significant
associations were found between both DBP and SBP levels and estimated decline in
information processing speed from peak, prior cognitive level. Perhaps for the
aforementioned reasons, our findings contrast with the null-findings observed by
previous studies where both blood pressure and cognitive function in old age have
been determined cross-sectionally (Farmer et ah, 1987; Schcrr et ah, 1991).
Whereas the first set of results described above adjusted for age, sex, baseline
cognitive scores, education, non-stroke vascular disease and fibrinogen levels, the
latter further controlled for several other lifestyle and physiological parameters. In
contrast, few studies examining the relation of blood pressure with cognitive
outcomes have statistically controlled for concomitant vascular risk factors, CVD,
and use of antihypertensives. Although in the present data we cannot exclude the
possibility that the presence of either stroke or antihypertensive use might have
explained our results (antihypertensive use data were only collected at baseline in
1987-1988 in the EAS), our inability to demonstrate statistically an association with
decline in information processing speed in the fully adjusted analysis might in part be
attributed to lack of sufficient statistical power.
Additional control for different indices of clinical and asymptomatic vascular
disease also led to an attenuation but not disappearance of a significant relationship
between mid-life systolic blood pressure and cognitive impairment found in a sample
ofmore than 3000 older men in the Honolulu-Asia Aging Study (Launer et ah,
1995). Whereas the above results might suggest a role for blood pressure in cognitive
decline independently of atherosclerotic vascular disease, our study was not designed
to test different hypotheses underlying such an association. This is likely, however,
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to be a major challenge for future investigations in this area of epidemiological
inquiry.
6.4.5. Blood Viscosity
Our finding of an association between blood viscosity assessed at baseline in
1987/8 and cognitive decline is novel given that few previous population
investigations have examined cognitive outcomes in relation to blood rheology. In
particular, significant, inverse effects of blood viscosity on the estimated decline in
both general cognitive ability (see table 20) and information processing speed (see
table 31) from best prior level were found. Further analyses showed that the latter
relationship was totally mediated by the effects of blood viscosity on the general
cognitive factor. In addition, we observed inverse yet non-significant associations
with four-year decline in non-verbal reasoning skill and in decline from peak, prior
level in information processing speed when either fibrinogen or haematocrit were
also included in the final multivariate model. The statistical adjustment for these
factors, both major determinants of blood viscosity, is likely to be the explanation for
the absence of significant findings.
Although not directly comparable due to differences in the rheological
parameters examined, cognitive measures and study design, our observations are
partly in line with those noted in the only previous population-based study to
examine this association (Elwood et al., 2001). Although whole blood viscosity was
not measured, plasma viscosity, an important contributor to blood viscosity, was
significantly and linearly associated with performance on a task of verbal and
mathematical reasoning as well as with choice reaction time. On the other hand, a U-
shaped association between haematocrit and reaction time was found. Interestingly,
fibrinogen did not have significant effects on cognitive performance. Therefore,
other determinants of plasma viscosity might possibly play a role in cognitive
function, including lipoproteins (Lowe, 2001), although as noted above, our
association failed to exist after fibrinogen was statistically controlled for.
Blood viscosity and its determinants have been associated with an elevated
risk of both acute coronary events (Yarnell et al., 2004) and stroke (Lowe et al.,
262
1997). The relation with stroke might partly stem from any rheological effects on the
pathogenesis of atherosclerotic disease in the carotid circulation (Lee et ah, 1998).
Importantly, however, in addition to demographic factors and estimated pre-morbid
ability level, our associations were also independent of diagnosed stroke. Although
silent brain embolism cannot be excluded as a potential link between blood viscosity
and cognitive decline, such a relationship might also be mediated through the
negative effects of elevated blood viscosity on cerebral blood flow at the
microvascular level (Kee and Wood, 1984; Lowe, 2001). Whereas additional
research is needed to address the different causal mechanisms likely to underpin the
association between blood rheology and cognitive decline, experimental studies are
also required where potential modification of rheological parameters in older age
groups may result in demonstrable beneficial effects on cognitive outcomes.
6.4.6. Markers of Inflammation and Haemostasis
Relatively few population studies have investigated the association between
circulating markers of inflammation and haemostasis and cognitive function. Such a
relationship is of interest given the role of inflammation in atherosclerosis and the
observed correlations with acute vascular events, including stroke (Chamorro, 2004;
Rost et ah, 2001). Moreover, a low-grade systemic inflammatory response may
contribute to the pathogenesis of degenerative cognitive pathology (Gupta et ah,
2005). Despite some contradictory cross-sectional findings, there are observational
data showing the risk of cognitive decline may be significantly increased in relation
to elevated levels of selected inflammatory markers (Weaver et ah, 2002; Yaffe et
ah, 2003).
Our findings are also largely in line with these results. In particular, in the
present study, we demonstrated significant, negative, linear effects of IL-6
determined at baseline in 1987/8 on the estimated decline in information processing
speed from peak, prior level after statistical control for demographic factors, vascular
disease, mood and a number of physiological parameters (see table 29 and 30). This
relationship was further found to be totally mediated by the association of IL-6 with
general mental ability.
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Furthermore, additional associations were found in a more comprehensive
unpublished analysis based on the same sample as examined here (Rafnsson et al.,
2007). For example, baseline ICAM-1 was associated with a greater estimated
decline from 'best-ever' level in general cognitive function and non-verbal
reasoning. Similarly, fibrinogen independently predicted decline in non-verbal
intellectual ability. Although not addressed in previous studies, we further showed
empirically that the different inflammatory markers were not surrogates but exerted
independent influence on the cognitive outcomes. Given the fact that our associations
persisted after adjustment for diagnosed stroke, atherosclerosis, and major vascular
risk factors, is further suggestive of the possibility that diverse inflammatory
pathways may contribute directly to neuropathological changes and cognitive
decline.
6.5. POSSIBLE NEUROPATHOLOGICAL SUBSTRATES OF VASCULAR
COGNITIVE DECLINE
The identification of likely pathophysiological mechanisms for the
association under study constitutes an important aspect of any epidemiological
inquiry. The absence of structural neuroimaging in the Edinburgh Artery Study
prevented the determination of the potential neuropathological substrates underlying
the relationships examined herein. It is likely, however, that vascular risk factors and
atherosclerotic pathology may induce diverse changes in the cerebral tissue which,
individually or collectively, ultimately may lead to disruption of normal
neurocognitive processes. For example, cognitive dysfunction may be the result of
ischaemic damage, with or without immediate clinical symptoms, to either the
cerebral cortex or grey matter structures located deep within the brain, or both. Also,
alterations in the subcortical white-matter, characterised by structural and functional
changes in fibres and tracts connecting diverse cortical and subcortical grey matter
areas, may induce diffuse changes to higher cortical functioning. Potential
neuropathological substrates thought to be associated with vascular cognitive decline
are discussed in the following sections.
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6.5.1. Cortical Damage
There is published evidence indicating that ischaemic infarcts classified as
symptomatic (strokes) tend to comprise relatively large lesions in either the cerebral
cortex and/or in deep subcortical grey matter structures (for example the basal
ganglia and thalamus). In the general population, approximately one third of clinical
strokes occur in the cerebral cortex (Vermeer et al., 2002). While a similar frequency
has been described for those affecting subcortical grey matter areas, the same data
show that only a very small proportion of cortical infarcts are asymptomatic
compared to approximately 80% of subcortical lesions (the neurocognitive
consequences of subcortical infarcts are discussed in the next section). These
findings suggest that a direct, isolated damage to the cerebral cortex caused by
ischaemic infarction is likely to be a major pathological feature underlying
neurological and cognitive disturbances in a substantial proportion of stroke patients.
On the other hand, in the absence of overt stroke, direct cortical injury may seem a
less likely mechanism for impairment of higher cortical functions.
Typically, cortical stroke results in focal or multifocal neurobehavioural
deficits, although the range of clinical and neuropsychological findings is likely to
reflect, among other things, the vascular territory affected by thrombo-embolic
disease, the extent of the ischaemic damage, and its laterality within the brain. Signs
of occipital cortical damage, manifest clinically as a spectrum of visual field deficits
are, for example, commonly seen in patients with CT/MRI-determined superficial
cortical infarction in the posterior cerebral artery (PCA) territory (Cals et al., 2002).
In addition, verbal memory deficits may be frequent in these patients, particularly
among those with either left hemispheric or bilateral lesions, or large infarcts
expanding to other cortical areas. General cognitive function, as determined by the
MMSE, may also be impaired in a significant proportion of patients with PCA
cortical infarcts, although frequently more so in those with combined cortical and
subcortical lesions within this cerebral artery region (Kumral et al., 2004). In patients
with stroke in the anterior cerebral artery region, extensive sensorimotor disturbances
are common (Kumral et al., 2002). Decreased verbal fluency and executive
dysfunction are also frequently observed in such patients, although it is not clear
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whether such disruptions of higher frontal lobe cortical functioning are the result of
ischaemic damage to the cortex per se, subcortical areas, or these combined.
Even in the absence of extensive, multi-lobal, cortical infarcts or ischaemic
damage traversing both cortical and subcortical structures, focal cortical lesions may
lead to neural dysfunction in both adjacent and distant cortical regions (Brown and
Eyler Zorrilla, 2001; Witte et ah, 2000). In experimental models, small cortical
strokes in the territory of the middle cerebral artery (localised within the parietal
lobe) cause an immediate decrease in relative metabolic activity determined with a
PET scanner in both the frontal and parietal cortex adjacent to the infarct
(Carmichael et al., 2004). Although stroke-induced cortical hypometabolism shows
improvement over time, full recovery to pre-stroke levels may not occur, particularly
in adjacent cortical areas. The fact that the permanently hypometabolic territory is
significantly larger than either the ischaemic lesion or the slightly larger
hypoperfused area surrounding the infarct, is strongly indicative of cortical
diaschisis. Although this term has been used for any remote effects initiated by a
focal cerebral lesion, several different aetiological mechanisms may produce such
changes following stroke (Brown and Eyler Zorrilla, 2001). In particular, it is
possible that an ischaemic infarction destroys neuronal projections to a remote
cortical site, disconnecting it from adequate sources of neuronal innervation. Also,
neural functioning distant from the site of infarction may be altered through
repetitive neuronal depolarisation that can cross both borders of normal brain tissue
and cerebral artery territories to cover an entire cerebral hemisphere (Witte et al.,
2000).
In addition to inducing long-lasting cortical hypometabolism, spreading
waves of depolarisation may activate multiple molecular cascades in remote areas,
characterised by increased microglial activity and upregulation of diverse
proinflammatory proteins. Although limited and contradictory evidence exist
regarding the independent effects of diaschisis on neurological and
neuropsychological outcomes after ischaemic infarction (Bowler et al., 1995; Witte
et al., 2000), it is not impossible that such a process, possibly mediated by a
neuroinflammatory response, may exist to explain the pattern of generalised deficits
in higher mental functions following cortical stroke.
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6.5.2. Subcortical Grey Matter Lesions
Further to the above, symptomatic infarcts may involve the subcortex, either
in combination with superficial cortical structures or in isolation. With respect to the
latter, there is, however, substantial evidence showing that a direct ischaemic injury
to subcortical grey matter structures, most commonly the basal ganglia and thalamus,
occurs significantly more often without any apparent neurological symptoms
(clinically 'silent') (Vermeer et al., 2002; Vermeer et al., 2003). On MRI scanning,
subcortical infarcts manifest themselves as areas of focal hyperintensity on T2-
weighted images that are usually less than 15 mm in diameter in the deep territory of
small, non-branching end arteries, arising directly from larger cerebral arteries.
It has been suggested that atherosclerosis may contribute directly to
subcortical grey matter infarction. For example, microatheromatous vessel pathology
may induce lumen stenosis or occlusion of small penetrating arterioles, leading to
ischaemia and necrosis. Similarly, an atherothrombotic lesion at the origin of the
penetrator, or at the wall of a large, proximal cerebral artery, might lead to an
obstruction of its opening. In other circumstances, artery-to-artery embolism or
cardioembolism may be suspected as the underlying aetiology in subcortical
infarction. In selected samples of stroke patients, between 25 and 40% have had
evidence of clinically silent infarcts shown by either CT or MRI scanning (Boon et
al., 1994; Corea et al., 2001; Corea et al., 2002; Jorgensen et al., 1994; Mok et al.,
2003; Ricci et al., 1993). Even among those with first-ever stroke, between 27 and
38% had evidence of previous asymptomatic brain infarction (Boon et al., 1994;
Ricci et al., 1993; Jorgensen et al., 1994). In a sample of 775 consecutive patients
with a first-ever cortical stroke, Boon et al. (1994) classified over 80% of all silent
lesions as small, subcortical grey matter infarcts.
Asymptomatic infarcts are also common in patients with symptomatic large-
vessel disease other than overt stroke. Pardo et al. (1998) described silent brain
infarcts in one-third of 100 consecutively admitted stroke-free coronary heart disease
patients (mean age 61.3 years), half of which were located in the basal ganglia.
Although the number of coronary arteries affected (assessed using coronary
angiography) was not related to the presence of silent brain infarcts, the degree of
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ultrasonographically-determined carotid stenosis was. In another study, the
prevalence of MRI-based silent infarcts increased linearly and significantly with the
number ofmajor coronary vessels affected by atheromatous lesions (Uekita et al.,
2003). Relative to those without significant stenosis of a major coronary artery (the
prevalence of silent lesions was 27.3%), the frequency of infarcts in patients with
one, two, or three diseased vessels ranged from 55.6 to 81.3%. In addition, both the
size and number of silent infarcts was positively and significantly related to the
number of affected vessels. In addition, the use of intracranial magnetic resonance
angiography (MRA) allowed the determination of both the association of coronary
disease severity with intracranial artery atherosclerosis and that ofMRA findings
with silent infarcts. Significant cerebral artery atherosclerosis was positively related
to coronary disease severity and occurred more commonly in patients with infarcts
(51.1% in those with brain infarcts versus 6.5% in those without). Furthermore,
Hoshide et al. (2001) investigated the occurrence of silent brain infarcts in 208
angiographically-assessed coronary disease patients. In multivariate analyses, the
number of diseased coronary arteries independently predicted silent infarcts in the
grey matter territories of deep perforating cerebral vessels but not those located in the
subcortical white matter. As a result, the authors suggested that, whereas silent brain
infarcts in the areas of the deep perforators may partly be caused by subclinical
systemic atherosclerosis, those occurring in the white matter might rather be
attributed to other aetiological mechanisms, including hypertensive small vessel
vasculopathy.
Limited data have been produced on the presence of silent brain infarcts in
relation to lower-extremity atherosclerosis, highlighting the need for further research.
In a recent small-scale analysis of a relatively young sample (mean age 58.4 years)
from the Second Manifestations of Arterial Disease (SMART) Study, Giele et al.
(2004) found a non-significant trend toward a greater proportion of subjects with
clinically silent brain infarcts also having a low ABPI (ABPI <0.9). A similar non¬
significant trend was observed for self-reported history ofMI. However, the mean
level of intima-media thickness (IMT), possibly acting as a more sensitive marker of
atherosclerosis than those above, proved to be significantly higher in those with
silent lesions.
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In the light of the above, two inter-related questions may be worth asking:
although clinically silent, is it possible that deep subcortical infarcts could induce
measurable changes in higher cortical functioning as indexed by mental tests? Also,
could cognitive deficits in patients with CVD to some extent be attributed to silent
brain infarcts? In modestly-sized samples of healthy elderly subjects, the presence of
subcortical brain infarctions has been associated (albeit non-significantly) with worse
domain-specific cognitive test performance (including perceptual speed, episodic,
working, and semantic memory, and visuo-spatial abilities) but not with reduced
global cognitive function (based on summarising the scores of all tests) (Schneider et
al., 2003). In other cross-sectional-based analyses, silent infarcts determined by MRI
and located in the basal ganglia were associated with slower verbal memory retrieval
speed and worse executive functioning (O'Brien et al., 2002). Similarly, thalamic
lesions were further related to worse focused attention in addition to both slower
verbal memory retrieval speed and executive functioning. In the Rotterdam Scan
Study, silent thalamic infarcts at baseline predicted a steeper four-year decline in
verbal memory performance, whereas non-thalamic infarcts (mostly located in the
basal ganglia) were negatively associated with change in psychomotor speed
(Vermeer et al., 2003). Also, relative to a single lesion, multiple silent infarcts were
more strongly associated with cognitive decline. The effects were restricted to those
with incident silent infarcts, irrespective of whether they had silent lesions at
baseline, suggesting a stepwise deterioration in higher cortical functioning following
silent subcortical infarction.
Although undetermined in non-stroke vascular patients, Sachdev et al. (2004)
demonstrated that, in subjects with a history of TIA/stroke, the degree of subcortical
grey matter involvement was negatively and significantly associated with a general
cognitive factor score, representing the variance shared by the individual mental tests
in the study. In contrast, the relation with stroke volume proved not to be significant.
This empirical finding prompted the authors to conclude that: "while large cortical
strokes do leave a signature on the neuropsychological deficits, they are best
regarded as being superimposed on a baseline subcortical pathology." Given the
intricate cortico-subcortical circuitry networks connecting the superficial and deep
structures, such subcortical infarcts may lead to wide-ranging effects on cortical
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functioning (Mori, 2002; Tekin and Cummings, 2002). Specifically, up to 20%
reduction in metabolism in cortical areas both ipsi and contralateral to unilateral
thalamic infarcts has been observed (Baron et al., 1986). Although this pattern is
likely to reflect the fact that, in addition to specific systems connecting relay nuclei
with specific cortical areas, the thalamocortical connections include non-specific
systems that project diffusely into the cerebral cortex, it is unclear how precisely
wide-ranging cortical inactivity might come about following a focal thalamic
infarction. As a result, Baron et al. (1986) proposed these changes might be due to: a)
anterograde degeneration of thalamocortical terminals, b) retrograde degeneration of
the corticothalamic neurons, secondary to damage to their thalamic terminals, c)
transsynaptic degeneration of the cortical neurons, following damage to the
thalamocortical system, or c) reduced activity of cortical neurons without structural
damage following the loss of activating afferences from the thalamus.
6.5.3. Subcortical White Matter Changes
Alterations to the subcortical white matter, visualised as bright,
hyperintensive periventricular or deep white matter regions on T2-weighted MRI
scans, are frequently observed in neurologically-intact older people. Demonstrated
MRI-based hyperintensities have been found in quarter to third of older persons
(Breteler et al., 1994; Uehara et al., 1999). Although diverse pathogenic processes
may induce changes in the cerebral white matter, most lesions in the elderly are
thought to be vascular in origin (Malloy et al., 2005). In clinical samples, more than
half of patients with diagnosed stroke have been found to have radiological evidence
of white matter hyperintensities (Gerdes et al., 2006). Moreover, an early literature
review concluded that white matter lesions were more frequently seen in relation to
specific stroke subtypes, such as ischaemic infarction and deep intracerebral
haemorrhagic stroke (Leys et al., 1999). Various peripheral markers of
atherosclerosis have also been associated with a greater white matter involvement,
including both the degree of carotid artery intima-media thickness (Takahashi et al.,
2006) and ABPI (Bots et al., 1993). About a fifth of older MI patients had signs of
white matter changes, either in periventricular or deep white matter regions (Gerdes
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et al., 2006). However, in the same study, approximately a third of subjects with
intermittent claudication had similar evidence. Furthermore, in the Rotterdam Study,
both an ABPI less than 0.9 and possible or definite myocardial infarction were
associated with an increased likelihood (OR=2.4 and 3.1, respectively) of cerebral
white matter changes (Bots et al., 1993).
Further to vascular disease, potentially modifiable CVD risk factors have
been found to be associated with increased white matter hyperintensities, particularly
blood pressure level (Waldstein and Katzel, 2001). For example, in population cross-
sectional data, clinically-defined hypertension has been related to significantly
increased odds of MRI-based white matter lesions (Liao et al., 1996). Moreover,
treated uncontrolled hypertensives are found to have greater odds of such lesions
than those with treated controlled blood pressure. In a recent prospective study,
baseline hypertension was associated with a greater risk of severe white matter
hyperintensities at a four-year follow-up (Dufouil et al., 2001). Similarly, de Leeuw
et al. (2002) demonstrated greater periventricular and subcortical white matter
lesions at follow-up in 60 to 70 year-old subjects diagnosed as hypertensive more
than 20 years earlier.
Further evidence of the aetiological role of blood pressure comes from
clinical trials showing beneficial effects of active blood pressure lowering on the
progression ofwhite matter changes in selected patient samples (Dufouil et al.,
2005). Comparatively weaker evidence exists for other risk factors, including
smoking, but both smoking status and duration significantly predicted increased
periventricular hyperintensities in a selected patient sample of middle aged adults
(Fukuda and Kitani, 1996). Similarly, increased BMI was positively related to
greater brain atrophy, including of the white matter, in middle aged men and women
(Ward et al., 2005). Also, in the Rotterdam Study, both increased coagulation and
inflammatory activity were independently and significantly associated with the
presence of radiologically-determined white matter abnormalities (Breteler et al.,
1994). Whatever the mechanisms, it is thought that the white matter changes seen in
relation to vascular risk factors and CVD generally arise from either complete or
incomplete ischaemic infarctions and/or hypoperfusion-hypoxic injury due to diverse
blood vessel alterations which may include atherosclerosis and thickening
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(hyalinisation) of deep perforating arterioles (Malloy et al., 2005). These may then
induce loss of axons, demyelination, inflammation (gliosis) and necrotic changes
which are characteristic neuropathological correlates of vascular-related white matter
hyperintensities (Englund, 2002).
The significance of the integrity of the cerebral white matter for higher
cortical functioning is well established (Malloy et al., 2005). The burden ofwhite
matter hyperintensities was found to be associated with poor performance on
cognitive tasks in a recent quantitative review of 23 empirical studies (Gunning-
Dixon and Raz, 2000). In particular, greater white matter involvement was related to
worse performance in global cognitive function, processing speed, delayed memory
and executive functioning. More specifically, hyperintensities in both periventricular
and deep regions have been related to a specific decrease in implicit learning of
sequences (Aizenstein et al., 2002).
Other studies have associated white matter lesions with a greater decline in
aspects of cognitive function, including mental processing speed (van den Heuvel et
al., 2006). White matter lesions also contributed significantly and independently of
childhood ability level to lifetime decline in general cognitive ability rather than
individual mental functions per se (Deary et al., 2003). Moreover, a population study
showed that six-year decline in performance on tests ofmemory, conceptualisation
and visuopractical skills was directly related to the progression of white matter lesion
burden (Schmidt et al., 2005). Still further evidence comes from studies using
diffusion tensor MRI (DT-MRI) where markers sensitive to the ultrastructural
integrity of the cerebral white matter have been associated with cognitive outcomes.
Thus, Shenkin et al. (2005) showed a strong and consistent, inverse relationship
between white matter water diffusion parameters and performance on a non-specific
measure of executive functioning. Interestingly, the association was not limited to
any of the anatomical regions studied, including the frontal lobe area. Collectively,
these reports provide evidence for the influence of white matter hyperintensities on
higher cortical functions, particularly those that may be dependent on either speed of
processing or the integrity ofwidely-distributed neural networks (e.g. executive
functions) (Gunning-Dixon and Raz, 2000; Malloy et al., 2005).
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Importantly, there is currently limited evidence regarding the importance of
white matter lesions as a substrate of cognitive deficits in non-demented patients
with established atherosclerotic vascular disease. In particular, few studies have
examined this association in the context of non-cerebrovascular disease. In contrast,
in a small sample (n=96) of older (>75 years) stroke survivors, both the total and
frontal volume ofwhite matter hyperintensities correlated significantly and
negatively with measures of processing speed and attention (Burton et al., 2004).
Moreover, hyperintensities in the region of the temporal lobe were associated with
worse memory performance. The strength of the individual associations was modest,
however, with the predictor variables explaining between 5 and 10% of the variance
in the outcome measures.
Also, in a larger sample (n=323) of consecutively recruited stroke patients,
who were administered a comprehensive battery of cognitive tests, total white matter
hyperintensities were significantly related to cognitive deficits independently of
demographic confounders, infarct volume and cortical atrophy (Jokinen et al., 2005).
In particular, performance on tasks assessing processing speed, executive functions,
visuospatial ability, visual memory and delayed recall of object learning were
affected. In contrast, story-based verbal recall was not related to white matter
hyperintensities. An important additional observation was that the association
between hyperintensities and memory deficits proved to be either totally or partly
mediated by executive function and mental speed, respectively. As a result, these
studies also underscore the importance of the integrity of the white matter for both
normal processing speed and executive functioning, further to suggesting that
impairment in other cortical functions may be secondary to suboptimal functioning
of either of these. However, whether such radiological abnormality in the white
matter is associated with cognitive decline in these and other vascular patients
remains to be explored.
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6.6. METHODOLOGICAL ISSUES
Several methodological issues need to be considered in relation to the
findings presented above. First, the study sample was recruited from the pool of
surviving participants in the EAS who are likely to have differed in several aspects
from the representative original baseline cohort. Although a direct comparison with
the general population may not be possible, subjects surviving up to follow-up
cognitive testing proved to be younger (mean age 63.3 versus 67.6, PO.OOl), better
off socioeconomically (12.8% and 33.8% in social classes I and II compared to 6.6%
and 28.4% of non-survivors, P for trend <0.001) and physically healthier (e.g. the
stroke prevalence was 1.4% versus 6.2%, PO.OOl; the prevalence ofMI was 2.1%
versus 9.1%, PO.OOl; mean SBP was 141.6 versus 149.7, PO.OOl; and mean pack-
years of smoking were 13.8 versus 23.4, PO.OOl) at baseline compared to the non-
survivors. In addition, only about half of the survivors were eligible for the current
study. Of these, approximately two-thirds participated in follow-up cognitive testing.
A comparison of tested and non-tested survivors showed those attending cognitive
assessment in 2002/3 had lower mean age, less CVD and more favourable vascular
risk factor profile at baseline in 1987/8 (see table 1). These participants also had
substantially better outcomes on all neuropsychological measures at the baseline
cognitive testing in 1998/9 (see table 2).
Second, evaluation of cognitive function was not included in the original
EAS protocol and therefore not conducted at the baseline clinical examination in
1987/8. At a later time point during follow-up, a battery of cognitive tests was
administered for the first time to surviving participants. Given the already high
average age (74.1 years) as well as the size of the sample (n=717) by the time of
baseline cognitive assessment, only a modestly-long, subsequent cognitive follow-up
was inevitable. Although a longer follow-up would have allowed the examination of
a greater magnitude of change in cognitive performance over time, and therefore
possibly stronger associations than reported here, there is likely to be an important
trade-off between follow-up length and attrition in longitudinal studies of older
samples. Partly in order to address this issue, we also estimated cognitive decline
over effectively a much longer interval than the actual four-year observational period
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by including the NART as a covariable in our analyses. In doing so, our data
contributed a vastly extended study period, albeit imputed rather than actual,
compared to that used in previous investigations for the examination of cognitive
decline in relation to CVDs. However, only the difference between NART and scores
on the RPM has been validated as a measure of lifetime change in cognitive function
(Deary et ah, 2004). In contrast, the NART might not have adequately reflected the
test elements represented by the other neuropsychological measures we used in the
study. Possibly, such a discrepancy between the NART and the other cognitive tests
could have contributed to the relatively greater inconsistency in findings in the
NART-based models than those where the actual decline from baseline performance
was the outcome.
Moreover, the cognitive test battery used in the present study was designed to
include widely used, validated measures ofmajor components of human cognition
known to be sensitive to the effects of biological ageing and neurological damage.
However, only one test was administered for assessing any particular cognitive
domain. In this regard, it is likely that only some or limited aspects of what may be
considered complex mental functions were actually determined in the present study
(Lezak, 1995). For example, only verbal memory but not other memory components,
including visual memory and working memory which also may show significant age-
associated changes, were assessed. In addition, we measured verbal memory using
both immediate and delayed story-based recall but free recall of random words is
thought to be cognitively more demanding for older subjects and has solely been
used in some previous studies. Similarly, executive functioning was assessed using
only a brief, simple measure of word fluency. It is very likely that on its own this test
did not adequately reflect the complexity and importance of this particular cognitive
domain and that several different executive functioning measures would have been
needed. Indeed, the executive functioning domain may be very sensitive to the
adverse influence of neurological insults and biological ageing. Possibly as a
consequence of the above, few consistent associations with either CVD or vascular
risk factors were observed in the present study. In addition, we did not assess other
important aspects of human cognitive function, including creativity, which also
might be vulnerable to the potentially adverse effects of vascular-induced
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neuropathological mechanisms. However, in the light of the fact that our outcome
data were collected using predominantly brief, easily-administered, simple, single
tasks, they are unlikely to fully reflect the magnitude or scope of cognitive deficits
experienced by the study sample. Under these circumstances the associations
reported herein would underestimate the true level of vascular-induced decelin in
general cognitive function in the elderly general population.
Also, our approach to the control for potential confounders of the association
between CVDs and cognitive decline was both robust and extensive in comparison to
previous studies. However, the information on the majority of covariables we
statistically adjusted for was collected at the baseline clinical examination in 1987/8,
or more than a decade earlier to the assessment of cognitive functions. Similarly,
these acted as predictor variables in our analyses of the relationship between vascular
risk factors and cognitive decline. Therefore, two possible consequences of the above
need to be considered. Regarding the latter, due to any subsequent random variation
or instability in a covariable that was measured at baseline, the associations we report
here between vascular risk factors and decline in cognitive function are likely to be
conservative estimates. Further to applying to those factors that might have changed
over time due to any of a number of reasons (e.g. blood pressure levels, smoking,
concentrations of markers of inflammation and coagulation) this could also be of
relevance to those covariates for which less accurate methods ofmeasurement
existed. On the other hand, regarding our examination of cognitive decline in relation
to CVD status where the above covariables were considered as possible confounders,
the risk of potential residual confounding by co-existing vascular risk factors might
have been increased to an unknown extent.
Other characteristics which also might be thought as potential confounders of
the relationships presented here, including cardio -or other vascular surgery and
medication history, were not taken into account in our multivariate analyses. With
respect to the latter, a detailed structured questionnaire on medication history was
administered only at baseline in 1987/8. As a result, up-to-date information on
medication use was not available for use in the present analysis. In contrast, at the
time of follow-up cognitive testing in 2002/3, subjects were asked open-ended
questions about current medication use. When analysed (data not shown) the
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responses primarily revealed that too few subjects were taking any given type of
medication. Therefore, these data were also not used in the current study. As a
consequence, however, the possibility of confounding of the associations reported
herein by medication use, whereby diseased subjects were more likely to be taking
drugs with the capability of interfering with cognitive performance, cannot be ruled
out. Similarly, the study findings must be viewed with the possibility in mind that, in
some instances, sensorimotor difficulties could have negatively impacted the
cognitive test performance of diseased participants (particularly those with a history
of stroke when cognitively tested).
Furthermore, as the number of statistical tests conducted was considerable,
the probability of a type I error (incorrect rejection of a true null hypothesis) may
have been increased (Parker and Rothenberg, 1988). In other words, some of the
findings might have occurred from chance alone despite being statistically
significant. There is currently no formal consensus on the use of analytical
techniques, including the commonly encountered Bonferroni procedures, to control
this problem (Nakagawa, 2004; Parker and Rothenberg, 1988). Indeed, it has been
pointed out that adjusting statistical significance for the number of tests performed
might lead to additional problems, such as an increased likelihood of type II error
(incorrect acceptance of a null hypothesis when the alternative is true). Also, the use
of such methods may not be appropriate when assessing evidence about specific
hypotheses which should better be described and discussed with respect to what tests
were conducted, their biological plausibility and in the context of previous research
findings (Perneger, 1998; Savitz and Olshan, 1995).
In the current study, the associations examined were specified a priori thus
minimising the number of possible comparisons (the possibility of type 1 error was
likely to be further reduced by data reduction resulting in the computation of a
general cognitive factor). Also, the relationships were generally in the direction
expected given the overall similar empirical findings from previous studies and the
pathophysiological plausibility of these. Finally, in a majority ofmultivariate
analyses, the associations were reasonably consistent (either statistically significantly
or not) across the hierarchical models. Importantly, the significant relationships
highlighted and discussed herein were those showing larger effects (and lower
277
significance levels) as these would be more likely to be replicable. In some instances,
however, associations either emerged or became stronger when adjusted for further
possible confounding factors. While these might have occurred by chance, such an
observation could also be an indication of the complexity of the association between
vascular pathology and cognitive outcomes.
Finally, to the extent to which vascular-based or other (e.g. AD pathology)
neuropathological mechanisms existed to explain our findings, any such processes
would in a majority of instances have done so at sub-clinical levels. Specifically,
prior to each wave of cognitive testing, GPs would have been expected to exclude
any patients with overt dementia although it is possible that some cognitively
impaired patients might have been missed despite the screening by GPs. However, it
is likely that most patients developing dementia during the four-year cognitive
follow-up would have been excluded prior to cognitive assessment in 2002/3. In
addition to the above, on both occasions, the MMSE was administered for screening
for dementia. In 2002/3, only about five percent of the 452 subjects scored less than
24 on the MMSE, a widely used cut-off point for cognitive impairment. However,
preliminary exploration of the data showed that performing poorly on the MMSE
was not related to CVD status.
6.7. CHAPTER SUMMARY
The major findings of the current study are that both atherosclerotic vascular
diseases and risk factors are associated with a modest yet progressive decline across
diverse cognitive functions in older survivors from the general population. In
particular, stroke was related to an accelerated decline in both general ability (0.32 to
1.25% of the total variance was explained by stroke) and verbal memory skill (stroke
accounted for 1.21% of the total variance). In the absence of overt stroke, MI was
associated with a steeper decline in non-verbal reasoning (and accounting for about
0.90% of the total variance) but angina did not predict cognitive decline in the
present sample. Peripheral arterial disease was also associated with an increased
decline in both general cognition and verbal memory (accounting for about 0.29 and
0.88% of the total variance, respectively). Several established as well as novel
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vascular risk factors were also associated with a greater decline in
neuropsychological test performance.
The present findings further add to those previously demonstrating an
association between vascular diseases and cognitive impairment and decline in
global cognitive function and across restricted sets of mental abilities (Elwood et al.,
2002; Haan et al., 1999; Singh-Manoux et al., 2003; Zhu et al., 1998). The results
also contribute to the still limited literature available on the relation of novel CVD
risk factors with cognitive function of older people. Specifically, the inverse
associations of both markers of inflammation and coagulation, and blood viscosity
with decline in domain-specific cognitive tests are new. The robust control for a
large number of potentially confounding factors of the associations between
atherosclerotic CVDs and cognitive decline suggest these relationships may in fact
depend on the underlying pathological process. Similarly, the observed independent
effects of vascular risk factors also favour distinct negative influences on
neurocognitive processes. The unavailability of structural neuroimaging in the
present study prevented the determination of the neuropathological changes likely to
underlie these relationships although both the effects of CVD and risk factors with
decline in individual mental tests were either totally or largely mediated through the
relationship of these with general cognitive function. To the extent to which general
intelligence is thought to reflect neurocognitive processes that depend on intact deep
white and grey matter integrity, the findings point in the direction of subcortical
pathology as a major neuropathological substrate associated with cognitive decline in
the current sample.
In the final chapter of this thesis, the major implications of the current
findings are discussed. Moreover, recommendations for future research are presented
which are based on the current results as well as the review of past investigations
examining the associations between vascular diseases, risk factors and cognitive
function of older people.
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CHAPTER SEVEN
Implications, Recommendations and Conclusions
7.1. IMPLICATIONS
The main implications of the present study and of previous research of the
association between CVDs, vascular risk factors and cognitive function in the
elderly, relate to the potential value of controlling or preventing vascular risk factors
and diseases in order to preserve the cognitive health of older age groups. Regarding
the associations with individual CVD risk factors, the results might also inform
strategies aimed at reducing or preventing cognitive decline through blood viscosity
reduction, neuroprotection and the facilitation of cognitive reserve in older people.
However, it must be borne in mind that any cognitive effects of individual CVDs and
vascular risk factors are generally very modest and the need for identifying yet other
potentially modifiable risk factors for cognitive decline (which may contribute to
individual differences in cognitive decline to a greater extent) is still unmet. On the
other hand, from a public health point of view, it is importance to acknowledge the
fact that several risk factors may be present in old people and their effects on
cognitive function may be cumulative (see point 1 in section 7.2 below).
In particular, the present findings would support strategies aimed at the
primary prevention of cardiovascularmorbidity through the reduction of levels of
major CVD risk factors. At the general population level, the use of full range of
primary preventive measures to reduce smoking and to lower population blood
pressure and serum cholesterol levels might not only decrease the total burden of
CVD in society but possibly also lead to the control of other chronic conditions
which share the same risk factors (Beaglehole and Dobson, 2005; Purandare et al.,
2005). Specifically, the magnitude of benefit against CVDs achievable through diet
and lifestyle modification may be large and may outweigh that resulting from the
medical treatment of either elevated blood pressure or cholesterol levels (Hu and
Willett, 2005). With respect to cognitive impairment and decline, reducing the
cardiovascular morbidity (particularly if the cumulative effects of several risk factors
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are addressed) in older people might slow down the deterioration in mental function
and/or delay or prevent the onset of cognitive impairment (Gow and Gilhooly, 2003;
Purandare et ah, 2005). Moreover, based on the current results, it is possible that
further to reducing the progression of atherosclerosis and its potential effects on the
neural substrate, CVD risk factor lowering per se might prove beneficial for the
neuropsychological functioning of older persons. Any positive effects of such efforts
might be realised most clearly in relation to efforts to deliberately lower elevated risk
factor levels in older people at high absolute risk of a cardiovascular event.
In persons with established atherosclerotic CVDs, the risk of recurrent
vascular events in the same or different arterial beds is significantly increased. The
secondary prevention of further vascular episodes in these patients is ofmajor
importance and aggressive treatment of potentially modifiable CVD risk factors,
irrespective of their level, has been advocated for this purpose (Anand et ah, 2005).
In people with stroke, for example, treatments for the prevention of repeated events
are well established and, in addition to antihypertensive medication, include the use
of antiplatelet agents, carotid endarterectomy and warfarin for atrial fibrillation
(O'Brien et ah, 2003). In the present study, older non-demented subjects with
symptomatic CVDs were further found to be more vulnerable to cognitive decline
relative to those without major vascular morbidity. Importantly, both the presence of
stroke as well as clinically-manifest coronary and peripheral atherosclerosis was
associated with an increased decline in cognitive function. Despite being strong
predictors of subsequent vascular events in CVD patients, high blood pressure,
smoking, atrial fibrillation, elevated blood glucose and cholesterol levels may not be
significant predictors of the level of cognitive function in people with stroke
(Sachdev et ah, 2006). Similarly, in selected samples of stroke-free patients with
advanced lower-extremity arterial disease, the extent or severity of disease may be a
more important predictor of cognitive function than conventional CVD risk factors
(Phillips, 2001). These findings could imply that the part played by known CVD risk
factors in cognitive decline is predominantly that related to the promotion of
atherosclerotic disease which, once manifested clinically, assumes the role of the
major vascular mechanism underlying cognitive decline in CVD patients. In turn,
these results further highlight the importance ofboth the primary prevention of
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CVDs in healthy adults as well as of those approaches needed to reduce or reverse
the progression of atherosclerosis in older vascular patients in order to preserve
cognitive health.
A novel finding in the current study was the inverse relationship observed
between blood viscosity and decline in cognitive function. Possibly, age-related
increases in blood viscosity disrupt cognitive processes by inducing chronic
reductions in the cerebral blood flow of older people. These findings highlight the
importance of strategies aimed at identifying and treating older persons for increased
viscosity with the aim of improving levels of cognitive function (Lowe, 2001).
Further to the above, additional ways to either enhance neuroprotection or
build up cognitive reserves may be the focus of other strategies aimed at maintaining
cognitive health in later-life (Purandare et ah, 2005). For example, reducing stress
levels, engaging mentally, exercising regularly and adopting a healthy diet have been
advocated as important low-risk strategies for the maintenance of brain health of
older people (Small, 2002). Also, evidence from observational epidemiological
studies suggests that use of antioxidant vitamins and non-steroidal anti-inflammatory
agents (NSAIDs) may be associated with a lower risk of cognitive impairment
(Purandare et al., 2005). Ageing is accompanied by increased immune dysregulation
and circulating proinflammatory molecules may play a key role in chronic brain
inflammation and neurodegeneration (Solfrizzi et al., 2006). In the current study
sample, circulating markers of inflammation were associated with decline in
cognitive function. Possibly, inhibition of key components of the inflammatory
response with the aid ofNSAIDs may offer neuroprotective effects resulting in
reduced cognitive decline in non-demented individuals found at an elevated risk.
Furthermore, we demonstrated that more formal education was associated with less
cognitive decline in adult life. Despite the exact mechanisms of this relationship
remain unknown such an observation may still have practical implications. In
particular, it has been suggested that increased levels of education in the general
population at large might lead to lessening of the burden of cognitive impairment and
decline (Albert, 1995).
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7.2. RECOMMENDATIONS FOR FURTHER RESEARCH
The current study raises a number of questions that need to be addressed in
future research of vascular-related cognitive decline in older people. These are
presented and discussed each at a time below.
1) More observational research is required to examine the potential impact of
modifiable atherosclerotic risk factors on change in different cognitive functions in
representative samples of patients with established vascular diseases. Previous
studies have been few and mainly focused on post-stroke cognitive impairment
(Sachdev et al., 2006). On an individual basis, vascular risk factors may not
contribute independently, or only weakly, to cognitive function in the presence of
clinically-manifest atherosclerotic disease (Phillips, 2001). However, there is limited
evidence suggesting that the overall CVD risk factor exposure in vascular patients
may be associated with impaired cognitive function (Sachdev et al., 2006).
Therefore, in future studies, the possible cumulative impact ofmultiple risk factors
on diverse aspects of neuropsychological functioning needs to be evaluated in
relation to different cardiovascular morbidity types. The importance of such research
is further emphasised in the light of empirical data showing CVD risk factors tend to
be largely undertreated and undercontrolled in CVD patients (Bhatt et al., 2006) and
relatively more so in relation to PAD than CHD (McDermott et al., 1997).
2) Further studies are needed in order to better understand how different pathological
indices of cardiovascularmorbidity may be associated with neuropsychological
functioning and decline in CVD patients. For example, in selected samples of
patients with symptomatic lower-extremity arterial disease, disease severity has
emerged as a relatively important predictor of cognitive function (Phillips, 2001).
Similarly, haemodynamic pressure variables (i.e. pulmonary artery pressure) and
cardiac output have been associated with worse pre-operational cognitive test
performance among cardiac transplant patients (Putzke et al., 1998). It is of
importance that similar work is replicated in large, representative population samples
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involving older survivors with clinical CVD in different arterial territories in the
body.
3) Now that evidence showing greater cognitive impairment and accelerated mental
decline in older survivors with vascular diseases is accumulating, it is imperative that
further studies characterising the substrate possibly underlying such findings are
conducted. Although still limited, previous studies have highlighted the importance
of MRI-detected sub-cortical white matter changes for post-stroke
neuropsychological function (Burton et al., 2004; Jokinen et ah, 2005; Sachdev et ah,
2004). Identical work needs to be carried out on larger samples of community-based
stroke survivors recruited from different populations. Also, an important gap exists
with respect to the relation between structural imaging and outcomes on
neuropsychological tests in patients with non-stroke vascular diseases that needs to
be filled. The careful assessment of both the location and severity of brain lesions as
well as the detailed examination of cognitive functions must be the minimum.
Furthermore, where possible, future studies should also consider the use ofmore
sensitive techniques (i.e. diffusion tensor MRI) for the measurement of cerebral
white matter integrity in order to determine the potential cognitive impact of early or
very small changes in the white matter structure.
4) Intact cognition remains a critical dimension of the health of older people yet few
studies have examined real-life functioning in relation to subtle neuropsychological
deficits. In particular, there is currently a great need for additional research regarding
how change in neuropsychological test performance might influence everyday
functioning of high-risk populations, including CVD survivors. Based on data from
small clinical samples, performance on tests of visuospatial ability, memory and
attention may be predictive of informant-reported, everyday adaptive functioning in
patients with advanced-level peripheral arterial atherosclerosis (Phillips, 1996). The
potential effects of subtle decrements in different cognitive functions on everyday
activities such as driving, reading and adherence to medical regimens would need
particular attention in future studies.
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5) Further prospective data are required in order to determine the predictive value of
subtle changes in neuropsychological performance for further ongoing cognitive
deterioration and dementia onset in older vascular patients. In particular, information
is needed regarding the value of changes in specific neuropsychological domains in
predicting future cognitive impairment. In samples of community-resident elderly,
poor performance on aspects ofmemory may be predictive of future dementia
(Grober et al., 2000) but similar data are lacking from survivors with CVD. In
addition, the clinical significance of cognitive function decline for other adverse
events, including mortality and institutionalisation, needs to be investigated in older
people with vascular diseases.
6) The greatest potential for halting or delaying cognitive decline in older adults may
be tied to the adequate prevention and control of cardiovascular risk factors (Roman,
2003). The major emphasis placed on the cognitive effects of elevated blood pressure
levels and diabetes in neuroepidemiological investigations needs to continue (Elias et
al., 2001). Future studies need to resolve the current controversy regarding the
association between hypertension and cognitive function by focusing on
methodological issues such as the definition and measurement of hypertension and
cognitive decline and the choice of study population. In addition, potential
confounding by comorbidity and medical treatment needs to be adequately addressed
in older samples (Birns and Kalra, 2006). With respect to research of cognitive
function in adult diabetics, the need for agreed standards of study design and a
consensus on a core battery of neuropsychological tests has been highlighted
(Strachan et al., 1997). The possible role of other modifiable risk factors, including
smoking, obesity and cholesterol, needs much further attention in large-scale
prospective studies. In particular, the combined impact of several vascular risk
factors should be investigated.
There is also much needed research on neuropsychological functioning in
relation to other less established vascular factors, including markers of inflammation
and coagulation, blood rheology, plasma homocysteine, and low B-vitamin levels
(Elias et al., 2001). The detailed quantification of the potential impact of these
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factors on cognitive functions would ideally need to be performed in well-powered,
prospective, population studies where data on different aspects of cognitive function
were also gathered. Moreover, the collection of structural imaging data would also
provide valuable information on the nature of the cerebral changes underlying
cognitive decline associated with unfavourable risk factor levels. A further strand of
research would be based on examining the possible interaction or synergism between
these exposures and common polymorphisms (e.g. apolipoprotein E e4, APOE e4 )
on the rate of mental decline in the elderly. Such study might further facilitate the
stratification of older people who may be at an increased risk of cognitive decline
(Haan et al., 1999).
7.3. CONCLUSIONS
Cognitive function represents a vital component of the health status of older
people. Observed age-related decrements across various cognitive abilities may in
part be attributed to influence of cardiovascular risk factors and systemic
atherosclerotic diseases which increase in frequency with age. Despite this, cognitive
impairment and decline has been an understudied outcome in cardiovascular
epidemiological research. In particular, few population studies have prospectively
examined change in neuropsychological function in older people with clinically-
manifest vascular diseases, taking into account potential confounding effects of
multiple co-existing sociodemographic and atherosclerotic risk factors. Also,
vascular risk factor research has hitherto focused on cognitive function in relation to
a few established exposure variables while largely ignoring the potential impact of
several other conventional and novel vascular risk factors.
The present thesis described findings based on an investigation of the
associations between vascular diseases, risk factors and longitudinal change in
cognitive test performance in a population-based sample of older survivors with
vascular diseases.
The results showed that stroke was associated with a significantly steeper
decline in both general cognitive function, as indexed by a general cognitive factor
representing the variance common to all the cognitive tests used, and verbal memory
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over a four-year follow-up. When decline was estimated from peak, prior cognitive
level, stroke was related to a greater decline in both general cognition and verbal
fluency. Similarly, general cognition and most individual mental tests were
negatively affected in subjects with CVD other than stroke. With respect to the
specific non-stroke vascular morbidity groups, accelerated four-year decline in non¬
verbal reasoning ability was noted in relation to MI but angina was not associated
with cognitive decline in this study. Subjects with PAD also experienced a faster
decline in both general cognition and verbal memory over the four-year follow-up.
Several potentially modifiable vascular risk factors were also related to a
greater cognitive decline. In particular, significant associations were observed with
body mass index, smoking, diastolic blood pressure, inflammatory markers and
blood viscosity. In contrast, more formal education in early life was related to less
cognitive decline.
The associations with CVDs were found to be independent ofmajor potential
confounding factors. The findings therefore suggest that the progressive cognitive
decline in both stroke and non-stroke survivors might in part be attributed to the
underlying atherosclerotic process. Similarly, CVD risk factors were associated with
cognitive decline independently of clinical markers of atherosclerosis. In this
context, both atherosclerosis and risk factors may induce neuropathological changes
in sub-cortical structures which lead to progressive deficits in higher cortical
functioning. Possibly, alterations to complex neural networks and/or intemeuronal
connectivity following damage to deep sub-cortical grey and white matter structures
may mediate the association between vascular pathology and neuropsychological
function. The finding that decline in performance on specific mental tests was
principally accounted for by the impact ofCVD and risk factors on general cognitive
ability, rather than on the individual functions per se, might lend further support to
such a notion.
The results also bring up several questions that need to be addressed through
further research. Specifically, future studies need to examine the potential impact of
multiple vascular risk factors on cognitive decline in CVD patients. Further
understanding of predictors of cognitive function in such patients must come from
studies collecting data on various aspects of the underlying vascular pathology. The
287
use of neuroimaging is imperative if understanding of the neuropathology underlying
vascular cognitive decline is to be gained. In addition, it is important to determine
through further study the clinical relevance subtle cognitive decrements may have for
older vascular patients. Exposures to atherosclerotic risk factors need to be quantified
in relation to neuropsychological functioning of older people. There is much scope
for further research involving novel risk factors and of the potential synergism
genetic-environmental interactions may show in increasing risk for cognitive decline.
Despite the challenges posed by the above with respect to time and funding, the true
test of aetiological research is likely to be the extent to which the knowledge
generated can be utilised to halt or delay cognitive decline in both at-risk individuals
and the elderly general population at large.
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APPENDIX B: The Edinburgh Artery Study design
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APPENDIX C: Documentation relating to recruitment to follow-up cognitive
function testing
C-l: Letter to general practitioners regarding subject's suitability to take part
in cognitive function testing
To the Medical Centre/General Practice:
19th June 2002,
Dear Dr
Edinburgh Artery Study: Risks of cognitive impairment associated with vascular
disease in the general population (EAS Cognitive Project - Follow-up Phase)
In 1998, the Edinburgh Artery Study conducted the first of two parts of a study
examining the relationship between cardiovascular disease and cognitive function in
men and women from the 11 general practices participating in the study. You and
your colleagues very kindly allowed us to approach the Edinburgh Artery Study
subjects registered at your practice and we then invited them to take part. We would
now like to re-test these same people, so that we can relate changes in vascular status
to changes in cognitive function over time.
As before, we intend to invite the participants to a clinic at the Medical School in
Teviot Place, or if they prefer, we will visit them at home. We will be using the
same tests to assess verbal skills, memory and logic. The tests which take about one
hour to administer are: National Adult reading Test (NART), Raven's Standard
Progressive Matrices and the Digit Symbol Substitution Test, the Logical Memory
Test, a test of verbal fluency and the Hospital Anxiety Depression Scale. We would
also like to include the Mini-Mental State Examination to assess cognitive ability and
daily function.
We have enclosed a list of surviving participants from your practice who are,
according to our records, still able to take part if they wish to do so. However, we
would be very grateful if you could notify us of any patient who should not be
approached by us to participate in this follow-up phase of the study. We have
enclosed a form and a pre-paid envelope to assist you. Ifwe have not heard from
you within a month or so, we shall assume that we can go ahead and write to your




C-2: Letter to general practice manager regarding approval to invite subject to
cognitive function testing
To the Practice Manager of:
3rd July 2002.
Dear Sir/Madam,
Edinburgh Artery Study: Risks of cognitive impairment associated with vascular
disease in the general population (EAS Cognitive Project-Follow-up Phase)
The Edinburgh Artery Study began in 1988 and is a population-based cohort study of
cardiovascular disease of 1592 men and women from the general population. The
survey has been approved by the Lothian Health Research Ethics Committee. The
study subjects were selected at random from 11 general practices spread throughout
the city and were aged 55-74 years at baseline. In 1998, the Edinburgh Artery Study
conducted the first of two parts of a study examining the relationship between
cardiovascular disease and cognitive function and we would now like to re-test these
same people so that we can relate changes in vascular status to changes in cognitive
function over time.
However, several of the participants have now moved and changed general
practitioner. According to our records, one of our study subjects is now registered at
your practice, and I have enclosed his name and date of birth. I would be grateful if I
may be given permission to approach this patient to invite him to take part. If so, it
would be very helpful if you could notify us of any circumstances in which he should
not be approached by us, for example, sight or hearing problems, previous strokes or
dementia. I have enclosed a form and a pre-paid envelope to assist you.
To test their cognitive function, I intend to invite the participants to an interview at
the Medical School in Teviot Place, or if they prefer, visit them at home. We shall
be using the same tests as in 1998 to assess verbal skills, memory and logic. The
tests which will take about one hour to administer are: National Adult Reading Test
(NART), Raven's Standard Progressive Matrices and the Digit Symbol Substitution
Test, the Logical Memory Test, a test of verbal fluency and the Hospital Anxiety
Depression Scale. We would also like to include the Mini-Mental State Examination
to assess cognitive function and daily function.
I shall be happy to answer any queries that you may have, and can be reached on
(0131) XXX-XXXX. Ifwe have not heard from you within a month or so, we shall




C-3: Subject's information sheet, letter of invitation and reply form
EDINBURGH ARTERY STUDY: Second Phase of the Cognitive Project
Subject Information Sheet
♦The purpose of this research:
Approximately four years ago, you took part in a series of tests which assessed
memory, reasoning and verbal skills through written and spoken questions. This is
called cognitive function testing. We are now interested in finding out how thinking
skills change over time, and how they are influenced by changes in a person's
arteries.
We would like to repeat these same tests on everyone who was tested four years ago.
We would also like to include a new test that asks you to identify or do simple
everyday activities. By comparing this with information we have already collected
about your arteries, we can see if changes in arteries can influence thinking
processes.
♦Arranging an appointment:
Your own general practitioner has been contacted again, so that we could explain
about this second part of the project and to ensure that your doctor is happy for us to
invite you to take part.
If you would like to participate, please return the reply slip, ticking the 'yes' box and
including your current telephone number. We can either see you at the university or
we can visit you at home, whatever is more convenient for you. We shall contact
you by telephone at a later date to arrange an appointment. If you do not have a
telephone, we will write to you with a provisional appointment. If you do not wish
to take part, please tick 'no' and return the slip in the pre-paid envelope.
♦The appointment:
As before, the tests will last approximately one hour. We will begin by asking you a
few short questions about your health and mood. We will then repeat the tests that
you underwent the last time, including word pronunciation, memory, and reasoning.
We will also include a new test that asks you simple questions about every day life.
You are not obliged to complete any of the tests and you may withdraw at any point.
The information we obtain is completely confidential and will only be used for data
analysis in which study participants are identified by their study number. Data are
not available to any person outside the research team, although you may wish us to






Many thanks for taking part in the Edinburgh Artery Study over the last several
years. With your help, we have found out much useful information about the causes
of heart attacks, strokes and diseases affecting the arteries of the legs. We have now
completed the third and final clinic examination which took place at the Royal
Infirmary of Edinburgh (or at your home) between 1999 and 2001. Although we
have finished collecting data on your physical health, we would like to complete the
study by carrying out a second series of the tests looking at your verbal skills,
memory and thinking skills. This is known as cognitive function testing. You will
already have undergone these tests with Dr or Mrs in 1998. We are now interested in
seeing how you have changed over the last four years.
As before, there are the five tests ofmemory, word pronunciation and reasoning. We
would also like to include another test that asks you to respond to simple questions.
The series of tests will take approximately one hour and the information we obtain is
completely confidential. We have enclosed an information sheet that gives you
further details about these tests, and a reply slip and a pre-paid envelope. If you
would like to take part, we can see you either at the university or, if you prefer, at
your own home. Any travel expenses which you incur will be reimbursed by the
Edinburgh Artery Study.
Reply slip:
Ifyou would like to take part: Please tick 'yes' on the slip and also indicate
whether you would like a university or home visit. Please return this in the pre-paid
envelope. We will then contact you to arrange an appointment.
Ifvou do not wish to take part: Please tick 'no' and return the slip in the
envelope.
Please do not hesitate to contact me on 0131-XXX-XXXX if you have any questions
about the tests or what is involved in the appointment. My address and telephone








Thank you for agreeing to take part in the second part of the Edinburgh Artery Study
Cognitive Project. I am writing to confirm that your appointment has been arranged
for Tuesday 14th January at 2pm at the Medical School in Teviot Place and I have
also enclosed a map to help you find your way to the room where the tests will take
place. These tests take approximately one hour to complete but you may withdraw at
any point during the interview if you so wish. I shall also be pleased to reimburse any
travel expenses which you may incur.
If this appointment becomes unsuitable for any reason, please telephone me on
XXX-XXXX to arrange an alternative time. I look forward to seeing you.
Yours sincerely,
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APPENDIX D: Cognitive function test battery
D-l: Consent form
Study no
EDINBURGH ARTERY STUDY: Second Phase of Cognitive Project
Consent Form
I have read the Subject Information Sheet and have had an opportunity to ask
questions and discuss the study
I understand that I do not have to take part in this study and that a decision not to
participate will not affect my standing with my general practitioner
I understand that I am free to withdraw from the tests at any time without having to
give a reason
I understand that this is research from which I personally cannot expect to derive any
direct benefit








Do you have any of the following at present? Yes No
1. Difficulty reading because ofpoor vision? j j [
2. Arthritis in your hands? j j [
3. Hearing difficulties? I f
4. Parkinson's Disease?
5. A registered disability?
Have you ever had:
6. A stroke?
7. An injury that still affects your co-ordination?
8. An injury that still affects your thinking or memory?







10. Is there anything else that you can think of which could get in the way of doing
these tests?
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D-3: Hospital Anxiety and Depression Scale
I feel tense or 'wound up'
Most of the time
A lot of the time
From time to time, occasionally
Not at all
I still enjoy the things I used to enjoy
Definitely as much
Not quite so much
Only a little
Hardly at all
I get a sort of frightened feeling as if
something awful is about to happen
Very definitely and quite badly
Yes, but not too badly
A little, but it doesn't worry me
I can laugh and see the funny side of things
As much as I always could
Not quite so much now
Definitely not so much now
Not at all
Worrying thoughts go through my mind
A great deal of the time
A lot of the time






Most of the time





I feel as if I am slowed down




I get a sort of frightened feeling





I have lost interest in my appearance
Definitely
I don't take so much care as I should
I may not take as much care
1 take just as much care as ever






I look forward with enjoyment to
things
As much as ever I did
Rather less than I used to
Definitely less than I used to
Hardly at all
















Score one pointfor each correct answer
Correct?
1. What day of the week is it? Yes No
What date is it today?
2. Day Yes No
3. Month Yes No
4. Year Yes No
5. What is the season? Yes No
(Allow flexibility when season changes)
Total correct,,.
Orientation-Place
Score one pointfor each correct answer
Correct?
Can you tell me where we are now?
For instance, what county or region we are in? Yes No
7. What is the name of this town (city)? Yes No
8. Which country are we in? Yes No
9. What floor of the building are we on? Yes No
What is the name of this place? (or: What
is the address? If the subject is tested at home) Yes No
Total correct
Memory-registration
I am going to name three objects. After I have finished saying all three, I want you to repeat them.
Remember what they are because I am going to ask you to name them again in a few minutes.
Name the following three objects taking one second to say each:
LEMON, KEY, BALL. Go!
















Could you please tell me the three objects




14. Could you please tell me what this is
show WATCH
show PENCIL
15. 1 would like you to repeat the following


















Please read and obey the following:
Give the patient the paper with the printed sentence 'Close your eyes'







Read the following statement and then hand to the subject a sheet of paper. Make a point of handing
to the subject's midline.
Please listen carefully to the instructions as I will explain it only once: I am going to give you a piece
of paper. When I do, take the paper in your RIGHT hand. Fold the paper in half with both hands, and
put the paper down in your lap.
Do not repeat instructions or coach. Score a move as correct only if it takes place in the correct
sequence. Note each correct move and enter total number correct (Maximum score = 3 points).
Correct?
Right hand Yes No
Folds Yes No








Write a complete sentence in the space
































D-6: Logical Memory Test
LOGICAL MEMORYI: Score 1 pointfor each correct item (see Appendix A in
Manualfor Scoring Criteria)
STORY A
Anna/ Thompson/ of South/ Boston/ employed/ as a
cook/in a school/ cafeteria/ reported/ at the City Hall/ Station/
that she had been held up/ on State Street/ the night before/ and
robbed/ of fifty-six dollars/. She had four/ small children/ the rent
was due/ and they had not eaten/ for two days/ The police/ touched
by the woman's story/ took up a collection/ for her/
STORY B
Robert/ Miller/ was driving/
at night/ in the Mississippi/ Delta/
Nashville/ when his axle/ broke/,
road/ into a ditch/. He was thrown/
badly shaken/. There was no traffic/
come/. Just then his two-way radio/
"This is Grashopper/."
a ten-ton/ truck/ down a highway/
carrying eggs/ to
His truck skidded/ off the
against the dashboard/ and was
and he doubted that help would
buzzed/. He quickly answered/
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APPENDIX E: Baseline and follow-up criteria for fatal and non-fatal CVD
E-l: Angina pectoris
Baseline Examination Criteria
Three methods were applied in order to detect angina pectoris at the baseline clinical
examination:
a. Subject's recall of a doctor's diagnosis of angina pectoris. Participants were asked
if they had ever been told by a doctor that they had had angina.
b. WHO Questionnaire. Participants were enquired about whether they ever got pain
or discomfort in the chest which met certain criteria with regard to site, onset, and
duration.
c. Ischaemic changes on ECG. The ECG was coded according the Minnesota coding
system and the following codes were used: 1.3.1-1.3.6; 4.1.1-4.1.2; 4.2-4.3; 5.1-5.3;
and 7.1.1.
Five and 12-Year Follow-Up Examination Criteria
At the five-year examination, detection was based on the WHO questionnaire and
ECG changes indicative of ischaemia. At the 12-year examination, only the WHO
questionnaire was administered.
Criteria for new events during follow-up
A diagnosis of angina pectoris during the follow-up period was recorded if there was
no WHO questionnaire evidence of angina at baseline, in addition to one of the
following:
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a. WHO evidence of angina during follow-up plus subject's recall of a doctor's
diagnosis of angina,
OR
b. WHO evidence of angina during follow-up plus ischaemic changes on ECG,
OR




Presence of intermittent claudication at baseline was investigated with the use of the
following procedures:
a. Subject's recall of a doctor's diagnosis of intermittent claudication. Subjects were
asked if they had ever been told by a doctor that they had had hardening of the
arteries in the leg.
b. WHO questionnaire on intermittent claudication. Participants were asked whether
they ever experienced pain in either leg on walking which met specific criteria with
regard to site, onset, and duration.
Five and 12-Year Follow-Up Examination Criteria
At baseline, intermittent claudication was assessed by using both subject's recall of a
doctor's diagnosis and the WHO questionnaire. At five-year and 12-year
examinations, subject's recall of a doctor's diagnosis of intermittent claudication had
been replaced with a question (personal history) about whether participants had
experienced pain at the back of either leg below the knee when walking.
Criteria for new events during follow-up
Intermittent claudication was diagnosed using the WHO angina and'intermittent
claudication questionnaire. Grade 1 was recorded if calf pain occurred when walking
uphill or hurrying. Grade 2 was recorded if the pain also occurred while walking at
ordinary pace on the level. 'Probable' intermittent claudication was defined as calf
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The detection ofmyocardial infarction at baseline was made on the basis of the
following:
a. Subject's recall of a doctor's diagnosis of myocardial infarction. Participants were
asked if they had ever been told by a doctor that they had had a heart attack
(coronary thrombosis, myocardial infarction).
b. WHO Questionnaire. Subjects were asked whether they had ever experienced a
severe pain across the front of the chest lasting for half an hour or more.
c. Diagnostic ECG. The following codes were used (Minnesota coding system):
1.1.1-1.1.2; 1.1.4; 1.2.1-1.2.2; 1.2.4-1.2.5; 1.2.7-1.3.0; and 9.2.
Five and 12-Year Follow-Up Examination Criteria
At five-year and 12-year examinations, identical to the baseline examination, the
evaluation ofmyocardial infarction was made on the basis of the WHO questionnaire
and diagnostic ECG codes. Instead of using subject's recall of a doctor's diagnosis,
however, personal history was obtained by asking participants whether they had
experienced for the first time a heart attack during the previous year.
Criteria for new events during follow-up
1. Non-fatal
a. Definite myocardial infarction if two of the following three below were
present:
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i) Prolonged and lasting (>20 minutes) cardiac pain, anywhere in the
anterior chest, left arm, or jaw (possibly also involving back,
shoulder, right arm, or abdomen).
ii) The following diagnostic ECG codes (Minnesota coding system):
1.1.1-1.2.5; 1.2.7; or 9.2 plus 5.1 or 5.2.
iii) Elevated cardiac enzyme levels: creatine phosphokinase greater
than twice the upper limits of normal, and one of the following also
greater than twice the upper limits of normal: lactate dehydrogenase,
glutamic oxalo-acetic transaminase, or the MB isoenzyme of creatine
phosphokinase. The enzymes must have been measured within 72
hours of an acute event.
b. Possible myocardial infarction was coded if:
i) One of the above definite criteria was met plus either:
-equivocal ECG codes: 1.2.8-1.3.6; 4.1-4.3; 5.1-5.3; or 9.2.
-equivocal enzyme levels: above normal but not twice the
normal or one was twice above the normal but could be
attributed to another cause.
ii) Equivocal ECG codes and equivocal enzyme levels.
2. Fatal
a. Definite myocardial infarction was coded if one of the criteria below was
met:
i) Post mortem evidence of acute myocardial infarction
ii) Definite criteria for myocardial infarction existed within four
weeks prior to death.
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iii) ICD-9 codes (International Classification of Disease) for cause of
death were: 410-414 in addition to the participant having had a history
of a definite or possible myocardial infarction; or 410-414 plus
definite or possible criteria for myocardial infarction immediately
preceding death; or 410-414 plus post mortem evidence of severe
coronary atherosclerosis or previous myocardial infarction,
b. Possible myocardial infarction was recorded if:
-codes on death certificate were 410-414 without any other
evidence of an acute event to be found.
3. Silent
Registered if the following Minnesota ECG codes were present: 1.1.1-1.2.5;
1.2.7; or 9.2 in addition to 5.1 or 5.2, in the absence of elevated levels of




At baseline, subject's recall of a doctor's diagnosis was used to enquire about history
of stroke by asking participants whether they had ever been told by a doctor that they
had had one.
Five and 12-Year Follow-Up Examination Criteria
As above, subject's recall of a doctor's diagnosis used at baseline had been replaced
with personal history at five-year and 12-year examinations, enquiring participants
about whether they had experienced a stroke for the first time in the year before the
examination.
Criteria for new events during follow-up
1. Non-fatal
a. Definite stroke was recorded if one of the following criteria was present:
i) A history of onset of symptoms of less than 48 hours, plus clinical
confirmation of a focal or global disturbance of cerebral function
lasting for more than 24 hours.
ii) Computerised tomography (CT) scan showed evidence of cerebral
infarction or haemorrhage.
b. Possible stroke was coded if:
-primary or secondary discharge diagnosis included ICD-9
codes of 431, 432, 434, 436 or 437.
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2. Fatal
a. Definite stroke was recorded if one of the following was present:
i) Post mortem evidence of cerebral infarction or haemorrhage.
ii) Criteria for definite stroke were met within the six weeks prior to
death.
b. Possible stroke was coded if:
-death certificate codes of underlying or immediate cause of
death were ICD9 431-437, without any other evidence
available.
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APPENDIX F: Number of subjects meeting individual confirmatory criteria for






Positive WHO Questionnaire AND recall of a doctor's
diagnosis of angina
OR






Five and 12-year Follow-up Examination
-Positive WHO Questionnaire AND ECG evidence of
ischaemia (5-year examination) 14 12.4
-Positive WHO Questionnaire (12-year examination) 23 20.4
Follow-up
No WHO evidence at baseline plus either.




ii) Positive WHO Questionnaire AND ECG evidence of
ischaemia 5 4.4
OR









Recall of a doctor's diagnosis of intermittent claudication 0 0.0
OR
Positive WHO Questionnaire:
-Grade 1 2 3.2
-Grade 2 5 8.1
-Probable 0 0.0
Five and 12-year Follow-up Examination
Recall of a doctor's diagnosis of intermittent claudication 0 0.0
OR
Positive WHO Questionnaire:
-Grade 1 9 14.6




-Grade 1 4 6.4









Positive WHO Questionnaire AND recall of a doctor's diagnosis of
MI
OR






Recall of a doctor's diagnosis ofMI AND ECG evidence of previous
MI
6 11.3
Five and 12-year Follow-up Examinations
Positive WHO Ouestionnaire AND ECG evidence of previous MI 8 15.1
Follow-up
Definite MI
Chest pain (Tor at least 20 minutes') AND ECG evidence of previous
MI
OR






ECG evidence of previous MI AND elevated enzvme levels 0 0.0
Possible MI
One of the above definite criteria plus either:





















Recall of a doctor's
diagnosis of stroke 6 30.0
Five and 12-year Examinations
Recall of a doctor's









(positive results) 5 25.0
Possible stroke
Hospital discharge
diagnosis 2 10.0
Total 20 100.0
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